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Abstract 
 
Recent advances in studying the mammalian transcriptome arised new questions about how genes 
are organized and what is the function of noncoding RNAs. Furthermore, the discovery of large 
amounts of polyA- transcripts and antisense transcription proved that a portion of the transcriptome 
has still to be characterized. 
The complex anatomo-functional organization of the brain has prevented a comprehensive analysis 
of the transcriptional landscape of this tissue. New techniques must be developed to approach 
neuronal heterogeneity. 
 
In this study we combined Laser Capture Microdissection (LCM) and nanoCAGE, based on Cap 
Analysis of Gene Expression (CAGE), to describe expressed genes and map their transcription start 
sites (TSS) in two specific populations, A9 and A10, of mouse mesencephalic dopaminergic cells. 
Although sharing common dopaminergic marker genes, these two populations are part of different 
midbrain anatomical structures, substantia nigra (SN) for A9 and ventral tegmental area (VTA) for 
A10, project to relatively distinct areas, participate to distinct ascending dopaminergic pathways, 
exhibit different electrophysiological properties and different susceptibility to neurodegeneration in 
Parkinson`s disease.  
Specific neurons were identified by the expression of Green Fluorescent Protein driven by a cell-
type specific promoter in transgenic mice. High-quality RNAs were purified from 1000-2500 cells 
collected by LCM.  
 
We adapted the CAGE technique to analyze limiting amounts of RNAs (nanoCAGE). We took 
advantage of the cap-switching properties of the reverse transcriptase to specifically tag the 5`end 
of transcripts with a sequence containing a class III restriction site for EcoP15I. By creating 32bp 
5`tags, we considerably improved the TSS mapping rate on the genome. A semi-suppressive PCR 
strategy was used to prevent primer dimers formation. The use of random priming in the 1st strand 
synthesis allowed to capture poly(A)- RNAs.  5`tags were sequenced with Illumina-Solexa 
platform.  
 
Here we show that this new nanoCAGE technology ensures a true high-throughput coverage of the 
transcriptome of a small number of identified neurons and can be used as an effective mean for 
gene discovery in the noncoding RNAs, to uncover putative alternative promoters associated to 
variants of protein coding transcripts and to detect potentially regulatory antisense transcripts. 
 
A further experimental validation by 5`RACE (Rapid Amplification of cDNA Ends) and RT-PCR 
on few candidate genes, have confirmed the existence in vivo of alternative TSS in the case of key 
regulatory genes involved in specifying and maintaining the dopaminergic phenotype of these 
neurons such as α-synuclein (Snca), dopamine transporter (Dat), vescicular monoamine transporter 
2 (Vmat2), catechol-O-methyltransferase (Comt). Furthermore the differential expression of an 
antisense transcript overlapping to the polyubiquitin (Ubc) gene was detected as potentially 
interesting candidate gene accounting for differences in the ubiquitin-proteasome system (UPS) 
function in the two neuron populations. The potential implications deriving from these newly 
discovered alternative promoters and transcripts are discussed, considering also the potential 
consequences for the corresponding protein isoforms. 
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SECTION 1. INTRODUCTION 
 
 
The complexity of the Eukaryotic Transcriptome: Large part of the genome is 
transcribed 
 
In recent years a lot of efforts were made to determine the genomic sequence of most of the so 
called “model organisms” in order to identify how many are the genes and to clarify which is their 
structure. 
With the recent availability of genomic sequences, publicly accessible in databases, it became 
evident that the number of transcripts exceeds of at least one order of magnitude the number of 
annotated genes along the chromosomes. 
Many independent experimental works in the last five years, using different technologies to explore 
genome-wide gene expression, conveyed to a common surprising conclusion: the genome is much 
more active than previously thought as transcription is widespread than existing genome 
annotations would predict.  
And this is clearly contraddicting what only few years ago was regarded as the functional 
interpretation of the genome.   In fact, according to the classically accepted view, about 97% of the 
genome was defined as “junk DNA” due to the lack of a clear associated function whereas only 3% 
was associated with protein-coding sequences, and “genes” were generally assumed to be 
synonymous of “proteins”, or protein-coding sequences. In the past decades few pioneering studies 
showed evidences of a much larger complexity of the transcriptomes . In the 1970s, in sea hurchin 
embryos heterogeneous nuclear RNA (hnRNA) were found exibihiting 10-fold more complexity 
than the cytoplasmic fraction of mRNA associated with polysomes. In the 80s it was shown that in 
amphibian oogenesis the transcription levels are an order of magnitude greater than expected for 
mRNAs alone (Varley et al. 1980). Furthermore, an evaluation based on nucleic acid reassociation 
kinetics found 10-fold more hnRNA than mRNAs (Hough et al. 1975). In human cells the nuclear 
RNA fraction showed to be 10-fold more complex than the cytoplasmic fraction and 5’capped 
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RNAs outnumbered poly-adenilated RNAs 3:1 in hamster ovary cells (Salditt-Georgieff et al. 
1981). All of these cases were considered with skepticism and treated more like exceptions than 
like a general property of genomes. 
More recently, some important technological advancements made possible to take a global snapshot 
of the output of the genome, shading some lights on the nature of this transcriptional diversity. 
Using genomic tiling arrays, a widespread transcription along most of the human chromosomes has 
been observed including a significant proportion of antisense transcription as well as many non 
coding and intergenic transcripts (Kapranov et al. 2002; Bertone et al. 2004; Cheng et al. 2005). 
These data were largely confirmed and expanded by studies involving other technologies like full-
length cDNA sequencing (Okazaki et al. 2002), SAGE tags expression profiles (Chen et al. 2002; 
Saha et al. 2002), and CAGE tags profiling (Carninci et al. 2005; Carninci et al. 2006). All of these 
evidences pointed out to disclose a hidden layer of transcriptional acitivity mostly arising from non 
coding regions, intergenic trans-acting regulatory regions, mobile genomic elements, pseudogenes. 
All these were elements previously regarded as a silent part of the genomic structures without any 
associated function. 
Clearly, one cannot completely rule out that transcription in mammals could be inherently sloppy 
and at least part of those non coding transcripts may represent an unexplained large excess of  
“unspecific transcription”. However, many of them are expressed in a developmentally regulated 
manner, being gender-, or tissue- or cell-specific, which suggest that most of them are not spurious.  
So it may be considered true, for instance, that the number of human genes, considered as tracts of 
genomic DNA transcribed to produce functional information, is much higher than previously 
anticipated solving at least in part the diatribe between evaluations based on genomic sequences 
analysis (30-40,000) (Lander et al. 2001; Venter et al. 2001) or cDNA cluster analysis (65-70,000) 
(Zhuo et al. 2001). 
However, although in the past few years tremendous efforts were made to assembly the complete 
sequence of the genome of a growing number of different organisms, we are still far away to have a 
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comprehensive view of all the molecular diversity of the corresponding transcriptomes. This is 
mainly due to the lack of a uniform methodological approach and of a systematical collection of 
samples. Since the transcriptome discovery rate has not reached a plateu, this is a still growing 
process (Carninci P. 2007).   
 
The complexity of the Eukaryotic Transcriptome: alternative splicing, 
alternative transcription initiation and termination 
 
After the discovery of exons and introns in the Adenovirus hexon gene in 1977 (Sambrook J. 1977) 
Walter Gilbert proposed that different combinations of exons could be spliced together to produce 
different mRNA isoforms of a gene (Gilbert W.1978). In the `80s researchers documented 
alternative splicing in several genes and estimated that 5% of the genes in higher eukaryotes might 
have alternative splicing (Sharp P.A. 1994). Now we know this represents a much more common 
mechanism to create transcript diversity.  
Most of the eukaryotic genes exhibit a completely different structure from Prokaryotes, being 
composed from small coding sequence tracts (exons) interconnected by large non coding segments 
known as introns. The joining of the coding portions in different orders, a process known as 
“alternative splicing”, may originate additional transcripts diversity in the respective protein 
products. This diversity can explain, at least in part, how the relatively similar numbers of protein-
coding genes estimated for fruit fly (13,985 BDGP release 4), nematode C.elegans (21,009 
Wormbase release 150), and human (23,341 NCBI release 36) result in the remarkable phenotypic 
differences observed among these species. 
Exon inclusion into a mature mRNA is a complex choice whose outcome is influenced by a variety 
of different factors. Many exons are “cryptic”, in the sense that they are included only in some but 
not all transcripts, through mechanisms that are so far not completely understood. On average, 
cryptic exons are reported to be shorter than constitutive exons (Berget 1995) and to be flanked by 
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weaker splice sites (Stamm et al. 2000).  Although is known that exonic splice enhancers can 
compensate for weaker splice sites (Berget 1995, Fairbrother et al. 2002), it is unclear at present if 
cryptic and constitutive exons differ in the content of splice enhancers.  
The percentage of intronic genes vary among species, as well as the intron : exon ratio, but in 
mammals the vast majority of  these genes are intronic. 
The developing of better strategies for full-length cDNA cloning together with the advent of 
genomic tiling arrays and an improvement in the algorithms for gene structure prediction revealed 
the existence of an hidden layer of complexity even in the protein-coding genes. The emerging view 
is that most of the “transcriptional units” present, at different extent, alternative splicing, alternative 
transcription initiation and termination.  
In mouse, the completion of the genomic sequence 
(ftp://wolfram.wi.mit.edu/pub/mousecontigs/MGSCV3) and the availability of high quality full-
length cDNA libraries obtained with the cap trapping method on polyadenilated and capped RNAs 
(Carninci et al.1996) made possible to analyze large datasets of multiple full length cDNA 
sequences derived from the same “transcription unit”, revealing the entire spectrum of exon 
combinations and contributing to disclose the cis-acting sequences which mediate the choice of 
each particular exon. In a recent study, an extensive analysis of the data coming from RIKEN 
Fantom 2 mouse 60,770 full-length cDNA collection and 44,122 public mRNA sequences, revealed 
that at least 41% of the cDNAs exihibit at least one variant form. 54,490 (70%) out of 77,640 
cDNA sequences mapping at 95% identity on the mouse genome were “multiexon transcripts”.  
7,293 of these multiexon transcripts (13%) didn`t cluster with any transcripts and they were called 
singletons whereas the remaining part (47,197 cDNA sequences) were multiexon transcripts 
clustering into 11,677 multitranscript clusters. Of these, 41% were variant, originated by alternative 
splicing events (Zavolan et al. 2003). 
However, the real value of alternative spiced forms could be much higher as predicted from the fact 
that the estimated frequency of genes with alternative splicing increases with the depth of sampling 
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and with the average number of transcripts sequenced for a gene (Zavolan et al 2002; Kan et al. 
2002).  In the same study previously reported, a Bayesan statistical model was constructed to 
estimate the probability that a gene has multiple splice forms even though in the case when only an 
identically spliced form was observed in the experimental dataset. This mathematical model set the 
upper bound for the incidence of genes with multiple splice forms (Zavolan et al. 2003). 
This estimation fits well also with other studies in human where between 40% and 60% of all the 
genes were predicted to have alternative splice forms (Modrek et al. 2001, Modrek B. and Lee C. 
2002). This is mainly based on EST and available mRNA sequences alignment to the genomic 
sequence. More recently also tiling array analysis of human chromosome 21 and 22 showed that the 
number of detectable transcribed exons that are expressed in at least one out of 11 different  cell 
lines tested is 10-fold larger than the number of the currently annotated exons (Kampa et al. 2004). 
All these studies show that the alternative splicing is far more abundant, ubiquitous and functionally 
relevant than previously thought. 
Despite an initial study where most alternative splicing events occur within the 5` untranslated 
regions (Mironov et al. 1999), more recent reports indicate that 70-88% of the alternative splices 
change the protein products, having functional impact such as replacement of the amino or carboxy 
terminus, or in-frame addition and removal of a functional domain (Modrek B. and Lee C. 2002). 
Furthermore, the alternative splicing events tend to preserve the integrity of the coding frame since 
in human only 19% of the alternative protein forms are shortened due to frameshifts (Modrek et al. 
2001). The functional pattern of alternative splicing across the genome seems to affect mainly 
certain categories of genes as in a random sample of 50 human genes, over 75% were involved in 
signalling, regulation and transcription, with a strong occurrence for genes expressed in immune 
and nervous systems (Modrek B. and Lee C. 2002). A very low occurrence frequency is observed 
for genes coding for enzymatic proteins implying that may be a very limited potential for 
diversification of enzymatic function through splice variation (Zavolan et al. 2003).  
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In general multiple alternative splicing in the same transcript is not so frequent, However, notable 
examples of combinatorial alternative splicing of multiple exons, generating up to 40,000 isoforms 
of a single gene, has been recently discovered in the nervous system, including Dscam (axonal 
guidance receptor in Drosophila) and neurexin, a neuropeptide receptor (Graveley B.R. 2001). 
Some additional interesting considerations about the role played by alternative splicing in the gene 
function regulation come from the analysis of CAGE tag libraries. 
Mapping the transcription start sites (TSS) with CAGE technique it was shown that in mouse there 
are at least 236,000 TSS and 153,000 transcription termination sites (TTS) for only 44,000 
transcriptional units, implying that many transcriptional units have large TSS-covered regions and 
TTS variability. On average, a defined 3’end has 1.32 start sites while for every 5’end an average of 
1.83 of 3’ends are associated (Carninci et al. 2005). These data are also confirmed by a 
comprehensive long-SAGE analysis in mouse with associated 3.3 alternative 3’ends to each 
transcript (Siddiqui et al. 2005). 
Alternative TSS usage could be important for driving the expression of different mRNA isoforms. 
Clustering tags-derived TSS based on their CAGE-determined level of expression showed that 
different TSSs belonging to the same transcription unit fall into different expression patterns. 
Furthermore, 58% of protein-coding genes had two or more alternative promoters based on non- 
overlapping tag clusters. The variability at the TTS could have a relevant role for mRNA 
localization and stabilization as suggested by the fact that 27 sequence motifs are statistically over-
represented within 120bp of the polyadenilation site (Carninci et al. 2006).  
 
The dark side of the Eukaryotic Transcriptome –Transcripts of Unknown 
Function (TUF) 
 
A large fraction of the genome of higher eukaryotes does not encode for proteins at all (Eddy 1999; 
Erdmann et al. 1999; Mattick and Gagen 2001). The initial discovery of many non coding 
transcripts was limited to some isolated cases. However, independent experimental studies reported 
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the existence of a growing number of ncRNAs. Well documented examples comprise XIST, 
involved in female X chromosome inactivation (Brockdorff 1998; Hong et al. 2000), and the 
H19/Igf2 locus, whose mutation affect cell proliferation (Wrana 1994; Hurst and Smith 1999) both 
of which are imprinted and differentially spliced without encoding any protein. Other examples are 
roX1 and roX2 RNAs involved in male X-chromosome activation for the dosage response in 
Drosophila, heat shock response RNAs in Drosophila, oxidative stress response RNAs in 
mammals, His-1 RNA involved in viral response/carcinogenesis in humans and mice, SCA8RNA 
which is antisense to an actin-binding protein mRNA and mutated in spinocerebellar ataxia type 8 
(Eddy 1999; Erdmann et al. 1999; Prasanth and Spector 2007).  
Many examples were found in imprinted loci. In the murine Igf2r/Air locus, a differentially 
methylated region (DMR2) within the promoter of the ncRNA Air act as a critical bidirectional 
element, controlling silencing of the paternal allele of three protein-coding genes Igf2r, Slc22a2 and 
Slc22a3 (Zwart et al. 2001). Another locus (KCNQ1) is associated with human Beckwith-
Wiedemann syndrome (BWS) whose etiology is complex because involves many genes at two 
different loci, and where the transcription of a paternally expressed ncRNA appears to be critic to 
establish the imprinted profile of the nearby genes (Szymanski and Barciszewski 2003; Mancini-
Dinardo et al. 2006). Interestingly, the ncRNA promoter lies within a differentially methylated 
region overlapping with the silenced gene (Beatty et al 2006). 
One of the first examples of imprinted disorder to uncover the role of ncRNA genes was the Prader-
Willi/Angelman syndrome (PWS/AS). This results from the distrupted expression of imprinted 
genes spanning a region of more than 4Mb on human chromosome 15 (mouse proximal 7). 
Maternal disomies result in PWS, whereas paternal disomies result in AS (O`Neill 2005). In the 
case of PWS the expression of a group of paternally transcribed protein genes (SNURF/SNRPN, 
MKRN3, MAGEL2, ZNF127) is lost and a spliced and polyadenylated ncRNA (IPW) has been 
suggested to control silencing and expression at this chromosomal region. At the same locus the 
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ncRNA (ZNF127AS) is transcribed antisense to a brain and lung expressed transcript (Wevrick et al. 
1994; Jong et al. 1999). 
AS disorder is characterized by loss of function mutations in a maternally transcribed locus UBE3A. 
The paternal silencing of UBE3A locus is confined to brain subregions and interestingly there is a 
paternal-specific expression of a large, alternatively spliced antisense transcript (UBE3ATS) 
spanning for about 450 kb in human and 1Mb in mouse, whose expression may be directly linked to 
the etiology of the disease (Runte et al. 2004). The PWS/AS locus also contains several clusters of 
mostly intronic C/D-box snoRNAs, exclusively expressed from the paternal chromosome. Most of 
these snoRNAs, which overlap the UBE3A gene on the opposite strand, are overexpressed in AS 
patients (Runte et al. 2001). 
The intergenic transcription has been observed to produce many ncRNAs which can play essential 
roles in the coordination of gene expression, considering the fact that most of the regulatory 
elements of the genome like enhancers, insulators, genomic bordering elements and locus control 
regions (LCR) are often located outside the coding tracts of the protein-coding genes. The active 
transcription of these intergenic regions seems to suggest that they can exert their effects, at least in 
part, in a trans-acting way (Mattick and Gagen 2001). 
In many cases non coding genes are expressed in a developmentally-regulated manner like in 
Drosophila for the Bithorax/Abdominal A-B locus. This comprises at least 7 major transcriptional 
units. While three of them encode for protein products, some have associated phenotypic signatures 
and are developmentally regulated (Akam et al. 1985; Lipshitz et al. 1987; Sanchez-Herrero and 
Akam 1989). 
Another example of intergenic transcription comes from the β-globin locus, which was discovered 
long time ago to exhibit the constitutive production of specific ncRNAs from both intergenic 
regions and the locus control region (LCR) (Ashe et al. 1997). Several models have been advanced 
to find out a role for these non coding transcripts in the regulation of the locus. In the so called 
“tracking model” the recruitment of erythroid-specific and ubiquitous transcription factors may 
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account for helping the transcription initiation from the promoters of protein encoding genes of the 
β-globin locus (Li Q. et al. 2002). In a second model, intergenic transcription may be required to 
establish and maintain the open state of the chromatin in the locus. The persistence of DNase I 
hypersensitivity following deletion of the LCR in cell lines argue against this role (Gribnau et al. 
2000; Plant et al. 2001). Alternatively the intergenic transcription could mediate the formation of a 
silent chromatin in the absence of erythrocyte-specific transcription factors (Haussecker and 
Proudfoot 2005). 
More recently, a lot of different techniques and approaches have been developed to study on a large 
scale the gene expression in different organisms. The conclusion was that the genome is widely 
transcribed producing many non coding transcripts of unknown function (TUFs). Most of these 
TUFs map in unannotated regions of the genomes previously erroneously called “junk DNA” 
(Mattick 2003; Cawley et al. 2004; Gustincich et al. 2006; Willingham and Gingeras 2006; Taft et 
al. 2007; ENCODE Project Consortium 2007).  
Comparative analyses of the mouse genome (chromosomes 10,16, 17) with human chromosome 21 
revealed that there is almost two times more evolutionary sequence conservation observed than 
expected and that these conserved sequence regions are located distal from the well-annotated 
exons (Dermitzakis et al. 2002). Approximately 37% (837) of the conserved sequence regions 
(>100 bp and >70% identity) on mouse chromosomes 10, 16, and 17 were determined to be 
transcribed.   A series of studies based on genomic tiling arrays involving different species has been 
showing that a large fraction of the genome produce unannotated transcripts with reduced coding 
potential and of unknown function. A first attempt to evaluate the global transcriptional output of 
the human chromosomes 21 and 22 has shown they were one order more active than expected based 
on the predicted protein coding genes, suggesting the presence of many non coding transcriptional 
units (Kampa et al. 2004). Similar results were obtained in a tiling array-based whole genome 
analysis in Arabidopsis where more than 50% of the observed transcription came from intergenic 
regions and about 30% of the annotated loci were found to associate with antisense transcription 
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which in some cases was tissue-specific (Stolc et al. 2005; Hanada et al. 2007). Also in Drosophila 
about 40% of the transcription has been ascribed to intergenic or intronic regions of the genome, 
which are subject to developmentally coordinated regulation (Oliver B. 2006).  
In a study aimed to evaluate the functional role of pseudogenes in humans, the pseudogene Makorin 
p1 was shown to be responsible for stabilizing the mRNA of Makorin1 covering a cis-regulatory 
decay-mediating sequence within the 5’ region that shares homology between the two loci 
(Hirotsune et al. 2003). In the same study, at least 20% of the 20,000 human annotated pseudogenes 
was shown to be expressed, raising the question of how common may be a pseudogene-mediated 
regulation of gene activity (Mighell et al. 2000).  
By combining chromatin immunoprecipitation (ChIP) to genomic tiling arrays, an unbiased high-
resolution mapping of transcription factors binding sites (TFBS) across the genome was obtained. 
The binding sites of the NF-kB family member RelA/p65 were mapped across human chromosome 
22, revealing that about 28% of the binding sites lie more than 50kbp away from known protein-
coding genes (Martone et al. 2003). In another study, Sp1, c-Myc and p53 transcription factors 
binding sites along human chromosomes 21 and 22 were mapped, showing that 36% of the binding 
sites were within or 3’ flanking to known genes and correlating with non coding RNAs, 17% of the 
TFBS were associated to pseudogenes or ambiguous sequences whereas only 22% of these TFBS 
regions were located at the 5' termini of protein-coding genes (Cawley et al. 2004).  
To obtain a general picture of the active promoters along the entire human genome, a ChIP-on-chip 
strategy was carried out to immunoprecipitate DNA bound to TAFII250, a component of the RNA 
polymerase II preinitiation complex (PIC). DNA fragments were then hybridized on a tiling array 
containing 14.5 milion 50-mer oligonucleotides, designed to represent all the non-repeat DNA 
troughout the human genome. More than 10,000 binding sites were found to be representative of 
active promoters and 13% of these were mapping in unannotated transcription units (Kim et al. 
2005). 
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In this case the low representation of the non coding genes among the observed binding sites could 
be explained by the highly conservative thresholds used to identify the TFBS and by the low 
occupancy by RNA polymerase of low abundance transcripts.  
In a more recent analyses conducted by the RIKEN Genome Research Group for the Functional 
Annotation of Mouse Genome FANTOM 3 Project, it has revealed that in the mouse 34,030 full-
length cDNAs clusters lack any protein coding potential and are annotated as “non coding RNA”. 
So far, the number of non coding transcriptional units (34,030) exceeds the number of protein-
coding (32,129) TUs in mouse (Carninci et al. 2005). About 63% of these ncRNAs are spliced and 
their expression has been proved and confirmed that they are not byproducts of genomic 
contamination during cloning procedures (Carninci et al. 2005, Ravasi et al. 2006). Furthermore, 
the vast majority of the non coding transcripts shows a very low cross-species conservation at the 
level of the transcribed sequence (Pang et al. 2006). Interestingly, their promoters seem having a 
much higher degree of conservation (5kb versus 500bp from the starting site) (Carninci et al. 2005). 
Furthermore, ncRNAs are transcribed starting from the 3’UTR of protein-encoding genes (Babak et 
al. 2005; Pang et al. 2006) suggesting some functional link between the regulation of these two 
classes of genes. 
Widespread unannotated transcription has been confirmed by many other experimental means, 
including mapping 5` ends of transcripts using cap analysis of gene expression (CAGE), 3`ends by 
serial analysis of gene expression (SAGE), massively parallel signature sequencing (MPSS) and 
high-throughput full-length cDNA cloning and sequencing (reviewed in Mattick and Makunin 
2006). Sequencing of 3 milion human CAGE tags from various tissues confirmed that human cells 
have a similar level of transcriptional diversity as revealed by the FANTOM 3 full-length cDNA 
collection (Carninci et al. 2005; Carninci et al. 2006; Gustincich et al. 2006).  
Analysis of human gene expression by MPSS showed that more than 65% of signature sequences 
do not overlap with annotated transcripts, around 38%  of them map to introns, 21% are antisense to 
known exons and 5% map to intergenic regions.  
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Expression analysis by SAGE tags found at least 15,000 previously uncharacterized 3’ends used in 
the genome, suggesting that new isoforms and genes are in the order of thousands, representing a 
significant portion of the genome. 
A fundamental question arise from all these genome-wide observations: are all of those transcripts 
biologically functional or do they represent just transcriptional noise of the complex cellular 
biological processes? Once the new transcripts are confirmed to exist in the cell, it takes time to 
uncover their function. In the past 35 years seven major functional classes of ncRNAs were 
recognized: ribosomal (rRNA), transfer (tRNA), small nuclear (snRNA), small nucleolar 
(snoRNA), micro (miRNA), and Piwi-interacting (piRNA). With the exception of perhaps rRNAs 
and tRNAs, which were discovered in 1958, all the other classes are believed to be incomplete, and 
it’s very likely to suppose that many other different functional classes are still to be discovered.  
Many functions for ncRNAs have been identified so far, including transcriptional activation, gene 
silencing, chromatin epigenetic regulation, imprinting, dosage compensation, translational 
inhibition, modulation of protein function, binding as riboswitches to regulatory metabolites (Kiss 
2002; Zamore and Haley 2005; Mattick and Makunin 2006). 
 
The complexity of the Eukaryotic Transcriptome:  Poly A+ versus PolyA- 
transcripts 
 
It was 1974 when Christine Milcarek, Richard Price and Sheldon Penman at MIT found that about 
30% of HeLa cell mRNA lacks poly(A) when labeled in the presence of different rRNA inhibitors. 
Their method of RNA fractionation precluded contamination of the poly(A)− mRNA with large 
amounts of poly(A)+ sequences. The poly(A)− species was showed to be associated with 
polyribosomes, having an average sedimentation value equal to or greater than poly(A)+ mRNA, 
and behaving like the poly(A)+ mRNA in its sensitivity to EDTA and puromycin release from 
polyribosomes. Very little, if any, hybridization at Rot values characteristic of abundant RNA 
sequences between the poly(A)− RNA fractions and 3H-cDNA made from poly(A)+ RNA was 
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detected. This indicates that poly(A)− mRNA does not arise from poly(A)+ mRNA by 
nonadenylation, deadenylation, or degradation of random abundant mRNA sequences. The 
poly(A)− mRNA was stable in a long (20 hr) time period. These data indicated that poly(A)− mRNA 
is not short-lived nuclear or cytoplasmic heterogeneous RNA contamination, and that the half-life 
of the poly(A)− mRNA may parallel that of the poly(A)+ mRNA. (Milcarek, Price and Penman 
1974).  In a later report (Milcarek 1979) the same group showed that if poly(A)-free mRNA larger 
than 12 S labelled for 2 h in vivo is hybridized with total cellular DNA, it hybridizes primarily with 
single-copy DNA. When a large excess of steady poly(A)-containing RNA is added before 
hybridization of labelled poly(A)-free RNA, no inhibition of hybridization occurs. This indicates 
the existence of a class of poly(A)-free mRNA with no poly(A)+ counterpart. Some mRNA species 
can exist solely as poly(A)+ mRNAs. These mRNAs in HeLa cells are found almost exclusively in 
the mRNA species present a few times per cell (scarce sequences). Some mRNA species can exist 
in two forms, poly(A) containing and lacking, as evidenced by the in vitro translation data 
(Kaufmann et al. 1977). In addition, if cDNA of total poly(A)+ mRNA is fractionated into abundant 
and scarce classes, 47% of the scarce class cDNA can be readily hybridized with poly(A)-free 
mRNA. 10% of the abundant cDNA to poly(A)+ mRNA will hybridize with poly(A)-free 
sequences very rapidly while the other 90% hybridize 160 times more slowly, indicating two very 
different frequency distributions. Therefore, from these early studies the existence of three distinct 
mRNA classes emerged: predominantly poly(A)-free, predominantly poly(A)+ and bimorphic 
(Milcarek 1979). 
In the following years, other studies confirmed and extended these observations demonstrating that 
the poly(A)-free transcripts account for a large part of the complexity of the entire transcriptome in 
many different systems, like, among others the mouse brain (Van Ness et al. 1979), Drosophila 
(Zimmerman et al. 1980) and tobacco leaves (Goldberg et al. 1978). 
After almost 30 years, our understanding of poly(A)- transcripts has not significantly increased. 
Replication-dependent histone genes were classically considered to be the only well-characterized 
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class of transcripts synthesized exclusively as poly(A)- transcripts (Birnstiel, Bussslinger and Strub 
1985). More recently, other classes of non coding genes have been proven to be non polyadenylated 
(Steinmetz et al. 2001; Morlando et al. 2004; Kim et al. 2006). Several genes coding for box C/D 
and H/ACA snoRNAs and for the U5 and U2 snRNAs contain sequences in their 3` ends which 
direct the cleavage of primary transcripts without being polyadenylated (Morlando et al. 2002). 
Very recently, the use of genomic tiling arrays for 10 human chromosomes allowed a global 
analysis of the gene expression profile at 5 nucleotide resolution, using both polyadenylated and 
non polyadenylated RNA fractions extracted from cytoplasm or nucleus of HepG2 cells (Cheng et 
al. 2005). In this study, the full-length structures of many TUFs were determined using a rapid 
amplification of cDNA ends (RACE) technique and resolving the RACE products on high-density 
arrays. Overall, they showed that there are 2.2 times as many uniquely poly(A)- (43.7%) transcribed 
sequences as uniquely poly(A)+ (19.4%), while the rest (36.9%) of the transcripts are bimorphic. 
The subcellular distribution of the transcripts revealed that a large proportion of the sequences 
found in the nuclear or the cytoplasmic compartments appear to be exclusive of these 
compartments. The amount of poly(A)+ RNA (9.7%) exclusively detected in the nucleus is less 
than one third of the amount of the poly(A)- transcripts (31%). Of the poly(A)+ nuclear sequences, 
25% are associated to known exons, 34% map into introns, and the remaining 41% map in 
intergenic regions. Similarly for the poly(A)- nuclear specific sequences, 18% associate with exons, 
57% with introns and 25% with intergenic tracts. Importantly, 10.6% of the transcripts exclusively 
present in the nucleus are bimorphic. In summary, 75% of the polyadenylated nuclear transcripts 
and 82% of the poly(A)-free nuclear RNAs are currently unannotated. 
Poly(A)+ (3.1%) sequences exclusively detected in the cytosol are less than half as abundant as 
poly(A)- (6.5%) cytosolic sequences. Bimorphic transcripts esclusively detected in the cytosol are 
the 0.6% of the total. Of the poly(A)+ transcripts exclusively in the cytosol, 43% are associated 
with known exons, 22% with introns and the remaining 34% with intergenic regions. Whereas 
regarding the poly(A)- cytosolic RNA fraction, the distribution is 16% mapping to exons, 36% to 
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introns and 48% allocated into the intergenic tracts. In total, 56% of the polyadenylated cytosolic 
transcripts and 84% of the poly(A)-free cytosolic transcripts result to be without any annotation. 
Taken together, these observations show that almost 80% of the non polyadenylated transcripts and 
a percentage between 56 and 75% of  the polyadenylated transcripts are not yet characterized, with 
the introns and the intergenic non coding regions being the most rich source of unknown genes 
(Cheng et al. 2005). 
 
The complexity of the Eukaryotic Transcriptome: Nuclear versus cytoplasmic 
transcripts 
 
Till only few years ago, it was generally accepted that in a typical mammalian cell, about 14% of 
the total RNA is present in the nucleus (Alberts et al. 1994) and about 80% of this nuclear fraction 
of RNA was believed to be processed before leaving for the cytoplasm. The other 20% was 
estimated to be composed of snRNAs and snoRNAs, playing an active role in the processing events. 
Some of these molecules had been in the cytoplasm where they were coated with different proteins 
before being transported back into the nucleus.  Recent experimental studies dramatically changed 
this view, reporting that, depending from the cell line, between 40% and 50% of all the transcripts 
remain into the nucleus as can be detected only in this compartment, whereas between 10% and 
15% are exclusively retrieved in the cytosolic fraction. The remaining part (35-50%) are shared 
between the nucleus and the cytoplasm (Cheng at al. 2005; Kapranov et al. 2007). By the use of 
tiling arrays covering all the human genome at 5bp resolution, Kapranov et al. identified three 
major classes of RNAs: promoter-associated shortRNAs (PASRs), termini-associated shortRNAs 
(TASRs) and promoter-associated longRNAs (PALRs). Interestingly, a significant fraction of 
shortRNAs (44%) overlapped longRNA transfrags and showed a significant enrichment for 
evolutionary conserved sequences. Most of the longRNA transfrags overlapped to 5’ boundaries of 
protein-coding genes but only around the first exon-intron region. 39% of the PASRs and 35% of 
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the TASRs showed a syntenic conservation between mouse and human. Overall, these RNA maps 
provided a virtual genealogy of the transcripts in the cells, suggesting that an appreciable fraction of 
protein-coding genes are expressed only in the first exon and intron, and that transcription may have 
different states characterized by different lenghts of the transcripts. The ultimate fate of the RNAs 
derived from a particular locus could be predicted based on their retention in the nucleus, transport 
to cytosol or processing into shortRNAs. The functional role of these shortRNAs covering both 
5’start sites and 3’termination sites could be related to chromatin modifications. This is also 
suggested by other studies in which unstable longRNAs were postulated to be involved in 
regulation of gene expression (Davis et al. 2006; Martianov et al. 2007).  Most of mammalian RNA 
molecules undergo extensive processing and the “left-over” RNA fragments (excised introns and 
RNA sequences 3′ to the cleavage/poly-A site) are completely or partially degraded in the nucleus. 
Incompletely processed and otherwise damaged RNAs are also eventually degraded in the nucleus 
as part of the quality control system of RNA production. This degradation is carried out by the 
exosome, a large protein complex that contains, as subunits, several different RNA exonucleases.  
The export of RNA molecules from the nucleus is delayed until processing has been completed. 
Therefore, any mechanism that prevents the completion of RNA splicing on a particular RNA 
molecule could in principle block the exit of that RNA from the nucleus. This feature forms the 
basis for one of the best understood examples of “regulated” nuclear transport of mRNA, which 
occurs in HIV. The virus encodes a protein, called Rev, that binds to a specific RNA sequence 
(called the Rev responsive element, RRE) located within a viral intron. The Rev protein interacts 
with a nuclear export receptor (exportin 1), which directs the movement of viral RNAs through 
nuclear pores into the cytosol despite the presence of intron sequences. The only way for RNAs to 
leave or enter the nucleus is via one of the many nuclear pore complexes that cover the nuclear 
membrane. Nuclear pore complexes are highly organized structures that play an active role in 
movement of molecules into and out of the nucleus (Wente 2000). As in many biochemical 
systems, the energy is obtained by hydrolysis of one of the high-energy phosphate-phosphate bonds 
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in a ribonucleotide triphosphate, in this case by converting GTP to GDP. Energy generation is 
carried out by a protein called Ran, and transport requires receptor proteins called “karyopherins”, 
or exportins and importins depending on the direction of their transport activity. There are at least 
20 different human karyopherins, each responsible for the transport of a different class of molecule 
- mRNA, rRNA, etc. Examples include exportin-t that has been identified as the karyopherin for 
export of tRNAs in yeasts and mammals. Transfer RNAs are directly recognized by exportin-t, but 
other types of RNA are probably exported by protein-specific karyopherins which recognize the 
proteins bound to the RNA, rather than the RNA itself. This also appears to be the case for import 
of snRNA from cytoplasm to nucleus, which makes use of importin β, a component of one of the 
protein transport pathways (Nigg 1997; Weis 1998). Export of mRNAs is triggered by completion 
of the splicing pathway, possibly through the action of the protein called Yra1p in yeast and Aly in 
mammals (Zhou et al. 2000; Keys and Green 2001). Once outside the nucleus, there are 
mechanisms that ensure that mRNAs are transported to their appropriate places in the cell. It is not 
known to what extent protein localization within the cell is due to translation of an mRNA at a 
specific position or to movement of the protein after it has been synthesized, but it is clear that at 
least some mRNAs are translated at defined places. For example, those mRNAs coding for proteins 
that are to be transferred into a mitochondrion are translated by ribosomes located on the surface of 
the organelle. It is assumed that protein ‘address tags’ are attached to mRNAs in order to direct 
them to their correct locations after they are transported out of the nucleus. However, very little is 
known about this process. When mRNAs encode a protein that is destined to be secreted or 
expressed on the cell surface, it will be directed to the endoplasmic reticulum (ER) by a signal 
sequence at the protein's amino terminal. Components of the cell's protein-sorting apparatus 
recognize the signal sequence as soon as it emerges from the ribosome and direct the entire 
complex of ribosome, mRNA, and nascent protein to the membrane of the ER, where the remainder 
of the polypeptide chain is synthesized. In other cases the entire protein is synthesized by free 
ribosomes in the cytosol, and signals in the completed polypeptide chain may then direct the protein 
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to other sites in the cell. Some mRNAs are themselves directed to specific intracellular locations 
before translation begins. Presumably it is advantageous for the cell to position its mRNAs close to 
the sites where the protein  is required. The signals that direct mRNA localization are typically 
located in the 3′ untranslated region (UTR) of the mRNA molecule. A striking example of mRNA 
localization is seen in the Drosophila egg, where the mRNA encoding the bicoid gene regulatory 
protein is localized at the anterior tip of the developing egg by attachment to the cytoskeleton. 
When the translation of this mRNA is triggered by fertilization, a gradient of the bicoid protein is 
generated that plays a crucial part in directing the development of the anterior part of the embryo. 
Many mRNAs in somatic cells are localized in a similar way. The mRNA that encodes actin, for 
example, is localized to the actin-filament-rich cell cortex in mammalian fibroblasts by means of a 
3′ UTR signal.  The 5′ cap and the 3′ poly-A tail are necessary for efficient translation of protein-
coding genes, and their presence on the same mRNA molecule thereby signals to the translation 
machinery that the mRNA molecule is intact. The 3′ UTR often contains a “zip code,” which directs 
mRNAs to different places in the cell. mRNAs also carry information specifying the average length 
of time each mRNA persists in the cytosol and the efficiency with which each mRNA is translated 
into protein. In a broad sense, the untranslated regions of eucaryotic mRNAs resemble the 
transcriptional control regions of genes: their nucleotide sequences contain information specifying 
the way the RNA is to be used, and proteins that interpret this information bind specifically to these 
sequences. Thus, over and above the specification of the amino acid sequences of proteins, mRNA 
molecules are rich with many additional types of information. Thus a cell can control gene 
expression by controlling when and how often a given gene is transcribed (transcriptional 
control), controlling how the RNA transcript is spliced or otherwise processed (RNA processing 
control), selecting which mature mRNAs in the cell nucleus are exported to the cytosol and 
determining where in the cytosol they are localized (RNA transport and localization control), 
selecting which mRNAs in the cytoplasm are translated by ribosomes (translational control), 
selectively destabilizing certain mRNA molecules in the cytoplasm (mRNA degradation control), 
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or selectively activating, inactivating, degrading, or compartmentalizing specific protein molecules 
after they have been made (protein activity control). For most genes transcriptional controls are 
paramount. This makes sense because, of all the possible control points, only transcriptional control 
ensures that the cell will not synthesize superfluous intermediates. 
The complexity of the Eukaryotic Transcriptome: What’s the function of many 
repeat elements? 
 
About 98% of the mammalian genomes is composed of DNA of unknown function and for this 
reason is also known as “junk DNA”. Most of this junk DNA is composed of repetitive or 
semirepetitive DNA: up to 45% of the human genome is covered by transposable elements, a result 
of over 3 milion SINE- LINE- DNA- LTR-transposon insertion events (Lander et al. 2001). Their 
average length is about 400bp, ranging from 0.1 up to 8kbp, with an average distance between them 
of 476bp (Simons et al. 2006). A similar transposon density is also observed in mouse, although 
most of transposons present in human and mouse have entered these two lineages independently 
since their divergence (Waterston et al. 2002). In the past few years a sort of molecular gold rush 
has being started to uncover the hidden functional elements present in this huge unexplored part of 
the genomes, which can provide some funtional clues about how the genomes operate and change 
through time. Since they were discovered by Barbara McClintock about 50 years ago, they were 
called “control elements”, due to the fact they were able to influence the expression of neighbouring 
genes (McClintock 1956), and in 1969 Roy Britten and Eric Davidson suggested that they can 
provide the means for fortuitous evolutionary innovations. In their theory, new branches on the tree 
of life and more complex organisms arose, at least in part, from changes in the way genes were 
regulated. They also argued that these changes were often caused by repetitive elements, many of 
which were later identified as transposons. Sets of genes are turn on at particular time and specific 
places during development, and transposons may copy themselves into different parts of the 
genome and occasionally reconfigure these controls. Bringing, for instance, two independent gene 
networks under a common regulatory control, changing position along the genome, transposons can 
 30 
contribute to generate new cell types and new structures (Britten and Davidson 1969). Over the 
years this idea lost momentum, also due to many difficulties to be tested. But after 35 years, when 
researchers started to compare genomes, it became clear that not all the junk DNA was junk and 
also the idea of Britten and Davidson started to be revaluated. The discovery that 481 stretches of at 
least 200bp were exactly the same in human, rat, mouse, chicken, dog, and to a less extent fishes, 
led to define a set of “ultraconserved elements” (Bejerano et al. 2004). Three-quarters of these 
sequences lie outside protein-coding genes, particularly nearby genes involved in the regulation of 
transcription and development. 
The remaining ones are most often located either overlapping exons in genes involved in RNA 
processing or in introns.  And even more recently, Venkatesh and collaborators analyzed the draft 
genome of the elephant shark comparing with human genome, and found that these two species 
separated 350 milion years ago share 4800 conserved sequences.  The conserved sequences tend to 
cluster near genes coding for DNA binding and transcription regulatory proteins (Venkatesh et al. 
2007). According to other studies, many conserved non coding elements appeared for the first time 
with the evolutionary division between lampreys and sharks, suggesting that these sequences could 
have been playing a key role in the establishment of the vertebrate development gene-regulatory 
networks (Woolfe and Elgar 2007). 
A deeper analysis of these conserved sequences has revealed that some of them are transponsable 
elements. Okada Norihiro and collaborators have sequenced the coelacanth Lathimeria, a “living 
fossil” species which dates back 400 milion years ago, and found a couple of short interspersed 
repetitive elements (SINE) which are enough conserved among them to have a common origin. 
Then they searched other genomes for the presence of similar sequences and found that in sea 
urchin, zebrafish, catfish, trout, salmon, hagfish, dogfish shark and amphioxus a common set of 
SINEs were conserved. They called this superfamily of repetitive sequences DeuSINEs, as they 
were commonly present in all Deuterostomia. This group is actually composed of five families of 
tRNA-derived SINEs, in which a 5S rRNA-derived promoter is flanked by a highly conserved core 
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(Deu domain) and a 3`tail (Nishihara, Smit and Okada 2006). The same authors also found about 
1000 copies of a subset of these SINEs called AmnSINE1 (Amniota SINE1) which are conserved 
from humans to birds, and some copies date back before the mammalian-bird split about 310 milion 
years ago. Also AmnSINE1 share the common chimeric structure of a 5S rRNA-derived promoter 
and a tRNA-derived central core, previously seen in the DeuSINE superfamily. Out of 1000 copies 
in the human genome, 105 map to loci evolutionary highly conserved among mammalian orthologs, 
being good examples of a transposable element of which a significant fraction of the copies have 
acquired and maintained genomic functionality (Nishihara, Smit and Okada 2006). In an 
independent study, Xie and collaborators reached similar conclusions. In a search for DNA 
sequences present in the human genome in multiple copies, they found one element which showed a 
high homology with the 180 bp core of the active transposon in Zebrafish SINE3 family, and is 
present in 124 different genomic locations. Surprisingly this core sequence is retrieved in the same 
places in many other genomes, including few copies in the coelacanth. Their family of conserved 
SINEs has been proved to be the same discovered by the group of Okada (Xie, Kamal and Lander 
2006). They also identify additional 95 families of conserved noncoding elements (CNE) which 
likely predate the mammalian radiation, bringing attention to the importance of both transposons 
and other types of non coding repetitive elements in the functional organization of the genome. 
Bejerano and collaborators found that among the ultraconserved elements is present also a family of 
transposons which was first discovered in 10,000 copies in the coelacanth and called “LF-SINEs” 
were LF stands for “lobe –finned” fish. The same family of SINEs was also found in all the 
tetrapods genomic sequences available in databases (Bejerano et al. 2006). They demonstrated that 
some of these transposons are likely to function as enhancers to control the spatial and temporal 
expression profile of specific set of genes. In particular, out of 167 conserved elements tested in a 
transgenic mouse enhancer assay, 45% showed to have a reproducible tissue-specific enhancer 
activity at embryonic day 11.5. Furthermore, the majority were directing the expression in various 
regions of the central nervous system.  Recently, another study support with experimental evidence 
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the importance of retrotransposition events in neuronal differentiation. Muotri and colleagues 
studied the L1 retrotransposition events in a transgenic mice concluding that L1 retrotransposons 
can alter the expression of neuronal genes and produce somatic mosaicism in the neuronal precursor 
cells (Muotri et al. 2005). 
Interestingly, a survey of the Opossum genome searching for conserved non coding elements 
(CNE) led to identify some CNEs specific of placental mammals and diverged from marsupials. Up 
to 16% of these eutherian- specific CNEs were mapped to at least one of 12 different families of 
transposable elements. On contrary, the eutherian CNEs that are also present in Opossum only 
rarely overlap to recognizable transposable elements (0.7%) (Mikkelsen et al. 2007). Those CNEs 
are likely to be derived from transposable elements, as is difficult to recognize the future of a 
transposon copy in the genome that appeared above 100-200 milion years ago. The authors of this 
study concluded that transposable elements were likely instrumental for regulatory changes 
underlying features characteristic of placental mammals. Overall it seems that conserved repetitive 
DNA in the genome, at least in part overlapping with known transposons, have retained a function 
which has not been eliminated by the strong negative pressure to which non coding conserved 
elements are usually subjected (Ashtana et al. 2007; Kamal et al. 2006; Ponjavic et al. 2007)  
 
The complexity of the Eukaryotic Transcriptome:  S/AS pairs  
 
Detection of potential sense-antisense (S/AS) pairs has contributed to increase our description of the 
transcriptome. While previous analyses of the mammalian transcriptome suggested that about 20% 
of protein encoding genes have sense-antisense transcription (Okazaki et al. 2002; Kiyosawa et al. 
2003; Yelin et al. 2003; Chen et al. 2004; Werner and Berdal 2005), SAGE indicated that at least 
50% of all the transcripts have a corresponding antisense transcript, even considering the brain 
alone (Siddiqui et al. 2005). CAGE tags combined with a detailed analysis of mouse full-lenght 
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cDNAs shows that up to 72% of the transcriptional units exhibit S/AS transcript pairs (Katayama et 
al. FANTOM Consortium and RIKEN Genome Exploration Research Group 2005).  
Out of 43,553 total genome-mapped non redundant transcriptional units, 72% overlap with some 
cDNA, 5’ or 3’ EST sequence, or CAGE tag or PET tag on the opposite strand. In mouse, S/AS 
pairs are found in 87% of the protein coding TUs (20,714) and in 58,7% of the non coding TUs 
(22,839). Even considering only S/AS pairs supported by full-length cDNA overlap, for 4,520 TUs 
S/AS pairs were detected on the exons while 4,129 TUs have S/AS pairs overlapping to non exonic 
regions, suggesting that immature RNAs in the nucleus and introns can originate smaller RNAs 
with biological activity (Mattick and Makunin 2005). 
Furthermore, the antisense ncRNAs expression level could be still underestimated, since random 
primed CAGE libraries showed to have a larger content of antisense ncRNAs compared to oligodT-
primed CAGE libraries (Katayama et al. 2005). 
This is concordant with the observation that antisense transcripts are poorly polyadenylated 
(Kiyosawa et al. 2005) and suggest that S/AS pairs could involve poly(A)- RNAs as well as long 
non coding transcripts. Antisense transcription is very often associated to imprinted loci, as more 
than 81% of the imprinted TUs show S/AS pairs, when sequences antisense to introns are taken into 
account. S/AS pairs are unevenly distributed along the genome, as mouse chromosomes 4 and 17 
clearly show a S/AS pairs density larger than average while chromosomes 6, 9 and 13 less 
frequently contained them. The X chromosome has the fewest S/AS pairs, probably related to the 
monoallelic inactivation, due to the strong association of the antisense transcription to the imprinted 
loci. Interestingly, the mouse underrepresented chromosome 6 is mostly homologous to the human 
chromosome 7, which is known to be rich in genes transcribed by RNA polymerases I and III, 
which may be not captured by the approach used in this study (Katayama et al. 2005).    
A differential expression of S/AS pairs is noticed among different tissues and conditions. A 
preference for certain types of genes is also showed as summarized by GO terms distribution, with a 
clear overrepresentation of cytoplasmic proteins and a significant underrepresentation of genes 
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encoding for membrane and extracellular proteins. This suggests that S/AS pairs are subjected to a 
specific regulation and unlikely represent transcriptional noise (Katayama et al. 2005).  
Overlap of cis-S/AS pairs can involve different portions of the corresponding TUs, giving rise to 
three basic types of configurations: “head-to-head” or divergent in which the TUs overlap at their 
5’ends, “tail-to-tail” or convergent in which the TUs overlap at their 3’ends, and fully overlapping.  
Although various studies (Lehner et al. 2002; Yelin et al. 2003; Chen et al. 2004, 2005) suggest that 
the most common S/AS transcripts overlap as tail-to-tail, CAGE tags suggest that head-to-head 
overlap is more frequent than convergent antisense (Katayama et al. 2005).  
Monitoring their expression in a time-course experiment of macrophage cells activation by 
lypopolysaccharide, most of the S/AS pairs showed a proportional co-regulation in response to the 
stimulus, whereas only a minority showed a reciprocal regulation, with increased level of the sense 
transcript corresponding to a decreased level of the antisense transcript. 
Although concordant regulation is observed more frequently, there are few well characterized 
examples in which the two transcripts are expressed reciprocally. For instance, a targeted siRNA-
mediated inhibition of the transcript of Ddx39 led to an increase in the level of CD97 mRNA, but 
the reciprocal effect was not observed (Katayama et al. 2005). 
When a direct correlation was observed, a decrease of sense hypothetical aminoacyl-tRNA synthase 
class II-containing protein resulted in decreased antisense C/EBP delta expression. The reverse was 
not found.  A positive correlation was also noticed when a non coding RNA was the partner in the 
S/AS pair. 
All these evidences argue against a simplistic assumption of a negative regulatory role of antisense 
transcription.  S/AS pairs can potentially provide a dsRNA intermediate, which is the substrate of 
the enzyme Dicer, the main player of RNA interference (Ambros 2004). Dicer is involved in the 
production of small interfering RNAs (siRNAs), which direct the cleavage of the complementary 
mRNA. siRNAs can also take part in the transcriptional gene silencing in the nucleus (Matzke and 
Birchler 2005), while Dicer has been involved in the heterochromatin formation in vertebrates 
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(Fukagawa et al. 2004). When non coding antisense RNAs overlap the sense promoter, they seem to 
play a role in the local chromatin modification or methylation, (Imamura et al. 2004; Murrell et al. 
2004; Andersen and Panning 2003). 
To summarize, in 30% of the cases in which experimental validation after perturbation was carried 
out, S/AS pairs showed both a negative and a positive regulation of each other. The existence of 
both positive and negative correlations in the levels of S/AS pairs transcription suggest that 
mechanisms other than siRNA-like mode of action account for the antisense transcripts function in 
the genome. 
 
The complexity of the Eukaryotic Transcriptome: the impact of the technical 
limitations on gene discovery and genome annotation 
 
Recently, many technological advancements have increased our ability to study the mammalian 
genome and transcriptome. Among them, the shotgun sequencing strategy of expressed sequence 
tags (EST) together with in silico computer-assisted assembly of sequences, many different genome 
projects have been very important. 
The development of full-length cDNA libraries (reviewed in Das et al. 2001), together with the 
appearance of cDNA microarrays (Schena et al. 1995), oligonucleotide gene chips (Kane et al. 
2000) and tag-based platforms (Harbers and Carninci 2005), made possible to start a fine 
characterization of the output of the trascriptome. In parallel, the development of other relatively 
high-throughput methods as yeast two- and three-hybrids system (Uetz et al. 2000), phage display 
libraries (Cwirla et al. 1990; Scott and Smith 1990), chromatin immunoprecipitation (ChIP) 
(Orlando, Strutt and Paro 1997), ChIP on chip (Ren et al. 2000), 2D electrophoretic separation 
coupled with mass-spectrometry (Mann and Wilm 1995) have greatly enhanced the analysis of the 
proteome output, giving a more global view of the network of protein-protein and protein-DNA 
interactions within the cells. All these different approaches are producing huge amount of data, 
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usually stored in relational databases, which demanded for new bioinformatic algorithm and 
infrastructures to extract useful informations and integrate different data sets into a functional 
description of cellular activities. 
Despite many progresses, it has been evident that we are still further away from having a 
comprehensive and exhaustive view of how molecular biological systems work, and researchers 
worldwide just started to uncover the tip of an iceberg, as many limitations still prevent them from 
having a deep integrated view of the dynamics that are generated and maintained inside the cells. 
One of the most relevant limitation is represented by the minimum scale to which biological 
investigations of gene expression can reliably be conducted.  Suddenly the importance of cellular 
diversity came out as one of the most striking features accounting for the biological complexity of 
higher eukaryotes. During the past decades, many studies have been focused on single cell types, 
often describing single aspects of the biology of those cells, but with the advent of the post-genomic 
era, there is a growing need for developing reproducible methods to analyze gene expression of 
single cells in an unbiased high-throughput way. 
These small scale-technologies are needed since the expression profiles obtained from complex 
tissues are likely to miss most of the complexity of the transcriptome, which is largely composed of 
low expressed cell-specific transcripts. 
Furthermore, the emerging picture furnished by the current methodologies is more or less a static 
snapshot of the gene activities in the cell, still far away from being representative of what is the true 
dynamical status of a cell. 
To achieve this goal, a great contribution it would probably come from the development of new 
“real-time” techniques, capable of detecting and monitoring the global variations in gene expression 
in real time, taking into account all the genes at the same time. 
Importantly, new approaches must aim to the analysis of expression in sub-cellular compartments 
or different nuclear bodies.
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Several advancements have already opened the way in this direction: live molecular imaging studies 
(reviewed in Ottobrini et al. 2006) made possible for instance to monitor single neurons activation 
in real time, while chromosome conformation capture technology (3C) rendered available a tool for 
analyzing the chromatin arrangement into the nucleus over long distances (Dekker et al. 2002), 
giving a preliminary view of the higher-order chromatin domains. 
The future development of a 4C technique, which can combine the chromosome capture 
conformation assay to DNA microarrays or tag-based technologies, would further help to uncover 
the links between nuclear architecture and genome activity. 
More traditionally, cell-biologist`s approaches like multicolour DNA and RNA fluorescence in situ 
hybridization (FISH) (Carter 1994) or three – four-dimensional light microscopy have been also 
employed to complement the molecular approaches, although these techniques are currently limited 
by the Abbey limit for the maximum resolution. 
Even focusing only on gene discovery and genome annotation, a series of limitations prevented 
access to large part of the transcriptome, as many transcripts are expressed in a cell-specific manner 
and at low level, and many of them are thought to be poorly polyadenylated. 
Traditional cDNA libraries are made by priming the transcripts with oligodT and yield on average a 
20-30% of full-length molecules (Marra et al. 1999). Starting from the ‘90s several methods have 
been developed to enrich for full-length cDNAs up to 90%, in order to clarify the number and the 
structure of protein-coding genes, including the untranslated regions (Das et al. 2001). 
These libraries became a standard for high-quality large-scale sequencing projects due to the fact 
that they yield the full-length sequence data at a fraction of the cost of the entire genomic DNA 
sequencing. The full-length library construction took advantage of the presence of a cap structure at 
5`end of the genes transcribed by RNA polymerase II. This is usually represented by an inverted 3`-
5` pppGm7 nucleotide, which is added at the 5`end at very early stage of RNA synthesis, and may 
serve to control mRNA localization, mRNA stability and translation efficiency according with the 
mRNA factory model (Miura 1981; Bentley 2002). 
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At least three main systems were employed to synthesize full-length cDNA libraries: (1) SMARTR 
which makes use of strand-switching activity of a MMLV reverse transcriptase to add a GGG 
containing oligonucleotide at the 5`end and selectively recover the full-length molecules, 
subsequently amplified by PCR (Zhu et al. 2001); (2) oligo-capping method, in which uncapped 
RNAs are dephosphorylated by a phosphatase whereas all the capped mRNAs are treated with 
tobacco acyd  pyrophosphatase to remove the cap and leave a 5` phosphate group, to which an 
oligonucleotide is covalently added by RNA ligase, followed by library preparation and PCR 
amplification (Maruyama and Sugano 1994) ; and (3) the cap-trapper method, which after oxidation 
of the diol group of the cap site with NaIO4 and a biotinilation with a long-arm biotin hydrazide, 
makes use of RNAse I to cleave and remove truncated and incomplete cDNA/mRNA hybrids, with 
a good efficiency, without need for an additional PCR. 
Importantly, all of these methods have to optimize synthesis of full length cDNA for long 
transcripts. 
To overcome this problem, lambda vectors specifically designed for long cDNA cloning were 
employed to host up to 37.5 kb long insert, yielding libraries with up to twofold larger sequence 
diversity compared to libraries of shorter size (Carninci et al. 2001). 
Furthermore, to increase the gene discovery rate by sequencing randomly selected cDNA clones, 
removal of undesired common and highly expressed sequences was achieved by normalization and 
subtractive hybridization (Bonaldo et al. 1996). On average, few genes account for 20-30% of the 
total mass of mRNAs, while intermediately expressed genes (about 1000-2000 distinct transcripts) 
and rarely expressed species (which constitute the large majority of the transcripts) constitute about 
30-50% and 30-40% respectively of the total cellular mRNAs. 
This implies that in order to have a better coverage and avoid prohibitive sequencing costs it is 
mandatory to enrich the libraries for rare transcripts using subtractive hybridization strategies. 
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Subtraction and normalization have been widely used in many EST projects to enrich for novel 
transcripts in various organisms (Hillier et al. 1996; Marra et al. 1999; Sheetz et al. 2004) as well as 
for full-length cDNA-based EST libraries (Carninci et al. 2003). 
Despite the great increase in the discovery rate, the subtraction and normalization negatively select 
against alternative splicing forms, which makes those libraries unsuitable for studying alternative 
splicing isoforms.  On the other hand it has been noticed that full-length cDNA libraries still 
represent one of the best tool to characterize alternative splicing events, due to the fact that other 
methods do not usually yield the entire structure of the transcripts but interrogate only parts of it, 
like in the case of genomic tiling arrays. 
To circumvent this limitation, new approaches in the library construction are needed, which could 
take advantage from the selection of mis-paired nucleic acid hybrids as suggested from recent 
studies (Watahiki et al. 2004; Thill et al. 2006). 
Besides displaying single alternative exons, new methods should include full-length structure 
determination, because is not possible to reconstruct the structure of full-length mRNA without full-
length cDNAs (Carninci 2007). 
Another limitation in the subtraction and normalization of cDNA libraries derives from the use of 
dsDNA drivers for subtraction which may result in under-representation of S/AS transcripts in the 
library as demonstrated by human and rat EST non full-length libraries (Bonaldo et al. 1996).  
 
Technologies to unveil transcriptome complexity: cDNA microarrays, 
oligonucleotide Gene Chip and tiling arrays 
 
Array technologies take advantage of the universal inherent property of all the complementary 
nucleic acid molecules to hybridize to each other in a highly specific way. 
The traditional solid-phase array is a collection of microscopic DNA spots attached to a solid 
surface, such as glass, plastic or silicon chip. The affixed DNA segments are known as probes, 
thousands of which can be placed in known locations on a single DNA microarray. Microarray 
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technology evolved from Southern blot, whereby fragmented DNA is attached to a nitrocellulose 
membrane and then probed with a known labeled gene or fragment.  In spotted microarrays (or two-
channel or two-colour microarrays), the probes are cDNA, oligonucleotides or small fragments of 
PCR products that correspond to mRNAs and are spotted onto the array surface. This type of array 
is typically hybridyzed with cDNA derived from two samples to be compared, labelled with two 
different fluorophores. 
Fluorescent dyes commonly used for cDNA labelling include Cy3, (fluorescence emission at 570 
nm), and Cy5 (fluorescence emission at 670 nm). The two Cyanine-labelled cDNA targets are 
mixed and hybridized to a single microarray, then scanned to visualize fluorescence of the two 
fluorophores after excitation with a laser beam of a defined wavelength. Relative intensities of each 
fluorophore may then be used in a ratio-based analysis to identify up-regulated and down-regulated 
genes. Absolute levels of gene expression cannot be determined in two-channel microarrays, but 
relative differences in expression among different spots can be estimated with some oligonucleotide 
arrays. 
Since the first report of application in 1995 to a study conducted in Arabidopsis (Schena et al. 
1995), cDNA microarrays have been progressively established as a high-throughput platform for 
gene expression profiling, due to the growing availability of cDNA collections from various 
organisms. 
Several improvements and technical advancements have been carried out, from the screening of 
large tissue preparations to the potential analysis of small number of cells, with the support of a 
variegated set of amplification techniques, which operate either at the level of the signal detected or 
in the sample preparation. 
A step forward in the customization of the microarrays as platforms for gene expression profiling 
has been represented by the advent of oligonucleotide based probes, because these do not rely from 
already existing cDNA collections and can be designed based on in silico annotated genes present 
in publicly available genomic sequences. 
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In a pioneer report (Kane et al. 2000), the validity of 50-mer oligonucleotide probes spotted on a 
glass slide was tested in comparison to adjacent PCR products having the complementarity for the 
same targets. No significant difference in sensitivity between oligonucleotide probes and PCR 
probes was observed and both had a minimum reproducible detection limit of approximately 10 
mRNA copies/cell. Specificity studies showed that for a given oligonucleotide probe any 'non-
target' transcripts (cDNAs) >75% similar over the 50 base target may show cross-hybridization. 
Thus the authors concluded that non-target sequences which have >75-80% sequence similarity 
with target sequences will contribute to the overall signal intensity.    
Further improvements in the array technologies became possible with the advent of more 
sophisticated synthesis and assembly techniques. Originally developed by Affymetrix in 1994 
(Pease et al. 1994; Chee et al. 1996), the photolitographic process, typically used in the electronic 
microcircuits production, has been applied for a light-assisted oligonucleotide synthesis, which 
allows a high-throughput and automated pipeline for the production of the, so called, gene chips. 
These microarrays give estimations of the absolute value of gene expression and therefore the 
comparison of two conditions requires the use of two separate microarrays. Currently, 
commercially available oligonucleotide-arrays can be either produced by piezoelectric deposition 
with full length oligonucleotides or in-situ synthesis. Long oligonucleotide-arrays are composed of 
60-mers, or 50-mers and are produced by ink-jet printing on a silica substrate. Short 
oligonucleotide-arrays are composed of 25-mer or 30-mer and are produced by photolithographic 
synthesis (Affymetrix) on a silica substrate or piezoelectric deposition (GE Healthcare) on an 
acrylamide matrix. 
One of the major drawback of the cDNA and oligonucleotide microarrays is represented by the fact 
that the output of expression profiles is completely hypothesis-bound, since they rely for the probe 
design from the currently known gene annotations. 
More recently Affymetrix has developed GeneChip Tiling Arrays, which can be used to interrogate 
genomes at regular intervals, including both annotated and so called “junk” regions. The genomic 
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tiling arrays have been employed as discovery tool to identify novel transcriptional elements and 
evaluate antisense transcription (Kapranov et al. 2002; Rinn et al. 2003; Chen et al. 2005). 
In a study in which tiling arrays with 25-nt probes at 35bp resolution have been used to interrogate 
human chromosomes 21 and 22, 26.5% of the probes were positive in at least one out of 11 human 
cell lines using poly(A)+ RNA for target preparation (Kapranov et al. 2002). 
In a more wide study using 5bp resolution tiling arrays covering 10 human chromosomes, 
accounting for 43% of the human genome, 10.1% of the probes were positive in at least in one cell 
line and 4.9% were common to all of them (Cheng et al. 2005). 
Another study using tiling arrays at the same resolution (25nt probes in 5bp spacing), and 
interrogating the same human chromosomes revealed that in the case of HepG2 liver cells, when 
poly(A)+ and poly(A)- RNA from the nucleus and the cytoplasm was used as target, 15% of the 
probes were positively detected and 41.5% of the transcripts were found to be in the nuclear 
fraction.  The Yale group, using tiling arrays containing all the human chromosomes (36nt probes at 
46bp spacing) and screening poly(A)+ pooled liver RNA, reported of 10,595 novel transcription 
active regions (TARs) which were not previously annotated, and 14,884 transcripts were predicted 
by Genscan without any other cDNA or EST support. 
Even more recently, genomic tiling arrays in conjunction with other methods have been applied in 
the ENCODE project to characterize the funtional elements of the transcriptome for a selected 
portion of the genome (ENCODE project consortium 2007). 
However, despite the great results in gene expression profiling achieved by challenging microarrays 
technologies, the drawbacks of these systems remain many. The major limitations are represented 
by: (1) dependence of the platform design from the experimental system subjected to investigation, 
(2) inherent noise related to the hybridyzation kinetics and to the fluorochromes signal 
amplification (3) no clear distinction between different transcript isoforms as alternatively spliced 
transcripts (4) no direct way to analyze the regulatory regions of the transcriptomes like alternative 
transcription initiation or termination sites (5) limitations in the detection of rare transcripts as 25-nt 
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Affymetrix GeneChips, the basis of tiling arrays, was reported to detect <55% of the rare 
transcribed mRNAs (Draghici et al. 2006). 
 
Technologies to unveil transcriptome complexity: Serial Analysis of Gene 
Expression – SAGE 
 
SAGE has opened the field of expression profiling to the use of short sequence tags (Velculescu et 
al. 1995).  Its striking success depends on the ability to provide absolute expression values without 
need for any probe design, which proved to be instrumental for the quantitative analysis of 
biological samples. The concept is based on cleaving a cDNA with a so called “anchoring enzyme”, 
commonly NlaIII, to create a recognition site for a class IIs restriction endonuclease adjacent to the 
cloning site. This class of restriction enzymes cleave outside of their recognition sites, and those 
cutting 14-20 bp away from their binding sites are particularly useful for tag preparation.  
This allows for the isolation of short sequencing tags at locations defined by the distribution of the 
anchoring enzyme recognition sites along the genome. 
Both 5’end-related and 3’end-related sequences can be isolated and cloned into concatamers by the 
classical SAGE methodology, but the great majority of the published studies have focused only on 
the tags from the 3’ends of transcripts.  
Long SAGE (MmeI; 20bp tags) (Saha et al. 2002) and SuperSAGE (EcoP15I; 26bp tags) 
(Matsumura et al. 2003; Matsumura et al. 2008) can produce tags which are long enough to be 
unambiguously mapped to the genome since employing different class IIs endonucleases and other 
modifications of the protocol. 
In the case of classical SAGE, a virtual reference tag dataset can be constructed by scanning 
publicly available mRNA sequences for the presence of the 3’-most anchoring restriction site, 
followed by the extraction of the sequence downstream of that site. 
Subsequent transcript identification is performed matching the virtual tags in the reference database 
to the experimentally obtained tags (Lash et al. 2000).  
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In the case of LongSAGE and SuperSAGE experimentally obtained tags can directly be alligned to 
the genomic sequences for the assignment of their locations. 
A statistical analysis of the tag frequencies is required to compare the expression values of different 
samples and to assess how the noise affects method-to-method or sample-to-sample variability 
(Powell 2000; Man, Wang and Wang 2000; Wang 2005). Some tags can ambiguously match to 
several different genomic locations, for instance due to the presence of repetitive elements in 
3’UTRs, which could result particularly problematic for 3’end-related tags. Depending on the 
possibility to be confirmed by means of other independent experimental approaches, the mapping 
strategy has to be evaluated case by case. 
In general for high-throughput studies, only stringent mapping conditions ensure satisfying results.  
Even at risk of losing some information, mapping should always be tested to assure high quality and 
reliable output data. “Orphan SAGE 3’-tags” that cannot be unambiguously assigned to any 
genomic locations, may derive from internal priming in the cDNA synthesis, incomplete digestion 
with the anchoring enzyme, alternative polyadenylation, or even more in some rare cases from 
splicing events near the 3’end of transcripts. 
Furthermore, single nucleotide polymorphisms (SNPs), which occur every 100-300bp in the human 
genome (Wang et al. 1998; Sachidanandam et al. 2001), may result in different sequences and/or in 
the disruption of the recognition sites for the anchoring enzymes.  
One big limitation of the SAGE technique is its relying on the presence of the “anchoring enzyme” 
recognition site, since a transcript lacking this signal in the 3’end or 5’end-related sequences cannot 
be detected.  
Another big limitation of the SAGE approach is that this method cannot be used to directly identify 
and isolate regulatory regions, which limits understanding of the logic behind the transcriptome. 
The great advantages are represented by the fact that SAGE provides absolute levels of gene 
expression without need for any probe design, and the great sensitivity, which has been proved to 
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be 26-times more sensitive than EST methods to detect low-abundance and rare transcripts (Sun et 
al. 2004).   
 
Technologies to unveil transcriptome complexity: Cap Analysis of Gene 
Expression – CAGE 
 
Among the currently available gene expression profiling methods, the Cap Analysis of Gene 
Expression (CAGE) technique is the most relevant sequencing-based approach for extracting 
biologically relevant informations about transcriptional regulatory regions..  
CAGE allows direct transcription start sites (TSS) identification, isolation and cloning of the 5’end-
related tags, providing useful informations about promoters activity (Shiraki et al. 2003). 
Since TSS cannot be accurately predicted by computational means, the determination of 5’end 
sequences of transcriptional units, responsible for their regulation, entirely depends on strategies to 
map experimentally obtained tags to genomic sequences. 
The concept of CAGE is based on capturing the true 5’ends of transcripts by using the “cap-
trapping” technology (Carninci et al. 1996), which takes advantage of the presence of the cap 
structure for binding and selection of full-length cDNA molecules. After the partially truncated 
cDNA, which do not reach the starting site, are discarded by using RNAse H to degrade the RNA in 
hybrid duplexes, an adaptor containing a recognition site for a classIIs restriction enzyme (MmeI) is 
ligated to the 5’end. As result of the digestion with the restriction enzyme, 18bp 5’fragments are 
released and, after the ligation of a second adaptor containing a different restriction site, the 20 bp 
long 5’end-tags can be concatenated for sequencing. 
Tags from 5’end can be particularly reach in G/C, and their sequencing may require the use of 
additives in the sequencing reaction like betaine, which decrease the melting point of such 
structures (Shnoor et al. 2004).  
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On contrary to SAGE, CAGE is not restricted to the presence of an anchoring recognition site but 
only depends from the selection of true 5’ends and consequently from the capacity to synthetize and 
select full-length cDNAs in an effective way (Das et al. 2001). 
In optimal conditions, using high-quality RNA, more than 90% of the full-length cDNAs are 
recovered, as observed from mapping the tags on full-length coding regions (Sugahara et al. 2001). 
In contrast to SAGE for which a virtual reference database can be use for direct comparison, the 
analysis of 5’end tags entirely depends on strategies to map the tags to genomic sequences. 
Full-length cDNA sequences and other sequence informations from transcribed regions can be used, 
although these are incomplete and nonrepresentative datasets, due to their low transcriptome 
coverage. Reference Sequences (RefSeq), which is a curated mRNA sequences collection, can 
integrate multiple forms of mRNAs into most likely transcript models, but often presents a larger 
version of an mRNA, because it contains more extensive 5’ and 3’ ends than other GenBank entries 
and the literature (Pruitt et al. 2005).  
This has to be accounted in the interpretation of the CAGE tags mapping results. 
In the case of CAGE tags from mouse and human tissues, mapping rates of 65-70% can be achieved 
using BLAST alignment (Altshul et al. 1997) and stringent mapping conditions. 
Recently, CAGE data are available in a format which can be easily loaded into a Genome Browser 
(UCSC or Fantom3 Genome Browsers). Furthermore, the DNA Data Bank of Japan (DDBJ) has 
designed a new data format for deposing CAGE tags into public databases. 
Whereas SAGE tags have defined ends which invariantly depend from the position of the anchoring 
enzyme recognition site in the genome, CAGE tags associated to the same TSS tend to cluster over 
short regions, displaying a slight variation in the position, owing to the inherent variability of TSS. 
Therefore, CAGE tags are grouped into “tag clusters” (CTSS or TK) comprising CAGE tags that 
map to the same genomic region and have at least one base pair in common.  
One gene or transcriptional unit (TU) can have associated more than one tag cluster bacause it may 
have many different alternative promoters (Okazaki et al. 2002; Carninci et al. 2005). 
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Therefore, the information associated to one CAGE tag cluster is different from the use of a virtual 
tag per transcript in the annotation of SAGE tags. 
In the case of nonclassifiable 5’-end tags, these can be confirmed by RACE experiments to ensure 
that they identify true TSS and to relate them to informations about transcripts, as it has been 
observed in a more systematic way for many of them (Kodzius R. unpublished observations). 
The cross-validation by independent experimental means is particularly needed in the case of low-
frequency tags derived from low-expressed transcripts. Some interesting considerations have been 
made comparing the results of two studies, which applied two different technologies, genomic tiling 
arrays and CAGE, to analyze the same type of human cell line (HepG2 liver cells).  
In an initial tiling-tag comparison performed by sequencing 997,000 CAGE tags from total RNA of 
HepG2 cell line, only 20% of the tiling array transfrags had hits corresponding to CAGE tags. This 
was indeed expected, since CAGE tags are mostly concentrated around 5’ends of mRNAs, while 
the tiling transfrags are positive also in internal exons (Kapranov et al. 2002; Carninci et al. 2005). 
Futhermore, there was a dramatic decrease in the percentage of common hits when “novel 
transfrags” mapping 1kbp away from the current RefSeq annotations were examined, with only 2-
3% of the CAGE tags matching the same positions. If the transfrags matching RefSeq are clustered 
together, more than 66% of these groups have overlapping CAGE tags within a 100bp distance, and 
even more 75% of the RefSeq clustered transfrags have CAGE hits within 1kbp distance. The 
dramatic difference in the overlapping between RefSeq-matched and novel transfrags suggest that 
novel transfrags detect rare RNAs that are expressed at less than one copy per milion, which could 
be more difficult to detect by CAGE with the current depth of sequencing (around 1milion tags). 
Alternatively, the novel transfrags may represent false positives in tiling arrays, or false negative 
hits, or some transcripts lack the cap structure (Carninci 2006). Furthermore, another possibility is 
that potential hits were discarded since they did not map to a unique genomic site (multimapped 
CAGE tags).  When the partially overlapping CAGE tags were clustered together and compared to 
high-resolution 5bp-spaced tiling array transfrags  from another study (Cheng et al. 2005) a 
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remarkable correspondence was found: 74% and 92% of the HepG2 CAGE tags map within 100bp 
and 1,000 bp distance respectively. This indicates that CAGE tag clusters reliably indicate the 
starting sites of mRNA identified by the transfrags and help to refine the 5’end structure of these 
transcripts. Out of 997,000 HepG2 CAGE tags, 97,353 represent distinct TSS, and are associated to 
24,423 distinct transcriptional units, with an average of 3,98 tag clusters per TU. Among these 
CTSSs, 65,501 map within 1kbp upstream of a known mRNA or 5’EST, of which 41,974 are 
represented by only one tag, 7,444 have associated two tags whereas 16,083 have three or more 
hits. 
Hence, most the tag clusters are represented by only one tag, suggesting that most of the 
transcriptional events in the cell are rare. This is confirmed by other studies, according to which in a 
HeLa cell, on average, there are about 3.5x106 copies of 28S 18S rRNA and together make up to 
75% of cellular RNA, in the cytoplasm tRNAs and mRNAs comprise 10% and 2.5% of cellular 
RNA, with about 3x107 and 0.4x106 molecules respectively. Of these 400,000 mRNA molecules, a 
small number have many thousands copies per cell, while the vast majority have less than 10 copies 
(Bishop et al. 1974; Holland, Mayrand and Pederson 1980). Similar estimations have been shown 
for hepatocytes (Coupar, Davies and Chesterton 1978). 
One of main advantage of CAGE is that the tags extracted by this technique are directly related to 
regulatory regions and therefore provide useful informations about the mechanisms behind the 
regulation of transcription in different cell context. 
CAGE 5’end-tags together with 5’SAGE tags could then be used to build relationships between 
transcription levels, regulatory elements and trascription factors, and could potentially be related to 
other features of the transcriptomes, making feasible their application to gene network analysis and 
studies in systems biology (Ideker, Galitski and Hood 2001; Hieronymus and Silver 2004) where 
integration between experimental data and computer-aided theories requires that a significant 
amount of data are produced in an high-throughput way. 
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This latter point has still to be improved in the case of CAGE, because despite the great number of 
CAGE libraries have been analyzed (more than 400 mouse libraries with 7.1 milion CAGE tags and 
236,000 TSSs and 40 human libraries with 5.1 milion CAGE tags and 180,000 TSSs), the classical 
CAGE protocol for tag production is still not easily applicable to an high-throughput scale. 
 
Technologies to unveil transcriptome complexity: GIS, GSC, STAGE, DACS 
and other methods 
 
The present sequencing-based approaches in gene-discovery are mainly limited by the end 
sequencing costs of randomly isolated clones. The discovery rate of different projects indicate that 
these approaches have not yet reached a plateau in their possible outcome (Carninci et al. 2003; 
Sheetz et al. 2004). Therefore, they remain still valid for driving the discovery and annotation of 
new transcriptional units and regulatory elements, as recently pointed out by deep sequencing of 
SAGE libraries (Pleasance, Marra and Jones 2003). 
Recently, some more specialized methods have been developed. Among them, the gene 
identification signature (GIS) technique, where tags are sequenced from both ends of a cDNA (Ng 
et al. 2005).  
5`end and 3`end tags derived from the same cDNA are combined into paired end-ditags (PETs) and 
cloned into concatamers for sequencing. 
In GIS, a modified oligodT bearing the sequence for a methylation sensitive restriction enzyme 
(GsuI) is used for directional priming in the cDNA synthesis step. The cap-trapper method is 
employed to selectively recover only the full-length cDNA molecules and the digestion by GsuI is 
used to remove the terminal polyadenylated tract in the 3`ends, making them available for the 
ligation of an adaptor. Linker I and linker II contain the recognition site for a classIIs restriction 
endonuclease (tipically MmeI) and are ligated to the 5` and 3`endsof cDNAs. Ditags are generated 
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by the digestion with the classIIs enzyme and ligated to form concatamers for sequencing (Ng et al 
2005). 
The GIS approach overcomes the limitations deriving from the analysis of tags produced by two 
separate 5`end and 3`end tag libraries, improving the success rate in mapping the tags to the same 
transcriptional unit. In that sense, GIS could be seen as a better method for gene discovery and 
genome annotation, and could integrate 3`end SAGE-derived tags with 5`end tags obtained by 
CAGE or 5`SAGE. 
However, a series of disadvantages prevent GIS to be applied to a very wide scale: (1) GIS libraries 
require special vectors for the library construction because commonly used standard vectors contain 
many MmeI sites in their sequence, (2) mapping rates for the half site (18bp) of a ditag is lower 
than for 20bp CAGE or 5`SAGE tags, (3) the identification of trans-splicing events may be difficult 
since both half sites of ditags have to map on the same chromosome (4) the larger length of the 
ditags has an impact on the quality and the cost of the sequences, (5) by introducing a bias against 
long fragments altering the representation of different transcripts. Last but not least (6) GIS cannot 
be applied to the analysis of poly(A)- RNA since using oligodT is mandatory for full-length cDNA 
synthesis from which both 5`ends  and 3`ends have to be recovered.  
An alternative to the GIS method is represented by cloning the full-length cDNA into special 
vectors having classIIs recognition sites adjacent to the cloning sites, to avoid the need for special 
adaptors in the library preparation. 
Other more specialized tag-based methods have been developed to analyze particular aspects of the 
transcriptomes and to interrogate and identify certain regions in the genome. 
A method called digital karyotyping is based on sequencing tags derived from specific genomic loci 
defined by digestion with a “mapping enzyme”. It aims to characterize large chromosomal changes 
associated to specific genomic regions of interest. It may be used to study naturally occurring copy 
number variations, which may have important functional roles associated to diseases. 
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Another approach is represented by DACS (digital analysis of chromatin structure), a quantitative 
method for a high-throughput mapping of DNAse I hypersensitive sites associated with cis-
regulatory elements (Sabo et al 2004). 
Another interesting method to characterize in vivo regulatory elements is STAGE, sequence tag 
analysis of genomic enrichment, which identifies direct binding sites for transcription factors on a 
genome wide scale (Kim et al. 2005, Bhinge et al. 2007). 
 
Technologies to unveil transcriptome complexity: High-throughput 
sequencing technologies 
 
DNA sequencing had a great impact on biomedical research and markedly influenced the 
development of genomic science. Large scale sequencing projects, including whole-genome 
sequencing, have usually required the cloning of DNA fragments into bacterial vectors, 
amplification and purification of individual templates, followed by Sanger sequencing (Sanger 
Nicklen and Coulson 1977) using fluorescent chain-terminating nucleotide analogues and either 
slab gel or capillary electrophoresis (Prober et al. 1987). 
Current estimates evaluated the cost of the human genome in the 10 and 25 milion USD range 
(http://wwwgenome.gov/12513210).  Alternative sequencing methods have been described (Bains 
and Smith 1988; Jett et al. 1989; Jacobson et al. 1991). However, no other technology has overcame 
the need for cloning in bacterial vectors while Sanger sequencing remained the most widely used 
method for generating DNA sequence data. 
More recently, a great effort has been made to find alternative and more cost-effective strategies for 
DNA sequencing, which will have a significant scientific, economic and cultural impact. 
In particular, the so called pyrosequencing has started some time ago to emerge as a good 
altermative method for sequencing short DNA fragments. This technique enables sequencing of 
millions of bases, by integrating an emulsion-based method for isolating and amplifying DNA 
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fragments in vitro, and an instrument which performs pyrophosphate-based sequencing in picoliter-
sized wells (Margulies et al. 2005). 
Pyrosequencing is a method of DNA sequencing based on the "sequencing by synthesis" principle 
developed by Mostafa Ronaghi and Pål Nyrén (Ronaghi et al. 1996; Ronaghi, Uhlen and Nyrén 
1998; Nordström T et al. 2000; Nyrén 2007). Pyrosequencing AB was started to commercialize the 
machine and reagents for sequencing of short stretches of DNA. Then, it was renamed to Biotage 
and licensed to 454 Life Sciences. 454 developed an array-based pyrosequencing which has 
emerged as a rapid platform for large-scale DNA sequencing. Latest platform of pyrosequencing 
(GS FLX from 454 Life Sciences which is owned by Roche) can generate 100 million nucleotide 
data in a 7 hours run with a single machine. It is anticipated that the throughput may increase by 5-
10 fold with the next release. Since each run may cost about 8 to 9 thousand USD, de novo 
sequencing of mammalian genomes are in million dollar range. Therefore, pyrosequencing opens 
the way to many applications to be achieved in a shorter time and at a fraction of the cost of the 
Sanger sequencing. 
More recently, other platforms for high-throughput sequencing became available: Solexa 
sequencing by synthesis (Illumina, Inc., San Diego, CA, USA), SOLiD sequencing by 
oligonucleotide ligation and detection with 2-base encoding (Applied Biosystems, Foster City, CA, 
USA), and true single molecule sequencing by Helicos (Helicos BioSciences Corp., Cambridge, 
MA, USA).  
Each of these platforms have their own advantages but all of them skip the concatenation step 
needed by the 454 system. In this way the number of bp that can be read in 1 day by high-
throughput sequencers is orders of magnitude larger than conventional sequencers based on Sanger 
sequencing (see Table 1).  
These features makes them particularly suitable for short sequence reads of the kind generated by 
CAGE, SAGE and other tagging technologies, in contrast to genome sequencing, for which longer 
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sequence reads are preferred. Hence, transcriptome sequencing and SNP genotyping projects can be 
primary applications of high-throughput sequencers. 
 
 
                                                                                                                      taken from De Hoon and Hayashizaki 2008 
The increased throughput of sequencers enables CAGE sequencing at a much deeper scale than 
previously possible. This implies that it is becoming increasingly possible to detect RNA molecules 
present at very low-copy numbers in the cell. This could be critical in time-course experiments, for 
instance, where transcripts coding for regulatory molecules may be present only transiently and at 
low concentrations. 
But how many tags would be enough to sequence in order to have the maximum depth of coverage 
of all the transcripts present in a given cell at a given time? 
Approximately, the probability to detect an RNA molecule that is present in k copies per cell is 
equal to 1 – exp(-nk/m), where n is the number of CAGE tags extracted and m is the total number of 
RNA molecules in the cell. A 454 sequencer (454 Life Sciences, Branford, CT, USA) generating 
400,000 reads per run of a length of about 250 bases can produce ∼1,000,000 mappable CAGE tags 
in one run. Assuming a total mRNA concentration of 200,000 molecules per cell, the probability to 
detect an RNA molecule present in one copy per cell is 99.33%. The Solexa sequencer can generate 
about 5× more CAGE tags per run, making it possible the detection of an RNA molecule present in 
one copy per five cells (De Hoon and Hayashizaki 2008).  
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Recently, Zhu and colleagues found that sequencing tens of thousands of tags in an ordinary 
EST/SAGE experiment was far from sufficient to cover all the transcriptome of single cell types.  
 
Technologies to unveil transcriptome complexity: PCR-based and 
Transcription-based methods for RNA amplification 
 
Over the past few years a growing need to bring the gene expression analysis to a scale of few cells 
has contributed to develop a variety of different approaches to amplify the RNA from amount 
equivalent to single or few cells. It has been estimated that a single eukaryotic cell contains 
approximately 0.1pg of mRNA and 10pg of total RNA. This amount would need to be amplified 
106 – 108 fold to generate enough DNA/RNA targets for hybridization on two-channel microarrays. 
In order to solve this problem and overcome the technical inherent limitations of the current array 
technology, a series of different strategies have been explored, which can be basically divided into 
two broad categories: signal amplification and sample amplification. 
In the first strategy the main goal is to improve and optimize the labelling reaction increasing the 
number of signal molecules per transcript; this can be achieved using technologies such as 
dendrimer (Stears, Getts and Gullans 2000), or tyramide signal amplification (TSA) (Karsten et al 
2002). The dendrimer application uses two-step hybridization, in which the cDNA is synthesized 
with an olidodT primer containing a capture sequence and then hybridized to the microarray slide. 
In a subsequent step, dendrimers each containing multiple fluorescent molecules, are hybridized to 
the capture sequence. Genisphere claims that 0.25-1 µg of total RNA (2.5x104 – 105 cells) can be 
used as starting material for having a good quality array preparation using dendrimer technology. 
For the other strategy, focused on sample amplification, two different approaches have been used: 
methods which make use of exponential polymerase chain reaction (PCR) and methods which 
employ linear isothermal amplification by in vitro transcription (IVT) of the cDNA into labeled 
complementary RNA (cRNA) (reviewed in Nygaard and Hovig 2006). 
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All of them present both advantages and drawbacks, but all of them have some intrinsic bias, which 
are also function of the starting amount of RNA (Zhao et al 2002), of whether antisense or sense 
RNA is produced (Goff et al 2004) and of the number of rounds of amplification performed. In 
addition, time-dependent RNA degradation during IVT can introduce some noise into the resulting 
microarray data (Spiess, Mueller and Ivell 2003). 
The methods which make use of linear isothermal amplification by in vitro transcription (IVT) have 
been originally developed by Van Gelder et al. in 1990, commonly known as Eberwine method. 
This method consists of a general RT step using an oligodT primer, bearing a T7 RNA polymerase 
promoter sequence, which is used to in vitro transcribe the cDNA into antisense RNA (aRNA) after 
conversion of the mRNA/cDNA hybrid into ds-cDNA (Van Gelder et al 1990). This T7 IVT-based 
method has been used in several studies, scaling down the RNA amount to single cell level 
(Eberwine et al 1992, Phillips and Eberwine 1996, Crino et al 1998, Chow et al 1998). aRNA has 
been radioactively labeled and hybridized to either known genes on dot blots or to cDNA libraries 
from specific tissues (Crino et al. 1996 among others).  
Many later studies have been showing the technical limitations of the Eberwine method and have 
modified the procedure in order to optimize and improve the reprobucibility and to reduce some 
primer-dependent artifacts produced during in vitro tramscription in absence of a legitimate 
template. In particular two pioneer studies were the first to quantitatively evaluate the differences in 
gene expression profiles between amplified and unamplified samples, using cDNA or 
oligonucleotide arrays (Wang et al. 2000; Baugh et al. 2001). 
Baugh and collaborators have maintained almost the same protocol used by Eberwine but they 
noticed that lowering the volume of RT reaction and the amount of RT primer could avoid the 
accumulation of primer-dependent artifacts in the subsequent IVT step. Furthermore they have 
shown that using single stranded binding proteins like T4gp32 could improve the processivity of the 
RT reaction in vitro as previously reported for other retro-viral capsid proteins (Ji, Klarmann and 
Preston 1996). 
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On the other hand, Wang and colleagues have used a template switching effect at the 5’end to 
ensure a full-length cDNA synthesis and solve, at least in part, the problem of the 3’bias in the 
original Eberwine method. The template switching effect is based on the addition of non template 
residues, primarily cytosines, to the 3’ end of the cDNA, in correspondence of the cap structure, by 
the reverse transcriptase, with a mechanism not completely understood. The use of an 
oligonucleotide containing a 3’end polyG tract in the RT reaction mixture, which pairs with the 
newly synthesized dCTP stretch, allowes the reverse transcriptase to switch template and extend the 
annealed oligonucleotide, producing full-length cDNAs (Wang et al. 2000). A subsequent IVT step 
has been used to synthesize aRNA, which has been then labeled and hybridized to cDNA 
microarrays (Onco-chip containig 2,008 human genes). Both studies (Wang et al. 2000; Baugh et al. 
2001) concluded that the concordance between amplified and unamplified samples was high (R2 
0.99-0.96) although some discrepancies emerged, increasing as the amount of starting total RNA 
decreased. 
In particular Wang et al. found that a labeling bias affected low transcript levels in which the 
background of the fluorescence in one channel was higher than the signal, but not in the other 
channel, resulting in an increased false positive rate when the amplification started from amount of 
total RNA comprised in a range of 0.125-0.001 µg, and that this bias is in part recovered if a second 
round of amplification is introduced ensuring 3 µg, usually considered as lowest limit for the target 
for array hybridizations. A series of other studies followed these pioneer works introducing some 
modifications to improve the fidelity, sensitivity or reproducibility of the T7 IVT-based method 
(Zhao et al. 2002; Moll, Duschl and Richter 2004; Naderi et al. 2004; Xiang et al. 2003). 
As alternative to the T7-based linear amplification methods, PCR-based exponential amplification 
strategies were introduced. These methods share the use of a global PCR step which is made 
possible by introducing PCR-priming sites at both ends of each reverse transcribed cDNA molecule 
(Hertzberg et al. 2001; Iscove et al. 2002; Li et al. 2003). 
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Li and collaborators applied the SMARTR technology, based on the same template switching effect 
previously described, to introduce the PCR-priming site at the 5’end and to ensure full-length 
cDNA at the same time. In another approach the template switching-generated ds cDNA was used 
to amplify selectively only one of the two strands then used in multiple rounds of reverse and in 
vitro transcription (Stirewalt et al. 2004). 
The PCR-based methods present several advantages over linear amplification strategies, as they 
usually yield better amplification rates (1-3x1011) starting from equivalent amounts of total RNA as 
template, are less labor intensive and consequently also more cost effective, and the ds-cDNA 
products generated are suitable for hybridization to array probes of either orientation, and are also 
more stable than the aRNA products (Wang 2005; Nygaard and Hovig 2006). 
At the same time, PCR-based methods have also a number of inherent limitations: first of all the 
relevant properties of the DNA polymerases used in the reaction such as misincorporation of bases, 
bias toward shorter transcripts and differential amplification efficiencies of templates which have 
different GC composition are important factors which can affect the final output of the protocol. 
The two latter properties result in non linear amplification, which could lead to a misrepresentation 
of the quantitative transcript values in a sample after performing multiple PCR cycles.  Use of the 
DNA polymerases could achieve a more linear representation of the transcript levels when using 
single primer amplification (SPA) as in the method described by Smith et al. 2003. In this case the 
primer extension actvity of the DNA polymerase, similar to a cycle sequencing reaction, has been 
employed instead of the double primer exponential polymerase chain reaction. A modified oligodT 
bearing a heel sequence (derived from the T7 promoter) was used for priming the reverse 
transcription and the ds-cDNA product was denatured and annealed to a single primer 
complementary to the heel sequence, and then extended in multiple cycles by the Taq DNA 
polymerase (Smith et al. 2003). 
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The Pearson correlation coefficients for two self-self hybridizations derived from two independent 
SPA amplifications of both kidney and liver cDNA were 0.985 and 0.986 respectively, 
demonstrating a semi-linearity with values comparable to those of  T7-based methods. 
A subsequent improvement of this strategy led to a linear isothermal amplification of cDNA using a 
single primer (Dafforn et al. 2004). 
Another issue is the strand-specific amplification: this has no implication when cDNA microarrays 
are employed but becomes important when oligonucleotide chips are used, since hybridization to 
oligonucleotide arrays requires the antisense strand of the nucleic acids. 
Unlike the PCR-based strategies which generate ds-cDNA, the in vitro transcription-based methods 
can produce either sense or antisense RNA, depending from the protocol used. 
The strategy adopted by Affymetrix involves the synthesis of biotin-labeled complementary RNA 
(cRNA) which can be directly used for hybridization. 
However, the use of cRNA  for target preparation presents some potential disadvantages, like the 
limited stability of the target and the lower specificity of RNA-DNA interactions compared to 
DNA-DNA, due to the increased stability of binding energy for the mixed hybrids, which are thus 
less sensitive to mismatches. 
In the case in which a template switching mechanism is applied with a primer matching the 3’end of 
the first strand to generate the ds-cDNA, the subsequent in vitro transcription sense RNA can be 
retrotranscribed into labeled antisense cDNA target suitable for oligo-array hybridization. 
Alternatively, the antisense RNA, normally generated by IVT-based protocols, can be 
retrotranscribed by 9-mer random primers bearing a T3 RNA polymerase promoter, which result in 
a sense-stranded RNA (Kaposi-Novak et al. 2004; Che and Ginsberg 2004). 
Irrespective of whether a linear or exponential method is employed, the applicability of a sample 
amplification strategy is evaluated by estimating a series of common aspects which can be 
summarized as amplification efficiency, reproducibility, 3’ bias and product length and fidelity in 
maintaining the relative transcripts abundance. 
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The amplification efficiency is defined as the ratio between the final aRNA product and the initial 
mRNA imput or the cDNA yield and the initial mRNA imput in the case of PCR-based methods. In 
general the total RNA content is measured and the mRNA is assumed to be a fraction variable from 
1 to 3%, depending on the type and the metabolic activity of the cells. 
Besides technical issues related to the particular amplification protocol of choice, the amplification 
fold factor is affected by RNA measurements and theoretically estimated mRNA content. 
For linear IVT-based protocols, a 103-105 fold amplification factor has been reported after two 
rounds of in vitro transcription (Baugh et al. 2001), whether for PCR-based amplification an 
average of 1011 fold factor is normally achieved (Iscove et al. 2002). 
Whereas for methods which use a mixed strategy conjugating both linear and exponential steps, a 
106-107 fold amplification factor has been reported, which lies between that of two rounds of linear 
amplification and exponential amplification. 
Most of the amplification methods, described till now, make use of an oligodT primer for the first 
round of cDNA synthesis and a random primer is usually used for the second round of 
amplification, leading to shortened products. The transcript lengths are dependent on the 
processivity of the reverse transcriptases and polymerases used and on the reaction conditions. 
After two rounds of amplification, product lengths, as assessed by gel electrophoresis or Agilent 
Bioanalyzer, are tipically in the range of 200-1000 bp with the peak at 400-500 bp, with a slight 
variation depending from the particular technique applied. In most of the cases, the amplified 
targets present a 3’end bias due to the shortening effect concomitant with the 1st to 2nd round 
transition. As observed by Baugh et al. the signal obtained from oligo probes which are 5’bias is 
markedly reduced due to the 3’ target bias and the lack of full-length products. However, this 3’bias 
has only a minimal effect on the oligoarray and cDNA microarray analysis of gene expression 
levels, considering that generally most of the probesets also exhibit a similar 3’bias. 
Regarding the reproducibility, many studies have shown that most of the amplification methods 
ensure on average highly reproducible results. Parallel but independent amplifications yield highly 
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correlated expression profiles (Wang et al. 2000; Baugh et al. 2001), even if diluting the imput 
RNA down to tens of nanograms (r 0.94). However, parallel studies have tried to assess whether 
serial dilutions of the starting RNA could affect the reproducibility rate, and actually the variabilty 
in the results increase as the quantity of RNA amplified was reduced (Kenzelmann et al. 2004). 
A comparison of the linear versus exponential amplifications, also revealed that the results 
produced from these two strategies are slightly different, although some of these comparisons have 
shown discordant results: in one study linear amplifications have been shown to be slightly more 
reproducible than exponential methods (Puskas et al 2002), while a second study found an opposite 
trend (Klur et al. 2004).  
Another important aspect that has to be considered is the assessment of the fidelity of the method of 
choice: this can be defined as the extent at which the abundance of the different transcripts is 
faithfully preserved.  It’s evident that fidelity is a prerequisite that has to be satisfied to apply the 
amplification technique in combination with microarray for accurately and quantitatively profile 
gene expression levels. Calculation of Pearson correlation coefficients has been widely used as a 
common statistical approach when comparing different expression profiles.   
Evaluation of consinstency of the outliers between non amplified and amplified samples has also 
been frequently used as parameter to assess the fidelity of the ampification procedure. In particular 
Wang et al. based all their analysis only on the mantenance of differentially expressed genes 
between two different RNA sources, revealing that when 0.25-3 µg of total RNA were used for 
IVT-based amplification, 85-92% of the outliers from the control unamplified sample were also 
found to be differentially expressed above the threshold (ratio greater than 2-fold) in the amplified 
dataset. Another approach has been used to show all the genes in common between non amplified 
and amplified samples, and although the absolute intensity levels were different, the relative 
abundance were preserved, with a relatively high correlation factor (r 0.84) (Scheidl et al. 2002). 
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However, for those genes whose signal intensity approach the background level on the array, the 
correlation coefficients dropped down. In that case most of these discordant ouliers could be 
recovered as another round of amplification has been performed as observed from Wang et al. 2000. 
Even more informative statistical analyses were conducted focusing on the components of a 
variance model (Zhao et al. 2002). In this study the authors have examined the variance of true 
expression and measurement errors for both array signals amplified with different methods and 
unamplified array signals and have found that a decreased variance in gene expression occurs after 
amplification, suggesting a dampening effect of the amplification itself on the true gene expression 
values. A compression effect, at least in the case of SMART-based amplification methods, as 
consequence of the bias introduced by PCR, have been also documented by other independent 
studies (Iscove et al. 2002; Petalidis et al. 2003). In particular Petalidis et al. observed that log ratio 
values of the genes identified as being differentially expressed between samples decreased with 
increasing numbers of PCR cycle amplification. This seems to suggest that PCR-based methods 
tend to dampen the relative ratio of the more highly differentially expressed transcripts, as well as 
raise up the level of the low expressed transcrips. Since they exhibit a level of expression close to 
the background in the non amplified (direct labeled) sample, their relative ratio after amplification 
is increased making appearing them as a group of differentially expressed genes while they are not. 
This is likely to be a consequence of the non-linearity of the PCR amplification process. The 
increase of the number of PCR cycles will raise the level of low represented transcripts, bringing 
the most highly expressed genes to reach a plateu, thus flattening the expression ratios for most of 
them. This incovenient could be presumably overcome assessing the most appropriate number of 
cycles to be used in order to preserve the relative expression levels of the largest part of the genes 
and maximize the fidelity of the procedure. 
Petalidis and colleagues have been used a simple template-switching PCR protocol for the 
amplification. By comparing the amplified samples to directly labelled, non amplified samples, they 
have found that 19 cycles of PCR exhibited the best performance in terms of fidelity and accuracy, 
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having the maximum true outlier identification rate at the expenses of a slight decrease in the total 
number of genes above the background. Surprisingly, even a modest increase in the number of 
cycles above 19 have been shown to severly affect the number of true outliers. 
The reported results from these analyses have been restricted to outliers or genes with a fold change 
of more than 2. However recently the 2-fold change criterion as a measure of significance has been 
replaced by the application of t-tests for sub-sets of genes, and, in addition, genes co-regulated in 
pathways or signatures rather than single differentially expressed genes have been extensively used. 
A comparison of t-scores or distribution of fold change for individual genes have been applied 
(Gold et al. 2004; Li et al. 2005; Nygaard et al. 2005), usually restricted to a small subset of genes, 
like the top ten ranked outliers.    
A general conclusion comes out comparing all of the more recent studies: the number of 
differentially expressed genes increases when amplifying from decreasing amounts of imput RNA. 
In a recent study (Nygaard et al. 2005) it has been found that only moderate/highly expressed genes 
were quantitatively reliable in experiments starting from less than 1000 cells, whereas low 
expressed genes were subjected to stochastic fluctuations, which limited the precision of gene 
expression measurements. 
 
CAGE data and the analysis of mammalian promoters 
 
 
CAGE data and the analysis of mammalian promoters: The classical concept 
of “core promoter” 
 
Many aspects of the cellular activities in eukayotes like homeostasis, growth, differentiation and 
development rely on the regulated production of specific mRNAs by RNA polymerase II 
(RNApolII). The mechanisms that underlie this regulation have been the subject of intense genetic, 
biochemical and computational studies (Smale and Kadonaga 2003; Gross and Oelgeschlager 
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2006).  The transcription start site (TSS) of a gene is defined as the first nucleotide which is copied 
at the 5’end of the corresponding mRNA.  
The region around a TSS is often referred to as the “core promoter”, which is required for 
recruitment of the transcription apparatus and can be thought of as the priming stage site for 
transcription initiation. Due to the strong link between TSSs and core promoters, the terms are often 
used interchangeably. In the case of many genes this can leads to a misunderstanding, since most of 
the genes can have more than one TSS and transcription starts from slighlty different positions. In 
these cases, the core promoter is defined like the region that spans all the different TSSs. 
The classical textbook model of an RNA polII core promoter is represented by an AT-rich motif 
(TATA-box) approximately located 30bp upstream of an Initiator (Inr) element which contains the 
TSS. Two different models for the assembly of the pre-initiation complex (PIC) have been 
described for TATA-box bearing core promoters: in both models the binding of the basal 
transcription factor TFIID to the TATA-box and the Inr sequences (-35 to -19bp from TSS) which 
causes a bending of 90° of the DNA, is the first event required for the formation of a stable basal 
transcription machinery (Burley and Roeder 1996). The TFIID binding is facilitated by TFIIA 
which seems to prevent the inhibitory effects of other factors such as Dr1 and Dr2 (Drapkin et al 
1993).  Then in the case of the so-called stepwise assembly model, the progressive association of 
other basal factors TFIIB-H and of RNApolII leads to the formation of a competent RNA 
polymerase II holoenzyme, which with other factors as the Mediator Complex, co-activators and 
co-repressors coordinates both basal and regulated transcription initiation (Lewis and Reinberg 
2003; Black et al. 2006; Thomas and Chiang 2006). 
Coordination of chromatin modification, mainly through the control of post-translational 
modification of histones, also plays an important role in transcription initiation (Black et al. 2006). 
Furthermore,,the recruitment of all of these co-activators and co-repressors of transcription 
initiation is controlled by transcription factor binding to cis-acting DNA sequences that can lie 
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within the core promoter or in more remote locations (enhancers and repressors) (Wasserman and 
Sandelin 2004). 
Apart from the TATA-box, subsets of promoters contain the Inr element, CpG islands and other 
sequence patterns, but their prevalence and role in the initiation of transcription are not as well 
characterized.  
In summary, several common DNA elements have been characterized in core promoters, and are 
linked to the expression of the downstream genes. Different elements can co-occur in the same 
promoter, although certain combinations are more likely than others. 
The TATA box is located 28-34 bp upstream of the TSS. It has the consensus TATAA. This 
sequence is bound by the TATA-box binding protein (TBP) which recruits the other components of 
the pre-initiation complex (PIC).  
From the inspection of large CAGE datasets became evident that TATA-box are mainly associated 
to strong-tissue-specific promoters and often co-occur with Initiator-like motifs. 
The Initiator element is defined by the consensus YYANWYY where A represents the +1 position 
from the main TSS. This DNA element can function independently from the TATA-box although 
these two elements often act sinergistically in the same promoters. The Initiator element alone is 
able to recruit the PIC complex (Smale and Kadonaga 2003). 
A class of TATA-less promoters in Drosophila melanogaster was found to share a common motif 
28-32 bp downstream of the TSS, called downstream promoter element (DPE), (Ohler etal 2002, 
Kadonaga JT 2002).  It has the consensus RGWYV and generally is found together with Initiator 
elements and functions similarly to the TATA-box, recruiting the PIC complex to a close TSS. 
Another common element is the TFIIB recognition element (BRE) which has the consensus 
SSRCGCC and is located upstream of the TATA-box in some TATA-dependent promoters. It may 
contribute to modulate the strenght of the promoter tuning the rate of transcription in an unknown 
way (Lagrange etal 1998). 
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Another DNA sequence pattern often associated to eucaryotic promoters is represented by CpG 
islands. These are genomic stretches where CG dinucleotides are overrepresented. Based on the 
most recent statistical definitions, 72% of human promoters seem to be associated to a CpG island 
(Saxonov etal 2006). CpG islands are most often associated to housekeeping or ubiquitously 
expressed genes, but there are also many exceptions like for instance brain-specific genes 
(Gustincich etal 2006).  
 
CAGE data and the analysis of mammalian promoters: classification of 
promoters classes 
 
The CAGE technique has disclosed several unexpected features of the core promoters associated to 
specific classes of TSSs paving the way for a more reliable description of the transcriptional 
regulation mechanisms. The most extensive core promoter identification study undertaken so far 
used CAGE tags to identify 184,379 human and 177,349 mouse core promoters, many of them 
being associated to at least one tag cluster (Carninci etal 2006). This genome-wide analysis 
indicated that most human and mouse promoters lack the distinct TSS commonly assumed to be 
located at one precise genomic position along the different TUs. Instead, the typical promoter 
architecture consist of an array of closely located TSSs spreading in an interval of 50-100 bp. These 
observations give the opportunity to employ a new system for promoter classification. 
Breafly two main categories can be distinguished, the “sharp” core promoters with single TSS 
clusters and the “broad” core promoters identified by broad TSS regions. Among these two 
categories there are some hybrid cases.  
In a more detailed study (Carninci etal 2006), 8,185 mouse and 5,928 human tag clusters supported 
by at least 100 CAGE tags were used to classify TSS distributions into four “shape” categories. The 
single dominant peak class (SP) where the majority of tags are concentrated around a single 
dominant TSS position, and other three broad cluster distributions: a general broad distribution 
(BR), a broad distribution with a dominant peak (PB) and a bi- or multimodal distribution (MU) in 
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which several main TSS can be distinguished. 
These four classes identify different promoter context. Using position-specific weight metrices, 
TATA-boxes seem to be overrepresented in promoters with sharp TSS, whereas CpG islands are 
associated to broad TSS regions. In 90% of the cases TATA-independent transcription initiation 
occurs in CpG islands, and this data was quite unexpected based on the previous studies when 
researchers mainly focused on studying highly expressed and tissue-specific genes, which usually 
contain a TATA-box in their core promoter. 
CCAAT-box and GC-box that are not associated to CpG islands are preferentially associated with 
Single Peak –type TSS. 
Another important feature emerged from the statistical analysis of the CAGE data was the 
estimation of the frequency of the initiator element and its consensus. 
58,6% of the CAGE tags have a pyrimidine-purine dinucleotide at position -1/+1. This pyrimidine-
purine dinucleotide corresponds in part to the Inr element or Cap motif which was determined by 
mutagenesis studies (Smale and Kadonaga 2003). Sequence logos for promoters aligned to TSS 
clusters have been constructed counting each tag and its flanking region as one sequence divided by 
promoter shape classes. This analysis unveiled that the most preferred initiators are CG, CA and TG 
more often associated to highly used TSS, whereas GG initiators are preferentially associated to low 
expressed transcripts (Carninci etal 2006). 
Substitutions of the pyrimidine-purine dinucleotides correlate with large differences in TSS usage. 
Transversion-type of substitutions negatively affect the rate of initiation whereas mutations from 
other sequences to pyrimidine-purine dinucleotides create new TSSs. Comparison of the mouse and 
human broad promoters confirm the general evolutionary conservation of TSS position inside the 
clusters.  
More recently, it has become clear that transcription initiation events are clustered on the 
cromosomes at multiple scales, with clusters within clusters, each subjected to multiple regulatory 
processes (Frith etal 2008). The smallest of these clusters is represented by core promoters and the 
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local sequence around TSS can predict the relative transcription start usage of each nucleotide 
position with a 91%-accuracy, implying the existence of a DNA code that determines TSS 
selection. Conversely the global transcriptional activity of a locus is controlled by distal features 
such as enhancers and chromatin state. Martin Frith et al. used a HepG2 CAGE dataset and applyed 
a Markov Model strategy to calculate the frequency of all k-mers combinations in a -50/+50 bp 
interval around each main TSS in the genome and predict the TSS usage rate directly from the local 
DNA sequence. 
This analysis revealed that there are three main motifs overrepresented in the -50/+50 interval: the 
most conserved and overrepresented is the TSS itself, which confirmed the main role of the 
pyrimidine-purine dinucleotide in determining the position for initiation events. But taking into 
account only this information (-1/+1 dinucleotide), the rate of success in TSS position prediction is 
78%. Therefore, other local sequence informations are necessary to correctly guide the transcription 
initiation events. The second most overrepresented k-mer is the TATA-box, although it is not 
present in the majority of the core promoters. The third overrepresented motif is a GCG 
trinucleotide repeat region, located downstream of the TSS. Actually, an Sp1-like binding motif is 
often found in the -50/-30 region which is thought to play a role similar to TATA-box in recruiting 
the PIC complex in TATA-less promoters (Butler  and Kadonaga 2002). 
This GCG repeat is often found to have an “echo” GCG repeat 10nt downstream of the TSS, which 
is located in the same phasing relative to the TSS, since 10nt is one turn of the double helix. The 
Inr, Sp1, gcg and gcg echo motif tend to co-occur with each other more often than expected by 
chance (Frith et al 2008).  
 
CAGE data and the analysis of mammalian promoters: transcription starts 
from unconventional sites (Exons, introns and 3`UTR) 
 
Not all CAGE tags map to previously identified 5`ends of full-length cDNAs. Typically, some of 
the main CAGE tag clusters mapped to 5`end but some CAGE tags were also associated to the 
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3`UTR region. The CAGE tags that map to genomic regions between these two main peaks map 
mostly to exons. In the case of relatively highly expressed genes, the internal exonic tags are 
supported by a considerable number of 5`EST and have been confirmed using RACE, based on the 
oligo-capping method (Suzuki etal 1997). In the comparative study of promoter architecture based 
on 159,075 CAGE tag clusters in mouse, 34,229 TSSs (21,5%) mapped within exons and 
presumably would generate transcripts that truncate or eliminate the predicted protein product 
(Carninci etal 2006).  
The exonic promoter activity varies among genes and it is often conserved across species. 
Exonic promoter activity does not correlate with the number of tags of the major promoters, but in 
general correlates with tissue-specific genes having a single dominant peak of transcription 
initiation (sharp promoters). This is not reciprocally true since there are many single peak sharp 
promoters that do not display any internal exonic associated tags. 
The evolutionary conservation of the internal exonic TSSs suggest that the transcripts produced 
from these sites are functionally important and they do not respresent just experimental artifacts, 
since they are confirmed also by other independent techniques like genome tiling arrays.  
There is a good coverage of known RefSeq transcripts exons with both arrays and tags. Most 
RefSeq exons can be identified by tiling arrays and most TUs (>70%) can be identified by CAGE 
tags, despite largely incomplete overlap in the tissues examined with the two technologies (Carninci 
etal 2005). 
However, CAGE tags detect both longer and shorter versions of annotated transcripts. Some of 
these transcripts partially overlap coding mRNAs (Carninci et al 2005), including the TSSs 
originating from within exons. These RNAs might not encode proteins; however, transcription is 
conserved between mouse and human, suggesting that these seemingly shorter transcripts, or 
transcription itself, can be functional.  
Although these RNAs could only be speculated as being involved in splicing regulation (Bentley etal 
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2005), it is noteworthy that ChIP mainly detects the hypophosphorylated form of RNA Pol II, 
which is associated with elongation and with alternatively spliced exons but not with the introns of 
human genes (Brodsky et al 2005).  
Brodsky et al. analysed the locations of active DNA-bound RNApolII in HeLa cells. Surprisingly, 
they found that RNApolII sites were concentrated preferentially in exons. The density of RNApolII 
sites in exons varied between genes, but did not correlate with mRNA levels. The authors attribute 
these unexpected results to a possible slowdown or pausing of RNApolII elongation within exons 
(Bai et al 2006). Indeed, an earlier study showed that variations in the speed of RNApolII 
elongation will affect the usage of splice sites (Kornblihtt et al 2004). 
Accordingly, the amount of exonic RNApolII sites was greater in alternatively spliced exons 
compared with the invariantly spliced ones (Brodsky et al 2005). These observations suggest that 
truncated internally initiated mRNAs constitute a significant class of noncoding mRNAs; this is 
also consistent with evidence that the initiation complex can bind to sequences within exons but not 
introns (Kim TH et al 2005).   
The possible function of weak initiation sites within internal exons requires further study, but it 
could contribute to the recently described phenomenon of exon-tethering — a physical connection 
between emergent splice sites in pre-mRNA and the RNApolII transcription complex (Dye et al 
2006). ChIP experiments and the complexity of TSSs show that transcription factors not only bind 
to putative promoter regions but also frequently bind to regions within or downstream of annotated 
genes (Cawley etal 2004). 
Another unconventional site in which many genes display promoters is represented by 3`UTR. 
There is a considerable increase in CAGE tags incidence in the 3` UTRs of protein-coding 
transcripts. These TSSs have been independently validated by a 5`RACE based on oligo-capping 
and are also supported by GIS and GSC ditag analysis (Carninci et al 2005, Katayama et al 2005). 
These TSSs also have a distinct sequence motif respect to tags in 5`end. Alignments of the most 
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tag-rich TSSs derived from 3`UTRs revealed a strong overrepresentation of three consecutive 
guanines (consensus RGGG), found at position –3 to–1 in 785 out of 1,327 cases, just before the 
TSSs. Analysis of cross-species conservation between sequenced vertebrate genomes in the region 
surrounding the 3`UTR TSSs revealed a highly conserved region located at positions +40 to +90 
relative to the TSSs (Carninci et al 2006). 
To confirm that these sequences can indeed initiate transcription, a reporter-gene assay has been 
performed with four distinct 3`UTR promoters. In each case, upstream regions of the TSS directed 
reporter-gene expression. 
Transcripts initiated in 3`UTRs might regulate downstream genes using a sense-antisense 
mechanism, as downstream genes on the opposite strand are located much closer than expected 
(Katayama et al 2005). If 3`UTR–derived transcripts function as regulatory noncoding RNAs, their 
transcriptional regulation might be discordant from the full-length transcript. 
In 43% (168/391) of testable representative transcripts, the tag distribution in 5` and 3` terminal 
exons was significantly divergent in at least one tissue, suggesting independent regulation of the 
3`UTR promoter (Carninci et al 2006).  
Notably, the incidence of 3` TSSs is tissue specific: it is prevalent among CAGE libraries derived 
from cerebellum and lung but reduced in libraries derived from embryo. Additional studies will be 
needed to further characterize a possibile mechanism of activity and functions of the 3`UTR 
promoters. 
 
CAGE data and the analysis of mammalian promoters: Widespread 
occurrence of alternative promoters 
 
Mammalian genomes make an extensive use of alternative splicing as a key mechanism to expand 
transcript and protein diversity. In this way different exon combinations are used to generate 
multiple mRNAs from a single gene to encode different protein isoforms with diverse and even 
antagonistic functions (Pajares et al 2007). The mRNA isoforms are usually transcribed by 
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alternative promoters including alternative first exons. Numerous genes displaying complex 
transcriptional regulation, because of the use of alternative promoters, have been identified (Ayoubi 
and Van de ven 1996, Landry 2003). Several genome-wide analyses indicate that >60% of the 
human genes use alternative splicing. Recent evidence suggests that 30–50% of the human and 
about 50% of the mouse genes have multiple alternative promoters that can span up to thousands of 
kilobases (Kimura et al 2006, Sun et al 2006, Baek et al 2007) . A comprehensive analyses of the 
ENCODE (http://genome.ucsc.edu/ENCODE/) regions (The ENCODE Project Consortium 2007), 
which corresponds to 1% of the human genome in 16 diverse human cell lines, using transient 
transfection reporter assays, identified >20% of genes having functional alternative promoters 
(Cooper et al 2006). One specific case is examplified by the erythroid genes of which 35% had 
evidence of alternative first exons and promoters in humans (Tan t al 2006). Kim et al. identified 
10,567 active promoters corresponding to 6,763 known genes in human fibroblast cells, using high-
density DNA microarrays that represented all the nonrepeat DNA throughout the human genome at 
100-bp resolution. Their analyses revealed 1,609 genes (24%) with active multiple promoters. This 
is quite a high percentage of genes showing multiple promoter use in a single cell type, and the 
other inactive promoters might be active in different cell types or under different environmental 
conditions, suggesting extensive use of multiple promoters by mammalian genes (Kim et al 2005).  
More recently, a genome-wide computational analysis of mouse and human genes demonstrated a 
strong functional correlation between usage of alternative promoters and presence of alternative 
splicing. Interestingly, the number of alternative promoters used by a gene is positively correlated 
with the number of alternative splicing forms (Xin, Hu and Kong 2008).  
These studies indicate the prevalence of alternative promoters in mammalian gene expression 
regulation but the functional significance and their role in disease etiology remains almost 
completely unexplored. 
There are several ways to create diversity in time and space in regulatory control  of gene 
expression. One is to provide a particular promoter region with all the cis-acting control elements 
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needed for the tissue- or cell-type- specific and/or developmental stage-specific expresssion and for 
its response to hormones or other signals.  Even genes expressed in a single cell type, like albumin 
in hepatocytes, may have a very complex array of cis-acting elements to which a large number of 
trans-acting factors bind, ensuring the proper timing, level of expression and cell specificity of the 
gene (Crabtree Schliber Scott 1992). 
Another way to generate diversity in expression is to duplicate a gene and to provide individual 
copies with their own regulatory elements. An example of this is the globin gene family for which 
the timing of expression of the various isoforms during embryonic development has to be titghly 
regulated. 
Alternative promoter usage resulting in alternative leader exons can affect the gene expression of 
the corresponding mRNA in a variegated range of ways and at multiple levels. It can affect the 
temporal pattern of expression (developmental stage), the level of expression, the cell-type 
specificity, the capacity to respond to particular cellular or metabolic conditions, the stability of the 
mRNA, the translation effficiency of the transcript and the structure of the amino-terminus of the 
protein. This in turn can lead to alterations in protein levels, functions, or subcellular distribution, 
again all through various mechanisms. 
For instance RUNX1 (runt-related transcription factor 1), a key regulator of early hematopoiesis 
and a frequent target of chromosomal translocations in acute leukemias, is regulated by two widely 
spaced alternative promoters, separated by more than 160 kbs, that create diversity in distribution 
and protein-coding potential of the corresponding mRNA isoforms, which are differentially 
expressed in various cell types, different developmental stages (Levanon and Groner 2004) and 
during embryonic hematopoiesis (Pozner et al 2007). The RUNX1 mRNA transcribed from the 
proximal promoter has a long 5`UTR, which contains a functional internal ribosome entry site that 
mediates a cap-independent translation (Pozner et al 2000). In that case the alternative promoters 
are used without modifying the protein coding potential of the gene. 
Similar examples are represented by OTX2 (orthodenticle homeobox 2) implicated in 
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medulloblastoma brain tumors and transcribed by three alternative promoters (Curtois et al 2003), 
and SHOX (short stature homeobox), a cell type–specific transcription factor involved in cell cycle 
and growth regulation. They use two alterative promoters producing two distinct 5’ UTRs (one is 
longer and highly structured than the other 50 UTR) with identical proteins (Blashke et al 2003), 
regulated by a combination of transcriptional and translational control mechanisms.  
Alternative promoters can also generate mRNA isoforms that encode distinct proteins, sometimes 
having opposing biological activities, if the translation start site of the corresponding mRNA 
isoform exists within the first exon. 
In most cases, activities of the protein isoforms differ because the promoters are separated by one or 
two exons that encode an important functional domain.  
For example, homer homolog genes Homer1 and Homer2 encode constitutively expressed long 
protein isoforms (Homer1b/c) and immediate-early response short isoforms (Homer1a) transcribed 
by alternative promoters (Tapper and Kuner 2006). Homers are synaptic scaffolding proteins, 
involved in neuronal signaling. Homer1b/c contain a coiled-coil (CC) domain at their C-terminus 
that enables the cell membrane localization and clustering of glutamate receptors and proteins 
involved in their intracellular signaling cascades. By contrast, Homer1a lacks the CC-domain and 
cannot multimerize and thus functions as a natural dominant negative of Homer multimers to 
influence synaptic plasticità (Tappe and Kuner 2006). Homer1b/c are highly expressed throughout 
the spinal cord, whereas Homer1a is expressed at very low levels in naive rats (Tappe et al 2006). 
Homer1a operates in a negative feedback loop to regulate the excitability of the pain pathway in an 
activity-dependent manner and protects against chronic inflammatory pain. 
These isoforms, driven by alternative promoters, differentially regulate cocaine-induced 
neuroplasticity (Szumlinsky et al 2006). 
Another example is  LEF1, which encodes lymphoid enhancer factor proteins that mediate the 
transcriptional regulation of Wnt/b-catenin target genes, is transcribed by two alternative promoters 
P1 and P2. The most 5` promoter P1 produces a full-length LEF1 protein (LEF1), which recruits β-
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catenin to Wnt target genes, whereas the intronic promoter P2 drives the shorter LEF1 (ΔNLEF1), 
which cannot interact with β-catenin and instead suppresses Wnt regulation of target genes (Arce et 
al 2006).  Another interesting example is represented by the entire p53 gene family of transcription 
factors, whose members, p53, p63 and p73 all display to be alternatively spliced and transcribed 
from alternative promoters (Murray-Zmijewski and Bourdon 2006). It has been shown that 
collectively all the members of this family have a dual gene structure, essentially determined by the 
use of two distinct alternative promoters, one upstream of the first exon and the other lying in an 
intron of the gene, which direct the production of multiple different splicing isoforms with different 
associated functions.  
The discovery of an internal promoter within the p53 family was first made with p63 (Yang et al 
1998). The human and mouse p63 genes express at least three alternatively spliced C-terminal 
isoforms (α, β, γ), and can be transcribed from an alternative promoter located in the intron 3. The 
transactivating isoforms (TAp63) are generated by the activity of the promoter upstream of exon 1 
while the alternative promoter in intron 3 leads to the expression of amino-terminally truncated 
isoforms (ΔNp63) lacking the transactivation domain. Altogether, the p63 gene expresses at least 
six mRNA variants which encode for six different p63 protein isoforms (TAp63α, TAp63β, 
TAp63γ, ΔNp63a, ΔNp63β, and ΔNp63γ). Importantly the TAp63 isoforms are able to bind the 
same DNA elements ( p53RE) as the ΔNp63 isoforms acting as dominant negative forms and 
inhibiting the function of the proteins containing the transactivation domain. At the same time the 
ΔNp63 isoforms are still able to activate specific gene targets not induced by the TA isoforms (Wu 
et al 2003). The TAp63 are expressed very early in the corse of differentiation in the progenitor 
cells and later in the development a promoter switch occur to change the expression pattern in 
favour of the ΔNp63 isoforms (McKeon 2004). 
In the case of the p73 gene many more isoforms exist, and even more diversity is generated by 
using different ATG translation initiation start codons further expanding the protein funtional 
diversification (Moll and Slade 2004). So far, 14 different p73 isoforms have been described.  
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The p73 gene expresses at least seven alternatively spliced C-terminal isoforms (α, β, γ, δ, ε, ζ and 
Ζ) (reviewed in Moll and Slade 2004 and Melino et al 2003) and at least four alternatively spliced 
N-terminal isoforms initiated at different ATG (Stiewe et al 2002). Like p63, the p73 gene can be 
transcribed from an alternative promoter located in the intron 3. The transactivating isoforms are 
generated by the activity of the promoter upstream of exon 1 while the alternative promoter in 
intron 3 leads to the expression of amino-terminally truncated isoforms (ΔNp73) lacking the 
transactivation domain. Altogether, the p73 gene expresses at least 35 mRNA variants, which can 
encode theoretically 29 different p73 protein isoforms. 
The ΔN isoforms bind DNA through p53RE and can exert dominant-negative effects over p53, p73 
and p63 activities either competing for DNA binding sites or by direct protein interaction, showing 
antiapoptotic characteristics. The p73 variants have been shown in mouse and cell culture studies to 
have distinct roles. During the normal ‘sculpting’ of the developing mouse neuronal system, ΔNp73 
isoforms are needed to counteract p53- mediated neuronal death. 
Moreover, an overexpression of the ΔNp73 isoforms, which inhibits apoptosis, is detected in 
several tumors including neuroblastoma, lung and ovarian carcinomas. 
A similar heterogeneity in alternative promoter usage coupled to alternative splicing and heavy 
rearrangement in protein domain composition has been seen at p53 locus (Murray-Zmijewski and 
Bourdon 2006), which is mutated in about 50% of all cancers. 
The p53 gene transcription can be initiated from two distinct sites upstream of exon 1 and from an 
internal promoter located in intron 4. The alternative promoter leads to the expression of an amino-
terminally truncated p53 protein initiated at codon 133 (Δ133p53). 
The intron 9 can be alternatively spliced to produce three isoforms p53, p53β and p53γ, where the 
p53β and p53γ isoforms lack the oligomerisation domain. Therefore, the human p53 gene can 
encode at least nine different p53 protein isoforms, which are named accordingly to p63/p73 
nomenclature p53, p53β, p53γ, Δ133p53, Δ133p53β and Δ133p53γ due to alternative splicing of the 
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intron 9 and usage of the alternative promoter in intron 4, and also Δ40p53, Δ40p53β, Δ40p53γ due 
to alternative splicing of the intron 9 and alternative initiation of translation or alternative splicing 
of the intron 2. 
p53 isoforms can have distinct biochemical activities. p53β binds preferentially the p53-responsive 
promoters p21 and Bax rather than Mdm2, while p53 binds preferentially to Mdm2 and p21 rather 
than Bax promoters (Bourdon et al 2005). 
Besides this complex view, one important aspect in the expression regulation by alternative 
promoters is how the different promoters are chosen. Many factors can contribute to promoter 
choice in different contexts, among them the diverse core-promoter structure at alternative initiation 
sites, a variable concentration of cis-regulatory elements in the upstream promoter region and local 
epigenetic mechanisms, such as DNA methylation, histone modifications and chromatin 
remodeling.  
There are few reports showing that such mechanisms influence the choice of which promoter is 
used. For example, Archey et al. 1999 reported that the lack of methylation within the proximal 
region of an alternative promoter for TGFB3 (transforming growth factor, b3) correlates with its 
activity in breast cancer cells. Similarly, a causal link between alternative promoter activity and the 
silencing of the respective isoforms through histone deacetylation and DNA methylation was 
demonstrated for the Ras association domain family 1 gene (RASSF1) (Dammann et al 2000) and 
the p66Shc longevity gene (SHC1) (Ventura et al 2002). Alternative promoters also regulate the 
genes encoding DNA methyltransferase (DNMT) enzymes, which mediate DNA methylation at 
various genomic regions in tissue- and developmental stage– specific manner (Schaefer et al 2007). 
Currently, there are four known families of DNMT enzymes encoded by DNMT1, DNMT3A, 
DNMT3B and DNMT3L. Most Dnmt genes contain sex-specific germline alternative promoters 
that are activated at specific stages of gametogenesis. The alternative promoters give rise to germ 
cell–specific transcripts that lead to the production of shorter forms of the proteins or to 
untranslated mRNAs that can have regulatory properties (reviewed in Schaefer et al 2007). 
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Although the functional consequences of Dnmt proteins isoforms are largely unknown, studies 
suggest that the alternative splice forms modify different chromatin domains and are expressed in a 
tissue- and developmental-specific manner (Chen et al 2002).  
Therefore, cell type–specific expression of Dnmt isoforms and their localization to different 
chromatin domains might be one mechanism for tissue-specific methylation of alternative 
promoters of mammalian genes. 
Another key component in the epigenetic machinery is the occurrence of histone modifications, 
which play a crucial role in remodeling of the chromatin state in and around the promoter region of 
a gene (Guenther et al 2007). A recent genome-wide study that mapped the chromatin state in 
pluripotent and lineage-committed cells showed that the promoter state reflected the lineage 
commitment of mouse embryonic stem cells, and alternative promoters have multiple and 
distinctive chromatin states (Mikkelsen et al 2007), suggesting that an active state at one of the 
promoters is sufficient to drive the expression of the corresponding transcript. 
MYC expression is controlled by two closely spaced but independently regulated alternative 
promoters. The downstream promoter P2 is the predominant promoter in normal tissues, making up 
to 75–90% of MYC mRNA, whereas the upstream promoter P1 produces only about 10–25% of 
MYC mRNA (Marku et al 1992). Amplification and chromosomal translocation of the MYC locus 
on chromosome 8 to one of the immunoglobulin loci on chromosomes 14, 2 or 22 are characteristic 
features of Burkitt’s lymphoma cells. On chromosomal translocation sites, the insertion of 
immunoglobulin enhancer elements causes a shift in promoter usage from P2 to P1, resulting in 50–
90% of MYC mRNA isoform derived by the P1 promoter (Marku et al 1992). 
Disruption of numerous developmentally regulated genes is also implicated in several 
neuropsychiatric disorders, including Parkinson’s disease, schizophrenia, bipolar disorder and 
autism. There is a growing body of evidence suggesting that most of the developmentally regulated 
genes produce different splice forms, whose expression in the human brain and other tissues is 
spatially and temporally regulated through differential transcription from alternative promoters. For 
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example, several genes including those encoding dopamine receptors (DRD2, DRD3 and DRD4) 
(Anney et al 2002), serotonin receptor 2A (HTR2A) (Parsons et al 2004), catechol-O-
methyltransferase (COMT) (Abdomaleky et al 2006), NMDA (N-methyl-D-aspartate) receptor 
genes (GRIN2A, GRIN2B, GRIN2C), brain-derived neurotrophic factor (BDNF) (Li uet al 2005) 
and lysinuric protein intolerance gene (SLC7A7) (Puomila et al 2007) encode different isoforms 
transcribed by alternative promoters. For most of these genes an association have been proved to 
the etiology of schizophrenia and related disorders through meta-analyses and large multicenter 
linkage studies (Abdolmaleky et al 2005). 
 
CAGE data and the analysis of mammalian promoters: Bidirectional 
promoters 
 
Promoters have been believed to occupy distinct, non-overlapping genomic regions separated by 
non-functional DNA. Early studies identified some of the exceptions to this rule: genes that lie on 
opposite strands with their TSSs lying in close proximity to each other form so-called bidirectional 
promoters (Sugimoto et al 1994, Albig et al 1997, Guargaglini et al 1997) . Trinklein et al in 2004. 
estimated that 1,352 gene pairs in the human genome have TSSs on the opposite strand that are 
separated by less than 1 kb; the corresponding number in the mouse was estimated to be 1,638 
(Engstrom et al 2006).  
Genome-wide analyses that take account of the many newly identified non-coding RNAs and 
associated CAGE tags have revealed that promoter overlap of this kind is even more common 
(Katayama et al 2005, Carninci et al 2006). In the large majority of bidirectional promoters, the TSS 
distribution is of the broad type, although each promoter in a bidirectional pair has independent core 
promoter elements since the TSS distributions in the two directions generally do not overlap 
(Carninci et al 2006). Accordingly, Trinklein et al. reported that 23% of bidirectional pairs produce 
sense–antisense pairs that overlap at their 5′ ends, where the TSS region of one gene is upstream of 
the TSS region of its partner. Interestingly CAGE data analysis suggests that this is an 
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underestimate. 
Hence, many bidirectional promoters might be more appropriately referred to as anti-directional or 
opposing promoter pairs. 
The genomic distribution of the bidirectional promoters and their associated sense-antisense pairs is 
not uniform: Sun and collaborators presented evidence for a preferential targeting of 3`UTRs by 
cis-encoded natural antisense transcripts (cis-NATs) (Sun et al 2005). 
Although it is well known that both the 5`- and 3`-UTRs of eukaryotic mRNAs may play a critical 
role in posttranscriptional gene regulation (Pesole et al 1998, Mignone et al 2002), from the study 
of Sun and collaborators it is suggested that both cis- and trans-encoded putative antisense RNAs 
prefer to bind at the 3`-UTRs of the potential target genes, and such a feature is highly conserved 
and potentially related to antisense regulation. While miRNA regulation may act on 3`-UTRs in the 
cytoplasm, 3`-UTR targeted sense-antisense (SA) regulation may occur in the nucleus. In that 
compartment SA interaction could lead to the formation of double-strand RNAs, activation of RNA 
editing and nuclear retention of transcripts, modification of chromatin, or other yet obscure 
consequences (DeCerbo and Carmichael 2005). In agreement with this model, Kiyosawa et al. 
recently observed that not only is antisense expression widespread, but that a large fraction of 
natural antisense transcripts are both poly(A) negative and restricted to the nucleus (Kiyosawa et al 
2005). Recently, the field of antisense transcription has received much more attention as many 
different studies demonstrated the huge potential for regulation of the gene expression on a global 
scale. Identification of NATs in whole genomes is possible due to screening of the large collections 
of sequence data available from multiple organisms. In silico methods for detecting NATs suffer 
from several shortcomings depending on the source of sequence information (Wang, Gaasterland 
and Chua 2005). Studies that use mRNAs have sequences whose orientations are known, but the 
amount of mRNA sequence information available is small (Lavorgna et al. 2004). Predicted gene 
models using algorithms trained to look for genes gives an increased coverage of the genome at the 
cost of confidence in the identified gene (Wang, Gaasterland and Chua 2005). Another resource is 
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the extensive EST libraries but these small sequences must first be assigned an orientation before 
useful information can be extracted from them. Some studies have used special sequence 
information in the ESTs such as the poly(A) signal-tail and splicing sites to both filter the ESTs and 
to give them the correct transcriptional orientation (Osato et al 2007). Combinations of the different 
sequence sources attempts to maximize coverage as well as maintain integrity in the data. 
Pairs of NATs are identified when they form overlapping clusters. There is variability in the cut-off 
values used in different studies but generally ~20 nucleotides of sequence overlap is considered the 
minimum for transcripts to be considered as overlapping clusters (Osato et al 2007).  
Currently there are a variety of web and software resources that can be used to look for antisense 
pairs. The Natural Antisense Transcript database (NATsdb) is a rich tool for searching for antisense 
pairs from multiple organisms (http://natsdb.cbi.pku.edu.cn/). Another web resource publicly 
available is AntiCode (http://www.anticode.org/) with more than 30,000 NATs from 12 species. 
Cis-NATs have a variety of orientations and differing lengths of overlap between pairs (Zhang et al 
2006). Five possible orientations for cis-NATs have been identified to date (Fahey, Moore and 
Higgins 2002). The most common orientation is head-to-head, where the 5' ends of both transcripts 
align together (Lavorgna et al 2004). This orientation would result in the greatest knockdown of 
gene expression if transcriptional collision is the reason for transcript inhibition. There is however 
some studies that have suggested that tail-to-tail orientations are the most common NAT pairs 
(Osato et al 2007). Others such as tail to tail, overlapping, nearby head-to- head, and nearby tail-to-
tail are less frequently encountered. Completely overlapping NATs involve the antisense gene being 
located completely over top of each other. In head-to-head and tail-to-tail orientations transcripts 
are physically discrete from each other but are located very close to each other. GO terms 
enrichment analyses suggests that there is an overrepresentation of NAT pairs in genes that have 
catalytic activity or implicated in metabolism and cell organization and biogenesis (Zhang et al 
2006). There may be something about these genes in particular that makes them more prone to this 
type of regulation. 
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Molecular mechanisms behind the regulatory role of cis-NATs are not currently well understood 
(Lavorgna et al 2004). Three models have been proposed to explain the regulatory effects that cis-
NATs have on gene expression. The first model attributes that a 6-8 nt long base pairing between 
the cis-NAT and its complementary transcript result in a knockdown of mRNA expression (Borsani 
et al 2005).  The assumption of this model is that there will be a precise alignment of at least 6 base 
pairs between the cis-NAT pair to make double stranded RNA which can give rise to siRNA (Osato 
et al 2007).  
Epigenetic modifications like DNA methylation and post-translational modification of core histones 
form the basis of the second model (Tufarelli 2006, Osato et al 2007). Although it is not yet clearly 
understood, it is thought that the reverse transcript guides methylation complexes and/or histone-
modifying complexes to the promoter regions of the sense transcript and cause an inhibition of 
expression from the gene (Tufarelli 2006). Currently it is not known what attributes of cis-NATs 
are crucial for the epigenetic model of regulation but recently siRNA targeted to gene promoters 
have been shown than can direct epigenetic modifications that result in transcriptional gene 
silencing (TGS) in human cells (Han, Kim and Morris 2007). 
Further support for the epigenetic modification model comes from the observation that for some 
non imprinted genes, alterations in the methylation pattern at the promoter regions are demostrated 
to be directly linked to the synthesis of antisense overlapping transcripts. 
Antisense-RNA transcription through the CpG island of a non-imprinted and autosomal tissue 
specific gene can lead to its silencing and methylation (Tufarelli et al 2003). This phenomenon was 
observed in a patient with an inherited form of α thalassaemia, whose decreased expression of the 
alpha globin gene (HBA) is due to changes in chromatin structure such as the hypermethylation of 
the CpG island (Barbour et al. 2000). In this patient, a small interstitial deletion resulted in the 
juxtaposition of the intact erythroid specific alpha globin gene to a truncated, widely expressed gene 
LUC7L, transcribed in the opposite orientation to that of the alpha globin gene (Tufarelli et al. 
2001). This results in a ‘gene within gene’ configuration of the HBA gene on the deleted allele. In 
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this patient and in a transgenic mouse model, methylation of the alpha globin CpG island is 
dependent upon the presence of AS-RNA transcripts (HBA-AS) transcribed in cis of the methylated 
gene from the promoter of the truncated LUC7L gene (Tufarelli et al. 2003). The cis nature of this 
AS-RNA mediated DNA methylation event is supported by the observation that the normal allele of 
the patient is not methylated (Barbour et al. 2000).  
It is thought that in malignant cancer cells with activated transposable elements, cis-antisense 
transcription can create a large amount of “transcriptional noise”. 
It is likely that aberrant antisense RNA transcripts resulting from this transcriptional noise may 
cause stochastic methylation of CpG islands associated with oncogenes and tumor suppressor genes 
(Zhang et al 2006). This inhibition would further progress the malignancy of the cells since they 
lose key regulator genes. By looking at upregulated antisense transcripts in tumor cells, researchers 
can find more candidate tumor suppressor genes.  Also, aberrant cis-NATs have been studied as 
potentially implicated in neurological diseases such as Parkinson`s disease (Liu et al 2005). 
The final proposed model that has gained favour due to recent experimental evidence is the 
transcriptional collision model. During the process of transcription of cis-NATs, the transcriptional 
complexes assemble in the promoter regions of the gene. Rna polymerases will then begin 
transcribing the gene at the transcription initiation site laying down nucleotides in a 5' to 3' direction 
(Carmichael 2003). In the areas of overlap between the cis-NATs the RNA polymerases will collide 
and stop at the crash site (Osato et al 2007). In this case, transcription is inhibited because RNA 
polymerases prematurely stop and their incomplete transcripts get degraded (Røsok and Sioud 
2005). 
CAGE data and the analysis of mammalian promoters: Mobile promoters 
 
 
A growing number of experimental data is accumulating showing that mobile elements may drive 
and modulate the transcriptional activity of the coding part of the genome. Approximately 45% of 
the human genome is composed of transposable element (TE) derived sequences, compared to 
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about 1% occupied from the protein-coding sequences, and this is probably an underestimate since 
many TE sequences would have evolved beyond recognition. TEs are similarly distributed also in 
other genomes as in human. Their incredible evolutionary success can be explained, at least in part, 
by their ability to out-replicate the host genome in which they reside, so that TEs can spread within 
and among genomes, at the expenses of a selective cost to their hosts.   This is at the basis of the 
“selfish DNA” concept which focused on the parasitic nature of those mobile elements, 
emphasizing the possible deleterious effects on the host (Orgel and Crick 1980). More recently, 
attention shifted on the potential contributions of TEs to the evolution and transcriptional activity of 
the host genome. TE sequences seem to contribute to creative and positive evolutionary changes for 
the host, such as emergine of new alternative promoters, antisense transcription controlling the 
overlapping sense transcript. There are many cases of  TE-induced changes in host gene regulation 
(Britten RJ 1996, Nekrutenko and Li 2001).  A bioinformatics analysis of more than 2000 
experimentally determined human promoters have shown that about 24% of these promoters 
contain some TE-derived sequences (Jordan et al 2003). Most of these TE-derived sequence are 
present within 3`UTR and 5`UTR of annotated mRNAs, much less along the CDS region. 
Two main classes of TE can be distinguished: retrotransposon derived elements (SINEs, LINEs and 
LTR) and non-coding tandem repeats (satellite DNAs and TTAGGG arrays). SINEs are mainly 
clustered in gene-rich regions and found in promoters. LINEs are concentrated in gene-poor 
regions, and more depleted from promoters. Satellite DNAs are mainly located in heterochromatin, 
implicated in gene silencing. TTAGGG arrays are involved in telomere capping and are also found 
at centromeres. Both TTAGGG arrays and satellite DNAs can provide binding sites for 
transcription factors and protect CpG island promoters from repressive chromatin modifications, 
thus controlling also the boundary among active and inactive sites of transcription in the nucleus 
(Tomilin 2008). Retrotransposons can act also during development to drive the expression of 
different isoforms of protein coding genes. In mouse oocytes, LTR class III retrotransposons make 
an unexpectedely high contribution to the maternal mRNA content, which persist in the embryo. 
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Many of these mobile elements can act as alternative promoters or first exons for a set of host 
genes, in a developmentally regulated manner (Peaston et al 2004). 
Moreover, other TE-derived RNA species can directly modulate the transcriptional activity of RNA 
polymerase II holoenzyme, as in the case of SINE B2 which is able to bind RNA polymerase II in 
response to a heat shock stress and repress transcription of a subset of genes. Noticeably B2 
represents the most abundant class of SINEs in mouse (Allen et al 2004, Espinoza et al 2008).   
 
The multitasking genome – a new view for gene expression regulation and 
transcriptome structure 
 
In molecular biology there are two intriguing paradoxes: the inconsistent relationship between 
organisms complexity and (1) cellular DNA content and (2) the number of protein-coding genes, 
referred to as the C-value and G-value paradoxes, respectively. The C-value paradox may be largely 
explained by varying ploidy. The G-value paradox is more problematic, as the extent of protein 
coding sequence remains relatively static over a wide range of developmental complexity and 
evolutionary distances. Recent analyses of sequenced genomes show that the relative amount of 
non-coding sequences, including introns, increases consistently with complexity (Taft et al. 2007). 
Eukaryotes and prokaryotes have evolved substantially different types of genomic architectures: 
with eukaryotes exhibiting a highly interconnected multitasking organization as opposed to the 
highly compact proteome-centric bacterial architecture. 
Bacterial genome sizes vary from 0.16 Mb as in the case of the obligate endosymbiont Carsonella 
ruddii containing only about 182 protein-coding sequences, and which heavily rely on the host 
functions, to free-living bacteria with autonomous metabolic and catabolic capacity, such as 
Burkholderia xenovorans (9.7 Mb and 8,602 protein coding genes) (Binnewies et al. 2006). 
Prokaryotes contain relatively low amount of non-protein-coding sequences, which mainly consist 
of 5’ and 3’ regulatory elements that control transcriptional and translational rates of different 
cluster of functionally related genes known as operons. In bacteria the transcription and the 
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translation occur at the same time and in the same compartment and introns are not present within 
protein-coding genes. Few genes for structural RNAs, like tRNAs, contain some autocatalytic 
ancient introns (group II introns) which are excised by a different mechanism and without a trans-
acting protein complex (Gottesman 2005). 
Higher eukaryotes have a much more complex genomic organization, a mosaic gene structure with 
a dual output, mRNA (protein coding) sequences and introns, which are released from the pre-
mRNA by spliceosome-mediated posttranscriptional processing. Additionally, many other 
transcripts (likely more than half) do not encode proteins at all, but appear to be developmentally 
regulated and having a genetic function. 
Introns have been enormously successful in the course of evolution of eukaryotes, as they comprise 
up to 95% of the protein-coding genes in mammals.   
Interestingly, the distribution of introns in complex organisms is non-random. Genes composed of 
large amounts of intronic sequence are significantly overrepresented amongst genes that are highly 
expressed in the nervous system, as well as among genes downregulated in embryonic stem cells. It 
has been suggested that the informational paradox in complex organisms may be explained by the 
expansion of cis-acting regulatory elements and genes specifying trans-acting non-protein-coding 
RNAs (Taft et al. 2007). Genome sequencing project have revealed that the core proteome sizes of 
Caenorhabditis elegans and Drosophila melanogaster are similar and each is only about the double 
of yeast and some bacteria, despite they appear to have more than twice the complexity of 
microorganisms, leading to suggest that “the evolution of additional complex traits is essentially an 
organizational one, a matter of novel interactions that derive from the temporal and spatial 
segregation of fairly similar components” (Chervitz et al. 1998; Rubin et al. 2000). 
Even the human genome has been estimated to contain only about 30,000 protein-coding genes, 
99% of which are shared in common with mouse (International Human Sequencing Consortium 
2001; Venter et al. 2001). The increase in the complexity of higher eukaryotes is at least in part 
explained by the production of many different protein isoforms from one single gene by alternative 
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splicing (Croft et al. 2000). However the most striking feature in the evolution of these organisms 
was the progressive accumulation of large amount of complex non-protein-coding sequences, which 
carry up to 98% of the information, as result from the demonstration that most of the genome is 
actively transcribed (Cheng et al. 2005; Carninci et al. 2005; ENCODE Project Consortium 2007).  
Moreover, less than 1% of the sequence differences between individual humans occurs in the 
protein coding sequences (Venter et al. 2001), which suggest that the majority of phenotypic 
variation between individuals and species results from differences in the control architecture rather 
than in the proteins themeselves. On the contrary, in bacteria phenotypic variation is primarily 
achieved by varying the proteome; for instance different strains of Escherichia coli have been found 
to differ by over 20% in their gene complement (Hayashi et al. 2001).    
The concept that phenotypic variation and functional complexity in higher eukaryotes arise from 
differential use of  a set of core components started to be represented and summarized by various 
models, in part inspired to electrical circuits design and mainly focused on the modules rather than 
on the interconnecting control architecture of the system. Some examples are represented by such 
concepts as “synexpression groups” (Niehrs and Pollet 1999), “syntagms” of  interacting genes 
(Huang 1998), reuse of modules in signalling pathways (Pawson 1995; T. Hunter 2000), or 
increased rates of evolution by varying connections between modular network components 
(Hartwell et al. 1999; Holland 1999).  
In particular, network models, ranging in size from simple regulated circuits (Almeida, Fernandez 
and Infantosi 1998; Mendoza and Alvarez-Buylla 1998; Yuh, Bolouri and Davidson 1998) to entire 
genomes (Thieffry et al. 1998) have proved that feedback-subnetworks can exhibit computational 
behaviors like “learned behavior” (Bhalla and Iyengar 1999), that switching networks and 
transcriptional control networks can exhibit dynamical stability (Wolf and Eeckman 1998; Smolen 
Baxter and Byrne 2000), and that feedback cinrcuits can implement oscillators governing cell 
cycles and circadian clocks (Dano, Sorensen and Hynne 1999; Shearman et al. 2000). Usually 
stochastic noise, time delays allowing feedback, molecular memory and oscillations can be 
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incorporated in such circuit models generating probabilistic phenotypic variation and amplification 
of signals (McAdams and Arkin 1997; Smolen, Baxter and Byrne 1999; Hasty 2000). 
The major limitation into these models comes from the fact that they are unsuited to describe a real 
global cellular connectivity and dynamics, because they cannot be scaled up to a large network size, 
since linear increase in the number of interconnected circuit nodes corresponds to a quadratic 
increase in the number of interconnecting molecules. This implies an exponential increase in the 
model size, which severely constrain numerical simulation using the current computing 
technologies. To bypass this problem, a series of alternative solutions have been sought, by treating 
subnetworks as active integrated logic components interconnected into a larger network, or 
considering the system as composed of hierarchically organized control subsystems (McAdams and 
Shapiro 1995; van der Gugten and Westerhoff 1997). 
In an interesting theory formulated by John Mattick and Michael Gagen, the biological systems 
could have been solved this problem in a different way: adopting a multitasking architecture 
(Mattick and Gagen 2001). Multitasking is generally referred to as the apparent simultaneous 
performance of two or more tasks at the same time. 
Multitasking is employed in every modern computer in which control codes (program instructions) 
of n bits set the central processing circuit to process 2n different operations.   In complex organisms, 
multitasked organization via n controls (single molecules) can, in theory, achieve an exponential 
(2n) multitasking of subnetwork dynamical outputs and allow a wide range of programmed 
responses to be obtained from limited numbers of subnetworks and consequently limited genetic 
coding information. The obvious advantage and exponential benefit deriving from using a 
controlled multitasking and the small linear cost of control molecules makes it likely that evolution 
would have been explored this option.  
What multitasking does it mean in practice, when applied to biological organisms? The meaning is 
obvious for the many different cellular activities which are subject to a fine tuning in time and 
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space. However, it is not so obvious what are the control molecules that makes it possible for such a 
system to work. 
Why bacterial genomes didn’t acquire larger genomes and how higher eukaryotes could develop 
such a complex organization without exponentially expanding their set of protein coding genes? 
Clearly, one of the most striking feature of higher eukaryotes compared to bacteria is the large 
expansion of the intergenic regions and the appearance of large portions of non coding tracts which 
separate the protein coding blocks in the pre-mRNAs. 
The multitasking hypothesis suggests that it is far easier to modify and expand the number of small 
control sequences than duplicate and mutate entire subnetworks of genes. Moreover, just turning off 
controls may reset the program which can be important for survival and reproduction. A control 
architecture makes it possible to coordinate activity across interacting sets of genes, ensuring a great 
degree of flexibility and plasticity to the system.  
However, a multitasking structure is only useful to the extent that the controls can convey 
informations about the dynamical state of the network and its surrounding enviroment. To do this, 
nodes within the network must generate multiple outputs in the form of endogeneous controls. In a 
fully integrated network, endogenously sourced controls are likely to be more abundant than 
externally sourceed controls. 
Therefore, each gene subnetwork within a cell must produce many different control molecules in 
parallel with their primary gene products, dynamically communicating with other subnetworks. 
They may employ all the available biological processes as transcription, splicing, capping and 
polyadenylation, transport and compartimentalization, decay and turnover, transcriptional and post-
transcriptional silencing, translational control, chromatin re-organization, transpositionand its 
suppression, antisense transcripts production, RNA interference, co-suppression. Interestingly, most 
of these processes are RNA-mediated events rather protein-mediated events. 
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Such a system should be able to explore new expression space at fast evolutionary rates over short 
evolutionary timescales. This fits with the longer average time per generation in the higher 
eukaryotes, compared to the very short time typically observed in bacteria. 
Such networks are generally stable and scale-free, in which some nodes have a high connectivity 
and others have low connectivity, similar to what is observed in other systems like social 
communication and internet (Albert, Jeong and Barabasi 2000). 
Bacteria have limited genome sizes and low phenotypic complexity, suggesting that advanced 
integrated organization is not widely employed in these microorganisms. The absence of a 
prokaryotic multiplex control system also implies that a system built primarily on proteins has 
inherent limitations. An highly interconnected control system in which endogenously sourced 
controls were relying on proteins, even just one additional protein ouput per node, would double the 
size of the genome. Therefore, the multiple outputs needed to have a true dynamical system would 
require huge increase in the size of the genome and in the energy cost. It is very likely that 
eukayotes have been used RNA to mediate such endogenous multiple controls: introns and non 
coding RNAs are both good candidate to play such a role. 
For many years the central dogma “one gene-one protein” has biased our perspective in a proteome-
centric vision of the biological processes. Only recently, a series of experimental evidences in years 
of studies, using different approaches in different systems, started to shade new lights on old topics. 
Introns size and sequence complexity correlates well with developmental complexity. 
In developmentally simple eukaryotes like Schizosaccharomyces pombe, Aspergillus, Dictyostelium 
introns represent only 10-20% of the primary transcripts and are generally small, with an average 
length of 100 bases and a density of 1 to 3 introns per Kbase of protein-coding sequence. 
In the higher plants there are 2 to 4 introns per gene with an average length of 250 bases, spanning 
for about 50% of the primary transcripts. In animals, a progressive evolutionary increase in the 
average intron size could be seen, ranging from 500 bases in Drosophila and C. elegans up to 3,400 
bases in humans, where there are 6 to 7 introns per gene, representing on average more than 95% of 
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the primary transcripts (Deutsch and Long 1999; Venter et al. 2001; http://isis.bit.uq.edu.au an 
extensive introns size database). 
Some exeptions are also known to this general trend among higher eukaryotes such as Fugu 
rubripes, which has almost no repetitive DNA in its genome and in which 75% of introns are very 
small with very few of them accounting for the major part of the unique sequences, and Arabidopsis 
thaliana which also has large part of the introns very small and a compact genome (Brenner et al 
1993; Carels and Bernardi 2000). 
Small introns are likely to represent vestigial forms, while larger introns characterized by a great 
sequence complexity may be considered as bearing a functionality. An interesting example is 
represented by the complex colonial pluricellular alga Volvox carteri which have large introns in its 
genome (Fabry et al. 1993). Since the algae of the order Volvocales comprise many closely related 
species with different levels of complexity, ranging from the simplest unicellular species like 
Clamydomonas to simple colonial forms and even more specialized ones, which resemble a true 
multicellular organism, this may represent a useful case to test the hypothesis of introns evolution.  
While introns generally show less conservation than adjacent protein-coding sequences, some of 
them are highly conserved over evolutionary distances (Garbe and Pardue 1986; Lloyd and 
Gunning 1993; John, Smith and Kaiser 1996; Aruscavage and Bass 2000; Sun et al. 2000), and 
often in large clusters (Jareborg, Birney and Durbin 1999), indicating that they are under functional 
constraint. 
Another point to take into account is that introns are more stable than generally thought.  
After splicing, introns, starting from a lariat form, are debranched in a regulated process (Ruskin 
and Green 1985) but subsequent events are still unknown. 
The widespread view of excised introns as highly unstable, and simply discarded and degraded 
comes from the unjustified a priori assumption that they don`t have any function. 
In their theory Mattick and Gagen propose that “it`s very likely that introns are subsequently 
processed by specific pathways and which generate multiple smaller species which can function 
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independently as trans-acting signals in the network (Mattick 1994) affecting the metabolism of 
other RNAs and the modulation of the chromatin strucure, among other things”. 
For instance, it has already been long time ago when it was demonstrated that introns are implicated 
in the production of small nucleolar RNAs (snoRNAs), a group of hundreds of stable small non 
coding RNAs localized in the nucleolus and involved in the posttranscriptional modification of 
ribosomal RNAs and other targets. Most of the intronic snoRNAs are found in introns of different 
genes coding for ribosomal proteins (L1, L5, L7, L13, S1, S3, S7, S8, S13 amongst the others), 
ribosome-associated proteins (eIF-4A), nucleolar proteins (nucleolin, laminin, fibrillarin, Nop58, 
Nop56), the heat shock protein hsc70 and the cell cycle regulated protein RCC1, among others 
(Prislei et al. 1993; Bachellerie et al. 1995; Maxwell and Fournier 1995; Nicoloso et al. 1996; 
Filipowicz et al. 1999; Filipowicz et al. 2000). It has also been observed that in some even more 
specialized cases, some genes have evolved at the point in which their protein coding tracts no 
longer exist (Tychowski, Shu and Steitz 1996; Bortolin and Kiss 1998; Smith and Steitz 1998; 
Tanaka et al. 2000; Runte et al. 2001). 
On the contrary to what is commonly believed, free excised introns, in both lariat and linear forms, 
have been found to be abundant (Zeitlin and Efstratiadis 1984) and some are relatively stable (Qian 
et al. 1992). Furthermore even a relatively insensitive technique like in situ hybridization, have 
shown that, after released from the spliceosome, intronic sequences are detectable in the nucleus, 
often in a spotted pattern (Xing et al. 1993). 
The decay characteristics of these smaller RNA species are likely to provide a molecular memory of 
pri- and post-activation status, giving a significant efficiency gain over the use of bistable regulated 
gene networks as memories (Gardner, Cantor and Collins 2000). 
Differential decay and diffusion rates as well as compartimentalization may create temporally and 
spatially complex signal pulses and contribute to a fine control over the cellular activities. 
The same considerations, already seen for introns, can also be noticed for other non coding 
sequences in the genome. The complexity of higher eukaryotes can then be correlated to the extent 
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of progressively more widespread presence of non coding elements in the genome. This is 
particularly evident from broad comparative genomics studies. In 1993, the team of Sydney Brenner 
showed that Fugu rubripes genome is only 390 Mb, about one-eighth the size of the human 
genome, yet it contains a similar repertoire of genes to humans (Brenner et al. 1993). By comparing 
the human and Fugu sequences, common functional elements such as genes and regulatory 
sequences can be recognized as having been preserved in the two genomes over the course of the 
450 million years since the species diverged from their common ancestor. By contrast, non-
functional sequences are randomized over this long time period. Over 30,000 Fugu genes the great 
majority have counterparts in human genes, and vice versa, with notable exceptions including genes 
of the immune system, metabolic regulation, and other physiological systems that differ in fish and 
mammals.  In the evolution of vertebrates we can observe a progressive increase in the amount of 
non coding sequences (Taft, Pheasant and Mattick 2007). 
Among large non coding sequences, there are only few scattered islands of functionally relevant 
and conserved elements, which are good candidates to play a regulatory role (Casillas, Barbadilla 
and Bergamn 2007; Ponjavic, Ponting and Lunter 2007; Pheasant and Mattick 2007). These islands 
of highly conserved noncoding sequences (CNSs) have proven to be reliable indicators of 
functionally constrained sequences  
All these evidences together with the recent findings about the complex patterns of transcriptional 
regulation in mouse as well as in humans have provided unparalleled insight into the complexity  of 
the eukaryotic transcriptome (Carninci et al. 2005; Cheng et al. 2005; Kapranov et al. 2005; 
Katayama et al. 2005) and suggest that a multitasking model for gene expression regulation has 
been very likely adopted in the course of evolution. 
 
Then what is a gene? 
 
Language evolves rapidly in contemporary biology. 
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The term ‘gene’ was originally coined to define a chromosomal tract that influence a phenotypic 
trait and was subsequently applied to the genomic elements that produce mRNAs, mostly associated 
with their protein products (Snyder and Gerstein 2003). 
Although such description fits bacterial genes, novel data show that our understanding of 
mammalian genes and genomes and their annotation are still overly simplistic. Novel data sets show 
that a large part of the genome is transcribed from multiple positions and in both directions. This 
will ultimately affect the way we understand and study genes. The multitudes of transcripts that 
exist have several TSSs, alternative splicing variants and transcripts joining together regions that 
are traditionally annotated as different genes. 
In currently and largely accepted tools used for curated gene annotation, such as RefSeq and 
LocusLink, priority in selecting the sequence to use as the provisional record is given to the longest 
sequence that maintains identity through the coding region.  
So in this way the representative sequence for a gene is biased from the fact that only the one that 
maximizes the number of included exons and/or protein domains, is considered valid. 
Biologists would be forced to rethink what is a mammalian gene and change the classical textbook 
definitions, in the light of these multiple evidences. Despite so much transcriptional complexity, it 
is imperative not only to complete the list of the transcribed parts, their coordinates, controlling 
elements and timing of expression but also to develop formal ways to treat each one of these.  
A first step to do this is to classify the overlapping sequences in TUs (Carninci et al 2005, Okazaki 
et al 2002), which are further divided into transcriptional frameworks (TKs) if they share TSSs, 
TTSs or splicing sites. However, this is only a first step in categorizing related transcripts and 
further logical subdivisions are required that take into account the presence and sequential order of 
transcriptional landmark elements for subsequent quantitative treatment of transcription. 
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Conclusion 
 
CAGE largely contributed to change the concept of core promoter itself, showing how on a genome 
wide scale, many different type of promoters can be distinguished based on the shape distribution of 
their associated TSS. Two large classes are represented by sharp-type promoters and broad-type 
promoters. The TATA-box bearing promoters are usually associated to tissue-specific transcripts, 
whereas CpG island broad promoters are mainly found in housekeeping or ubiquitously expressed 
genes. Functional promoters have been found not only in proximity of 5`TSS but also in 3`UTR and 
in internal exons. Many of these in 3`UTR display to have a consensus GGG for the initiator-like 
motif. Moreover in mammalian genomes there is a widespread occurrence of both alternative 
promoters and bidirectional promoters, which greatly increase the transcriptional output and variety 
of mRNAs that can be produced from a locus. Also many mobile genetic elements can drive the 
transcription of their host protein coding genes. 
In the light of all this massive and pervasive, partly overlapping, transcription the current 
definitions of genes appear to be clearly not suitable anymore, and must be revised in the next 
future. 
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Mesencephalic Dopaminergic Cells  
 
 
Mesencephalic Dopaminergic Cells: Overview of the system in mammals 
 
In 2007 it has been the 50th annyversary of the discovery of dopamine as an idependent 
neurotransmitter in the nervous system. DA was first identified as an intermediate in the 
biosynthesis of noradrenaline and adrenalin from tyrosine (Blaschko 1959). In 1957 Kathleen 
Montagu at Runwell Hospital near London and Arvid Carlsson with his group in Lund, made the 
first observations that paved the way for unravelling the role of dopamine as a transmitter in the 
CNS, demonstrating that DA was present in the brain in about the same concentrations like NA 
(Montagu KA 1957, Carlsson et al 1958). The marked differences in the regional distribution of DA 
and NA containing cells led to propose a biological role for DA independent from NA biosynthesis 
(Von Euler and Lishajko 1957, Bertler and Rosengren 1959). 
In 1957–1958, Carlsson and co-workers made the intriguing observation that the akinetic effects of 
reserpine, a natural alkaloid, could be reversed by an intravenous injection of the dopamine (and 
noradrenaline) precursor 3,4-dihydroxyphenylalanine (DOPA) and were correlated to a recovery of 
dopamine, but not noradrenaline, content in the brain, suggesting that depletion of dopamine, rather 
than noradrenaline or serotonin, was the cause of the akinetic state in reserpine-treated animals. One 
year later, Carlsson’s students Ake Bertler and Evald Rosengren, and Sano and collaborators in 
Japan, reported that most of the dopamine in the brain was located in the striatum, which contains 
little noradrenaline, thus providing further support for the hypothesis that this new, putative 
transmitter might have a central role in the control of motor functions (Bertler and Rosemberg 
1959, Sano et al 1959). 
This finding, in combination with the Levo-DOPA (L-dopa; 3,4-dihydrox-L-phenylalanine) 
treatment of PD patients, resulted in the Nobel Prize year 2000 given to Arvid Carlsson, together 
with Paul Greengard for the investigation of the molecular signaling cascade triggered by 
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dopamine, and Eric R Kandel who investigated memory formation and learning at the synaptic 
level.  
Dopamine, noradrenaline, and adrenaline are catecholamines, molecules derived from the amino 
acid tyrosine (Figure 1). The catecholamines (CA) are water-soluble hormones that circulate in the 
bloodstream, produced either by the adrenal glands or in the 
postganglionic sympathetic nervous system. In the central 
nervous system (CNS), dopamine is synthetized by different 
neuronal populations throughout the brain, where they exert a 
variety of functions on the basis of their wide connectivity 
within distinct pathways (reviewed by Prakash and Wurst 
2006).  
 
Figure 1. Synthesis of dopamine (DA), noradrenaline (NA), and adrenaline 
(A). Tyrosine (Tyr.) is converted to dihydroxyphenylalanine (DOPA) by the 
rate limiting enzyme tyrosine hydroxylase (TH). DOPA is then converted to 
dopamine by dopa-decarboxylase (AADC). Dopamine-β-hydroxylase (DBH) 
  converts dopamine to noradrenaline, and phenylethanol-amine-Nmethyltran- 
        sferase (PNMT) converts noradrenaline to adrenaline (epinephrine). 
 
The distribution of catecholamines within the brain was 
mapped in the beginning of the 1960s using the Falck-Hillarp 
catecholamine formaldehyde histoflouresence method. DA 
and NA were converted to isoquinoline molecules, which are yellow-green fluorescent (Falck et al 
1962). Later the use of immunohystochemical detection of tyrosine-hydroxylase and other specific 
markers have largely confirmed and expanded the first results (Bjorklund and Dunnett 1984). 
 
Mesencephalic Dopaminergic Cells: Anatomical organization 
 
CA-containing neurons have been found in the brainstem, in olfactory bulb and retina. Dahlström 
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and Fuxe (1964) described 12 different cell groups, which they designated A1-A12 (Dahlström and 
Fuxe 1964). Later few new cells were added: the A13 in rostral zona incerta, the A14 cell group in 
anterior perivetricular hypothalamus and the preoptic region (Bjorklund and Nobin 1973) and more 
recently the A15 cell group in the dorsal preoptic region and in the ventrolateral preoptic and 
hypothalamic areas (reviewed in Bjorklund and Dunnett 2007a). A16 is assigned to the olfactory 
bulb group. 
 
 
Figure 2. Distribution of DA neuron cell groups in the developing (a) and adult (b) rodent brain. The dopamine neurons in the mammalian brain 
are localized in nine distinctive cell groups, distributed from the mesencephalon to the olfactory bulb, as illustrated schematically, in a sagittal view, 
in (a) the developing and (b) the adult rat brain. The numbering of the cell groups, from A8 to A16, was introduced in the classic study of Dahlstro¨m 
and Fuxe in 1964 [3], and is still valid at present. (Drawing in (a) is modified from Marin et al. [65]; in (b) the principal projections of the DA cell 
groups are illustrated by arrows). Abbreviations: lge, lateral ganglionic eminence; mge, medial ganglionic eminence; p1–p3, prosomeres 1–3.                                                                                             
Taken from Bjorklund and Dunnett 2007  
 
The diencephalic DA cell system (groups A11-A14) comprise neurons which give rise to 
intradiencephalic projections and to descending diencephalospinal pathway (Figure 2). They are 
considerably fewer in number compared to the other DA nuclei.  
The most prominent assembly of DA-containing neurons are the mesencephalic DA cell system 
(groups A8, A9 and A10). By means of the tyrosine-hydroxylase immunohystochemistry, the 
number of mesencephalic DA cells it has been estimated. In rodents, the total number of TH-
positive cells in all three cell groups bilaterally is 20,000–30,000 in mice and 40,000–45,000 in rats, 
with about half of the cells located in the SN. This number increases to between 160,000–320,000 
in monkeys and 400,000–600,000 in humans, with >70% of the neurons located in the SN. The 
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expansion is particularly evident in SN and is accompanied  by an extension in the DA innervation 
territories, in particular in the neocortex, which is much more extensively innervated in primates 
and human than in rodents (Lewis DA et al 1998, Nelson EL et al 1996). In rodents the cortical DA 
innervation is limited to frontal, cingulate and enthorinal cortex, whereas in primates it covers 
almost all the cortical areas (Williams and Goldman-Rakic 1998). 
In the brainstem, CA-containing system comprises about 50,000 neurons in the rat, excluding 
olphactory bulb and retina, out of which 80% are dopaminergic and 20% are noradrenergic. About 
5% of the CA neurons are found in medulla oblongata, 15% in pons, 70-75% in mesencephalon and 
5-10% in diencephalon (Bjorklund and Hokfelt 1984).  
Most of the dopaminergic neurons are highly collaterized: it has been estimated in rat that each 
nigrostriatal DA neuron have an average total terminal length of about 30 cm, comprising of around 
250,000 terminal synaptic boutons (Anden et al 1966). The average content of DA in 
mesencephalic DA neurons has been estimated to be about 30 pg per neuron (Bjorklund and 
Lindvall 1984). 
Recently, many studies have also focused on the existence of TH immunoreactive cells in various 
brain regions which apparently do not contain any detectable level of CA (dopamine or 
noradrenaline). Mainly found in hypothalamus in rodents, and in basal forebrain, striatum and 
cortical areas in primates, those neurons also lack the decarboxylating enzyme DDC, and the 
vescicular monoamine transporter VMAT-2 (Ikemoto et al 1996, Ikemoto et al 1999, Weihe et al 
2006).  Most of these neurons resemble in morphology GABAergic interneurons, and at least in 
marmosets, they coexpress TH with choline acetyltransferase in magnocellular cholinergic neurons 
of the nucleus basalis of Meynert (Torres et al 1993). 
It is known that during development, the TH gene is expressed in a subset of interneuron precursors 
that migrate from the lateral and/or medial ganglionic eminences to the cortex, striatum and the 
olfactory bulb. In rodents, TH protein is transiently expressed in the cortex and striatum only during 
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the first postnatal month (Berger et al 1985, Satoh and Suzuki 1990). In adult mice and rats, those 
neurons express the TH mRNA, but no detectable levels of the TH protein, whereas the cells 
settling in the glomerular layer of the olfactory bulb express both TH protein and synthetize DA, 
probably as a result of synaptic activation from the olfactory afferents (Baker et al 2003).  
 
Mesencephalic Dopaminergic Cells: Nigrostriatal and Mesolimbic-
Mesocortical Pathways 
 
The vast majority of the dopaminergic neurons in the CNS are located in the ventral midbrain and 
can further be divided into the Retrorubral Field (A8), Substantia Nigra (SN, A9), and Ventral 
Tegmental Area (VTA, A10) cell groups (Dahlström and Fuxe 1964).  
It is often presumed, as a convenient representation, that the mesencephalon contains two major 
DA neuron subtypes based on their projections: the nigral A9 neurons projecting to the striatum 
along the nigrostriatal pathway and the A10 neurons of the VTA projecting to limbic and cortical 
areas along mesolimbic and mesocortical pathways. This has long been recognized as an 
oversimplification. The SN contains not only neurons projecting to the striatum, but also neurons 
that innervate cortical and limbic areas; also the DA neurons of the VTA project to the ventral 
striatum and the ventro-medial part of the caudate-putamen. The A8 cell group consisting of a 
dorsal and caudal extension of the A9 cell group, contains neurons that project to both striatal, 
limbic and cortical areas (reviewed by Bentivoglio and Morelli 2005). This intermixing is 
particularly prominent in primates, much more than in rodents, where the cells of origin of the 
mesolimbic and mesostriatal pathways are widely distributed throughout the dorsal tier, 
interspersed among the cells projecting to the striatum (Williams and Goldman-Rakic 1998). 
Although this heterogeneity in their established connections with other brain areas, three main 
functionally distinct pathways can be identified: a mesostriatal pathway, a mesolimbic pathway and 
a mesocortical pathway. 
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The “mesostriatal pathway” instead of the “nigrostriatal pathway” could represent a more correct 
definition to describe the intermixed way in which the anatomical connections are formed by the 
SN and VTA dopaminergic neurons to reach the two main different striatal compartments. 
Nevertheless, in a more restricted sense, when referring to the connections established with the 
sensorimotor striatum, the classical description of a nigrostriatal pathway formed from neurons of 
both the ventral and dorsal part of SNc remains valid,. 
The nigrostriatal pathway is infact involved in control of motor activity (Ungerstedt 1971). 
The loss of the nigrostriatal dopamine projections results in motor disturbances typical of 
Parkinson’s disease, which will be discussed in more detail below.  
The mesolimbic pathway consists of dopamine neurons located mainly in the VTA that project to 
the nucleus accumbens, olfactory tubercle, and amygdala and participate in motivated behavior, 
reward, and addiction. The VTA togheter with part of SN also projects to the frontal cortex, 
creating the mesocortical pathway, which is involved in memory and learning (Björklund and 
Lindvall 1984; Le Moal and Simon 1991, Ungerstedt 1971). 
Another useful scheme to classify mesencephalic DA neuron diversity based on connettivity, 
morphological features and specific molecular markers is the subdivision in dorsal and ventral tiers. 
In the dorsal tier are located DA neurons of the SN and lateral VTA, with a round or fusiform cell 
body, innervating ventral striatal, limbic and cortical areas, as well as the matrix compartment of 
dorsal striatum. These cells express TH together with the calcium-binding protein calbindin, and 
show to have low level of DAT (Gerfen et al 1987a, Gerfen et al 1987b, German and Liang 1993, 
Schein et al 1998). The ventral tier is composed of more densely packed angular cells, calbindin-
negative but expressing TH together with the G-protein-regulated inwardly rectifying potassium 
channel 2 (GIRK2) and high level of DAT. Notably, these neurons project almost exclusively to the 
striatum, in particular to the patch-compartment of the sensorimotor striatal system (Gerfen et al 
1987, Prensa and Parent 2001, Thompson et al 2005). 
Many of these cells project their dendrites also ventrally into the SN pars reticulata (Prensa and 
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Parent 2001) and are consequently important for controlling, from within the SN, the output of DA 
neurotransmittion from the ventral mesencephalon. 
Furthermore, the progenitor marker ALDH1 is preferentially expressed in the SN dopaminergic 
neurons (Chung et al 2005, Haque et al 1997, McCaffery and Drager 1994). 
Despite the fact that mdDA neurons in the SNc and VTA have distinct projection targets and 
functional properties, the population as a whole is often considered to be physiologically and 
pharmacologically homogeneous. Studies in vitro using explants or dissociated neurons prepared 
from early embrionic tissues, do often distinguish between SN and VTA. 
Interestingly, not only the caudate-putamen but also several other basal ganglia structures are 
innervated by midbrain DA neurons. This includes the external and internal segments of the Globus 
Pallidus (entopeduncular nucleus in rodents), parts of the ventral pallidum and of the subthalamic 
nucleus (Lindvall and Bjorklund 1979, Lavoie et al 1989, Gauthier et al 1999). 
In the SN itself, DA is known to be released from a plexus of dendritic terminals that is derived 
from the DA neurons located in the ventral tier of the SNc, and extends throughout large parts of 
the SNr (Bjorklund and Lindvall 1984). Although the density of their terminals in these nuclei is 
much less than in caudate or putamen, the ventral tier neurons are strategically placed to regulate 
some crucial aspects of neurotransmission in the basal ganglia circuitry. Thus, in addition to their 
potent influence at the level of the caudate nucleus and putamen, the midbrain DA neurons can 
directly modulate the activity of basal ganglia output neurons at both the pallidal, subthalamic and 
nigral levels. 
In the SN, dendritic DA release has been shown to provide a mechanism by which the nigral DA 
neurons can regulate not only the activity of the DA neurons themselves, but also the release of 
GABA within the SNr and the activity of its efferent projections (Robertson HA 1992). 
Parent and collaborators (Parent et al 2000, Prensa and Parent 2001) have shown that at least part of 
the DA innervation in the Globus Pallidus and subthalamic nucleus is derived from collateral 
branches of DA axons that pass through these nuclei before reaching their final target, the caudate-
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putamen. In primates, the internal segment of the Globus Pallidus receives a particularly dense DA 
innervation, which seems to be derived from a set of neurons located in both SNc and VTA, 
substantially separate from those innervating the caudateputamen (Lavoie et al 1989, Smith Y et al 
1989). This projection is relatively spared in MPTP-treated monkeys and in early cases of 
Parkinson’s disease (Parent et al 1990). Furthermore, Whone and colleagues have observed a 
compensatory increase in 18F-fluorodopa uptake in the internal segment of the Globus Pallidus in 
early stage PD patients, which is lost later with the progression of the disease (Whone et al 2003). 
This would imply the existence of compensatory mechanisms in DA neurotransmission through the 
Globus Pallidus which can help to maintain a normal motor function when the nigrostriatal pathway 
begins to be compromised. 
 
Mesencephalic Dopaminergic Cells: The Basal Ganglia circuitry and mDA 
electrophysiological properties 
 
The basal ganglia system is divided into four distinct brain nuclei; rostrally the striatum (composed 
of putamen and caudate nucleus), the globus pallidus externa (GPe), the globus pallidus interna 
(GPi); more caudally the subthalamic nucleus (STN), and the substantia nigra (SN), clasically 
subdivided in pars compacta (SNc), reticulata (SNr) and lateralis (SNl). The striato-pallido-nigral 
bundle, which is the core of the basal ganglia, is the anatomical link of the striatum with its primary 
targets, the pallidum and the substantia nigra. It engages the totality of spiny striatal axons. 
Estimated numbers are 110 millions in human, 40 milions in chimpanzees and 12 milion in 
macaques  (Percheron et al 1984, Yelnik et al 1987). 
These nuclei participate in the control of movements, cognitive, and limbic functions. The motor 
behavior is controlled in the dorsal striatum, whereas the limbic and cognitive inputs occur in the 
ventral striatum (Björklund and Lindvall 1984). The dorsal striatum consists of approximately 90-
95% γ-aminobutyric acid (GABA)-ergic medium-sized spiny neurons, which receives inputs from 
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large parts of the motor cortex, thalamus, and the SN (Gerfen and Wilson 1996). Hence, the 
striatum represents the main input nucleus of the basal ganglia.  
Besides the medium-sized spiny neurons, GABAergic medium aspiny interneurons and cholinergic 
interneurons are also present in the striatum (Gerfen and Wilson, 1996). 
Figure 3. The diagram represents a schematical drawing of the 
connettivity in the basal ganglia. The dopaminergic imput are 
colored in black, whereas glutamatergic pathways are in red 
and GABAergic pathways in blue. 
 
 
Striatal neurons express dopamine receptors, G-protein 
coupled receptors that can be divided into two groups: 
D1-like receptors (receptor D1 and D5) stimulate adenyl 
cyclase, whereas D2-like receptors (receptor D2, D3, D4) 
inhibit adenyl cyclase (Dearry et al 1990, Kebabian and 
Calne 1979, Missale et al 1998). These  two distinct functional classes of dopamine receptors are 
associated to different pathways that characterize the activity of the basal ganglia: the direct 
stimulatory pathway and the indirect inhibitory pathway. GABAergic medium-sized spiny neurons 
expressing D1 receptors mediate the direct pathway to the globus pallidus interna, while 
GABAergic medium-sized spiny neurons expressing D2-receptors mediate the indirect pathway via 
the globus pallidus externa and the subthalamic nucleus before the signal reaches the globus 
pallidus interna (Gerfen and Wilson 1996, Graybiel and Ragsdale Jr 1983). 
Normal dopaminergic input to the striatum results in an inhibition of the indirect pathway and an 
activation of the direct pathway. The net effect results in stimulation of the thalamus, which 
facilitate motor activity. However, in Parkinson’s disease, the input of dopamine to the striatum is 
reduced, which results in a decreased stimulation of the direct pathway and an activated indirect 
pathway. This results in an increased output from globus pallidus interna and less thalamocortical 
activity and thus, impaired motor activity (Albin et al 1989, Bjarkam and Sorensen 2004, Blandini 
et al 2000) (Figure 4). 
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Figure 4. Schematic illustration of the motor basal ganglia system. A) Under normal conditions, dopaminergic input to 
the striatum facilitate motor activity. B) In Parkinson’s disease, the striatum receives less dopaminergic input from the 
SN, which in the end results in impaired motor activity. The direct pathway is mediated by D1-receptors, and the 
indirect pathway is mediated by D2-receptors. Striatum (Str), globus pallidus externa (GPe), globus pallidus interna 
(GPi), subthalamic nucleus (STN), thalamus (Tha). Picture adapted from (Bjarkam and Sorensen, 2004). 
 
Mesencephalic Dopaminergic Cells: Differentiation and Development 
  
The central nervous system derives from the ectoderm germlayer and all the neurons are generated 
in a region-specific manner from the neuroepithelium by a series of inductive events. Early 
signalling from organizing centres, such as the midbrain-hindbrain border also known as the 
isthmus, generates a permissive region that is defined by a specific pattern of gene expression in the 
mesodiencephalon ventricular zone. This induces mitotic cells in this region to become postmitotic 
young neurons that are destined to become fully differentiated neurons, acquiring the DA 
phenotype (Crossley et al 1996, Echelard et al 1993, Hynes et al 1994; reviewed also in Smidt and 
Burbach 2007, Alavian et al 2008, Sillitoe and Vogel 2008).   
First, sonic hedgehog (Shh), together with fibroblast growth factor 8 (Fgf8), defines the specific 
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region  of the isthmus where the mDA neurons will be born. At least other three signalling 
pathways are involved in these early events and contribute to specify the proper positioning of the 
isthmus. Wnt signalling pathway (Wnt1 and Wnt5a) is also responsible for the activation of 
Engrailed transcription factors (En1 and En2) (Danielian and McMahon 1996, Castelo-Branco et al 
2003). Transforming growth factor-β (Tgf-β) is essential for the early Shh signalling and 
subsequent induction of mDA region (Farkas et al 2003). Finally, retinoic acid (RA) is also needed 
for the correct organization of the midbrain (Avantaggiato et al 1996, Clotman et al 1997). 
The isthmus is established very early during development by the mutual repression of two opposing 
transcription factors, the homolog of drosophila orthodenticle, Otx2, and the gastrulation brain 
homeobox 2 (Gbx2), thereby defining a sharp border. Wnt1 contributes to the mdDA neuronal 
phenotype by activating Otx2, which suppresses the expression of Nkx2.2, a transcription factor 
that is important in inducing the serotonergic neuronal lineage in the hindbrain, and that acts as a 
suppressor of the dopaminergic lineage (Prakash et al 2006). 
The transcription factors engrailed 1 and 2 (En1, En2) have been demonstrated to be essential for 
the generation and maintenance of mDA neurons (Simon et al 2001, Simon et al 2003, Sgado et al 
2006).  En1 is widely expressed in mdDA neurons, whereas En2 is expressed in a specific subset of 
neurons with different ontogeny. En1/2 double knockout mice initially show diminished generation 
of mdDA neurons, and those that do arise disappear completely later in development (Simon et al 
2001). This suggests two different roles for the En genes: one in the generation and/or 
differentiation and one in the maintenance of mdDA neurons. Expression of α-synuclein by 
midbrain dopaminergic neurons is diminished in En-1 null mice and absent in engrailed double 
mutants, although some TH-positive neurons are still present. These findings indicate that En-1 and 
En-2 regulate the expression of α-synuclein gene in ventral midbrain dopaminergic neurons (Simon 
et al 2001). 
After the expression domain of Otx2 is delineated, and regionalization events have begun, a second 
set of transcription factors appear:  the pair-ruled genes Pax2 and Pax5 (Urbanek et al 1997), the 
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lim-homeodomain factor Lmx1b (Adams et al 2000) and also the diffusible glycoprotein Wnt1 
(Prakash et al 2006). Shortly thereafter, En-1 (at the 1-somite stage) and En-2 (at the 3–5 somite 
stage) are expressed around the forming midbrain-hindbrain organizer. 
Recently, it has been shown that another transcription factor, Foxa2, plays a fundamental role in the 
specification of mDA precursor cells in the ventral floor plate (Kittappa et al 2007). Foxa2 is a 
member of the forkhead family of transcription factors, which is known to play a critical role in 
early development of endoderm and midline structures (Lai et al 1991, Sasaki and Hogan 1994).  
The expression of Foxa2 takes place when the transcription factors Lmx1b, Nkx2.2, and Phox2a 
between embryonic day E9.5 and 11.5, defines three adjacent ventral domains of neural progenitors 
before the first dopamine neurons are formed (Kittappa et al 2007, Wexler and Geschwind 2008) 
(Figure 5).                                                                      Figure5 taken from Kittappa et al 2007 Supplementary Materials 
 
Heterozygous Foxa2+/- mutant mice show no gross histological and behavioural defects throughout 
most of their life, but in late adulthood (18 months aged) about one third of animals begin to 
develop progressive muscle rigidity with asymmetric posturing and tremors, which are 
accompanied by an asymmetric selective loss of mDA neurons in SN but not in VTA region.   
The first indications of the cellular phenotype of mDA neurons are the appearance of Lmx1a and 
Msx1 in the still proliferating precursor cells. After this initial round of specification, the precursor 
cells gradually become postmitotic (in mice from about E10–E14) (Lumsden and Krumlauf 1996) 
and the first signs of the neurotransmitter phenotype appear, like the expression of the rate-limiting 
enzyme for dopamine synthesis, tyrosine hydroxylase. At the same stage, several transcription 
factors begin to be expressed, which are essential for their terminal differentiation and long-term 
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survival. Deficiencies in Lmx1b, Nurr1, Pitx3, and the Engrailed genes all result in the loss of mDA 
neurons before birth (Smidt MP et al 2000, Simon et al 2003, Sgado et al 2006) (figure 6). Nurr1 
regulates several proteins that are required for dopamine synthesis and regulation, such as tyrosine 
hydroxylase (TH), vesicular monoamine transporter 2 (VMAT2), dopamine transporter (DAT) and 
the receptor tyrosine kinase cRET. mdDA neurons are born and are able to develop in the absence 
of Nurr1. However, they fail to be maintained and have clear defects in transmitter synthesis and 
release. (Zetterstrom et al 1997, Saucedo-Cardenas et al 1998, Hermanson et al 2003, Smits et al 
2003).  The Pitx3 gene is expressed in all mDA neurons but in the Aphakia Pitx3-/- mice (which 
have a 652 bp deletion in the promoter region of Pitx3) the DA neurons in the SNc are lost (Smidt 
et al 1997, Hwang et al 2003, Nunes et al 2003, Smidt et al 2004), suggesting that Pitx3 could be 
involved in terminal differentiation or early maintenance of these subset of neurons. Induction of  
 
Figure 6. Early and late development, regional identity and induction of mesDA neurons. (A) Interaction of sonic hedgehog (Shh), secreted by 
the floor plate, and the fibroblast growth factor 8 (Fgf8), released from the mid-hindbrain organizer (MHO), induces mesDA neurons in the 
ventral midbrain. These neurons will later give rise to three distinct nuclei, retrorubral field (RRF), ventral tegmental area (VTA) and substantia 
nigra pars compacta (SNpc). The location of mesDA neurons is dependent upon the MHO, which is defined by the expression of two opposing 
factors, Otx2 and Gbx2, and also by Pax2, Pax5, and Wnt1, which participate in the regional specification of midbrain tissue. (B) Genes involved 
in the late development of mesDA neurons. After the early midbrain development and induction of mesDA neurons, the development of 
postmitotic neurons is controlled by at least three distinct pathways under the influence of Nurr1, the Engrailed genes, Lmx1b, and Pitx3. These 
factors start to be expressed in mesDA neurons around the same time (E10.5-13) and are important for their neurotransmitter phenotype, their 
survival and maintenance throughout the lifetime of the mouse. Expression of several vital genes is controlled by these transcription factors. In the 
mice lacking Engrailed genes, the expression of _-synuclein, is significantly reduced. The expression of tyrosine hydroxylase (TH), the rate-
limiting enzyme in dopamine synthesis, and of the GDNF receptor component, Ret, which is required for long-term survival of nigral DA 
neurons,47 is regulated by Nurr1. The Engrailed genes and Lmx1b are expressed in the region before induction of mesDA neurons (dotted lines); 
yet, their expression becomes relatively specific to postmitotic mesDA neurons during later embryogenesis (continuous lines). 
 
 
Pitx3 in mouse embrionic stem cells was also shown to lead to an up-regulation of genes highly 
expressed in nigral DA cells, like aldehyde dehydrogenase 2 (Ahd2), suggesting a role of retinoids 
during development, in part controlled by Pitx3 (Chung S et al 2005).  Pitx3 also seems to control 
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transcription of many DA-phenotype related genes, like TH and DAT (Lebel et al 2001, Maxwell et 
al 2005) and a coordinated action with Nurr1 seems to occur in many cases (Martinat et al 2006). 
Moreover mir133b controls in a negative feedback loop the action of Pitx3 (Kim et al 2007). 
At the same time when the dopaminergic precursor cells become postmitotic, they start to migrate 
along radial glia towards their final location (Shults et al 1990). In the rat, the development of VM 
dopaminergic neurons has been thought to occur between embryonic day (E) 11-15, with the peak 
at E14 (Altman and Bayer 1981).  
However, recent findings have demonstrated that the vast majority of the substantia nigra (SN) 
dopaminergic neurons are born already at E12 (Gates et al 2006). When the SN neurons have 
reached their positions in the midbrain, they form axons projecting towards the lateral ganglionic 
eminence (LGE), which develops into mature striatum. In the rat, TH-positive nerve fibers are 
found in the LGE already at E14, however, the dopamine innervation is not completed until weeks 
later (Smidt and Burbach 2007). Comparing the rat with humans, the ventral migration of TH-
positive cells in humans starts at approximately gestation week 7 and the first TH-positive nerve 
fibers are observed in the developing striatum at gestation week 9, although it takes years before the 
striatum is fully innervated (Freeman et al 1991).  
Different sets of molecules have been demonstrated, by means of different transgenic and knockout 
mice, to act as axon guidance cues in the migration of the young mDA neurons: Netrin1 (Ntn1) 
together with its receptor, deleted in colorectal cancer (Dcc) (Fazeli et al 1997, Flores et al 2005). 
Reelin has been implicated in the functional organization of the mDA system (Ballmaier et al 
2002); the proteoglycan phosphacan 6B4, proposed to act together with adhesion molecule L1CAM 
(Ohyama et al 1998); the expression of neural cell adhesion molecule (NCAM) and polysialic acid 
has been reported for migrating mDA neurons (Shults et al 1992).  
Furthermore, an extensive axonal pruning has been demonstrated to occur during the late stages of 
development to refine and consolidate the topographical organization of the established mesostriatal 
and mesolimbic connections (Hu et al 2004). Pruning is often used to selectively remove exuberant 
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neuronal branches and connections in the immature nervous system to ensure the formation of 
functional circuitry (Luo and O’Leary 2005). In contrast to the adult, axon collaterals originating 
from embryonic VTA and SNc neurons (E15 and E17) do not display a preference for the dorsal or 
ventral striatum (Figure 7). The molecular signals that regulate the selective pruning of mDA axon 
collaterals remain to be identified. 
 
Figure 7. At stage E15- E17, mDA axon collaterals from mDA SN or VTA neurons do not display any preference for the dorsal or ventral striatum; 
the topographical specificity of mesostriatal and mesolimbic projections observed in adult is achieved during late embryonic and early postnatal 
development by the selective elimination of VTA and SNc axon collaterals. Picture modified from Hu et al. 2004. 
 
 
Finally, once neurons have migrated to their final destination, they elaborate axons and dendrites 
along predetermined routes in the developing embryo to establish highly specific connections with 
their targets. This requires the proper growth and guidance of extending axons and dendrites as well 
as their subsequent branching and pruning, with the formation of functional synapses. Many other 
classes of molecules have been found to participate in these processes –among them ephrins and 
their receptors Ephs (EphB1, EphA4, EphA5, EphB3, EphA7; Liebl et al 2003, Yue et al 1999, 
Chung et al 2005, Grimm et al 2004, Willson et al 2006), semaphorins, plexins and neuropilins 
(Sema3A, Sema7A, plexinC1; Kawano et al 2003, Chung et al 2005, Pasterkamp et al 2007); and 
the repelling proteins Slits and their Robo receptors (Slit1. Slit2, Slit3, Robo1 and Robo2; reviewed 
by Dickson and Gilestro 2006). 
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Mesencephalic Dopaminergic Cells: DAT, VMAT2 and COMT 
are crucial components of their function 
 
Dopamine Transporter (DAT): function, expression and regulation 
 
It was about four decades ago when the concept of neurotransmitter reuptake was introduced 
(Hetting and Axelrod 1961) to explain how sympathetic nerve terminals are replenished by NA.  
It has been proposed that the reuptake process was an important mechanism for inactivating 
neurotransmitters. Soon afterwards the discovery of NA reuptake, similar but distinct uptake 
mechanisms were shown to exist for dopamine and 5-hydroxytryptamine (5-HT, serotonin) (Iversen 
1971). This led to the discovery that certain antidepressant and psychostimulants block the reuptake 
of monoamines in the brain. During the 1990s advances in molecular cloning techiniques led to the 
isolation of genes coding for monoamine transporters.  
The gene encoding the DAT was first cloned in 1991 by several groups (Kilty et al 1991, Giros et al 
1991, Shimada et al 1991, Usdin et al 1991). This transporter belongs to the Na+/Cl--dependent 
family of neurotransmitter transporters, which also includes transporters for the related biogenic 
amines norepinephrine and serotonin (NET and SERT respectively), as well as for the inhibitory 
neurotransmitters GABA and glycine (Masson et al 1999). All of these transporters have a common 
topological arrangement consisting of 12 transmembrane domains (TMs), a large glycosylated loop 
between TMs 3 and 4, and intracellular amino and carboxy terminal domains (figure 8).  
DAT can be considered a specific marker for dopaminergic neurons because it is expressed 
exclusively in neurons that synthesize DA as a neurotransmitter. There is increasing evidence 
suggesting that  DAT exists as an oligomeric complex in cells. The data are consistent with a model 
in which oligomerization is necessary for the efficient exit of DAT from the endoplasmic reticulum 
(Sorkina et al 2003, Torres et al 2003a). Several TMs have been postulated to be involved in the 
assembly of this oligomeric complex (Hastrup et al 2001, 2003; Torres et al 2003a). To carry out its 
role,  DAT must be targeted to specialized domains near sites of presynaptic DA release. 
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Figure 8. Amino acid sequence and topology of monoamine transporter proteins. a | Amino acid alignment of the human dopamine 
transporter, noradrenaline transporter and 5-HT transporter. Identical residues are shown in red, whereas similar residues (V, L, and I, K and R, F and 
Y, or D and E) are shown in orange. Asparagine residues that form part of N-linked glycosylation consensus sequences are shown in blue. A 
conserved aspartate residue in transmembrane domain 1 that is presumably involved in the interaction with monoamines is shown as a yellow box. A 
leucine-repeat in transmembrane domain 2, and a glycophorin-like motif in transmembrane domain 6, are shown in green. The intracellular loop 
between transmembrane domain 6 and 7 contains several residues involved in conformational changes during substrate binding and translocation and 
is shown in blue. Black bars represent putative transmembrane domains. The colour boxes covering the parts of the intracellular carboxyl termini 
represent interacting sites with Hic-5 (beige), synuclein (grey), and PICK1 (purple). DAT, dopamine transporter; h, human; NET, noradrenaline 
transporter; SERT, 5-hydroxytryptamine transporter.The samll red boxes over hDAT represent in frame methionines b | Proposed topology of 
monoamine transporters depicting 12 transmembrane domains connected by intracellular and extracellular loops.  Picture modified from (Torres et al 
2003). The M in blue represent the position of the internal TSS seen in A10 neurons in mouse. 
 
 
Immunoelectron microscopy studies have revealed that DAT molecules are not located at sites 
where neurotransmitter release takes place, but are confined to perisynaptic areas (Nirenberg et al 
1996), which implies that specific targeting mechanisms must exist for the proper localization of 
this transporter. Interestingly, these studies also demonstrated that DAT proteins are associated with 
intracellular compartments, particularly membranes of tubulo-vesicular structures. These findings 
supported the notion that DAT molecules are strategically targeted to perisynaptic sites in nerve 
terminals suggesting that a recycling mechanism might exist to shuttle the transporter proteins 
between intracellular compartments and the plasma membrane. 
At the cell membrane, the function of DAT can be regulated by multiple second messenger systems, 
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including protein kinase A, protein kinase C (PKC), protein kinase G, tyrosine kinases, 
phosphatases, calcium and calmodulin-dependent kinases, and arachidonic acid (reviewed in  
Doolen and Zahniser 2001, Mortensen and Amara 2003, Melikian 2004, Vaughan 2004). The best 
characterized effect is the down-regulation of the transporter activity by PKC activators, which has 
been described extensively in several systems, including striatal synaptosomes and heterologous 
cells. PKC activation down-regulates DAT by decreasing the transporter Vmax with little change in 
substrate affinity. This modulation occurs largely through redistribution of the transporter protein at 
the cell surface rather than changes in intrinsic transport activity. In PC12 cells stably transfected 
with DAT, PKC activation increases the rate of transporter internalization while decreasing the rate 
of transporter recycling to the plasma membrane (Loder and Melikian 2003). However, in MDCK 
cells expressing DAT, activation of PKC leads to internalization and subsequent degradation of the 
transporter (Daniels and Amara 1999). More recent studies suggest that trafficking of DAT can also 
be regulated by substrates and inhibitors of the transporter. DA and amphetamine induce 
internalization of DAT in heterologous cells (Saunders et al 2000), whereas cocaine increases cell 
surface expression of the transporter (Daws et al 2002, Little et al 2002). Together, these results 
suggest that rapid DAT endocytic trafficking mechanisms are established at neuronal synapses. 
Indeed, a non-classical endocytic signal has been identified recently in the most proximal region of 
the intracellular C-terminal of DAT (Holton et al 2005) and multiple residues in the same region of 
the transporter are responsible for export from the endoplasmic reticulum (Miranda et al 2004). 
However, to date very little is known about the regulatory components involved in trafficking of 
DAT. Several proteins have been reported to physically interact wiht DAT (Torres 2006). 
These interactions suggest that the synaptic distribution, targeting, compartmentalization, 
trafficking and functional properties of DAT can be regulated via interacting proteins. Most of the 
known DAT-interacting proteins have been identified using the yeast two-hybrid (Y2H) system. In 
this assay, protein–protein interactions can be detected by cotransforming the bait of interest with a 
library of clones and growing the transformants in yeast media selective for the genes expressed as 
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a result of the interaction (Fields and Song 1989). The DAT-interacting proteins identified to date 
using the Y2H system are: protein interacting with C kinase- 1 (PICK1) (Torres et al 2001), the 
focal adhesion protein Hic-5 (Carneiro et al 2002), SNAP-25 (synaptosome associated protein 25 
kDa) (G. Torres, unpublished observations), α-synuclein (Lee et al 2001), receptor for activated C 
kinase-1 (RACK1) and syntaxin (Lee et al 2004). Alternative approaches such as co-
immunoprecipitation resulted in the identification of the protein phosphatase PP2A (Bauman et al 
2000) and PKC-bII (Johnson et al 2005) as DAT interactors. 
Biochemical and functional studies have clearly demonstrated that the DAT exists as an oligomeric 
complex in cells and identified several TMs involved in transporter assembly (Hastrup et al 2001, 
2003, Torres et al 2003a). Hastrup et al. (2003) demonstrated that human DAT could be cross-
linked as a dimer at the plasma membrane of human embryonic kidney (HEK)293 cells providing 
evidence for a role of TM4 and TM6 in oligomerization process. Mutant transporter molecules that 
fail to oligomerize are retained in the endoplasmic reticulum (Torres et al 2003a, Sorkina et al 
2003).  
A leucine repeat in TM2 appears to be important for the initial steps in assembly of  DAT. Mutation 
of the leucine repeat in TM2 resulted in a transporter protein devoid of N-linked glycosylation, 
which suggests that DAT assembly precedes glycosylation during trafficking of the transporter to 
the plasma membrane (Torres et al 2003a). Based on these results we postulated a role for 
oligomerization in endoplasmic reticulum processing and cell surface trafficking (Figure 9). 
Cocaine and amphetamines, two important psychostimulants, interact with dopamine transporter. 
Cocaine and other chemically related drugs are nonselective, competitive inhibitors of monoamine 
transporters (Ritz et al 1987). By contrast, amphetamine-like drugs are substrates for monoamine 
transporters (Sulzer et al 1995, Jones et al 1998). Once inside the synaptic terminal, these drugs act 
as weak bases at synaptic vesicles, causing the redistribution of vesicular monoamines into the 
cytoplasm, and a reversal in the direction of neurotransmitter transport at plasma membrane 
monoamine transporters (Sulzer et al 1995, Jones et al 1998). As a result, the application of 
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amphetamines induces a massive release of monoamines into the extracellular space. 
 
 
Figure 9. Dopamine transporter is subjected to form oligomeric complexes. The model proposes that DAT assembly 
into an oligomeric complex is required for trafficking of the transporter complex to the cell surface. Mutant transporters 
that fail to oligomerize are retained in the ER. The DAT oligomers are mainly localised in presynaptic densities in 
lateral positions. Metamphetamines stimulate the DAT activity whereas cocaine and synthetic derivatives inhibits the 
reuptake. 
 
 
DAT: multiple transcript isoforms  
 
At least for the human SLC6A3 gene, there are accumulating experimental evidences that multiple 
transcript isoforms are produced from this locus, as summarized in the following scheme 
(figure 10). 
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Figure 10. Summary of all the known EST / cDNA clones at the human SLC6A3 locus. Most of them derives from 
oligo-capped cDNA from human substantia nigra (Kimura et al., Genome Res. 16-1: 55-65, 2006). - M are methionines. 
 
 
 
Vmat2: function, expression and regulation 
 
At the presynaptic site, availability and fusion competence of synaptic vesicles as well as the 
vesicular transmitter content contribute to the strength of postsynaptic responses. 
Vesicular monoamine transporters (VMATs) translocate monoamines from the cytosol into the 
secretory vesicles of monoaminergic neurons, neuroendocrine cells, and platelets (Liu et al 1992). 
Transport is driven by an electrochemical proton gradient (ΔµH+) across the vesicular membrane, 
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which is generated by a vacuolar H+-ATPase (Kanner and Schuldiner 1987). In mammals two 
closely related isoforms of the monoamine transporter, termed VMAT1 and VMAT2, respectively, 
were identified (Kanner and Schuldiner 1987, Erickson et al 1992). The transporter proteins 
presumably contain 12 transmembrane domains that are located on different vesicle subtypes 
(Erickson et al 1992, Nirenberg et al 1995). Both VMATs transport serotonin, dopamine, 
epinephrine, and norepinephrine but differ in their substrate preferences and affinities. In contrast to 
VMAT2, VMAT1 prefers epinephrine over norepinephrine, and the Kd for serotonin uptake is 
around 1 µM for VMAT1 but below 1 µM for VMAT2. Furthermore, histamine is only transported 
by VMAT2. The activity of both transporters is irreversibly inhibited by reserpine, whereas 
tetrabenazine (TBZ) exclusively inhibits VMAT2 (Peter et al 1994, Erickson et al 1996). 
VMAT2 mRNA is localized to monoaminergic neurons and VMAT2 protein is largely localized to 
synaptic vesicular membranes (Gonzalez et al 1994,  Peter et al 1995, Weihe et al 1994). 
VMAT2 function is important for proper packaging of monoamines for quantal, calcium-dependent 
vesicular release (Henry et al 1994, Johnson 1988, Kanner and Schuldiner 1987, Njus et al 1986). 
In addition, it may be important for sequestering toxins. The active metabolite, 1-methyl-4- phenyl-
phenydium  (MPP+) of the selective dopamine neuronal toxin N-methyl-1,2,3,6-tetrahydropyridine 
(MPTP) kills dopaminergic neurons or other cells that express the plasma membrane dopamine 
transporter, and causes a parkinsonian syndrome in vivo (Burns et al 1983, Heikkila et al 1984, Pifl 
et al 1993).  Overexpression of VMAT2, however, can suppress the toxicity of MPP+ by 
sequestering the toxin in vesicles away from presumed sites of cytoplasmic mitochondrial damage 
(Liu et al 1992, Liu et al 1994). Amphetamines cause cytoplasmic release of monoamines from 
vesicular stores through disruption of the pH gradient across vesicular membranes (Sulzer and 
Rayport 1990, Rudnick and Wall 1992). The balance between this release and VMAT2-mediated 
vesicular reuptake may be important for the non-quantal, calcium-independent extracellular 
dopamine release that modest amphetamine doses can yield, and for the dopaminergic toxicity that 
high-dose amphetamines can exert, perhaps through cytoplasmic oxidative stresses with dopamine 
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oxidation and free radical production (Seiden et al 1993, Zheng et al 2006). 
 
COMT: function, expression and regulation  
 
The catechol-O-methyltransferase (COMT) enzyme inactivates circulating catechol hormones, 
catechol neurotransmitters and xenobiotic catecholamines by methylating their catechol moieties 
(Axelrod and Tomchick 1958, Rivett and Roth 1982, Rivet et al 1983, Jeffery and Roth 1984). 
COMT has a role in the biosynthesis of melanin (Pavel 1993) and several investigators have 
postulated the involvement of this enzyme in such human mental disorders as depression and 
schizophrenia (Murphy and Wyatt 1975, Abdolmaleky et al 2008). COMT also inactivates L-Dopa, 
a catechol-containing drug used as a dopamine precursor in the treatment of Parkinson's disease 
(Ball et al 1972, Guldberg and Marsden 1975). Due to its harmful effect on the medication of 
Parkinson's disease, a great deal of interest has been directed towards the development of specific 
COMT inhibitors (Guldberg and Marsden 
1975, Mannisto and Kaakkola 1989) and the 
determination of the structure of the enzyme 
itself. Catechol-O-methyltransferase (COMT) 
inactivates dopamine by catalyzing the transfer 
of a methyl group from S-adenosyl-L-
methionine to dopamine, generating 3-
methoxytramine (3-MT) (figure 11).  
 
Figure 11. Two different uptake processes terminate the 
synaptic action of released catecholamines in brain: the 
high-affinity uptake to presynaptic nerve terminals 
(uptake1, followed by oxidation by monoamine oxidase, 
MAO) or glial cells uptake (uptake2, followed by O-methylation by COMT, and/or oxidation by MAO). For dopaminergic 
neurons, uptake by the high-affinity dopamine transporter (DAT) is the most effective mechanism, and the contribution of glial 
COMT remains secondary under normal conditions.  Picture modified from Cooper 2003 
 
COMT protein and enzyme activity are widely distributed in mammalian brain (Lundstrom et al 
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1995, Mannisto and Kaakkola 1999). In the striatum, the synaptic action of dopamine is thought to 
be largely terminated by neuronal uptake by abundant dopamine transporters (Giros et al 1996). In 
the prefrontal cortex, however, dopamine transporters are expressed at low levels within synapses 
and the rate of dopamine uptake is slow (Garris et al 1993, Sesack et al 1998, Lewis et al 2001, 
Wayment et al 2001). Thus, in the prefrontal cortex, one might speculate that alternative 
mechanisms, such as degradation by COMT, might be a key process in the regulation of dopamine 
availability. Consistent with this notion, studies of COMT knockout mice have demonstrated that 
dopamine levels are increased in the prefrontal cortex of these mice, but not in the striatum, 
suggesting a more critical role for COMT in cortical versus subcortical sites (Gogos et al 1998). 
COMT enzyme occurs in mammals as two distinct forms: in the cytoplasm as a soluble protein (S-
COMT), and in association with membranes as a membrane-bound form (MB-COMT). S-COMT 
activity is the most prevalent in all tissues, while MB-COMT activity represents generally less than 
5% of the total COMT activity (Jeffery and Roth 1984, Guldberg and Marsden 1975, Grossman et 
al 1985). However, in some human tissues, like the brain, the amount of MB-COMT activity has 
been reported to be higher (Rivett et al 1983). Two COMTspecific transcripts, 1.3-kb S-mRNA and 
1 .5-kb MB-mRNA, are synthesized from two separate promoter regions (Tenhunen et al 1994).  
The relative amounts of the COMT mRNAs vary in different human tissues and cell lines, 
suggesting a tissue-specific regulation of the expression. The two COMT promoters can be 
regulated by the methylation status: a CpG hypermerthylation specifically inactivates MB-COMT 
without affecting the S-COMT promoter in endometrial cancer (Sasaki M et al 2003). 
 
Comt: multiple transcript isoforms 
 
Recently, much attention has received the transcriptional regulation at the COMT locus, and some 
studies have been focusing on the presence of alternative mRNA variants for COMT transcripts. 
In one study Tunbridge and colleagues focused attention on potential mRNA variants present in the 
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brain. They detected 7 COMT variant mRNAs, resulting from both insertions and deletions within 
the known COMT brain transcript. Several of the variants alter the predicted coding sequence. 
Three of these variants correspond to sequences within the Aceview database and could be reliably 
amplified, while the remaining four do not correspond to any expressed sequence tags and were 
amplified only once (Tunbridge et al 2007). Here you can find a diagram containing all the variants 
(Figure 12). 
 
Figure 12. The primary COMT mRNA transcript and variants. The sequence of the primary COMT mRNA is shown, with individual exons 
numbered and represented by boxes. The variantCOMTmRNAsare shown below and are contrastedwith the primary sequence: additional sequence is 
indicatedwith color (each color indicates a particular additional exon; note that some pink sequence is shared byCOMTvariants 2–4 and some blue 
sequence by variants 5 and 7). Faded exons and features indicate deleted sequence. The position of stop codons (UGA), and selected AUG start 
codons are indicated. All variant mRNAs contain the functional Val158Met polymorphism, which is located near the 30 end of exon 4.   Picture taken 
from (Tunbridge et al 2007) 
 
Mesencephalic Dopaminergic Cells: previous gene expression studies 
 
The catecholaminergic cell system has been largely studied and extensively characterized from the 
anatomical, developmental and electrophysiological point of view, employing a combination of 
different approaches ranging from anatomical reconstruction with fluoro-labeled retrogade tracers, 
immunocytochemistry, reverse transcriptase-polymerase chain reaction of aspirated cytoplasm, 
patch-clamp whole cell recordings which gained a fairly global picture of the main features that 
distinguish anatomically distinct group of cells. With the advent of more high-troughput 
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technologies, like cDNA/oligo array platforms and high-throughput, partially automated, in situ 
hybridization (ISH) systems, more sophisticated tools became available for a more detailed and 
comprehensive description of cell diversity at the molecular level. 
One of the first hightroughput studies of gene expression profiling designed to uncover 
mesencephalic DA neuron diversity have been conducted in 2004. A microarray analysis has been 
applied to four different catecholaminergic neuron populations (SN, VTA, LC and A13), in their  
normal physiological condition, isolated from adult rat brain by laser capture microdissection 
(Grimm et al 2004). 200 cells from each population were used in 4 independent replicates, and the 
RNA amplified by two rounds of T7-based linear amplification was hybridized to 14,800 element 
rat cDNA microarrays. A common pool of amplified RNA from total brain was used as a common 
reference to evaluate the enrichment of set of genes, already known to be highly and specifically 
expressed in each CA population: tyrosine hydroxylase (Th) expressed in all CA cells, dopamine 
beta hydroxylase (Dbh) restricted to NA locus coeruleus cells, GTP cyclohydrolase I (Gtpch1), 
pterin-4-a-carbinolamine dehydratase (Pcd) and vescicular monoamine transporter 2 (Vmat2).  
Using a molecular phylogenetic approach, it was shown that SN and VTA neurons differed in only 
122 (<1%) of their expressed genes; on the contrary SN and A13 neurons had >5% of significantly 
differentially expressed transcripts, and the differences were even more when considering SN 
versus LC (>7%) and LC versus A13 (>10%). These results were somehow expected, considering 
that SN and VTA are functionally and developmentally more close to each other than with all the 
other groups. 
Despite their similarities, there are some critical differences in gene expression between SN and 
VTA neurons, both at the level of individual genes and in several potentially relevant cellular 
pathways. In general, unbiased gene expression profiling has successfully confirmed nearly every 
previously noted difference in gene expression between the regions (Table 1 and 2), proving that 
the large datasets produced by profiling experiments can be reliably used for developing testable 
hypotheses (Grimm et al 2004, Chung et al 2005, Greene et al 2005).  
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An unsupervised clustering analysis revealed relationship among classes of CA neurons, defining at 
some extent, the molecular signature of each class of CA neurons. First the authors described genes 
that are expressed in common with all the CA groups: among those pan-CA transcripts, the most 
represented categories were genes involved in neurotransmitter synthesis and transport, scanvenger 
of stress-induced cell damage, inflammation related genes, cell-adhesion molecules, different 
isoforms of the aldehyde dehydrogenase family and modulators of DA-receptor activity.  
Gene filtering and multiclass significance analysis revealed 534 genes whose expresssion differed 
between at least two groups of CA neurons. Several interesting individual genes (122) were 
differentially expressed between SN and VTA neurons in addition to those previously identified. 
Among these factors were transcripts from various categories, including transcriptional regulators 
(Sox-6, Zfp 288, HTF, and NGFI-A), molecules involved in vesicle trafficking (DOC2B, rab3B, 
and MARCKS myristoylated alanine-rich C kinase substrate), axon guidance (neuropilin 1, slit-2, 
and ephrinB3), ion channels [CLIC5 (chloride intracellular channel 5), VR1 (vanilloid receptor 1), 
and NMDAR2C], transporters (VGLUT2 and CNT2), and G protein-coupled receptors (α-1B-
adrenergic receptor and GPRC5C) The two most prominent functional classes encoded factors 
involved in synaptic plasticity and in cell survival and protection. Strikingly, most of these 
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transcripts were expressed at a higher level in the VTA neurons. 
Table 2  list five genes independently confirmed as differentially expressed in three separate large-
scale microarray experiments (Grimm et al 2004, Chung et al 2005, Greene et al 2005). Considering 
that these experiments were performed on different species, with different techniques, and on 
different microarray platforms, this is an extremely stringent list. 
MARCKS (myristoylated, alanine-rich C-kinase substrate) has recently been found to be an 
important regulator of dendritic spine plasticity through an activity and PKC-dependent pathway 
(Calabrese and Halpain, 2005). These functions of MARCKS are important for learning and 
memory and the plastic synaptic events that underlie them, such as long-term potentiation (LTP) 
(Matus 2005). Interestingly, MARCKS gene expression is altered in postmortem brains from 
suicide patients, and its expression is down-regulated by the mood stabilizer lithium (McNamara et 
al 1999, Wang et al 2001). Since dysfunctional VTA dopamine neurons are thought to be involved 
in addiction behaviour and mood disorders, higher MARCKS expression in this neuronal 
population provides a tantalizing clue for further investigation. Pituitary adenylate cyclase 
activating polypeptide (ADCYAP1 or PACAP) is known to support survival of dopamine neurons, 
and lipoprotein lipase may protect cells from damage caused by oxidized lipoproteins (Takei et al 
1998, Paradis et al 2003, Reglodi et al 2004). Both are intriguing in that VTA dopamine neurons are 
relatively protected from degeneration in parkinsonism. The neuronal role of γ -synuclein is not 
clear, but it has been reported to be involved in regulation of the cell cycle, abnormalities of which 
have been implicated in neurodegeneration (Inaba et al 2005).  NMDAR2C may possibly be 
involved in excitatory neurotoxicity in SN dopamine neurons (Kress and Reynolds 2005). Several 
single gene products discovered by expression profiling to be higher in the VTA have been 
successfully tested in vitro against dopaminergic neurotoxins, including the aforementioned 
PACAP, as well as gastrinreleasing peptide (GRP) and calcitonin/calcitonin gene-related peptide 
alpha (CGRP) (Chung et al 2005). Furthermore, an analysis of the associations to categories of 
genes revealed that there are concerted differences in gene expression between different 
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subpopulations of dopamine neurons (Figure 13), and it is likely that these broad categorical and 
pathway differences account for the distinctiveness of the neuron types (Chung et al 2005, Greene 
et al 2005). Profiling experiments have confirmed that neuropeptide genes as a category are more 
highly expressed in VTA dopamine neurons than in those from the SN (Chung et al 2005, Greene et 
al 2005). The other most prominent categorical difference between SN and VTA dopamine neurons 
is energy metabolism. Multiple genes related to energy pathways, electron transport and 
mitochondria are more highly expressed in the SN than the VTA (Chung et al 2005; Greene et al 
2005). This is particularly interesting because mitochondrial dysfunction may be critical to the 
pathogenesis of PD.  
 
Figure 13   - picture taken from Greene 2006 
 
Mesencephalic Dopaminergic Cells: neuropsychiatric disorders 
 
Even though SN and VTA neurons are located in close proximity, develop in response to the same 
inductive signals, and have partially overlapping axonal projection domains, they mature to 
innervate distinct targets, control different brain functions, and display different vulnerabilities to 
neurodegeneration and other phatologies. While SN neurons are selectively affected by movement 
disorders associated to neurodegenerative conditions such as Parkinson`s disease, VTA neurons are 
more linked to the development of mood disorders such as schizophrenia, bipolar disorder, 
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attention-deficit hyperactivity disorder (ADHD), depression and drugs addiction. 
Traditionally the VTA was thought to be composed of two main neuronal populations, the DA 
neurons (or primary neurons) representing the majority of cells, and γ-aminobutyric acid (GABA)-
ergic neurons, acting merely as local circuit neurons that make synapses onto neighbour DA cells 
(Johnson and North 1992, Lacey Mercuri North 1989). Recent studies however have suggested that 
VTA contains at least three main subpopulations on the basis of their electrophysiological (intrinsic 
conductances), pharmacological (response to DA, opioids and serotonin) and biochemical (presence 
of TH) properties (Margolis et al 2003). For this reason, VTA neurons are now distinguished in 
primary DA-ergic neurons, secondary GABA-ergic neurons, and tertiary neurons whose 
neutransmitter identity has still to be characterized (Figure 14). 
 
Figure 14. VTA different neuronal subpopulations - picture taken from: Miller Cummings “The Human Frontal lobes”  
The activity of VTA DA-ergic neurons is under the physiological control of several 
neurotransmitter systems from different afferent projections – Figure 15 (Grillner and Mercuri 
2002). These include GABA, from local GABA-releasing cells and from GABA-ergic projections 
from the basal ganglia; glutamate from several brain regions, including PFC, hippocampus, 
amigdala, and pontine nuclei; ascendine biogenic amine systems, comprising noradrenaline from 
locus coeruleus, serotonin from the raphe nuclei, acetylcholine from pontine nuclei, and several 
neuropeptides (Phillipson 1979). Importantly, dopamine itself is released somatodendritically 
within VTA (Beckstead et al 2004) and the balance of afferent imput to the VTA and the activation 
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of different neurotransmitter receptors on different VTA neurons determines their overall output 
activity. 
 
Figure 15. VTA different afferent projections - picture taken from: Miller Cummings “The Human Frontal lobes”  
 
These afferent imputs are possibile targets for addictive drugs, as well as for current 
pharmacological treatments in psychiatric disorders, including schizophrenia and depression. 
The PFC plays an important role in the neurobiology of  “attention”, in the choice of appropriate 
responses, spatial learning, temporal planning and sequencing of motor actions, planning of future 
actions based on prevoiusly acquired information, and working memory (Castner Goldman-Rakic 
and Williams 2004, Goldman-Rakic et al 2004). Disruption of DA receptor in the dorsolateral PFC 
is associated with profound working memory alterations, in agreement with a DA receptor 
mulfunction in schizophrenia (Castner et al 2004), This is particularly relevant since a working 
memory dysfunction is the most prominent deficit in patients with schizophrenia (Park et al 1999). 
Notably it has been observed that DA receptor antagonists alleviate the symptoms of schizophrenia 
(Seeman 2002) whereas elevated DA levels in PFC correlate with a more severe impairment 
(Angrist et al 1985). In particular D1 type of DA receptors are the most promising target for 
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treatment of PFC cognitive dysfunctions (Castner et al 2004).  
Increased dopaminergic activity in the mesolimbic pathway is consistently found in schizophrenic 
individuals. Schizophrenia is a psychosis, a disorder of thought and sense of self. Although it 
affects emotions, it is distinguished from mood disorders in which such disturbances are primary. 
Similarly, there may be mild impairment of cognitive function. However, it is distinguished from 
the dementias in which disturbed cognitive function is considered primary. There is no 
characteristic pathology, such as neurofibrillary tangles seen in Alzheimer disease. Schizophrenia is 
a common disorder with a lifetime prevalence of approximately 1%. It is highly heritable but the 
genetics are complex. PET studies suggest that the less the frontal lobes are activated during 
working memory task, the greater the increase in abnormal dopamine acivity in the striatum, 
thought to be related to the neurocognitive deficits in schizophrenia (Meyer-Lindenberg et al 2002). 
VTA neurons have been also strongly implicated in development of drug addiction behaviours.    
The mesolimbic pathway has been implicated in tranlation of motivation to motor behaviour- and 
reward-related learning. The most consistent part of VTA involved in these taskes establish its 
connections with the nucleus accumbens in ventral striatum.  
This system is commonly implicated in the seeking out and consumption of rewarding stimuli or 
events, such as sweet-tasting foods or sexual interaction. However, its importance to addiction 
research goes beyond its role in "natural" motivation: while the specific site or mechanism of action 
may differ, all known drugs of abuse have the common effect since elevate the level of dopamine in 
the nucleus accumbens. This may happen directly, such as through blockade of the dopamine re-
uptake mechanism (cocaine), or indirectly, such as through stimulation of the dopamine-containing 
neurons of the VTA that form synapses onto neurons in the accumbens (opiates). The euphoric 
effects of drugs of abuse are thought to be a direct result of the acute increase in accumbal 
dopamine (Wise 1996). Chronic elevation of dopamine will result in a decrease in the number of 
DA receptors available in a process known as “downregulation”.  
The decreased number of receptors changes the permeability of the cell membrane located post-
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synaptically, such that the post-synaptic neuron is less excitable. It is hypothesized that this dulling 
of the responsiveness of the brain's reward pathways contributes to the inability to feel pleasure, 
known as anhedonia, often observed in addicts. The increased requirement for dopamine to 
maintain the same electrical activity is the basis of both physiological tolerance and withdrawal 
associated with addiction. At the molecular level the drug addiction has been related to a change in 
the synaptic plasticity which normally takes place in learning processes.  
 
Parkinson`s disease 
Parkinson`s disease: retrospective, clinical features and epidemiology 
 
 
 
Parkinson`s disease was described for the first time by an english physician James Parkinson, in his 
essay “An Essay on the shacking Palsy” (1817). It is a clinical syndrome, with variable 
combinations of akinesia, rigidity, resting tremor and postural instability and a characteristic pattern 
of neurodegeneration, which predominantly affects dopaminergic neurons of the substantia nigra, 
leading to a depletion of dopamine in their striatal projection areas (Bernheimer et al 1973, Selby 
1984, Trétiakoff 1919). The prevalence of Parkinson’s disease is approximately 1-2% worldwide 
with a typical age-of-onset of about 60 years (Shastry 2001).  The characteristic symptoms appear 
first when about 50% of the dopamine neurons in the SN are lost, and the levels of dopamine in the 
striatum are reduced by 80% (Agid 1991, Bernheimer et al 1973, Kish et al 1988). Patients 
suffering from Parkinson’s disease often display reduced spontaneity, lack of motivation as well as 
dementia (Braak and Braak 2000, Jellinger 1991, Zweig et al 1993).  
The annual incidence of PD ranges between 16 and 19 individuals per 100,000 (Twelves et al 
2003). PD occurs throughout the world in all ethnic groups and affect both sexes roughly equally or 
with slight predominance among males (Zhang and Roman 1993). In 5-10% of the patients initial 
symptoms arise between age 10 and 40 years, hence is defined as young onset PD (Golbe 1991). 
However, the first symptoms of juvenile onset PD occur before the age of 20 (Muthane et al 1994). 
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Young onset and juvenile onset PD are familial PD since family history is found in these patients. 
Idiopathic PD or typical sporadic PD is the term probably reserved for PD cases without or known 
etiology or familial connection (Samii et al 2004). 
Another hallmark of Parkinson's disease is the presence of intraneuronal cytoplasmatic inclusion 
bodies, Lewy bodies. These eosinophilic protein aggregates composed of specific cytoplasmatic 
proteins, such as α-synuclein, parkin, ubiquitin, synphilin and oxidized neurofilaments, were first 
described in 1912 (Lewy 1912, Forno et al 1996). 
Lewy bodies are primarily, but not exclusively, found in the SN. However, the presence of Lewy 
bodies is not exclusive for Parkinson's disease. A group of disorders which are called Parkinson-
plus diseases, display the classical features of Parkinson`s disease with additional symptoms that 
distinguish them from the simple idiophatic PD. These include: multiple system atrophy (MSA), 
progressive supranuclear palsy (PSP) corticobasal degeneration (CBD), and dementia with Lewy 
bodies (DLB).  
All of these disorders have in common, the presence of Lewy body-like inclusions and for this 
reason they have been also known as alpha-synucleinopathies due to the fact that alpha-synuclein is 
a major component of the inclusions (Spillantini 1999, Iwatsubo 2007).   
In DLB cases, the distribution of Lewy bodies is denser and more widespread than in idiophatic PD.  
Lewy bodies are also present in Alzheimer’s disease,  as well as in healthy people during normal 
aging (Forno et al 1996, Gibb and Lees 1988, Spillantini et al 1998). However, the exact role for 
Lewy bodies in Parkinson's disease is not established (reviewed by Harrower et al 2005, Halliday 
and McCann 2008).  Neuromelanin, a polymer pigment, is present in the SN (black nuclei) and the 
LC (blue spot) and increases with age (Marsden 1983). The exact function is not known, but it has 
been suggested to be a waste product in the metabolism of catecholamines. Extracellular 
neuromelanin in the SN, however, is found to correlate to areas within the SN high in 
immunoreactive MHC class II microglia (Beach et al 2007).  Additionally, neuromelamin can 
stimulate the release of tumor necrosis factor alpha (TNFα), interleukin- 6, and nitric oxide from 
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cultivated microglia (Wilms et al 2003). The neuromelanin-pigmented neurons are the neurons 
undergoing degeneration in Parkinson's disease. The levels of neuromelanin are about half in brains 
from Parkinson’s disease patients compared to aged matched controls (Zecca et al 2002). This loss 
of neuromelanin in Parkinson's disease can be monitored using magnetic resonance imaging (MRI) 
(Sasaki et al 2006, reviewed by Zecca et al 2006). 
In addition to the loss of VM dopamine neurons in Parkinson's disease, the noradrenaline neurons in 
the LC (A7) are also degenerating (Ehringer and Hornykiewicz 1960). The loss of neurons in the 
LC is actually more extensive than that found in the VM (Ehringer and Hornykiewicz 1960, 
German et al 1992, Mann 1983, Zarow et al 2003). It has been demonstrated that noradrenaline 
reduces oxidative stress in VM cultures (Troadec et al 2001). Furthermore, the loss of noradrenergic 
neurons results in increased sensitivity in dopamine neurons to various insults, e.g. 1-methyl-4- 
phenyl-1,2,3,6-tetrahydropyridine (MPTP) (Heneka et al 2003, Mavridis et al 1991, Srinivasan and 
Schmidt 2004).  
 
Parkinson`s disease: Genetics  
 
Genetic discoveries in combination with epidemiologic studies have implied multiple putative 
causes for Parkinson’s disease, thus the term “Parkinson’s diseases” might be more appropriate 
(Galpern and Lang 2006, Lang 2007). 
Some of the features implicated to participate in the destruction of the dopaminergic neurons are 
age, genetic factors, environmental factors, neuroinflammation, and oxidative stress. Among these, 
age is the strongest risk factor for developing the disease (Semchuk et al 1993). 
Results of twin study, a frequently used tool to study the role of genetics, showed little difference in 
concordance in twins when PD develops after age of 50 years, whereas complete concordance was 
shown in monozygotic twins for PD with onset before 50 years of age. This finding suggests that 
genetic factors play a more significant role in the young-onset than late-onset or typical sporadic PD 
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(Tanner et al 1999). In the population of PD patients there were less than 5% patients with 
monogenetic inheritance of the disease, 10-15% patient with familial history and vast majority of 
patients, about 80%, were essentially sporadic or idiopathic with complex etiology (Lang and 
Lozano 1998, Olanow and Tatton 1999). Current information suggests that PD is likely to result 
from a combination of both genetic and environmental factors (Olanow and Tattonc 1999, Hardy et 
al 2003). Several genes have been suggested to participate in either dominant or recessive forms of 
PD with different age at onset and different associated features.  
These genes can be grouped in several functional categories: proteins involved in organelle 
trafficking and vescicular fusion (α-synuclein, tau), genes implicated in degradation pathways like  
ubiquitin-proteasomal mediated degradation (parkin, UchL1, DJ-1) and lysosomal function (β-
glucocerebrosidase), genes affecting mitochondria  (PINK1, DJ-1, LRRK2, HtrA2, PolG), proteins 
that modify oxidative stress response or antioxidant functions (sepiapterin, DJ-1, Fgf20) (Funayama 
et al 2002, Maroteaux et al 1988, Nagakubo et al 1997, Shimura et al 2000, Valente et al 2004, 
Zimprich et al 2004, reviewed in Gasser 2007, Inamdar et al 2007) (Table 3).  
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Table 3. Genes determined-suggested to be cause or suceptibility factors for primary parkinsonism. 
 
 
Parkinson`s disease: alpha-synuclein  
 
The A30P and A53T α-synuclein (α-syn) mutations were the first genes found to be linked to 
familial PD (Polymeropoulos et al 1997) and even before α-syn was detected as major component 
of Lewy bodies in PD, a role of α-syn in AD was discovered, when a peptide derived from the 
central hydrophobic region of this protein (aa 61-95), known as non-amyloid beta component of AD 
amyloid plaques (NAC), was found to represent the second major instrinsic element of the AD 
senile plaques (Ueda et al 1993, Han et al 1995). The Snca gene encodes for a small acidic protein 
first described in Torpedo californica and very abundant in brain (Clayton and George 1998, 
Tofaris and Spillantini 2005), which is highly expressed in neurons and glial cells of the peripheral 
and central nervous system, where it is primarily concentrated in presynaptic axon terminals. It 
belongs to the synuclein family which comprises β-synuclein and γ−synuclein sharing a common 
signature sequence in their N-terminal region containing a different number of repat regions while 
they differ in their carboxy-terminal part (Tofaris and Spillantini 2005). 
α-synucleins from different organisms possess a high degree of sequence conservation (Clayton and 
George 1998). At least three α-synuclein isoforms are produced in humans by alternative splicing 
(Beyer 2006). The best-known isoform is α-syn-140 (NACP140), which is the whole and major 
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transcript of the protein. Two other isoforms, α-syn-126 and α-syn-112 (NACP112), are produced 
by alternative splicing, resulting in an inframe skipping of exons 3 and 5, respectively. Exon 3 
encodes for residues towards the N-terminus, residues 41–54, and exon 5 encodes for residues 
towards the C-terminus, residues 103–130. The whole transcript, α-syn-140, can be divided into 
three regions: 
 The N-terminal region, residues 1–60, includes the sites of three familial PD mutations and 
contains four 11-amino acid, imperfect repeats with a highly conserved hexameric motif 
(KTKEGV). The N-terminal region is positively charged and predicted to form amphipathic 
α-helices, typical of the lipid-binding domain of apolipoproteins, with which α-syn shares 
homology (George et al 1995, Clayton and George 1998). 
 The central region, residues 61–95, comprises the highly aggregation-prone NAC sequence 
(Ueda et al 1993, Han et al 1995). 
 The C-terminal region, residues 96–149, is highly enriched in acidic residues and prolines. 
Three highly conserved tyrosine residues, which are considered a signature of the α- and β-
synuclein family, are located in this region. 
 
 
 
Figure 16. Motifs in the α-synuclein protein. The natively unfolded α-synuclein protein is shown in a linear form. PINK1 
shaded areas represent the imperfect KTKEGV repeats. Human mutations are shown in red and map to the repeat region. At 
the C-terminal end of the protein is an acidic tail, containing several sites of phosphorylation (green). The C-terminus also 
contains the alternatively spliced exon V and a calpain I cleavage site. The acidic tail tends to decrease protein aggregation, 
whereas a hydrophobic region near the imperfect repeats promotes aggregation.  Modified from (Cookson 2005). 
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The α-syn belongs to a family of natively unfolded proteins that lacks a typical secondary structure. 
Under pathological conditions, these disordered proteins can also undergo conformational changes 
leading to protein aggregation and deposition. In the case of α-syn, its pathological fibrillization 
results in the formation of intracellular inclusions and neurodegeneration. Different functions have 
been associated to the three main domains in the protein (Figure 16). The seven imperfect 11-
residue repeat sequences are predicted to form five amphipathic helices on the amino-terminal half 
(Bisaglia et al 2006, Davidson et al 1998, Jao et al 2004). On the other hand, the acidic, glutamate-
rich carboxy-terminal region remains unstructured even in the presence of membranes (Jao et al 
2004). α-syn helices 1–4 are predicted to associate with lipid vesicles (Biere et al 2000, Perrin et al 
2000), while helix 5 would be responsible for protein–protein interactions (Davidson et al 1998). 
Nevertheless, α-syn is a very dynamic molecule whose secondary structure depends on its 
environment (Davidson et al 1998, Perrin et al 2000). Thus, it adopts an unfolded random coil 
structure in aqueous solution (Weinreb et al 1996) and shows an α-helical structure upon binding to 
acidic phospholipid vesicles (Bussell and Eliezer 2004, Chandra et al 2003, Trojanowski and Lee 
2003). Finally, as with other amyloidogenic proteins, α-syn undergoes a pathological transition 
from random coil to a β-pleated sheet conformation accompanied by extensive aggregation and 
fibril formation resembling the filaments of Lewy bodies (Conway et al 2000, Giasson et al 1999, 
Serpell et al 2000). 
 
Figure 17. AFM images of R-
synuclein fibrils (right) and oligomers 
(left). The fibrils show the 
characteristic twist of mature fibrils 
and are 10 nm high. The oligomers are 
from the late lag phase period and are 
mostly 5 or 7 nm high. The images are 
3 µm square.   Modified from Fink 
Acc. Chem. Res. 2006, 39, 628-634 
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α-Syn exists as two different structural conformers in vivo, one of which is a membrane-bound 
form with a stable α-helical structure and the other an essentially disordered free cytosolic form 
(Bussell et al 2005, Eliezer et al 2001, Jo et al 2000). It has been shown that these membrane-bound 
α-syn forms initiate aggregation and provide the seeds responsible for accelerated deposition of the 
less aggregation prone but more abundant cytosolic form (figure 17). 
Some hints about the physiological function of α-syn comes both from the analysis of the structure 
of the protein, its cellular localization and the phenotype associated to its mutations. 
The biochemical structure of the protein predicts that α-syn may function as a molecular chaperone 
capable of binding to other intracellular proteins (Ostrerova et al 1999). This hypothesis was 
strengthened by two observations. First, α-syn shares structural homology with the 14-3-3 family of 
molecular chaperone proteins (Ostrerova et al 1999, Tzivion et al 1998). 
Second, α-syn expression is regulated throughout development, with up-regulation during periods 
of accelerated neuronal activity and plasticity (Petersen et al 1999, George te al 1995). 
Consistent with the chaperone hypothesis, α-syn interacts at axon terminals with numerous 
proteins, more than 250, some of which regulate dopamine homeostasis in nigrostratial dopamine 
neurons (Zhou et al 2004). One of the first identified interactors is phospholipase D2, which may 
regulate monoaminergic vesicle content and nerve terminal dopamine storage (Jenco et al 1998, 
Lotharius and Brundin 2002). Additionally, phospholipase D2 may be involved in cellular adhesion 
(Powner et al 2005) and the recycling pathway between endosomes and the plasma membrane 
(Padron et al 2006). 
α-syn expression also alters dopamine transporter- mediated uptake of synaptic dopamine, which 
suggests a role in terminating dopamine neurotransmission (Sidhu et al 2004). The catalytic activity 
of tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, regulates α-syn through 
phosphorylation (Perez et al 2002, Drolet et al 2006). Furthermore, α-syn plays a key role in 
mediating substrate-dependent enhancement of phosphorylated tyrosine hydroxylase and dopamine 
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synthesis in nigrostratial dopamine neurons (Perez et al 2002, Drolet et al 2006) and is directly 
involved in dopamine recruitment and presynaptic dopamine compartimentalization (Yavich et al 
2004). Recently, it has been shown that aggregated α-syn stimulates the phosphorylation of TH 
(Alerte et al 2008). 
Finally, an antiapoptotic function of α-syn by down-regulation of the p53 pathway has also been 
observed (Alves Da Costa et al 2002). 
Among the pathogenic genes implicated in PD, α-syn is probably the most studied since: 
 _ It is a major component of LBs and Lewy neurites (Spillantini et al 1997). 
 _ Overexpression of wild-type α-syn through gene multiplication (also known as the    
PARK4 gene for familial PD) triggers PD (Singleton et al 2003). 
 _ Virus-mediated α-syn overexpression can kill SN DA neurons (Kirik et al 2002). 
 _ α-syn knockout mice are resistant to DA neuronal death by MPTP toxicity  
         (Dauer and Przeborski 2003). 
 _ MPTP and 6-hydroxy-DA increase α-syn expression in rodent SN DA neurons  
         (Vila et al   2000, Kholodilov et al 1999). 
PD is now widely considered a ‘synucleinopathy’ as are ’parkinson-plus’ disorders such as multiple 
system atrophy (MSA) and diffuse Lewy body disease. These diseases also show accumulations of 
aggregated α-syn. The physiological role of α-syn might involve the control of vesicle exocytosis at 
a late stage before fusion (Larsen et al 2006). This might involve alternate binding and dissociation 
from membrane, shifting between an α–helical conformation in ‘lipid rafts’ to an unfolded 
conformation in the cytosol. Provocatively, the A30P PD mutation binds the membrane poorly and 
might be more subject to aggregation. The dissociation from the synaptic vesicle membrane seems 
to result from and regulate synaptic vesicle exocytosis (Fortin et al 2005). It is by no means clear 
whether the normal physiological function of α-syn is involved in PD, and it is widely suspected 
that problems in degradation might initiate a ‘toxic gain of function’, perhaps through aggregation. 
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Braak et al. (2006) examined immunolabeled α-syn to study aggregation in autopsy of PD patients 
and also in asymptomatic individuals who might have been en route to developing PD. They 
suggest a progression of PD through ascending brain regions, beginning with medulla 
oblongata/pontine tegmentum and olfactory bulb, to locus coeruleus (LC), raphe, then SN, and at 
late stages to the neocortex. There is no clear relationship between α-syn expression and neuronal 
cell death. Expression is much higher during early human development than at maturity (Raghavan 
et al 2004), when pathogenesis takes place. However α-syn expression has been shown to increase 
progressively during normal ageing in monkeys and humans (Chu and Kordower 2007).  
In normal adult humans, the α-syn mRNA label is strong in neuromelanin (NM) positive SN 
neurons but is also high in unaffected regions (Kingsbury et al 2004). Moreover, there are no data 
indicating extensive neuronal loss of cortical neurons in PD despite the presence of LBs. In other 
words, the presence of α-syn pathology in neurons does not indicate that the neuron will necessarily 
die. 
Not surprisingly, products resulting from the interaction between DA and α-syn have been 
extensively explored for toxicity. Originally presumed to be a covalent bond, recent results suggest 
that there is an ionic interaction between DA–quinone and residues 125–129 in the protein (Norris 
et al 2005). DA modification of α-syn seems to maintain small α-syn oligomers in a reactive 
protofibril conformation by inhibiting progression to a less reactive aggregate. Protofibrils damage 
the membrane and do so more effectively with the pathogenic α-syn mutations (Volles et al 2001). 
Micromolar concentrations of α-syn cause proton leakage from isolated chromaffin secretory 
vesicles (Mosharov et al 2006), and α-syn molecules with pathogenic mutations are particularly 
effective at causing leakage. It is not known whether the leak is caused by protofibril or native 
forms, as α-syn is amphiphilic and might have detergent-like properties. 
If DA synaptic vesicles are damaged by α-syn, a vicious cycle of dysregulated cytosolic DA and 
further α-syn damage may occur. DA-modified α-syn has been shown to block CMA in a manner 
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similar to that of the pathogenic mutants (Martinez-Vincente et al 2008). As a consequence, when 
neurons are stressed, CMA could be induced as a protective pathway, but for SN neurons with 
reactive levels of DA, the resulting α-syn modification could block CMA and lead to specific DA 
neuronal death.  
 
 
Parkinson`s disease: multiple transcripts of Snca  
 
At least four different alternative splicing variants of the α-syn transcript have been reported to 
exist in human (Beyer 2006). α-syn 140 is encoded by the larger transcript, whereas alternative 
splicing of exons 3 and 5 gives rise to α-syn 126 and α-syn 112, respectively. As shown in figure 
18, both α-syn 126 and α-syn 112 are characterized by the in-frame deletion of the correspondent 
exon sequence with no premature stop codons (Beyer et al 2006). More recently, another splicing 
isoform resulting from the in-fame deletion of both exon 3 and 5, called a-syn-98, has been 
described (Beyer et al 2008). Since alternative splicing generates potentially functional proteins 
with a different combination of domains, this has been believed it could be of particolar relevance 
for studying the functional roles associated to each specific isoform. 
α-syn 140 is a small protein with a molecular weight of 14.5 kDa. The isoforms generated by 
alternative splicing show small molecular weight differences (13.1 kDa for α-syn 126 and 11.4 kDa 
for α-syn 112) and, therefore, their SDS-page separation and Western blot detection are difficult to 
carry out, particularly when trying to distinguish between α-syn 140 and α-syn 126. Although Li et 
al analyzed C-terminal truncated α-syn forms, in their study the possibile existence of α-syn 
isoforms was not taken into account (Li et al 2004). The present lack of isoform-specific antibodies 
hampers the detection of α-syn isoforms at the protein level. Nevertheless, there exists some in 
direct proof that at least α-syn 112 is expressed as a protein. Studies on early α-syn accumulation 
preceding Lewy body formation (Kuusisto et al 2003) and on membrane bound α-syn (Lee et al 
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2002) failed to detect α-syn with antibody LB509. This antibody is commonly used in studies of α-
synucleinopathies and recognizes a minimum epitope at residues 115–122 of α-syn (Jakes et al 
1999), which is localized within the amino acid sequence corresponding to Snca gene exon 5 (this 
exon is lacking in α-syn 112). In contrast, in both studies α-syn detection was carried out with the 
aid of antibodies recognizing the C-terminal part (Jakes et al 1999, Lee et al 2002). 
 
Figure 18. Comparison of the alternative splicing isoforms of the α-synuclein gene that were experimentally 
determined; the four different human splicing isoforms (Snca 140, Snca 126, Snca 112, Snca 98) were confirmed to be 
expressed in human brain (Beyer et al 2008, Beyer 2006); whereas three splicing variants are described in rat (MacLean 
and Hyman 2002).  
 
α-Syn 140 is preponderantly transcribed in higher levels than α-syn 126 and α-syn 112 (Campion 
et al 1995). As α-syn 140 is the whole transcript of the Snca gene, it conserves its whole structure 
as well as all posttranslational modification sites. It is worth mentioning that all studies of α-syn 
structure and function have been carried out considering the whole protein only.  
Thus, although several α-syn functions have been identified in the last few years, nothing is known 
about the specific roles of each of the three α-syn isoforms (Beyer et al 2004). α-syn 126 is 
characterized by the in-frame deletion of the sequence corresponding to exon 3 (Figure 18). Exon 3 
localizes at the N-terminal of the protein and encompasses amino acid residues 41–54. The splice-
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out of exon 3 results in the interruption of the four helical protein–membrane interacting domain 
with the deletion of almost the entirety of helix 3 and part of helix 4 (Figure 18). Interestingly, two 
of the three α-syn mutations described up to now are located within the sequence corresponding to 
exon 3. Specifically, the E46K mutation is in the midportion and the A53T mutation at the end of 
exon 3 (Polymeropoulos et al 1997, Zarranz et al 2004). The importance of α-syn N-terminal half 
during aggregation was suggested by α-syn intrinsic structure (Bertoncini et al 2005, Bisaglia et al 
2006b). Fibrillation studies of A53T and E46K mutated α-syn further underscored the importance 
of α-syn N-terminus in modulating filament formation (Greenbaum et al 2005).  
Additionally, mutant E46K α-syn showed increased formation of α-syn aggregates when compared 
to cells expressing wild-type or mutant A53T or A30P α-syn (Narhi et al 1999, Pandey et al 2006). 
Since structurally the E46K mutation affects the fourth KTKEGV repeat, this sequence seems to be 
of special importance in α syn aggregation. Interestingly, important differences in α-syn 126 brain 
expression levels between the three neurodegenerative disorders and controls could be observed 
(Beyer et al 2006). The expression of α-syn 126 was markedly decreased in the cortex in three 
neurodegenerative disorders DLB, LBVAD, and AD, with an almost fivefold decrease in DLB 
when compared to controls (Beyer et al 2006). 
α-syn 112 lacks the sequence corresponding to exon 5, located on the C-terminal half of the protein 
(Figure 18). The result of this in-frame deletion is a 112 amino acid protein lacking amino acids 
103–130. It has been shown that α-syn is phosphorylated at serine 129. Although α-syn 112 lacks 
this site, a second α-syn phosphorylation site at serine 87 would remain unaltered in this isoform 
(Okochi et al 2000). So far no studies have been carried out to determine the consequences of α-syn 
112 phosphorylation at serine 87. However, it has to be noted that serine 87 is not conserved across 
species, and is absent in mouse and rat.  Finally α-syn 98 lack both exon 3 and exon 5 and has been 
shown to be expressed at variable levels in various areas of the human brain (Beyer et al 2008). 
Overexpression of α-syn 98 in LBD and AD patients compared to control subjects has been 
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reported  for this short isoform, suggesting that it can play important roles in the pahogenesis of 
these disorders (Beyer et al 2008).  
In mouse so far there is no experimental evidence of expression of alternative splicing isoforms of 
α-syn, but many gene structure prediction tools report some different transcript isoforms produced 
from the Snca locus. Here you can find Aceview annotations summarizing what is known about the 
possible mouse transcript isoform based on the EST and cDNA data from various databases. 
 
 
Figure 19. A scheme of the possibile alternative transcripts and their corresponding proteins associated to the mouse 
Snca locus as emerges from cDNA and  EST data collected from many tissues and summarized by the AceView gene 
prediction database. At least 6 different isoforms are reported for α-syn; the d isoform being the most represented one 
with 180 accessions and being expressed in brain, visual cortex, ofactory brain, embryo. The other isoforms are less 
abundant: transcript e (80 accessions from visual cortex, whole brain, lateral ventricle wall, liver, activated spleen); 
transcript c (17 accessions from brain, embryo, prostate and lung); transcript b (3 accessions from retina); transcript a (2 
accessions from mammari gland, offactory and respiratory epithelium); and transcript f (1 accession from fethus). 
 
 
On the other hand in rat, three alternative splicing isoforms for α-syn have been described (reported 
in figure 18). Interestingly, one of these isoforms, rat α-syn 2 is expressed in vivo in adult brain and 
it has been observed to accunulate in cytoplasmic spots when overexpressed in cultured transfected 
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H4 cells. Morover, the treatment with the proteasome inhibitor n-acetyl-leu-leu-norleucinal 
(ALLN), induces the α-syn 2 isoform to specifically forms aggregates that were not seen for rat α-
syn 1. The two isoforms differ in their C-terminal region where a different sequence of 48 aa, 
specifically found in α-syn 2, is absent in α-syn 1 (McLean and Hyman 2002). 
 
Parkinson`s disease: molecular pathways  
 
Although various groups of neurons exhibit pathology in PD, the parkinsonism is clearly caused by 
loss of DA following death of substantia nigra (SN) neurons, as shown by the extensive (about 
80%) loss of neuromelanin-pigmented (NM+) DA neurons in the SN with a comparative sparing of 
the neighboring NM- ventral tegmental area (VTA) DA neurons (German et al 1989, Hirsh et al 
1988). PD pathogenesis in nearly all cases converges upstream of LB formation and death of DA 
SN neurons. Some hints into the mechanisms for specific vulnerability in PD would come from a 
deep knowledge and understaning of the biology of the SN and VTA neurons, and what is unusual 
about the A9 cells in particular. It has been suggested that those neurons might have features that 
predispose them to be extremely susceptible to stress.  
Among the multiple events that can concurrently lead to Parkinson`s disease there are factors 
involved in many different pathways and functions. The link between Parkinson’s disease and 
mitochondria was first established with the identification of a deficiency in the activity of complex I 
(NADH ubiquinone reductase) in PD substantia nigra and subsequently in the peripheral tissues of 
patients. Importantly, inhibition of complex I resulted in increased free radical generation and could 
contribute to the oxidative damage seen in SN. Inhibition of mitochondrial respiration reduced the 
levels of ATP required for normal cellular function. 
These changes in turn may induce protein damage and misfolding (Cassarino and Benneltt 1999). 
Neurotoxic compounds as MPTP and rotenone, which selectively damage dopaminergic neurons 
and cause PD-like clinical features, are selective inhibitors of complex I of mitochondrial 
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respiratory chain (Greenamyre et al 2003). There is 30-40% decrease in complex I dysfunction in 
PD which could thus play a role in oxidative stress, free radical-mediated protein damage, impaired 
proteasomal function and protein accumulation (Shamoto-Nagai et al 2003). Mitochondria are also 
intimately involved with both necrotic and apoptotic cell death. Recently, gene mutations of 
mitochondrial proteins PINK1 and DJ1 caused Parkinson’s disease, and mutations of MtDNA 
polymerase (PolG) caused parkinsonism. The relation between mitochondrial dysfunction and PD 
has been highlighted further by the recent description of mtDNA abnormalities in PD patients. 
Occasional mtDNA point mutations have been identified in PD but these have not been present in 
the general PD population. 
A mutation in the mtDNA 12S RNA was identified in a patient with maternally inherited early 
onset PD, deafness, and neuropathy. Several studies that have sequenced mtDNA in PD patients 
have not identified any consistent mutations. Two studies have shown a link between mtDNA 
haplotypes and the risk for developing PD. The first showed a reduced risk for PD in individuals 
with haplotypes J and K and the second a 22% decrease in PD risk in those with the UKJT 
haplotype cluster. In contrast, a smaller study reported an increased risk for PD with haplotypes J 
and T. 
Futhermore, studies in animal model systems of PD gained more insights into the mitochondrial 
contribution to PD: PINK1 and Parkin have been implicated to act in common in  a pathway to 
control mitochondrial morphology (Poole et al 2008). Pink1 in Drosophila is required for 
mitochondrial function and interacts genetically with Parkin (Clark et al 2006) whereas loss of 
function mutations of human PINK1 lead to mitochondrial pathology which can be rescued by 
Parkin (Exner et al 2007). Recently, much attention has been focused on the mitochondrial fission-
fusion process which contributes to dynamically control the mitochondrial morphology in the cells, 
and seems to be compromised in many neurodegenerative conditions (Frank 2006) (Figure 20). 
Surprisingly a recent paper has shown evidenses supporting a role for Pink1 as a central regulator of 
the mitochondrial fission-fusion machinery (Yang et al 2008). 
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Figure 20. PD genes and their relation to mitochondria. Aggregation of mutant or overexpressed α-syn might be an upstream actor of 
mitochondrial alterations or with ts binding to OMM in a pH dependent manner. Parkin associates with the OMM and was shown to play a role in 
mitochondrial biogenesis by regulating both transcription and replication of mtDNA. PINK1 has an N-terminal mitochondrial targeting motif and is 
localized to mitochondrial membranes, whereas oxidation of a key Cys-residue in DJ-1 leads to its relocalization to mitochondria. LRRK2 resides 
diffusely throughout the cytosol, but is partly associated with the OMM. HTRA2 resides in the IMS, wherefrom it is released upon apoptotic stimuli. 
Picture modified from Bogaerts et al 2008. 
 
Oxidative stress develops from increased production of highly reactive free radicals, decreased 
scavenging of these reactive species, increased generation of oxidatively damaged proteins, lipids, 
DNA and decreased clearance of oxidized products that could be toxic for cells (Shang et al 2003). 
Signs of oxidative stress are abundant in the SN of patients of PD (Jenner P 2003). These include 
reactive oxygen species (ROS) such as hydrogen peroxide, hydroxyl, superoxide and peroxyl 
radicals. Other oxidants are reactive nitrogen species (RNS) as nitric oxide (NO). These strong 
oxidants react with DNA, protein and lipid altering their structure and causing cellular damage 
(Jenner  1998). The oxidants as ROS are produced by dopamine metabolism, the electron transport 
chain of mitochondria, iron metabolism and inflammation.  
The enzymatic metabolism or auto-oxidation of dopamine generates free radicals (Hald and 
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Lotharius 2005). Dopamine metabolism by MAO-A leads to production of dihydroxy-phenylacetic 
acid (DOPAC) and H2O2 with the consumption of O2 and H2O. Intracellular auto-oxidation of 
dopamine generates dopamine-quinone and H2O2. Dopaminequinone participates in nucleophilic 
reaction with sulfhydryl groups of proteins leading to structural modification and reduced 
glutathione levels (Stokes et al 1999), and it is shown to inhibit glutamate and dopamine transporter 
function in synaptosome (Berman and Hastings 1997), inhibit tyrosine hydroxylase (Kuhn et al 
1999) in cell free systems and promote H+ leakage from mitochondria resulting in uncoupling of 
respiration to ATP synthesis (Khan et al 2001). H2O2 produced can be converted to hydroxyl radical 
by Fenton reaction in presence of ferrous ion. Hydroxyl radical can react with virtually every 
cellular macromolecule. In the presence of ferrous ion, the superoxide anion and H2O2 two weakly 
reactive free radical species can combine in the Haben-Weiss reaction to produce the more reactive 
OH radical (Berg et al 2001, Hirsh and Faucheux 1998). ROS inhibit complex I and provoke 
mitochondrial dysfunction. 
The iron-mediated catalysis of hydroxyl radical generation could be a key mechanism in 
pathogenesis mediated by oxidative stress. Elevation of iron levels are detected in the SNc in 
patients of PD (Berg et al 2001, Hirsh and Faucheux 1998). The iron levels are increased by 35% in 
PD patients compared to age matched control (Sofic et al 1988).  
The concept of excitotoxicity has been applied to a number of neurodegenerative diseases including 
PD (Hallett and Standaert 2004). Glutamate is the principal excitatory neurotransmitter and mediate 
its action by interacting with receptors such as NMDA (N-Methyl D-Aspartate), AMPA (α-amino-
3-hydroxy-5-methyl 4-isoxalopropionate) and kainate receptors. Persistent activation of the 
glutaminergic NMDA receptor increases intracellular levels of Ca2+ ions potentially leading to 
activation of proteases, endonucleases, phospholipases and NO synthase with resulting generation 
of reactive NO. Increased intracellular Ca2+ concentration and the subsequnt events leading to cell 
death is supported by the observation that dopaminergic neurons expressing calcium binding 
protein calbindin may be selectively preserved in PD (Hirsch et al 1992). 
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Parkinson`s disease: Current therapies  
 
The most commonly medical treatment used for Parkinson’s disease is L-dopa therapy. L-Dopa is a 
precursor of dopamine that can cross the bloodbrain- barrier. The effects of L-dopa was discovered 
when the impaired motor activity found after reserpin treatment was counteracted by giving the 
animals L-dopa (Carlsson et al 1957, Carlsson et al 1958). Further studies demonstrated dramatic 
reversal of the symptoms, although the effect of the drug was brief (Birkmayer and Hornykiewicz, 
1962). Later, trials displayed that higher doses and oral administration of L-dopa were efficient 
(Cotzias et al 1967). Today, administration of L-dopa is given together with decarboxylase 
inhibitors to decrease the peripheral metabolism. However, after some years of treatment, the effect 
of L-dopa declines and the patients develop dyskinesias (involuntary movements) and/or on-off 
symptoms due to fluctuations in the drug dosage (Granerus 1978, Lang and Lozano 1998a, Lang 
and Lozano 1998b). Dopamine agonists acting on the dopamine receptors are also an important 
therapeutic alternative. Furthermore, treatments to hamper the breakdown of dopamine by 
inhibiting the catechol-O-methyltransferase (COMT) and monoamine oxidase B are undertaken. 
Various combinations of the above-mentioned drugs are used as therapies for Parkinson's disease. 
However, the medications only improve motor activity deficiencies while do not cure the disease. 
One way to counteract the symptoms of the disease is to use deep brain stimulation, where high 
frequency stimulating electrodes are implanted in the basal ganglia. Implanting the electrodes to the 
ventral intermediate nucleus of the thalamus can reduce tremor (Benabid et al 1991, Putzke et al 
2003). Stimulation of either the subthalamic nucleus or the globus palludus interna diminishes 
bradykinesia, rigidity, as well as reduces L-dopa induced dyskinesia (Benabid et al 1998, Kumar et 
al 1998a, Kumar et al 1998b). 
Another potential approach to counteract the symptoms of Parkinsons’s disease may be the 
replacement of the lost dopaminergic neurons. Already in 1979, fetal dopaminergic transplants were 
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evaluated as a putative method to counteract the symptoms of Parkinson's disease in a 6-
hydroxydopamine (6-OHDA) animal model (Björklund and Stenevi 1979, Perlow et al 1979). The 
transplants were proven to be long-term surviving (Freed et al 1980, Stromberg and Bickford 1996), 
and the striatum of the host was reinnervated in a target specific manner (Strömberg et al 1992, 
Wictorin et al 1992). Furthermore, new synapses were formed (Freund et al 1985, Mahalik et al 
1985, Stromberg et al 1988), and the grafts were able to release dopamine in the reinnervated 
striatum (Rose et al 1985, Stromberg et al 1988, Zetterstrom et al 1986). Ten years after the first 
animal transplantation, human fetal VM was grafted to patients for the first time. Post mortem 
analysis displayed graft survival and reinnervation of the striatum (Kordower et al 1998). 
Unfortunately, the outcome of the clinical trials revealed poor cell survival and.the striatum was not 
fully reinnervated (Barker et al 1996, Brundin and Bjorklund 1998, Freed et al 2001, Hagell et al 
2002, Olanow et al 2003). Thus, it is important to find various neuroprotective and neurotrophic 
factors that can enhance survival and neuritic formation. A major problem with grafting fetal tissue 
is the limited availability of tissue. Stem cells, (self renewal and multipotent cells), are alternative 
sources for neuronal transplantation. In the last two years, much effort has been done to obtain stem 
cells to be used in various neurodegenerative disorders. However, major concerns regarding 
scientific, clinical and ethical issues need to be solved before stem cells can be used in Parkinson’s 
disease as therapy (Newman and Bakay 2008, Parish and Arenas 2007, Wang et al 2007). Hereafter 
are summarized all the currently used therapies. 
Neurotropic factors such as glial-derived neurotropic factors (GDNF) and brain derived neurotropic 
factors (BDNF) have shown potent protective and regenerative effects on dopaminergic neurons. 
Delivering GDNF directly into the putamen of PD patients greatly improves their symptoms and 
significantly increases DA uptake and storage (Gill et al 2003). BDNF appears as an important 
determinant of dopamine cell survival and D3 receptor expression (Guilin et al 2001). The 
beneficial effects of BDNF and GDNF raise the possibility that the supply of these or other 
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neurotropic substances may be limited or that their downstream signaling pathways may be 
dysfunctional in PD leading to degeneration of DA cells 
 
 
Table 4. Currently used therapies for Parkinson`s disease – taken from Inamdar et al 2007 
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SECTION2. Materials and Methods 
 
Striatal Cells and RNA extraction 
For the SMART7 amplification 20 µg of total RNA was extracted from wild type and mutant 
striatal neurons (STHdhQ111/HdhQ111), from knockin mice bearing the HD mutation (Trettel F et al, 
2000; kindly provided by Persichetti F).  
RNA was extracted by adding 1ml of TRIzol Reagent (Invitrogen) to two 10cm2 Petri dishes 
containing approximately 106 cultured cells each.  
For each dish, the lysate was passed several times through a pipette and incubated for 5 min at R.T. 
for the complete dissociation of nucleoprotein complexes. After adding 0.2ml of Chloroform and 
vortexing to mix, the samples were incubated at R.T. for 10 min and centrifuged at 12,000 rpm for 
15 min at 4 °C. The acqueous phase was transferred into a clean tube and the RNA was precipitated 
with 0.5 ml of isopropanol, shaken vigorously by hand for 10 sec, incubated at R.T. for 10 min and 
centrifuged at 12,000 rpm for 10 min at 4 °C. The supernatant was carefully removed,  the pellet 
washed with 1 ml of cold 75 % ethanol, and centrifuged at 12,000 rpm for 5 min at 4 °C. The pellet 
was air-dried for 10 min and resuspended in 20 µl of RNase-free water (Ambion) and 1µl was 
mixed with 1µl of 5 x RNA loading buffer and 4µl of water, denatured at 65 °C for 5 min and 
analyzed on 10% formaldehyde - 1% agarose gel. 
RNA amplification using SMART7 
Total RNA was serially diluted using siliconized microtubes, to assess the reliability of the RNA 
amplification protocol starting from amount equivalent to few cells: 103 cells (10 ng RNA) and 102 
cells (1 ng RNA) were compared to not amplified sample 2 x 106 cells (20 µg RNA). 
The quality and purity of RNA was evaluated by electrophoresis on denaturing 10 % formaldehyde 
1% agarose gel as before and by Nanodrop UV spectrophotometer. 
For the 1st strand cDNA synthesis: 
1 µl of total RNA was mixed with 125 ng of the oligodT SMART7-24 
(TGAAGCAGTGGTAACAACGCAGAGTAATACGACTCACTATAGGGAGAAGCTTTTTTTT
TTTTTTTTTTTTTTTTVN) denatured heating at 65 °C for 5 min and immediately transferred on 
ice.  
A mixture containing 125 ng of the strand-switching oligo RiboSMART 
(AAGCAGTGGTAACAACGCAGAGTACGCrGrGrG), DTT 1 mM, dNTPs 1 mM, 1 x 1st strand 
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buffer (Invitrogen), 20 units of RNase Inhibitor Superase-in (Ambion), 100 units of SuperScript II 
(Invitrogen) was added to the RNA and incubated at 37 °C for 1 hour, 70 °C for 10 min. 
All the 1st strand reaction was used for the 2nd strand cDNA synthesis in a 100 µl mixture 
containing 1 x ExTaq buffer (Takara), 200 µM dNTPs (Takara), 0.4 µM PCR-SMART primer 
(TGAAGCAGTGGTAACAACGCAG), 5 units of ExTaq (Takara) and amplified by PCR using the 
following program 5 min 95 °C, 19 X (5 s at 95 °C, 5 s at 65 °C, 6 min at 68 °C), doing hot start. 
The cDNA was purified on a Qiaquick PCR purification column (Qiagen) according to the 
manufacturer`s instructions and eluted in 30 µl of water. An aliquot of 3 µl was analyzed on 1.5 % 
agarose gel stained by ethidium bromide. The rest of the eluate was concentrated in speedvac up to 
10 µl. 
The 1st in vitro transcription (IVT) was performed in 20 µl adding to 10 µl of cDNA, 4 µl of 5 x T7 
transcription buffer (Promega), 2 µl of NTPs (100 mM, Promega), 0.5 µl of 100 mM DTT, 0.5 µl of 
RNase OUT (40u/µl, Invitrogen) and 160 units of T7 RNA Polymerase HC (Promega) and 
incubated at 37 °C for 5 hours. 
The 1st amplified RNA (aRNA) was cleaned up using RNeasy Mini kit column (Qiagen) and eluted 
in 30 µl of RNase-free water (Ambion); an aliquote of 3 µl was analyzed on denaturing 
formaldehyde 1 % agarose gel as before, then the eluate was concentrated to 10 µl in speedvac.  
The 1st aRNA with 100ng of random hexamer (Invitrogen) was heated at 70 °C for 3 min and 
immediately transferred on ice for 2min. A mixture of 2 µl dNTPs (10 mM, Invitrogen), 4 µl of 5 x 
1st strand buffer (Invitrogen), 0.5 µl of RNase OUT (40 U/µl, Invitrogen), 2 µl of 100 mM DTT 
(Invitrogen), 1,5 µl of SuperScriptII (200 U/µl, Invitrogen) was added in a total volume of 20 µl and 
incubated at R.T. for 2 min and at 37 °C for 3 hours. 
At this point, in the case of evaluation of the amplification process by gene-specific RT-PCR, 1 µl 
of this 1st strand cDNA was amplified by PCR in 100 µl reaction using 0.2 µM of the gene-specific 
primers GAPDH forw (), GAPDH rev () or alternatively Bgn forw (), Bgn rev (), in a mixture 
containing 1 x ExTaq buffer (Takara), 200 µM dNTPs (Takara), 5 units of ExTaq (Takara) and 
amplified by PCR using the following program 5 min 95 °C, 19 x (30 s at 95 °C, 30 s at 60 °C, 
1 min at 72 °C), 10 min at 72 °C, doing hot start. 
A 2nd strand synthesis was accomplished in 100 µl using all the previous 1st strand reaction and a 
mixture of 1 x ExTaq buffer (Takara), 200 µM dNTPs (Takara), 1 µg of 1µg/µl T7T24 primer 
(AGTAATACGACTCACTATAGGGAGAAGCTTTTT TTTTTTTTTTTTTTTTTTTVN), 0,4 µl 
of RNase H (2U/µl, Invitrogen), 10 units of ExTaq (Takara) and incubating in a MWG 
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thermocycler using the following program 37 °C 10min, 1 min 95 °C, 2 x (5 s at 95 °C, 2 min at 
42 °C, 30 min at 68 °C). 
The cDNA was cleaned up as before and an aliquot of 3 µl analyzed on 1.5 % agarose gel stained 
by ethidium bromide. 
A second round of IVT was performed as previously described. The 2nd aRNA was also purified 
and analyzed the same way as before. 
The rest of the eluate was concentrated up to 10 µl and stored at -80 °C, then used for the 
preparation of the microarray probe. 
 
cDNA microarray: probe preparation, hybridizations and scanning 
 
The probe for microarray was prepared as follows: 10µl RNA sample was mixed with  
5µg  of oligo d(T)20 (Anchored oligo d(T)20 from Invitrogen, 2.5µg/µl) and 9µg of random hexamer 
(1.5µg/µl, Invitrogen) and incubated at 65ºC 5min and then put on ice for at least 1min. A mixture 
of 1µl of (dNTPs + AminoAllyl-dUTP), 6µl of 5x 1st strand buffer (Invitrogen), 3µl of 100mM DTT 
(Invitrogen), 0.2µl RNase Out (40 U/µl, Invitrogen) and 400 units of SuperScript II (Invitrogen) 
was added and incubated at 37ºC for 3 hours. After the reverse transcription was completed the 
RNA was hydrolized with 10µl 1M NaOH at 65ºC for 10 min and immediately neutralized by 
adding 10µl 1M HCl. The cDNA was purified on Qiaquick PCR purification column (Qiagen) 
according to the manufacturer’s instructions and eluted with 2 volumes of 30 µl of water, then 
concentrated in speedvac down to 4.5µl.  
4.5µl of 100mM NaHCO3 was added to the samples and incubated at R.T. for 15 min. 
The aminoallyl-containing cDNA was labeled as follows: the dyes Cy3 and Cy5 (Amersham 
Pharmacia) were dissolved each in 2µl of DMSO and were mixed to the samples and kept into the 
dark, at R.T. for 1 hour.  4.5 µl of 4M hydroxyamine were added to each vial and incubated at R.T. 
for 15 min.  3.5µl of 100mM sodium acetate pH 5.2 were added and the volume filled to 100µl with 
water.  The labeled cDNA was cleaned up with Qiaquick PCR purification column (Qiagen), 
eluting with two volumes of 40µl of water, and 2µl were analyzed by Nanodrop UV 
spectrophotometer to measure purity, concentration and Cy3/Cy5 incorporation (pmol/ µl). 
The speedvac was used to decrease the 80 µl volume of the samples to 5 µl. The two differently 
labeled samples (from wild type and mutant Striatal cells) were combined having a total volume of 
10µl.  cDNA glass slides (SISSAorf2 array) containing 7000 mouse full length-cDNAs from 
RIKEN Fantom2 collection, each spotted in triplicate, were pre-hybridized in 0.2 % SSC buffer at 
55 ºC for one hour. 10 µl of total labelled cDNA were mixed with blocking reagents mixture 
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(Salmon sperm, polyA RNA?, COTmouse?, tRNA), formamide, and and incubated at 80 ºC for 
10 min and the volume was increased up to 80 µl. Then each slide was allocated in the 
hybridization hermetic chamber, and the solution was poured to cover all the slide surface.  
Hybridization was performed at 65 ºC for 16 hours in a water bath.  The slides were washed in 
50 ml Falcon tubes filled with 2 x SSC buffer, 0.1 % SDS (Ambion), 1 mM DTT (Invitrogen), 
incubated at 55 ºC for 10 min, then the washing solution was discarded and 50 ml of 0.2 x SSC 
buffer were poured to the slides and incubated at 55 ºC for 10 min. A third washing step was 
performed at R.T. for 30 min in 50 ml of 0.02 x SSC buffer. The slides were then centrifuged at 
2,000 rpm for 5 min to dry and each slide was scanned at 532 nm and 635 nm using GenePix 
4100A scanner (Axon) applying different amplification values for the signal in each channel to 
normalize for the differences in the global intensity of emission.  All the slides were kept in the dark 
and scanned in a short time to avoid the signal degradation due to the quenching. 
Statistical analysis of microarray data 
 
The pre-processing (reading of the slide, intra-array normalization and inter-array normalization) of 
the data was executed on every group independently. The loading, normalization and statistical 
analysis were performed by using the Gene Pix 5.0.1 software package. The normalization intra 
array has been performed by using the function “normalizeWithinArrays” applying the LOWESS 
algorithm: “normalizeWithinArrays(RG,method="loess",bc.method="normexp",offset=50)”. 
The inter array normalization by using the function “normalizeBetweenArrays” by the application 
of quantile method: “normalizeBetweenArrays (MA,method="quantile")”. 
All the statistical analyses have been performed by using the eBayes function from the Gene Pix 
package. The filters used are the widely accepted: fold change ≤ log2 (-1) or fold change ≥ log2 (1) 
(which is a fold change of ± 2 on a linear scale) and corrected p-value ≤ 0.05. 
 
Real Time-PCR of differentially expressed genes in striatal cells 
 
To analyze the relative levels of  expression of abundant and rare transcripts, Biglican (Bgn) and β-
actin genes were analyzed by Real-Time PCR in wild type versus mutant Striatal cells. Single 
strand cDNA was obtained from 1 µg of purified RNA using the iSCRIPTTM cDNA Synhesis Kit 
(Bio-Rad, Laboratories, Hercules, CA, USA) according to manufacturer’s instructions. RT was 
performed in a thermal cycler at 25 °C for 5 min, 42 °C for 30 min, 85 °C for 5 min. cDNA was 
stored at - 20 °C. Real Time quantitative PCR was performed with an iCycler IQ (Bio-Rad 
Laboratories, Hercules, CA, USA); β-actin was used as an endogenous control to normalize the 
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expression level of target genes. The primers were chosen using the software Beacon Designer 2.0 
(PREMIER Biosoft International, Palo Alto, CA, USA). Primers used were: mouse-β-actin 5’- 
CCTTCTTGGGTATGGAATCCTGTG –3’ (sense); mouse-β-actin 5’-
 CAGCACTGTGTTGGCATAGAGG –3’ (antisense); mouse-Bgn 5’-
 TTCTGGGACTTCACCTTGGATG –3’ (sense); mouse-Bgn 5’ TGGCAGTGGCA ACCGAAAG 
–3’ (antisense). Twentyfive nanograms of cDNA was amplified by PCR using primers for the gene 
of interest and β-actin in separate wells with 1x iQ SYBR Green Supermix and 250nM gene 
specific sense and anti-sense primers in a final volume of 25 µl for each well. The PCR was 
performed in 96-well plates, each sample was performed in duplicate. The thermal cycler conditions 
consisted of 4 min at 95 °C and 40 cycles at 95 °C for 20 s, 60 °C for 20 s and 72 °C for 30 s. In 
order to verify the specificity of the amplification, a melt-curve analysis was performed, 
immediately after the amplification protocol, under the following conditions: 1 min denaturation at 
95 °C, 1 min annealing at 55 °C, and 80 cycles of 0.5 °C increments (10 s each) beginning at 55 °C. 
Non-specific products of PCR were not found in any case. A standard curve was generated using a 
“calibrator” cDNA (chosen among the cDNA samples), which was serially diluted and analyzed 
both for the gene of interest and β-actin. The iCycle iQ Real Time PCR Detection System Software 
generated the equation describing the plots of the log10 of the starting quantity (micromoles) of 6 
dilutions (240, 24, 2.4, 0.24, 0.024 and 0.0024 ng) of the calibrator cDNA versus the corresponding 
threshold cycle. The results were normalized to β-actin and the initial amount of the template of 
each sample was determined as relative expression versus one of the samples chosen as reference 
(in this case the control sample) which is considered the 1x sample. The relative expression of each 
sample was calculated by the formula 2xΔΔCt. ΔCt is a value obtained, for each sample, by the 
difference between the mean Ct value of the gene of interest and the mean Ct value of β-actin. ΔΔCt 
of one sample is the difference between its ΔCt value and Ct value of the sample chosen as 
reference (User Bulletin 2 of the ABI Prism 7700 Sequence Detection System). 
nanoCAGE –Illumina-Solexa 
All the nanoCAGE libraries in this study were prepared with the RNA extracted from three 
different dopaminergic cell populations (A7, A9, A10), harvested by laser capture microdissection 
from the Th-GFP/21-31 line of transgenic mice (Matsushita et al., 2002. J Neurochem. 82: 295-
304), and kindly provided from Christina Vlachouli.  For each type of dopaminergic neurons about 
2500 cells were used. 
5 to 10 ng of total RNA were heat denatured at 65 °C for 10 min in a final volume of 5 µl with 
50 pmol of strand-switching oligonucleotide riBOSS 
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(TAGTCGAACTGAAGGTCTCCAGCAGrGrG), 10 pmol of random-N15 primer 
(GTACCAGCAGTAGTCGAACTGAAGGTCTCCTCTN15), 10 pmol of oligodT18 
(GTACCAGCAGTAGTCGAACTGAAGGTCTCCTCT18) and then transferred quickly on 
ice/water mix. 
Reverse transcription was performed in a volume of 20 µl adding the following components to 
reach these final concentrations: 1 x 1st strand buffer (Invitrogen), 0.5 mM dNTPs (Takara), 1 mM 
DTT (Invitrogen), 0.75 M Betaine (WAKO), 0.41 M D-Threalose (Nacalai Tesque), 3.4 % D-
Sorbitol (WAKO) and 400 units of SuperScriptII (Invitrogen), and incubated at 12 °C for 10 min, 
50 °C for 45 min, 75 °C for 10 min in a MWG thermocycler. The tubes were then immediately 
transferred on ice/water mix. 
For the 2nd strand synthesis a small scale PCR reaction was performed to evaluate the optimal 
number of cycles, defined as the last cycle before the intensity of the product ceases to increase. 
10 µl aliquotes were taken every two cycles and analyzed on 1 % agarose gel. 
2 µl of 1st strand cDNA  were amplified in a total volume of 100 µl using a mixture containing 1 x 
ExTaq Buffer (Takara), 250 µM dNTPs (Takara), 100 nM Sup-
Forward primer (TAGTCGAACTGAAGGTCTCCAGC), 100 nM Sup Reverse primer 
(GTACCAGCAGTAGTCGAACTGAAGGTCTCCTCT), and 5 units of ExTaq (Takara) with the 
following PCR program 5 min 95 °C, n x (10 s at 95 °C, 15 s at 65 °C, 6 min at 68 °C) and using an 
hot start.  In the case of A9, A10 libraries 28 cycles PCR were performed. 
A large scale PCR preparation using all the 1st cDNA (18 µl) to avoid bottlenecks, was performed 
in 9 reactions of 100 µl. PCR products were cleaned using Qiaquick PCR purification columns 
(Qiagen) and all of them were pooled together. 
Half of the pooled cDNA was digested in 4 reactions of 300 µl each, using 150 units of EcoP15I 
(NEB), 1 x buffer 3 (NEB), 1 mM ATP (NEB), 1 x BSA (NEB) incubated at 37 °C for 4 hours. The 
low molecular weight cleavage products were purified through the Microcon YM-100 membranes 
(Millipore) and the flow-through was concentrated on Microcon YM-10 (Millipore) according to 
the manufacturer`s instructions. 
Equimolar amounts of the oligonucleotide linker up were annealed with the correspondent 
oligonucleotide linker down, in a water bath from 95 °C cooling down to R.T. to form the Illumina-
Solexa adaptors. 
Each pair contains a different tissue tag sequence, AG, TC or GT respectively.  
AG linker up (NNAGCTGTAGAACTCTGAACCTGT), AG linker down 
(ACAGGTTCAGAGTTCTACAGCT), TC linker up (NNTCCTGTAGAACTCTGA- ACCTGT), 
TC linker down (ACAGGTTCAGAGTTCTACAGGA), GT linker up 
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(NNGTCTGTAGAACTCTGAACCTGT), GT linker down (ACAGGTTCAGAGTT- 
CTACAGAC). 
The Illumina-Solexa adaptors were ligated to 15µl of the EcoP15I cleavage products using 2 µM 
adaptor and 1200 units of T4 DNA ligase (NEB) in 30 µl and incubated for 16 hours at 16 °C in a 
water bath. 
Optimal number of cycles for the ligation product to be amplified was determined by 
PCR with 5 µM long P5 primer (AATGATACGGCGACCACCGACAGGTTCAGA- 
GTTCTACAG), 5 µM long P7 primer (CAAGCAGAAGACGGCATACGATAGT- 
CGAACTGAAGGTCTCCAG), 1 x ExTaq buffer (Takara), 200 µM dNTPs (Takara), 5 units of 
ExTaq (Takara).  The program was 5 min 95°C, n x ( 20 s at 95 °C, 20 s at 57 °C, 20 s at 68 °C). 6 
PCR reactions in 100 µl for each sample were performed. The excess of the primers was digested 
with 20 units of Exonuclease I (Takara) at 37 °C for 30 min and then the enzyme was heat 
inactivated at 55 °C for 15 min.  Then the PCR products were purified by electrophoresis on 10 % 
polyacrylamide gel and the band corresponding to the expected size (112bp) was cut, passed 
through a syringe to break the structure of polyacrylamide and the DNA was extracted at R.T. in 
microtube on rotation with 800 µl of 1 x TE buffer over night.  
The tubes were centrifuged at 13,000 rpm for 10min and the supernatant was collected. 600 µl of 
1 x TE buffer were added to the polyacrylamide in the microtube and let to rotate at R.T. for 1 hour. 
This step was repeated once more. 
Then for each sample, all the collected fractions were pooled together and passed through a 
Microspin filter (GE Healthcare) to eliminate residual traces of polyacrylamide. 
A total of  2ml of  filtrate was concentrated to 100 µl passing through a Microcon YM-10 column 
(Millipore), further purified using a Qiaquick PCR purification column (Qiagen) and eluted in 100 
µl of EB buffer (10mM Tris.Cl pH 8.5). 
The purity and the concentration of the sample was estimated by Nanodrop UV spectrophotometer 
and Agilent 2100 Bioanalyzer and an aliquote of 10 µl was analyzed by PAGE to check for the 
correct size of the recovered DNA. 
One Solexa sequencing run was performed using all the channels for the same sample, to normalize 
against the bias due to channel`s variability. 
nanoCAGE –454 
 
All the initial steps of 1st strand synthesis by reverse transcription, 2nd strand cDNA synthesis by 
PCR amplification and EcoP15I digestion are the same like for nanoCAGE-Solexa. 
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454-adaptor forward (NNAGCATGAGACCTGTGAGTAG) and 454-adaptor reverse (Bio-
CTACTCACAGGTCTCATGCT) were annealed as for Solexa adaptors, to form the 454 adaptor. 
15µl of low molecular weight fraction of the EcoP15I digestion product was ligated using 2 µM of 
454 adaptor and 1200 units of T4 DNA ligase (NEB) in 30 µl and incubated for 16 hours at 16 °C 
in a water bath, then the volume of the reaction was increased up to 100 µl with water. 
Optimal number of cycles for 1 µl of the ligation product to be amplified was determined by PCR 
with 5 µM 5`nested PCR primer (Bio-CGAACTGAAGGTCTCCAGCA), 5 µM 454-adaptor 
reverse primer (Bio-CTACTCACAGGTCTCATGCT), 1 x ExTaq buffer (Takara), 200 µM dNTPs 
(Takara), 5 units ExTaq (Takara).  The program was 5 min 95 °C; n x (20 s at 95 °C, 20 s at 57 °C, 
20 s at 68 °C).  Then a large scale preparation of PCR product was done in 96 wells plate to ensure 
enough material for Eco31I digestion.   The 96 PCR reactions were pooled and split in 16 tubes and 
were extracted by using 600 µl of 25:24:1 Phenol-Chloroform-Isoamyl alcohol (Sigma-Aldrich), 
600 µl of Chloroform and then precipitated with 2 voll. of cold ethanol, 1/10 vol. of sodium acetate 
(pH 5.2) and 10 µg of glycogen (Roche). The pellets were washed with 400 µl of cold 70 % 
ethanol, dry at R.T. and resuspended in 10 µl of 1 x TE buffer each.   Then the content of 16 tubes 
were pooled together. 
All the PCR product was digested with Eco31I (Fermentas) in 10 reactions of 300 µl each 
containing 15 µl of DNA, 1 x buffer G (Fermentas), 150 units of Eco31I, and incubated at 37 °C for 
6 hours.  After the digestion was completed, 150 µl of streptavidin-agarose beads (Upstate) were 
added to each reaction and were incubated on rotation at R.T. for 1 hour to sequester the 
biotinylated digested end-products, leaving in solution the fraction corresponding to the 5` prime 
tags (32bp). 
The tubes were centrifuged at 13,000 rpm for 10min and the supernatants were recovered. Other 
300 µl of 1 x TE buffer were added to each tube to wash the streptavidin beads and incubated at 
R.T. on rotation. After centrifugation the supernatants were recovered as before. 
The 5` tags in the supernatants were extracted by 1 vol of (25:24:1) Phenol-Chloroform-Isoamyl 
alcohol (Sigma-Aldrich), 1 vol. of Chloroform (WAKO), precipitated with 2 voll. of cold ethanol 
1/10 vol. sodium acetate 3 M pH 5.2, 10µg glycogen (Roche), and washed with 1 vol. of cold 70 % 
ethanol, then dried at R.T. and resuspended in a total of 100 µl 1 x TE buffer.  Then this was 
purified by electrophoresis on a 8 % polyacrylamide gel and the band corresponding to the expected 
size (32bp) was cut, and purified in the same way as before for the Illumina-Solexa tags. In this 
case the DNA was extracted using 1 x SAGE buffer (LoTE* : 7.5 M ammonium acetate, 125 vol. : 
25 vol.; *LoTE buffer 3 mM Tris HCl pH 7.5, 0.2 mM EDTA pH 8) instead of 1 x TE buffer. 
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A total of 2 ml of filtrate was concentrated to approximately 10 µl in a Microcon YM-10 column 
(Millipore) according to the manufacturer`s instructions. 
The oligonucleotides 454-A short  (CCATCTCATCCCTGCGTGTCCCATCTGTTC- 
CCTCCCTGTCTCAG),  454-A long  (P-TGCTCTGAGACAGGGAGGGAACAGA- 
TGGGACACGCAGGGATGAGATGG), 454-B short  (Bio-TEG-CCTATCCCCTG- 
TGTGCCTTGCCTATCCCCTGTTGCGTGTCTCAG), 454-B long  (P-AGCACTG- 
AGACACGCAACAGGGGATAGGCAAGGCACACAGGGGATAGG) (Operon) were purified by 
electrophoresis on a denaturing 10% polyacrylamyde-urea gel.   The gels were stained by ethidium 
bromide, quickly inspected at 302nm UV  light and for each oligonucleotide, the band of the 
expected size was cut and the DNA was extracted as before for the 5`tags using the SAGE buffer. 
Then for each oligonucleotide all the collected fractions were pooled together and passed through a 
Microspin filter (GE Healthcare) to eliminate residual polyacrylamide. 
A total of 2 ml of filtrate was precipitated with 2 vol. of ethanol, 1/10 vol. of sodium acetate 3 M 
pH 5,2 and washed with 1vol. 70 % ethanol, dried and resuspended in 50 µl of 1 x TE buffer. 
Equimolar amounts of the purified primer pairs (454-A short / 454-A long) and (454-B short / 454-
B long) were annealed in 1 x T4 DNA ligase buffer in a water bath from 95 °C cooling down to 
R.T. to form 454-Terminator A and 454-Terminators B respectively.  An aliquote of 2 µl was 
analyzed by PAGE. 
After quantity evaluation by Nanodrop UV spectrophotometer, the filtrate corresponding to the 
5`tags (10 µl) was concatenated in a 20 µl vol. ligation reaction using a ratio 5`tags: 454-
terminators (20:1) and a mixture containing 9 µl of Eco31I digested 5`tags, 20 ng 454-Terminator 
A, 20 ng 454-Terminator B, 1 x T4 DNA ligase buffer (NEB), 5 % PEG 6000 (Fermentas), 2000 
units of T4 DNA ligase high conc. (NEB), incubated at 16 °C for 16 hours in a water bath. 
A mixture of 170 µl high-salt CTAB solution [1 % CTAB (Sigma-Aldrich), 4 M urea (WAKO), 
0.848 M sodium chloride], 2 µl EDTA 0.5 M pH 8 and 30 µl of water was added to the ligation 
reaction and incubated at 65 °C for 4min, then at R.T. for 10 min and loaded on a GFX PCR DNA 
purification column (GE Healthcare).  
After spinning in a microcentriguge at 13,000 rpm for 1 min the flow-through was discarded and 
600 µl of washing buffer (100 mM Tris-HCl pH 7.5, 5 mM EDTA, 300 mM sodium chloride, 60 % 
ethanol) was poured to the column and centrifuged at 13,000 rpm for 1 min and the flow-through 
was discarded. 
600 µl of 80 % ethanol was poured to the GFX column and centrifuged at 13,000 rpm for 1 min and 
then the column was transferred to a new tube and the DNA was eluted with 53 µl of pre-heated 
65 °C water. The purity and the concentration of the sample was estimated by Nanodrop UV 
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spectrophotometer and Agilent 2100 Bioanalyzer and an aliquote of 10 µl was analyzed by PAGE 
and ethidium bromide staining to check for the expected size distribution of the recovered DNA. 
One 454 sequencing run was performed using the big PicoTiterPlate of the Genome Sequencer 20 
system for the same sample. 
 
Bioinformatic Analysis of nanoCAGE data 
 
Briefly, raw sequence data obtained from a full run (8 channels) of Illumina-Solexa sequencer was 
processed for “tag extraction” to discard unspecific sequences that did not contain the restriction 
sites used for tag production and the 2 nt bar codes inserted in the oligonucleotides as well as to 
distinguish among different samples in the mixed library.  During tag extraction also the first G 
were removed as they came from the riBOSS strand-switching primer. A statistical evaluation of 
the frequency of occurence of each of the 4 bases at each position of the tags has been done together 
with the construction of an error estimation model for better implementing the extraction process 
and lowering the fraction of the false positives. 
The extracted tags were mapped to the ribosomal DNA coding for rRNAs and the tags that matched 
those loci were discarded from the rest of the analysis. All the other tags were mapped and aligned 
to the mouse genome (mm9 assembly) using Kalign software and chosing to have no mismatch in 
the alignment in a first run, and to tolerate one mismatch in a second run. Then the tags (TSSs) were 
clustered. Two strategies have been used to cluster TSSs: FANTOM3 style “proximity” tag 
clustering (TC) and Martin Frith Parametric clustering (PC). 
In the “proximity” tag Clustering (TC), TSSs are clustered together if they are separated by 20 or 
less base pairs regardless of the RNA library they are derived as in Carninci, Sandelin et al. Nat 
Genet. 2006. 
This clustering approach generated a total of 2,068,275 clusters(xxx clusters with a tpm_density 
over 1). 
With the Parametric Clustering (PC), TSSs are clustered using the method described by Martin 
Frith in “A code for transcription initiation in mammalian genome” (Frith et al 2007). As noted by 
Martin, a limitation of the proximity tag clustering approach is that TSS can only belong to one 
cluster while it is evident that one can observe the existence of clusters within clusters. 
His approach enable the definition of such clusters hierarchy. In short, the algorithm employed 
compute the local density (number of tags / length of the segment) of all genomic segments. The 
ratio of the minimum density value below which the cluster merges with another cluster and the 
maximum density value, above which the clusters splits into smaller clusters is used to score the 
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cluster “stability” (and relevance; if the ratio is small then the cluster is not strongly present in the 
data and could easily vanish with some changes in the underlying tag counts, while if the ratio is 
big, the cluster is a prominent feature of the data). 
This clustering approach generated a total of 4,736,538 clusters (526,461 clusters with a 
tpm_density over 1). It is important to note that those clusters are overlapping and that it generate 
clusters within clusters. 
A stability bigger or equal to 2 has been chosen in Fritch et al. as a threshold for stable relevant 
clusters. (Yet all clusters regardless of their stability score are being reported here). Clusters-
transcripts associations were estimated according to the following criteria: for each cluster the 
extent of the overlap with the transcript sets where extracted, as well as the overlap with region 
spanning [-500bp -1bp] from the start site of each transcript refered to as “proximal promoter”. 
Clusters that do not overlap with any transcript or their proximal promoter region were annotated as 
“intergenic”. For association with RefSeq transcripts, 20,649 RefSeq genes and their genomic 
coordinates were downloaded from UCSC mm9 release. 436 miRNA annotated in miRBase and 
their genomic location were retrieve from UCSC. Non coding transcripts sequences were collected 
from the FANTOM3 ftp site and blatted on the mouse genome mm9. Those with an alignment of 
less than 15% were discarded. When a single sequence aligned in multiple places, the alignment 
having the highest base identity was identified. Only alignments having a base identity level within 
0.1% of the best and at least 96% base identity with the genomic sequence were kept.  
All the information detailed above has been gathered in 2 tab text files (one for each PC and TC 
clustering methods), together with expression level for each of the A9 and A10 nanoCAGE 
libraries.  A multimapping rescue strategy similar to that used in Faulkner GJ et al 2008, was used 
to assign a value also to tags mapping in multiple genomic positions. To limit the subsequent 
analysis to potentially relevant clusters only tag clusters fulfilling the following criteria have being 
used: tpm_density (cluster tpm / cluster length) bigger than 1 for at least one library. stability_score 
(for PC clusters) bigger or equal to 2 and ambiguity_score smaller than 1 (thus retaining clusters for 
which at least one tag isnt a multi mapper). 
An extensive manual evaluation and visual inspection of the genomic distribution of the tag clusters 
specifically associated to A9-A10 differences have been performed to establish case by case the 
specific relevance of the findings. 
 
RT-PCR Validation of target genes from total Midbrain 
 
Total midbrain was dissected from adult C57Black/6 female mice. The tissue was homogenized in 
TRIzol reagent (Invitrogen, Carlsbad, CA, USA), and RNA was extracted according to the 
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manufacturer’s instructions. After DNase I treatment (Ambion, Austin, TX) at 37°C for 1 h, RNA 
was purified on RNA easy mini kit columns (Qiagen, Hilden, Germany), and RNA quality was 
tested on agarose gel. RT-PCR reactions were performed using the SuperScriptIII OneStep RT-PCR 
Kit with Platinum Taq polymerase (Invitrogen, Carlsbad, CA, USA).  
For each primer pairs, 250 ng of total RNA were used in a total volume of 50 µl according to the 
manufacturer’s instructions and RT-PCR reaction was performed using the following cycling 
conditions:  30 min at 57 °C, 5 min at 75 °C, 2 min at 94 °C; then 15 sec at 94 °C, 30 sec at 65 °C, 
1,5 min at 68 °C for 45 cycles. 
For each gene two isoforms corresponding to the mRNAs transcribed from a distal and a proximal 
promoter were screened using primer pairs specifically designed to discriminate the corresponding 
cDNAs. 
Primer design was done using Primer3 software (v. 0.4.0) 
(http://fokker.wi.mit.edu/primer3/input.htm) using the following criteria: primer length ranging from 
23 to 28 nt, annealing Tm in the interval 60-72 °C, and GC% content comprised among 50-70 %. 
For gene, primer pairs were: Snca-distal fwd 5'-CTTggCACTCAAATCCACTCTgC-3' and Snca-
distal rev 5'-CCAgCgAACAgACTCTTCTTCCA -3' [for mouse Snca, RefSeq ID: NM_009221]; 
Snca-proximal fwd 5'-CCTCCCTAggAAgAggAgCgAAg -3' and Snca-proximal rev 5'-
CACACggCTCCCTAggCTTCTgA -3' [for Snca, RefSeq ID: NM_001042451]; Slc18a2-distal-fwd 
5'- gAgATATAACCCTgCAggCAgTCg-3' and Slc18a2-distal-rev 5'-
CTgTACAggTAgCTgggAATgATgg-3' [for mouse Slc18a2/Vmat2, RefSeq ID: NM_172523]; 
Slc18a2-intronic-fwd 5' TCTggTTCAgggTCTgTgCACTAAg 3' with either Slc18a2-intronic-rev2 
5` AgCCTTTgACTCCTgAgCTCTgTT 3` or Slc18a2-intronic-rev3 
5` gggTTTTCCTTgggAgAAAgTCTg 3` [for a transcript corresponding to a new unannotated 
isoform of mouse Slc18a2, NM_172523 starting in the third intron at position chr19: 59,339,321 in 
mm9 assembly]; Comt-distal-fwd 5` gACACTCgCACAggCACCCTCTC 3` and Comt-distal-rev 
5` AACAggAgACCCAATgAgACAgCAg 3` [for mouse catechol-Omethyltransferase Comt long 
isoform, RefSeq ID: NM_007744]; Comt-proximal-fwd 
5` ggTATATAAAggCTCAggCCCAgTg 3` and Comt-proximal-rev 
5` AgAgTCTTTAgAggAggCAggTCCA 3` [for mouse catechol-O-methyltransferase Comt short 
isoform, RefSeq ID: NM_001111063]; Slc6a3-distal-fwd 
5` CgATAAgAgCTCAAggCTgAgACC 3` and Slc6a3-distal-rev 
5` TTCTgCTCCTTgACCAAgATgAgC 3` [specific for distal 5`UTR of mouse Slc6a3; RefSeq ID: 
NM_010020];  Slc6a3-proximal-fwd 5` CCTCATCTCTTTCTACgTgggCTTC 3` and Slc6a3-
proximal-rev 5` CAgCACACCACgCTCAAAATACTC 3` [for the internal part starting from exon 
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4 of mouse Slc6a3 NM_010020]; S-Ubc-fwd 5` AgCCCAgTgTTACCACCAAg 3` and S-Ubc-rev 
5` gCAAgAACTTTATTCAAAgTgCAA 3` [for mouse polyubiquitin/Ubc RefSeq ID: 
NM_019639]; AS-Ubc-rev 5` gACAggCAAgACCATCACC 3` and S-Ubc-rev as before [for an 
antisense transcript overlapping the Ubc locus and having multiple starting sites]. 
For mitochondrial fission/fusion genes the following primer pairs were used:  Drp1 1stfwd 
5` CTgATCCCggTCATCAATAAgCTg 3` and Drp1-2ndrev 5` ACgTgg 
ACTAgCTgCAgAATgAgA g 3` [for mouse Drp1 RefSeq ID: NM_134850];  Fis1 1stfwd 
5` gAgACTgTggCCCAgTAgAgACCTT 3` and Fis 2ndrev 5` CCTCTgC 
ggATgTCCTCATTgTAT 3` [for mouse Fis1, RefSeq ID: NM_025562]; Opa1 9- 10thfwd 5`-
gCTCTCCAgTgAAggTgACTC TCAg-3` and Opa1 11-12threv 
5` AgAgATATggTCTCggggCTAACAg 3` [for mouse Opa1, RefSeq ID: NM_133752]; March5-
1stfwd 5`- AAgCCCTTCAACAgATgCTggAC-3` and March5-2ndrev  
5` TTAAgTACTCggCgTTgCACTgAg-3` [for mouse March5, RefSeq ID: NM_027314]; Sh3glb2-
1stfwd 5` ggACgCgggCATCTTCTTCACTC 3` and Sh3glb2-3rdrev 
5` gCACCTTTCTgTCCAgCTTCTCAT 3` [for mouse Sh3glb2, RefSeq ID: NM_139302]. 
Total RNA from striatum used for negative controls was purified as before specified from the same 
C57Black/6 female mice.  
 
5`-RACE validation of target transcripts starting at specific TSSs 
 
The total midbrain was dissected from adult C57Black/6 female mice and the RNA was extracted 
and treated with DNAse as described before for RT-PCR analysis. 5µg of total RNA were used for 
each 5`RACE using the GeneRacer kit (Invitrogen, Carlsbad, CA, USA) according to the the 
manufacturer’s instructions.  
100ng of random primers were used for the reverse transcription step. 1 µl of the RT reaction was 
used for the first 5`RACE-PCR, and Platinum Taq -High Fidelity DNA Polymerase (Invitrogen, 
Carlsbad, CA, USA) was employed, performing touchdown PCR with the following cycling 
conditions: 2 min at 94 °C, then 30 sec at 94 °C, 2 min at 68 °C for 5 clycles; then 15 sec at 94 °C, 
30 sec at 65 °C, 2 min at 68 °C for additional 25 cycles.   The gene specific primers used are listed 
herein below. 
The resulting PCR products were checked on agarose gel and the samples which did not give rise 
any amplified visible products, were subjected to a second round of nested PCR (25 additional 
cycles) following the same conditions used for the first round PCR. Then the PCR reactions were 
separated on agarose gel and purified using the Qiaquick gel extraction kit (Qiagen, Hilden, 
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Germany), and directly cloned in either the pCR4-TOPO cloning vector (Invitrogen, Carlsbad, CA, 
USA) or in pGEM-T easy vector (Promega, Madison, WI, USA). DH5-α chemical competent 
bacterial cells were transformed and 5-10 colonies per plate were screened for the presence of an 
insert of the correct size by EcoRI (NEB, Ipswich, MA) digestion of  the corresponding plasmid 
DNA purified on Qiagen Miniprep columns (Qiagen, Hilden, Germany). Each positive clone was 
sequenced by the Sanger method with the M13 rev primer using the SequiTherm EXCEL™ II DNA 
Sequencing Kit (Epicentre Biotechnologies, Madison, WI, USA). The sequences were then aligned 
to mouse genome (mm9 release) using the BLAT implementation on the UCSC Genome Browser 
and scored by the percentage of identity, their length and their correspondence to the annotated 
gene structure (splicing pattern).  
In Situ Hybridization (ISH) analysis of transcript isoforms on mice 
midbrain cryosections  
 
For riboprobes preparation plasmid DNA (pCR4-TOPO or pGEM-T easy clones) was digested with 
an appropriate restriction enzyme to create a linear DNA template for digoxigenin-labelled 
riboprobe synthesis and then purified on PCR purification coulumns (Qiagen. 1 µg of linearised 
template DNA was transcribed in vitro in 20 µl in presence of 2 µl of 10x DIG-lageling mix (Roche 
diagnostics GmbH, Mannheim, Germany), 20 units of RNaseOUT inhibitor (Invitrogen, Carlsbad, 
CA, USA), and 10 units of T3 or T7 RNA polymerase (Ambion, Austin, TX) or alternatively SP6 
(Promega, Madison, WI, USA). Transcription was performed for 2 hours at 37ºC. The riboprobes 
were then purified by addition of 2.5M lithium chloride and 2.5 volumes of ethanol. After 
centrifugation for 30 minutes at 4ºC, the pellet was washed in ethanol 75% and air dried and 
resuspended in 50µl nuclease-free water (Ambion, Austin, TX). Riboprobes quality was assessed on 
agarose gel and their concentration estimated at ND-1000 spectrophotometer (Nanodrop 
technologies, Wilmington, DE, USA). Adult female C57Black/6 mice were anesthetized with 0.5 
ml urethane (100mg/ml) and perfused transcardially with 4% paraformaldehyde (PFA) filtered with 
a 0,22 µm filter (Millipore). Then the brain was removed and the midbrain region was dissected, 
rapidly washed in sterile PBS buffered solution (pH 7.4) and fixed for 2-3 hours at 4 °C and then 
left overnight in a 30% sucrose solution (Sigma-Aldrich, St. Louis, MO, USA) for cryoprotection. 
The day after, brain were included in OCT medium and rapidly frozen using a mixture of 2-
methylbuthane and liquid nitrogen and  18 µm-thick coronal sections were cut on a cryostat. 
Sections were air-dried for 2 hours, fixed with 4% PFA for 10 min at R.T. and then washed twice in 
diethyl pyrocarbonate (DEPC, Sigma)-treated PBS for 5 min at R.T. After 5 min treatment with 
HCl 0.2M, the slides were whased three times in PBS  and digested 15 min at 37 °C with 0.5 µg/ml  
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proteinase K (Roche diagnostics GmbH, Mannheim, Germany) in pK buffer (TrisHCl  pH8, EDTA 
pH8).  After washing twice in PBS 5 min, the slides were re-fixed with fresh 4% PFA 10 min at 
R.T. and then washed again in PBS. Acetylation was done in TEA buffer (Triethanolamine, 27mM 
HCl) adding twice 400 µl of acetic anhydride for 10 min, then washed with milliQ water and air 
dried for 1 hour.  500 ng of each ribobrobe were added to 150 µl of hybridization mix (composition 
for 10ml: 1ml salt mix 10x, 0.5ml DTT 1M, 0.5ml polyadenilic acid -10mg/ml, 50 µl tRNA – 10.7 
mg/ml, 2ml dextrane sulphate 50%, 5 ml formamide), heat denatured 10 min at 80 °C and then 
incubated in a humid chamber (made with 2xSSC-50% formamide) overnight with each slide at 63 
°C, keeping separated sense and antisense riboprobes.   The day after post-hybridization washes 
were done with increasing stringency:  30 min et RT in 5x SSC−β-mercaptoethanol, 30 min at 60 
°C with  2x SSC- 50% formamide β-mercaptoethanol, twice 15 min at 37 °C in NTE buffer (); 
finally 15 min at RT in 2x SSC and 15 min at RT in 0.2x SSC buffer. After two additional washing 
in B1 buffer (), the slides were blocked for 1 hour at RT using heat-inactivated fetal calf serum 
(FCS) (1:9 in B1 buffer) and then incubated overnight at 4 °C with 150 µl of a mix of blocking 
solution containing anti-digoxigenin antibody (Roche diagnostics GmbH, Mannheim, Germany) 
diluted 1: 1000. After washing in B2 buffer, the slides were incubated with levamisol 2 mM in B2 
buffer for 1 hour to inhibit the endogenous alkaline phosphatases. A stock solution of Tris-NaCl-
Polyvinyl alcohol by dissolving 10% (w/v) polyvinyl alcohol (PVA, 70-100 KDa, Sigma-Aldrich, 
St. Louis, MO, USA)  at 90 °C in 100 mM Tris HCl pH 9 and 100 mM NaCl. 
Then the slides were incubated with a BCIP-NBT-PVA development solution containing 0.35 mg/ml 
NBT (4-nitro blue tetrazolium chloride, Roche) and 0.35 mg/ml BCIP (5-bromo-4-chloro- 3-indolyl-
phosphate, Roche). The slides were visually inspected under the microscope and when colour had 
developed to the desired extent, embryos were washed with B2 solution with 2mM EDTA and slides 
were prepared for the immunofluorescence analysis with an anti-Tyrosine Hydroxylase (TH) antibody 
(TH-16 Sigma-Aldrich, St. Louis, MO, USA) as described herein after.  
 
 
Immunofluorescence (IF) 
 
Adult C57Black/6 mice were perfused transcardially as previously described for ISH. Dissected 
midbrain was removed and post-fixed in 4% formaldehyde in 0.1 M phosphate buffer pH 7.4, for 2 
h at 4°C, equilibrated in 30% sucrose overnight, and 18 µm-thick coronal sections were cut on a 
cryostat. Sections were air-dried for 30 min or even stored at -80 °C up to 2 months before use, 
blocked 1 hour at RT with 10% normal goat serum, 1% BSA, 1% fish gelatin in PBS, and incubated 
overnight at 4°C with the primary antibodies diluted in PBS, 1% BSA, 0.1% fish gelatin, 0.3% 
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Triton X-100. (For anti-TH antibody dilution 1:1000 was used whereas other primary antibodies 
were used following the manufacturer`s instructions). 
After rinses in 0.1% Triton X-100 in PBS, sections were incubated with fluorophore-conjugated 
secondary antibodies in the same solution as for primary antibodies for 2 h at room temperature, 
washed and mounted with Vectashield mounting medium (Vector Laboratories, Burlingame, CA). 
The staining was analyzed with a Leica DM500 digital microscope equipped with a DFC digital 
camera. Primary antibodies were: mouse monoclonal anti-TH (Sigma-Aldrich, St. Louis, MO, 
USA) was used at 1:1000; goat anti-Endophilin B2 (C-16 - SantaCruz Biotechnology Inc., Santa 
Cruz, CA), goat anti-Fis1 (K-14 - SantaCruz Biotechnology Inc.) and goat anti-Opa1 (C-15 - 
SantaCruz Biotechnology Inc.) all used at 1:50. Secondary antibodies were: Alexa 488-conjugated 
donkey anti-mouse, Alexa-594-conjugated donkey anti-goat, and Alexa 594-conjugated goat anti-
mouse diluted 1:250 (Molecular Probes-Invitrogen). Nuclei were labelled with DAPI diluted 1: 
10,000.  
 
 
Oligonucleotide sequences and functional grouping 
 
SMART7 primers: 
TGAAGCAGTGGTAACAACGCAGAGTAATACGACTCACTATAGGGAGAAGCTTTTTTTTTTT
TTTTTTTTTTTTTVN                     SMART7-24 
AAGCAGTGGTAACAACGCAGAGTACGCrGrGrG           riboSMART 
TGAAGCAGTGGTAACAACGCAG                      PCR-SMART 
AGTAATACGACTCACTATAGGGAGAAGCTTTTTTTTTTTTTTTTTTTTTTTTVN                                               
T7T24 
 
RT Primers for nanoCAGE 
          TAGTCGAACTGAAGGTCTCCAGCAGrGrG        riBOSS 
GTACCAGCAGTAGTCGAACTGAAGGTCTCCTCTNNNNNNNNNNNNNNN     
                                           random N15 
GTACCAGCAGTAGTCGAACTGAAGGTCTCCTCTTTTTTTTTTTTTTTTTT 
                                            oligodT18 
 
Second Strand cDNA synthesis Primers: 
TAGTCGAACTGAAGGTCTCCAGC                   Sup-Forward 
GTACcagcagTAGTCGAACTGAAGGTCTCCTCT         Sup-reverse 
 
Solexa Ligation Adaptors and PCR Primers: 
NNAGCTGTAGAACTCTGAACCTGT     AG linker up    - Solexa 
ACAGGTTCAGAGTTCTACAGCT       AG linker down  – Solexa 
NNTCCTGTAGAACTCTGAACCTGT     TC linker up    - Solexa 
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ACAGGTTCAGAGTTCTACAGGA       TC linker down  – Solexa 
NNGTCTGTAGAACTCTGAACCTGT     GT linker up    – Solexa 
ACAGGTTCAGAGTTCTACAGAC       GT linker down  – Solexa 
AATGATACGGCGACCACCGACAGGTTCAGAGTTCTACAG       long P5 
CAAGCAGAAGACGGCATACGATAGTCGAACTGAAGGTCTCCAG   long P7 
 
454 Ligation Adaptors and PCR Primers: 
NNAGCATGAGACCTGTGAGTAG                454-Adaptor fwd 
Bio-CTACTCACAGGTCTCATGCT              454-Adaptor rev 
Bio-CGAACTGAAGGTCTCCAGCA              SR 5'Nested PCR 
 
454 Concatenation Terminators: 
CCATCTCATCCCTGCGTGTCCCATCTGTTCCCTCCCTGTCTCAG 
                                          454-A short 
P-TGCTCTGAGACAGGGAGGGAACAGATGGGACACGCAGGGATGAGATGG 
                                           454-A long 
Bio-TEG-CCTATCCCCTGTGTGCCTTGCCTATCCCCTGTTGCGTGTCTCAG 
                                          454-B short 
P-AGCACTGAGACACGCAACAGGGGATAGGCAAGGCACACAGGGGATAGG  
                                           454-B long 
 
5`RACE-PCR and nested-PCR Primers: 
 
gTTTCCTTTgTgATCTCCCTgTCC               Slc6a3 3utrrev 
ATgTAgCAgCTggAACTCATCgAC               Slc6a3 10threv 
ggAgAAgCTCgTCAgggAgTTAAT                Slc6a3 8threv 
CACAgAgACggTAgAAgTCCACACT               Slc6a3 6threv 
CTgTACAggTAgCTgggAATgATgg          Slc18a2 distal rev 
AgCCTTTgACTCCTgAgCTCTgTT        Slc18a2 intronic rev2 
gggTTTTCCTTgggAgAAAgTCTg        Slc18a2 intronic rev3 
ATCATTCCCAgAAgAgCACACAgC              Slc18a2 11threv 
gAACACATggTCTCCATCATCCAg             Slc18a2  10threv 
gCgTTACCCCTCTCTTCATCATCTg              Slc18a2 6threv 
CCAgCgAACAgACTCTTCTTCCA               Snca distal rev 
CACACggCTCCCTAggCTTCTgA             Snca proximal rev 
AACAggAgACCCAATgAgACAgCAg             Comt distal rev 
AgAgTCTTTAgAggAggCAggTCCA              Comt proxi rev 
AAgCggAgTTCATAgAgCggAAC                   Jtv1 4threv 
CgTACTCTTCACACACAgCgTCACT                 Pms2 7threv 
gACAggCAAgACCATCACC                        AS Ubc rev 
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SECTION 3. RESULTS 
 
 
cDNA Microarray transcription profiling from limiting amount of 
starting material 
 
 
Overview and Validation of the SMART7 technique 
 
A study comparing the classical T7-based method with SMART-PCR on cDNA arrays found 
that,gene expression measurements of linearly amplified material showed better correlation with 
non amplified samples than material from SMART-PCR (Puskas et al. 2002) while in a more recent 
study SMART showed to have the highest true positive discovery rate (80%) compared to a more 
modest rate reached by a T7-based method (38.6%) (Subkhankulova and Livesey 2006). 
This suggests that a method which could take the advantages of both T7-based IVT and SMART-
PCR methods could result in a more effective strategy to better amplify small size samples RNA. 
SMART (Switching Mechanism At the 5’end of RNA Transcripts) was originally developed as a 
strategy to enrich for full-length in cDNA cloning. This technique has been used in combination 
with PCR to amplify minute samples obtained from sources such as biopses, laser captured 
microdissected tissues, embryos and small organisms (Puskas et al. 2002; Petalidis et al. 2003; 
Wang et al. 2003; Ji et al. 2004; Kenzelmann et al. 2004; Rox et al. 2004). 
Various modification of the SMART-PCR strategy have been reported so far.  
The SMART7 method has been previously developed to explore the transcriptome of single, 
genetically labelled dopaminergic neurons in the mouse retina (Gustincich et al. 2004). It combines 
an initial cDNA synthesis step based on SMART-PCR with T7 in vitro transcription (figure 3-1). 
The number of PCR cycles as well as the number of rounds of T7 linear amplification can vary 
according to the starting amount of input RNA. 
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Figure 3-1. Overview of the SMART7 protocol: total RNA is reverse transcribed by mean of a modified oligodT 
bearing a heel sequence with minimal promoter for T7 RNA polymerase in the presence of a strand-switching SMART 
oligonucleotide; the 1st strand cDNA is then amplified by single-primer PCR for 19 cycles. The 2nd strand cDNA is 
purified and subjected to two rounds of in vitro transcription to obtain a 2nd cDNA pool. (picture adapted from 
Gustincich et al 2004). 
 
In previous studies (Luo et al. 1999; Wang et al. 2000; Baugh et al. 2001) it has been shown that 
two rounds of in vitro transcription are required for profiling 1,000 cells or 2ng of total RNA as 
starting material. However, template-independent artefacts became prominent when smaller 
amounts of RNA were used and these strongly competed with the specific amplification of the 
transcripts (Baugh et al. 2001).  
In SMART7 the combination of two different techniques kept the number of the PCR cycles low 
and avoided strong competition from template-independent products. Furthermore, SMART-
SMART PCR products, formed by unspecific internal priming of the SMART oligonucleotide 
during cDNA synthesis, were not amplified by T7 RNA polymerase (Gustincich et al. 2004). 
Here I investigated the reproducibility and the fidelity of this technique finding out which is the 
lower limit of application. 
The SMART7 technique was applied with minor variations.  
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For the first strand cDNA synthesis step, scaling amounts of RNA (100ng, 10ng, 1ng, 100pg) were 
mixed to 125 ng of the SMART7-24 oligonucleotide 
(TGAAGCAGTGGTAACAACGCAGAGTAATACGACTCACTATAGGGAGAAGCTTTTTTTT
TTTTTTTTTTTTTTTTVN), a modified oligodT primer which contains in the 3` end a stretch of 
24 dT followed by the sequence for T7 RNA polymerase promoter and by a SMART tag at the 5` 
end. 
Another oligonucleotide, called riboSMART 
(AAGCAGTGGTAACAACGCAGAGTACGCrGrGrG), was added to the first strand synthesis 
mixture. It contained a stretch of three ribo-guanosines that annealed to the dC residues 
preferentially added by the reverse transcriptase at the 5`end of the first strand cDNA. This occurs 
in correspondence of the cap structure by a mechanism not yet completely understood, involving a 
terminal nucleotidil transferase activity. 
By means of a strand-switching effect, the reverse transcriptase changed template in 
correspondence of the annealed riboSMART oligonucleoide, thus incorporating its sequence into 
the 3`end of the newly synthesized cDNA. 
The second strand cDNA was then synthesized by a long cycle PCR using a single primer 
amplification strategy (PCR-SMART primer, see Materials and Methods for more details) to select 
for  full-length molecules.  To minimize the side-effects deriving from exponential overcycling, the 
number of PCR cycles has been kept as low as possible. 
Furthermore, the use of a single primer for the second strand synthesis resulted in a sort of semi-
linear amplification behaviour, similarly to what have been seen in other studies [single primer 
amplification (SPA) as in Smith et al. 2003]. 
This ensured that all the SMART-tagged full-length cDNAs containing the T7 RNA promoter 
sequence in the 5`end would be subsequently transcribed, resulting in a 1st round of aRNA. 
A second cDNA synthesis step was performed on the 1st in vitro transcription product. By using a 
random hexamer the 1st strand was synthesized. A T7T24 primer that annealed on the poly(A) tail 
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and on the T7 RNA polymerase promoter sequence was used to synthesize the 2nd strand cDNA. 
RNAse H was included to degrade the RNA in the mRNA/cDNA hybrids and exTaq DNA 
polymerase to extend double strand cDNAs. In a first attempt to test the methodology, the gene 
coding for beta actin cloned in the plasmid vector of the Ambion Maxiscript Kit was used as a 
template to produce a single in vitro transcribed species (pTRI IVT). The transcript was quantified 
and serial dilutions were used as starting material to perform the SMART7 amplification. 
The amplification factor estimated as a ratio between the initial amount of mRNA and the RNA 
produced by the first and second IVT step of the SMART7 protocol was 102 and 104 respectively , 
Starting from 1ng of a single RNA species (pTRI IVT), this is evaluated by ethidium bromide 
staining of agarose RNA gel electrophoresis and by semi-quantitative PCR evaluation of the cDNA 
produced after a first and a second reverse transcription steps (figure 3-2). 
 
Figure 3-2. SMART7 amplification of a single in vitro transcribed RNA species (pTRI act) starting from different 
initial amonunts (100 ng, 1 ng, 10 pg) as calculated from serial RNA dilutions, and corresponding to the RNA content 
of approximately 20,000 – 200 -2 cells respectively. A 104-fold increase is achieved after 2 rounds of in vitro 
transcription.  
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After the method has been proved to be effective in the amplification of single mRNA species, 
SMART7 was applied to the amplification of total cellular RNA, which represents the actual target 
fot the application of this technique. This method was in fact originally developed to circumvent the 
limitation derived from the need for a higher amount of RNA in gene expression microarray 
profiling of single neurons. 
 
Overview and Validation of the “Brownstein method” 
 
As said before, two main different strategies have been applied for sample amplification, one based 
on linear amplification methods and the other based on exponential amplification methods. 
Among the linear amplification studies, we chose to focus our attention on the method introduced 
by Brownstein (Xiang et al. 2003). They used oligo dT with a T7 RNA polymerase recognition site 
at the 5’end to prime the first cDNA synthesis step, and a random 9-mer with a T3 RNA 
polymerase recognition sequence at the 5’end, to prime the two subsequent RT reactions. Three 
rounds of  in vitro transcription were carried out (Xiang et al. 2003) (figure 3-3).  
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Figure 3-3. Overview of the Brownstein method – The 1st strand cDNA is synthetized in the presence of the classical 
T7-oligodT primer, the 2nd strand cDNA is produced using the classical Gubler-Hoffman protocol, then follows a 1st 
round of T7-mediated in vitro transcription, a second RT in the presence of a random 9-mer bearing the recognition 
sequence for T3 RNA polymerase. A second round of T3-mediated in vitro transcription and subsequent RT give the 
2nd cDNA pool.  
  
In order to evaluate if the SMART7 method performed at a similar level in terms of linearity and of 
global yield as the transcription-based Brownstein method, cDNA obtained from each reverse 
transcription step was used as template for gene-specific PCR reactions. 
In a first experiment, 100ng of the single in vitro transcribed RNA (pTRI IVT) was used to be 
amplified by using either Brownstein protocol or SMART7, and an aliquote of the resulting 1st 
strand and 2nd strand cDNA was directly loaded on agarose gel and stained by ethidium bromide 
(figure 3-4). 
 
Figure 3-4. Comparison between SMART7 and Brownstein amplification methods – A first quantitative evaluation of 
the yield for the amplified 1st strand and 2nd strand cDNAs resulting from either one of the two methods, starting from 
the same amount (100 ng) of the single in vitro transcribed RNA species (pTRI IVT). Furthermore there si no 
significant loss of material in the purification step of the ds-cDNA on Qiagen columns (pre-cleaning / post-cleaning).  
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As shown in figure 3-4, while the first strand cDNA synthesis performed at the same level for both 
the methods, in the 2nd strand cDNA synthesis step the SMART7 method has been showing to yield 
an amount of cDNA several orders greater than what obtained with the Brownstein protocol. This is 
expected due to the PCR exponential amplification, which is not present in the Brownstein method.  
To address potential alteration of the reciprocal ratio of level of expression, the relative expression 
of two transcripts already known to be present in striatal cells at very different levels, biglican 
(Bgn) and glyceraldehyde dehydrogenase (Gapdh), has been evaluated. Quantitative RT-PCR was 
carried out on aliquots of the cDNA taken after each cDNA synthesis step comparing three different 
amplification protocols: Brownstein method, SMART7 and a modified version of the SMART7 
(S*) in which the 2nd strand synthesis step was performed using the classical Gubler-Hoffman 
method (a mix of RNase H, E. coli DNA polymeraseI instead of ex Taq DNA polymearase on the 
random hexamer primed cDNA) (figure 3-5). Although the great difference in the yield for the 2nd 
strand cDNA due to the exponential amplification in SMART7, no significant difference in the 
relative transcripts ratio representation was observed since the intensity of the amplicons for all of 
three compared methods was fairly equal. Furthermore, when we estimated the reproducibility of 
three different replicas of the amplification starting from the same sample of total striatal RNA, we 
observed  a very high score,, as shown in figure 3-5. These results suggest that the PCR in the 
SMART7 method, at least for the genes examined, have not introduced any significant bias which 
could alter the relative expression ratios of the transcripts. 
 
Figure 3-5. Evaluation by gene-specific RT-PCR of the performance of three different amplification methods: 
Brownstein (B), SMART7 (S) and a modified SMART7 (*) in which 2nd strand cDNA was synthetized by the Gubler-
Hoffman method. Mouse biglican (Bgn) was used as low expressed gene, and glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) was used as a basal transcribed gene. Total RNA from striatal cells was used. As shown in 
the upward scheme, a 1/20 aliquote of  the cDNA after each of the 4 steps (1) pre-incubation before RT, (2) the 1st  
dscDNA after the first amplification step, (3) the 2rd ds-cDNA after the 1st round of IVT, (4) the 3rd ds-cDNA after the 
2nd round of IVT. PCR amplification with gene-specific primers was performed and 5 µl aliquots were taken after either 
28 or 40 cycles, and loaded on agarose gel.      
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SMART7- and cDNA microarrays  
 
After the preliminary gene-specific RT-PCR-based evaluation of the SMART7 method, a more 
detailed evaluation on a much larger scale was necessary to assess the validity of SMART7 as a 
method of choice for the amplification of total RNA obtained from limited number of cells.  In 
order to do this, two lines of cultured cells have been chosen as a source of RNA. Total RNA was 
extracted from wild type striatal neurons and mutant striatal neurons (STHdhQ111/HdhQ111), from 
knockin mice bearing the HD mutation (Trettel F et al 2000; kindly provided by Persichetti F). 
These two cell lines have been previously used in our group for global gene expression profiling 
using the SISSA orf1 and orf2 glass slides, each containing about 7000 mouse full length-cDNAs 
from the RIKEN Fantom2 collection, each spotted in triplicate. 
Starting from 20µg of high-quality total RNA extracted from wild type and mutant striatal cultured 
neurons, serial dilutions were used to obtain scaling amounts (10ng, 1ng) of RNA used as template 
for the SMART7 method. Two rounds of in vitro transcription have been performed in order to 
obtain enough aRNA to produce a sufficient amount of probe for microarray hybridization (figure 
3-6). 
The probes labeled by AminoAllyl-dUTP incorporation and alternatively Cy3 or Cy5 dye, 
corresponding to wild type and mutant striatal RNA, were mixed and hybridized together onto 
SISSAorf2 cDNA microarray slides. The images were acquired at 532 nm and 635 nm using 
GenePix 4100A laser scanner (Axon), and the data analyzed with the Gene Pix 5 software package 
(figure 3-7).  
A scatter plot, showing the global correlation in the gene expression profiles corresponding to 
different starting amounts of imput RNA (10ng, 1ng), was compared to the profile in the case of 
non amplified sample (20µg) as shown in figure 3-8. 
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Figure 3-6. SMART7 amplified aRNA resulting from 19 cycles of PCR and two rounds of in vitro transcription, was 
loaded on agarose RNA gel (1/10 vol. aliquots) and stained with ethidium bromide to compare the yield of 1st and 2nd 
round amplification, and check for size distribution. The resulting cDNA amplified respectively from 10 ng and 1 ng 
was labelled for cDNA microarray hybridization. Total RNA from wild-type or mutant Striatal cells was used.  
 
 
Figure 3-7. Comparison of the fluorescence intensities of spots on SISSAorf2 slide after hydridization and washing 
steps, as acquired by the GenePix Laser Scanner. An enlargement of a small portion of the slide is represented here, to 
show the signals for unamplified sample (20 µg) compared to amplified samples (10 ng, 1 ng). Cy5-labelled probe 
corresponds to wt striatal RNA, and Cy3-labelled probe correponds to mutant striatal RNA. 
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Figure 3-8. Scatter plot representing the distribution of all the signals detected by the microarray, calculated as the ratio 
of the logarithms of the signal intensities in the two separate channels (Cy3 and Cy5). The distribution is compared 
among the amplified samples (10 ng and 1 ng) and the unamplified sample (starting from 20 µg). It can be seen from 
the histogram distribution that there is a significant overlap. Only in the 1ng sample, before normalization is visible a 
more enlarged distribution after amplification, which is in part expected since amplification tends to amplify the relative 
differences. Although this could be acceptable untill the same trend in gene expression ratios is preserved. Reasonably a 
safe limit can be settled at 10 ng as minimal starting material for a more  reliable preservation of the relative ratios of 
mRNAs. 
 
The analysis of the data has been performed to assess the conservation in the relative ratios using 
the “true outliers” method, limiting to the differentially expressed genes and to the top candidates 
list (figure 3-9). As shown, the logarithms of the ratio of signal intensities in the two separate 
channels Log2(Cy3/Cy5) are significantly preserved for most of the outliers in the amplified 
samples as compared to the not amplified sample (20 µg). From all these data, we can conclude that 
the SMART7 amplification may effectively be used as a method of choice for gene expression 
profiling of small amounts of total RNA starting in the range of 1-10 ng.   
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Figure 3-9. Comparison among the lists of top ranked upregulated and downregulated outlier genes, amongst not 
amplified and amplified samples. As it can be seen from the values of the Log2(Cy3/Cy5) of the ratios of signal 
intensities in the two channels, the relative levels of the top differentially expressed genes are preserved at a good extent 
by the amplification process.  
 
Developing of a new tecnique for Genome-Wide Tagging and Mapping of the 
Transcription Start Sites from limited amount of starting material: 
nanoCAGE and high-throughput sequencing 
 
The classical CAGE protocol requires micrograms of RNA 
 
Cap Analysis of Gene Expression (CAGE) has been establishing as the method for studying at a 
very large scale the distribution of the transcription start sites (TSS) and consequently the promoters 
usage in the genome (Shiraki T et al. 2003).  
CAGE makes use of the cap-trapper technology (Carninci et al. 1996) to capture the 5` prime ends 
of the transcripts selecting the full-length 1st strand cDNA molecules. After the ligation of a 
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biotinilated 5`end linker to the single strand cDNA containing the recognition sites for two different 
restriction enzymes, XmaJI and MmeI, a 2nd strand synthesis step is performed and the ds cDNA is 
digested by MmeI, which cuts 18-20 nucleotides downstream, generating short 5`end fragments, 
retained on streptavidin beads. 
A second linker containing the restriction site for XbaI is ligated to the 3`end of these fragments 
and, after a PCR amplification step, the cleavage by XmaJI and XbaI generates 5` end tags, 20bp 
long, which can be ligated to each other to form concatamers and cloned into a vector for 
sequencing.  
CAGE has been widely and successfully applied for the construction of hundreds of libraries from 
different mouse and human tissues, giving a great contribution to the understanding of the 
transcriptome structure.  
In its original version, the CAGE protocol requires 25-50 µg mRNA as starting material, resulting 
in a big limitation in the scale to which it can be applied. 
Although great efforts have been done to optimize each single step of the CAGE protocol, leading 
to sensible improvements of the method (Kodzius et al. 2006), the needs for large amounts of RNA 
as starting material makes this technique not suitable to investigate the transcriptome in the case of 
very small samples. 
 
nanoCAGE – what is new: random priming, semi-suppressive PCR, starting 
from 10 ng 
 
Here, we developed a completely new technique to apply CAGE to small scale samples. To this 
purpose, the initial “cap-trapping” step was substituted by taking advantage of a modification of 
SMART, a technique we previously used for small scale gene expression profiling.  
The strand-switching properties of the reverse transcriptase were used to incorporate a small 
sequence tag in correnspondence of the cap structure of the transcripts during the 1st strand cDNA 
synthesis and then used to amplify selectively all the molecules that reached the 5’end. Priming 
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took place with a mixture of oligodT and random primer, ensuring that even the estimated 43% of 
the transcriptome which lacks a poly(A) tail (Chen et al 2005) may be studied. 
A small single strand oligonucleotide, containing the recognition sites for Eco31I and the class IIs 
restriction enzyme EcoP15I, together with a terminal stretch of one dG and two riboguanosines in 
the 3’end, hav been designed to function in the strand-switching mechanism. 
This oligonucleotide bears an additional sequence in the 5’end for PCR amplification which has no 
significant complementarity to the mouse and human genomes/transcriptomes as determined by 
running BLASTN 2.2.17 on the genomic and transcripts assemblies of those two species present in 
NCBI. 
At first total RNA from whole body mouse embryo (C56BL/6  E17.5) was used as template. Serial 
dilutions provided scaling amounts of input RNA for a preliminary estimation of the lower limit of 
application of the technique. 
In those first attempts, only directional priming by a modified oligodT, bearing a sequence 
employed for subsequent PCR amplification, was used. 
Since random priming would result in a great improvement of the global representation of the 
transcriptome, we carried out several experiments to introduce this priming. However, our first 
attempts were not successful due to the massive formation of primer dimers which make artefactual 
products competing with the legitimate template in the PCR reaction. 
Many different trials have been performed but without showing any significant improvement in 
reducing the formation of primer dimers (data not shown). Among them, we used short 
oligonucleotides complementary to the tail of the random primer; random primers containing a 
partial self-complementarity in the 5’end;  a T7 endonuclease I, which recognizes and cleaves non-
perfectly matched DNA sequences and heteroduplex DNAs or cruciform structures,  
To overcome this problem, we decided to modify the design of the primers and to adopt a semi-
suppressive PCR strategy, which basically takes advantage of a partial sequence complementarity 
among all the primers and makes possible to specifically inhibit the amplification of the byproducts 
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which are not fully complementary at the endpoints, avoiding the formation of artefacts in the PCR-
mediated 2nd strand cDNA synthesis. 
One of the major drawback of the template-switching technique is that the strand-switching 
oligonucleotide (TS-oligo) undergoes unspecific priming during 1st strand cDNA synthesis (Matz et 
al. 1999). Theoretically, in the process of the 1st strand synthesis, the strand-switching 
oligonucleotide may also function as RT primer, being extended in the 3’end, and the random 
primer could provide unspecific strand-switching activity at the 5’end as well: both of them will 
result in the formation of a single strand cDNA with a “panhandle-like structure” with fully 
complementarity at the endpoints. 
Such kind of intramolecularly, paired structures would be more stable than the structures formed by 
the legitimate templates, which only display a partial complementarity at the endpoints. 
The difference in the kinetics of fomation of more or less stable “panhandle-like structures” and of 
the corresponding relaxed structures can be used to selectively inhibit the PCR amplification of the 
byproducts taking place in the reverse transcription reaction. 
A PCR-suppression effect (PS-effect) was described for the first time by Siebert et al. in 1995. 
When in complex samples containing short and long molecules with inverted terminal repeats (ITR) 
at the ends, after denaturation the single strand DNA tends to form a “panhandle-like structure” as a 
consequence of intramolecular pairing of the terminal ITRs. Importantly, shorter molecules are 
more easily suppressed than long fragments (Lukyanov et al. 1999; Shagin et al. 1999), because the 
intramolecular annealing is faster than the intermolecular annealing with the PCR primers. Since 
the intramolecular pairing is function of the length of the molecule, varying the Tm of the primers 
and the annealing temperature used for PCR would affect the proportion of molecules whose 
“panhandle-like structure” will have a kinetics compatible with the primer pairing in the PCR: on 
this basis one can modulate the size of the resulting amplification products in complex PCR 
mixtures, like full-length cDNA libraries. 
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In particular, four parameters are critical for the PS-effect: (1) the length of amplified DNA, (2) the 
concentration of primer, (3) the ratio of ITR lenghts to primer length (the difference in their melting 
temperature) and (4) the annealing temperature used in the PCR. 
The suppressive PCR effect has been already used in previous studies (Siebert et al. 1995; 
Lukyanov et al. 1995; Diatchenko et al. 1996; Shagin et al. 1999; Piao et al. 2001). It proved to be 
effective in avoiding the formation of undesired short products during the amplification and to 
correct for the bias against long molecules which tend to be under-represented, due to the more 
efficient amplification of the shorter molecules in complex PCR. 
The main difference between our strategy and the previously published studies is in the design of 
the primers and the terminal sequences used for tagging the cDNAs, which ensures that only the 
legitimate templates with a partially paired ends can be amplified but not the unspecifically primed 
products. Another possible approach to prevent the unspecific priming of the strand-swithcihng 
oligo (TS-oligo) would be to chemically modify this oligonucleotide in the 3’end to make it non 
extensible by the reverse transcriptase, as with the addition of a 3’ phosphate group. However, in 
this case the problem of the unspecific cap-switch activity provided by the random primer may be 
more difficult to be solved. 
The semi-suppressive PCR approach can circumvent both of these incovenients at the same time. 
For the 2nd strand synthesis the number of cycles is particularly important: a small scale PCR 
reaction was performed to evaluate the optimal number of cycles, defined as the last cycle before 
the intensity of the products ceased to increase. Aliquotes (1/10 vol.) were taken every two cycles 
and analyzed on 1 % agarose gel. 
The entire protocol has shown to be robust and highly reproducible, even starting from 1ng of total 
RNA, and even using partially degraded RNA obtained by laser capture microdissected cells, as 
shown by the pattern of the amplified cDNA in replicate experiments.   
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nanoCAGE-454 and nanoCAGE-Illumina-Solexa: new platforms for high-
throughput gene expression profiling from small samples 
 
The use of nanoCAGE has been coupled to high-throughput sequencing technologies such as 454 
Life Sciences or Illumina-Solexa, to be effectively applied to a genome-wide scale from small 
samples and obtain a true full coverage of the transcriptome. It has been estimated that only 
sequencing millions of tags can ensure to cover all the different RNA species which could be 
present in a cell that are in the order of 400,000 or more.    
More details about the specific results obtained by this new technique and its applications will be 
further illustrated in Section 4.  
 
 
3.3  Application of the NanoCAGE technology to the 
mesencephalic dopaminergic neurons 
 
LCM purification of A9 and A10 neurons and nanoCAGE amplification 
 
 
A new technological improvement has been made to allow the Cap Analysis of Gene Expression 
(CAGE) technique to be applied to very small biological samples. The new CAGE-based technique 
was adapted for profiling gene expression starting from ngs of total RNA, hence named nanoCAGE.  
Briefly, Laser Capture Microdissection (LCM) was used by Christina Vlachouli to isolate 2000-
3000 cells from each of two distinct populations of midbrain dopaminergic neurons, A9 and A10 
respectively, from Th-GFP transgenic mouse, which express the Green Fluorescent Protein under 
the control of the rat tyrosine hydroxylase promoter.  Total RNA extracted from these cells was 
retro-transcribed in the presence of a mix of oligodT and random primer (molar ratio 1:1) and a 
strand-switching oligonucleotide (riBOSS), which takes advantage of the cap-switching properties 
of the reverse transcriptase to specifically tag the 5`end of capped transcripts with a sequence 
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containing a class III restriction site for EcoP15I. The 1st strand cDNA was then amplified by means 
of a semi-suppressive PCR which minimize the risk to amplify primer dimers and other aspecific 
products (figure 3-10). The 2nd strand cDNA was purified on microcon filters to recover only the 
low molecular weight fraction containing the 5`tags. Then, the Illumina-Solexa adaptors, each pair 
containing a different dinucleotide barcode sequence (AC for A9, GA for A10), were ligated to the 
EcoP15I fragments. After another PCR amplification with low number of cycles (6-12 cycles), all 
the PCR products were separated on polyacrylamide gel and DNA (112 bp) was extracted, 
concentrated  and sequenced with the Illumina-Solexa platform.  
 
 
 
Figure 3-10. The various sequential steps necessary for 5`tags production in the nanoCAGE described in the text 
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By creating 32bp long 5`tags, we considerably improved the TSS mapping rate on the genome. The 
use of random priming in the 1st strand synthesis allowed to capture poly(A)- RNAs.  The use of 
barcodes in the ligation step has the advantage to enable to mix different cDNA samples which in 
turn minimizes the bias introduced by the PCR in different reactions. Sequencing with Illumina-
Solexa platform allows to have millions of sequence reads per experiment, making possible to reach 
an almost complete coverage of the transcriptome in a cell.  
 
 
Figure 3-11. General scheme of the nanoCAGE procedure for library production  
 
 
 
Bioinformatic analysis of sequencing data 
 
The raw sequence data obtained from a full run (8 channels) of Illumina-Solexa sequencer was 
processed for “tag extraction” to discard unspecific sequences that did not contain the restriction 
sites used for tag production and the 2 nt barcodes inserted in the ligated oligonucleotides, to 
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distinguish among different samples in the mixed library. During tag extraction the first Gs were 
also removed as they came from the riBOSS strand-switching primer.  
A statistical evaluation of the frequency of occurence of each of the 4 bases at each position of the 
tags has been done together with the construction of an error estimation model for better 
implementing the extraction process and lowering the fraction of false positives. Furthermore, a 
Pearson correlation coefficient was calculated for the sequence reads obtained from each of the 8 
channels of the Solexa sequencer to assess if we could effectively mix all the sequences in the 
subsequent step of mapping and clustering without having any bias.  Pearson correlation was quite 
high (0.991-0.998). 
Here is an example of the Tag extraction process that has been applied to the raw sequences: 
59045  GACCTTCAGTTCGACTACTGCTGGTACCCCTGC 
49899  CTACCACTGAGCTAAATCCCCAACCCCCCCTGC 
47199  CTTACCACTGAGCTAAATCCCCAACCCCCCCTG 
44156  ACCCTTCAGTTCGACTACTGCTGGTACCCCTGC 
21600  GAACCTTCAGTTCGACTACTGCTGGTACCCCTG 
19704  CTCCTTCAGTTCGACTACTGCTGGTACCCCTGC 
17717  ACTACCACTGAGCTAAATCCCCAACCCCCCCTG 
14848  CTACCTTCAGTTCGACTACTGCTGGTACCCCTG 
14468  ACACCACTGAGCTAAATCCCCAACCCCCCCTGC 
14078  GATACCCCTGCTGGAGACCTTCAGTTCCCCTGC  
 
59045   GA      CCTTCAGTTCGACTACTGCTGGTAC  CCCTGC 
49899   CT      ACCACTGAGCTAAATCCCCAACCCC  CCCTGC 
47199   CT      TACCACTGAGCTAAATCCCCAACCC  CCCCTG 
44156   AC      CCTTCAGTTCGACTACTGCTGGTAC  CCCTGC 
21600   GA      ACCTTCAGTTCGACTACTGCTGGTA  CCCCTG 
19704   CT      CCTTCAGTTCGACTACTGCTGGTAC  CCCTGC 
17717   AC      TACCACTGAGCTAAATCCCCAACCC  CCCCTG 
14848   CT      ACCTTCAGTTCGACTACTGCTGGTA  CCCCTG 
14468   AC      ACCACTGAGCTAAATCCCCAACCCC  CCCTGC 
14078   GA      TACCCCTGCTGGAGACCTTCAGTTC  CCCTGC 
 
Sequences start with GA, CT, or AC. These are the reverse-complement of the 2nt "barcodes" used for different DA-cell libraries (LC is AG, A10 is 
TC, and A9 is GT). All the reads finish with a given number of Cs, followed by TGC. This is due to the terminal addition of Cs to the first-strand 
cDNAs of capped transcripts, and CCCTGC is the reverse-complement of the 3' end of our strand-swiching oligo (riBOSS). Between these landmarks 
are the extracted tags. 
 
After extraction was completed, the tag sequences were mapped to the mouse genome (assembly 
mm9) using KAlign software, and all the tags aligning with 100% identity to rDNA were discarded 
from subsequent analyses. The frequency of occurrence of each of the 4 nucleotides has been 
calculated for each position in the mapped tags to assess the quality of the data (Figure 3-12). 
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The catecholaminergic cell libraries were also compared to another library (OE olfactory 
epithelium), for which the same conditions of the nanoCAGE procedure were applied, and this was 
used as a useful outlier for statistical analyses. 
 
Figure 3-12. Distribution of the four bases at each nucleotide position along the nanoCAGE tags in A9-A10 libraries 
 
As it can be seen in the following chart, all the libraries gave comparable ratios among total 
sequence reads, mappable tags and tags matching ribosomal DNA, even if they were processed 
independently and starting from different samples taken in independent LCM sessions. 
 
 
The tags mapping to rDNA were only a minority. Considering that uncapped ribosomal RNA 
represents more than 90% of the RNA present at steady state in a cell, this can be interpreted as a 
high success rate of the strand-switching mechanism to specifically targeting capped mRNAs. 
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As it can be seen in Figure 4-4, the percentage of the tags that mapped on more than one position in 
the genome (multimapping) was quite high. Dealing with multimapping CAGE tags rendered 
necessary to apply a special strategy for computing the associated tpm or tag count value. Briefly, if 
a tag match exactly more than one positon in the genome one can even decide to assign the value to 
that tag dividing it for the number of different mapped locations, or assign the value to the closest 
and bigger of the neighbour tags. The latter has been applied by Goef Faulkner who called it “guilty 
by association” method (Faulkner et al 2008).    
Multimapping CAGE tags were rescued in a similar manner as the “guilty by association” method 
with the following modifications : 
1.When a tag failed to be mapped onto the genome, NextAlign software then try to realign it 
allowing for one mutation or indel. This may give raise to tag multimapping (one mutated version 
aligning at a given position, while another mutated version align at another position). Those 
mutation are not equiprobable. The best example being the first G removal versus an indel within 
the tag. Goef's methods doesnt not take it into consideration, giving all mutated versions an equal 
probability to influence the guilty by association rescuing of multi mappers. 
2.The weight given to each possible position of a multimapping tag is a function of the number of 
tags in a [-200bp..+ 200bp] window. Tags in close proximity to the position under consideration 
weight as much as tags distant of 100bp. 
The tags distribution in the vicinity of a given tag (TSS) (considering both single mappers only and 
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single + multi mappers) was plotted as function of the distance, in order to model the influence of 
surrounding tags to weight potential positions of multimappers. 
Because the frequency of tags at long distance is several order of magnitude smaller than tags in 
close proximity, a more permissive window of 
[ -1kb..+1kb] was used to rescue mutlimappers. 
This yields a higher number of rescued tags, but 
also the inclusion of tags that do not have any in 
a [-200..+200 bp] window. An “ambiguity score” 
was computed which simply is the proportion of 
multi mapping tags (over all tags) for each TSS, 
which allow for further scrutiny when analyzing 
CAGE tag libraries and looking for novel TSSes. 
 
TSSes clustering strategies – (this part was contributed by Nicolas Bertin RIKEN,GSC, Japan) 
 
Two strategies have been used to cluster TSSes : FANTOM3 style “proximity” tag clustering (TC) 
and Parametric clustering (PC). 
In the FANTOM3 style “proximity” Tag Clustering” (TC), TSSes are clustered together if they are 
separated by 20 or less base pairs regardless of the RNA library they are derived, as in Carninci et 
al 2006. This clustering approach generated a total of 2,068,275 clusters (34% of the clusters with a 
tpm_density over 1) (Figure 3-13). 
With the Martin Frith`s Parametric Clustering (PC) TSSes are clustered using the method described 
in Frith et al 2007. As noted by the author, a limitation of the proximity tag clustering approach is 
that TSS can only belong to one cluster while it is evident that one can observe the existence of 
clusters within clusters. 
This approach enables a hierarchical definition of such clusters. In short, the algorithm employed 
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compute the local density (number of tags / length of the segment) of all genomic segments. The 
ratio of the minimum density value below which the cluster merges with another cluster and the 
maximum density value, above which the clusters splits into smaller clusters is used to score the 
cluster “stability” (if the ratio is small, then the cluster is not strongly present in the data and could 
easily vanish with some changes in the underlying tag counts, while if the ratio is big, the cluster is 
a prominent feature of the data). 
This clustering approach generated a total of 4,736,538 clusters (526,461 clusters with a 
tpm_density over 1). It is important to note that those clusters are overlapping and that it generates 
clusters within clusters. A stability index bigger or equal to 2 has been chosen in Frith et al. to retain 
for relevant clusters. (all clusters regardless of their stability score are reported) (Figure 3-13) 
Figure 3-13. TC clusters tpm density distribution. The majority of the tags are associated to low expressed transcripts 
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Figure 3-14. Stability scores of PC clusters are either low (<10) or extremely high 
(>100), 12% of PC clusters have a stability score < 2. 
 
 
If we only retain clusters for which at least one tag has 
a non ambigous genomic location, ~34% of the TC 
clusters and ~42% of the PC clusters are retained as can 
be seen in figure 3-15. 
 
 
Figure 3-15. TC and PC clusters selection on the basis of the ambiguity score/density score ratio 
 
 
Those 3 parameters (stability score, tpm 
density and ambiguity score thresholds) are 
not mutually exclusive. 
 
 
 
Figure 3-16. A stability score/density score ratio 
showes that the majority of PC clusters falls into two 
main ranges, one enriched in highly stable clusters 
and another one enriched in very isolated tags. Both 
of these groups show a similar distribution of tpm 
density. The red dashed line represents the threshold 
over which the PC clusters have been retained. 
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Tag clusters-Transcripts associations 
 
 
The genomic distribution along genes relative to the current annotations of the mouse genome has 
been calculated computing tag counts associated to each of the annotated RefSeq regions (exons, 
introns, proximal promoter and 3`UTR). As shown in figure 4-8 for A10 library and figure 4-9 for 
A9 library, there is a high percentage of TSSs in last exons, more than expected based on previous 
studies.  
 
 
This 3`bias of the libraries could be in part explained by the usage of an equimolar mix of oligo dT 
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and random primer to prime the reverse transcription reaction. This effect could be due both to a 
more efficient priming of the poly(A)+ RNAs by the oligodT, compared to a relatively less efficient 
priming of the random primer. On the other hand, the RNA quality may have also played a role, 
since total RNA obtained by LCM from limited amounts of samples has a lower quality than the 
RNA extracted and purified from abundant cultured cells. For partially degraded RNAs the use of 
random primer is needed. 
However, alternative hypothesis may suggest that previous analysis may have underestimated the 
number of true promoters lying in 3’UTR regions of the genes. Carninci and colleagues have 
actually demonstrated that many promoters overlapping with 3`UTR regions guide the production 
of transcripts confirmed both by classical CAGE analysis and RACE experiments (Carninci et al 
2006). 
Then the informations about the tag clusters (single-mappers, multimapping, or both of them) were 
sorted based on the mouse genome annotations in three main categories: refseq genes, microRNAs 
and intergenic as it is summarized in the following Table 5.  
 
For each cluster, the extent of the overlap with the transcript sets was extracted, as well as the 
overlap with region spanning [-500bp..-1bp] interval from the start site of each transcript annotation 
(later refer to as “proximal promoter”). Clusters that do not overlap with any transcript or their 
proximal promoter region have been annotated as “intergenic”. Clearly, cluster transcript 
associations are not mutually exclusive; a cluster can be associated to more than one transcript, as in 
the case of overlapping genes.  For each class data are as follows: 
(1) REFSEQ genes set 
20,649 refseq genes and their genomic coordinates were downloaded from UCSC mm9 release. 
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They map to a total of 20,871 location on the 
genome. Break down of the multi-mapping refseq 
genes is illustrated in the Table 6. 
 
Table6. RefSeq genes associated Tag counts distribution 
 
(2) miRBase miRNA set 
 
Table 7. miRNA genes associated Tags counts distribution 
 
 
436 miRNA annotated in miRBase and their 
genomic locations were retrieved from UCSC. 
Mature and precursor miRNAs from the miRNA 
Registry (miRBase) were aligned against the genome using blat. The extents of the precursor 
sequences were not generally known, and were predicted based on basepaired hairpin structure. 
miRBase is described in Griffiths-Jones et al 2006. The miRNA Registry is described in (Griffiths-
Jones 2004 and Weber MJ 2005). Those 436 miRNA map collectively to 463 genomic locations. 
Break down of multi mapping miRNA is illustrated in the Table 7. 
 
(3) Fantom3 ncRNAs set 
Table 8. Fantom3 ncRNA associated Tag counts 
distribution 
 
Noncoding RNA sequences were collected 
from the FANTOM3 ftp site 
(ftp://fantom.gsc.riken.jp/FANTOM3/noncoding) and realigned onto mm9 using criteria similar to 
that used by UCSC blat based aligment pipeline. Sequence alignement against the mouse genome 
were performed by using blat. Those with an alignment of less than 15% were discarded. 
Furthermore, when a single sequence aligned in multiple places, the alignment having the highest 
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base identity was chosen. Only alignments having a base identity level within 0.1% of the best and 
at least 96% base identity with the genomic sequence were kept. 
The FANTOM 3 ncRNA dataset is composed of the following 3 overlapping subsets : 
• fantom3_noncoding (F3) including 34,030 potentially noncoding transcripts in FANTOM 3 clones, as 
determined by manual annotation. 
• f3_ncRNA_conservative including 3,652 FANTOM3 clones that are annotated as noncoding, and in addition 
have experimental support for completeness of their 5' and 3' ends, and are not upstream of A-rich tracts in the 
genome. This set was made by intersecting f3_ncRNA_liberal with f3_mm5_fulllength in the 
artifact/truncation directory.  
• f3_noncoding_vote comprising 38,129 FANTOM3 clones predicted to be noncoding by a majority vote of 
CRITICA, mTRANS040701, and rsCDS gene structure prediction tools. 
•  
Our most stringent set of 2,881 ncRNAs can be obtained by intersecting f3_ncRNA_conservative 
with f3_noncoding_vote (F3 conservative vote in Table 9). 
 
Table 9. Tag counts distribution 
across the ncRNA subclasses. 
Those 41,560 mcRNA map 
collectively to 47,967 genomic 
locations. 
Break down of multi mapping 
miRNA is as follow 
 
 
 
 
 
In order to pinpoint interesting validation candidates, mm9 phastcons annotations from UCSC were 
retrieved. Predictions of conserved elements produced by the phastCons program are based on a 
whole-genome alignment of vertebrates, the placental mammal subset of species in the alignment, 
and the euarchontoglire subset of species in the alignment. They are based on a phylogenetic hidden 
Markov model (phyloHMM), a type of probabilistic model that describes both the process of DNA 
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substitution at each site in a genome and the way this process changes from one site to the next.  
Only the “Vertebrates set” phastcons scored segments. They were retrieved as corresponding to the 
most conservative set (30 species all the way down to fugu). 
For each cluster, the mean and maximum phastcons score (allowing to quickly determine when the 
cluster spans on several phastcons segments with different score) were computed. A score 3 of 1 
means that the cluster seats on a genomic segment that is fully conserved down to fugu, a score of 0 
means that this genomic region isn’t conserved. 
 
Figure 3-17. Distribution of the degree of conservation of PC and TC tag clusters 
There aren’t any clusters (PC or TC) completely conserved down to fugu (maximum phastcons 
score of 0.817). However, PC clusters associated to proximal promoter regions are more conserved 
than clusters associated to transcripts or intergenic regions. Whereas TC clusters associated to 
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transcript are more conserved than those associated to transcripts or intergenic regions. It might be 
important to keep in mind the hierarchical nature of PC clusters (existence of clusters within 
clusters) in interpreting these results. Imposing at least some level of conservation would get ride of 
~60% of the clusters 
Taking the maximum scoring segment or the average didn’t seem to yield a very different outcome 
for clusters associated with proximal promoter or intergenic regions. Whole transcript exon painting 
might explain the difference between TC cluster avg phastcons score distribution and TC cluster 
max phastcons score distribution. 
Furthermore, an analysis of the clusters length distribution reveals that about 14% of PC clusters 
and about 31% of  TC clusters, respectively, are longer than 1bp. Clusters associated to transcripts 
are longer than those associated to promoters or intergenic regions.  
 
Figure 3-18. Clusters length distribution 
 
This may reflect the so called “exon painting”, probably due to the presence of functional promoters 
in internal exons of known genes. This phenomenon has been already described (Carninci et al 
2006). This result could be particularly striking since the exon painting was originally observed in 
classical CAGE libraries which used a completely independent method for 5`tags production. 
 196 
Generation of a list of potential target genes for further experimental 
validation 
 
For the validation of potential target genes, all the informations detailed above has been gathered in 
2 tab text files (one for each PC and TC clustering methods), together with the expression level for 
each of the A9, A10 libraries, and conservation, stability (PC only) and ambiguity scores. 
Entries in both tab delimited files are ordered in decreasing values of A9/A10 expression ratio to 
favor the quick retrieval of A9 but non A10 expressed clusters. 
One line for each unique cluster / position / associated transcript 
And contains the following columns : 
[1] "cluster_id" : internal cluster_id 
[2] "chr" : coordinate of the cluster (in the form chr1, chr2, ...chrX, chrY, chrM) 
[3] "strand" : coordinate of the cluster (one of ''-, '+') 
[4] "start" : coordinate of the cluster (start position of cluster with start < end systematically) 
[5] "end" : coordinate of the cluster (end position of cluster with end > start systematically) 
[6] "length" : the length of the cluster 
[7] "avg_phastcons_score" : the mean phastCons score of the segments overlapping the cluster (in the range [0..1]) 
[8] "max_phastcons_score" : the phastCons score of the highest scoring segment overlapping the cluster (in the range 
[0..1]) 
[9] "ambiguity_score" : the ratio of multimapping position within the cluster (in the range [0..1]) 
[10] "stability_score" : for PC cluster only (blank for TC cluster), higher the value, more “stable” the cluster 
[11] "has_associated_transcript" : one of 
• 'transcript'; the cluster overlap at least in part with a refseq gene, miRNA or ncRNA 
• 'proximal_promoter'; the cluster overlap at least in part with the proximal promoter region ([500.. 1bp]) of a 
       refseq gene, miRNA or ncRNA  
• 'proximal_promoter,transcript'; the cluster overlap at least in part with a refseq gene, miRNA or ncRNA and 
      in part with a refseq gene, miRNA or ncRNA proximal promoter region (remark : not necessarily the same 
       transcript in principle ... in practice, this is very likely) 
• 'intergenic'; the cluster does not overlap with any transcript or any proximal promoter 
[12] "transcript_name" : the name of the refseq gene, miRNA or ncRNA overlapping with the cluster (blank if the 
cluster map to an intergenic region) 
[13] "transcript_annotation" : one of 'mRNA', 'miRNA' or 'ncRNA' (blank if the clustre map to an intergenic region) 
[14] "annotation_origin" : one of 'refseq', 'mirbase', 'F3', 'F3_vote', 'F3_conservative' or 'F3_conservative_vote' (blank 
if the cluster map to an intergenic region) 
[15] "co_direction" : one of 'S' : the cluster map on the same strand as a transcript 'AS' : the cluster map on the 
opposite strand to a transcript; blank if the cluster map to an intergenic region 
[16] "association_span" : the relative position of the cluster start to the transcript or proximal promoter of the transcript 
(ranges from [1.. 0] when mapping to a proximal promoter and [0..1] when mapping to a transcript) 
[17] "association_span" : the relative position of the cluster end to the transcript or proximal promoter of the transcript 
(ranges from [1.. 0] when mapping to a proximal promoter and [0..1] when mapping to a transcript) 
[18] "A9" : cluster tpm (sum over all TSSes) for the A9 library 
[19] "A10" : cluster tpm (sum over all TSSes) for the A10 library  
[20] "OE" : cluster tpm (sum over all TSSes) for the OE library 
 
 
 
Figure 3-19. Example of how appears the header of those Table files 
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Starting from those tables, a first screening was done looking at the ratio of expression in A9 versus 
all (sum) other libraries. In figure 4-13 the x-axis is the log10(tpm) for A9, whereas the y-axis 
represents the ratio tpm(A9) / total tpm(A9, A10, OE) plotted on an exponential scale to emphasize 
larger, more interesting, ratio values. 
 
Figure 3-20. Distribution graph of A9 tpm density versus all other libraries tpm, in log scale. In red are represented 
clusters associated to proximal promoters, in black are the clusters associated to all toher annotaions 
 
Restricting the analysis to only proximal promoters-associated PC clusters, similar results were 
obtained. In the following figure, clusters are also colored according to max-phastcons-score. 
 
Figure 3-21. Distribution graph of proximal promoter associated PC clusters sorted by A9/all density and conservation 
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The same kind of analysis have been done selecting the PC clusters on the basis of annotation type 
 
Figure 3-22. Distribution graph of proximal promoter associated PC clusters sorted by A9/all tpm density and color – 
              coded according to different annotation types. Protein coding mRNAs (red) ncRNAs (blue) miRNAs (green). 
 
 
GO terms and categories distribution 
 
In order to look for GO terms categories distribution among A9 and A10 nanoCAGE clusters 
associated RefSeq genes, a first attempt was performed with FatiGo+ bioinformatics open-source 
tool (Al-Shahrour et al 2007). This did not detect any significant enrichment for any specific 
category. 
One limitation in GO terms analysis is that only protein-coding genes can be considered. Moreover 
also many of the coding genes still lack any GO associated classification. 
But it has to be noted that with nanoCAGE tags one have to deal with the additional information 
about the precise location of the tags along the transcripts. So if only proximal promoter associated 
tags are considered, then the number of different genes in the analysis can become a limiting factor. 
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To have a raw idea of which are the most expressed genes among A9 and A10 cells, a selection has 
been done using R programming, sorting the clusters on the basis of their tpm values in crescent 
order in each library. Herein after are the top 10 most expressed clusters detected in A10 and A9 
respectively (Table 10). 
 
 
Table 10.       Top 10 clusters in A10 library                                       Top 10 clusters in A9 library (values are in tpm) 
 
From this top 10 list emerges that metabolism related genes seem to be very important for the 
function of these neurons. 
A more time-consuming analysis was done by visual inspection of the values and positions of the 
tag clusters for entire sets of genes, classified based on common Pathways (retrieved from KEGG, 
Common Pathways, Ingenuity, BioCarta, GeneNet), using nanoCAGE custom tracks in wig format 
uploaded on the UCSC Genome Browser. Moreover, for each gene present in the pathway, 
additional informations in the literature were retrieved and screened either using the automated 
PubMed links present in UCSCS Genome Browser or consulting other sources of informations, 
such as GeneCards, Gene Profiles, or other specific databases for specific categories of genes. 
First of all, some basic controls were performed looking at the expression of the genes involved in 
the catecholamine synthesis (figure 3-23) pathway, dopamine degradation pathway, and dopamine 
uptake and signalling pathways (figure 3-24). Furthermore, a series of other controls were 
performed on the quality of the data, looking for the expression of genes which are considered 
markers of other neuronal cell types including, among others, Dbh for NA-ergic neurons,  GFAP 
for glial cells and  Ermap for erythoid cells. Almost all of these control marker genes have no 
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associated tag clusters in A9 and A10 DA cell libraries.  
 
 
 
 
           
Figure 3-23. Catecholamine biosynthesis pathway genes are all represented in A9 and A10 libraries 
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Figure 3-24. Dopamine degradation pathway genes associated tag clusters are epresented for A9 and A10 libraries 
 
Furthermore, we examined the information about main pathways already known to be implicated in 
Parkinson`s disease, such as mitochondrial function, ubiquitin-proteasome system related genes, 
and the Parkinson`s disease pathway from KEGG. For many genes in those pathways a significant 
difference was present in the expression (max tpm) amongst A9 and A10 libraries. 
Here there is a table with all the tpm values of clusters associated to the genes in the Parkinson`s 
Pathway as rom KEGG (Kyoto Enciclopedia of Genes and Genomes) table11 
 
Table 11. Parkinson`s disease KEGG Pathway associated genes- the Expression associated to a given transcript has 
been splitted into proximal (promoter and 1st half of the transcript genomic span) and distal (last half of the transcript 
 202 
genomic span). Numbers in bracket are the [-2stddev +2stddev] I mentioned earlier. 
 
 
Differentially expressed protein-coding transcripts in SN and VTA neurons 
 
In general, many interesting candidate genes for further validation were found among those 
implicated in the DA metabolism, uptake and recycling. Some of these differ only in the relative 
level of expression. Others may also show alternative TSSs, hence possibly controlled by cell-type 
alternative specific promoters.  Some of these protein encoding genes have been selected as targets 
for further experimental validation and will be object for discussion later. Other candidate genes for 
validation have been also found implicated in the mitochondrial homeostasis, regulation of 
mitochondrial fission and fusion dynamic process, and among those implicated in the function of 
the ubiquitin-proteasome system.  Herein are the statistical analysis of the nanoCAGE clusters 
associated to genes implicated in crucial aspects of mitochondrial functions (Figure 3-25). 
 
Figure 3-25. distribution of the nanoCAGE tag clusters (expressed as tpm) among three libraries, two A9, A10 and the 
olfactory epithelium (OE) library used as reference for comparison. 
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The genes represented in figure 3-25 are sorted in four functional categories: Drp1 and Fis1 are 
implicated in the control of mitochondrial fission, which is suspected to be involved in critical 
aspect of the neurodegeneration which affect the DA SN neurons in PD. Recently it has been shown 
that 6-hydroxydopamine could induce mitochondrial fission (fragmentation) in SH-SY cells in a 
Drp1-dependent manner (Gomez-Lazaro et al 2008). Moreover Pink1, implicated in familial forms 
of PC, has been shown regulate the mitochondrial dynamics in vivo interacting with the fission-
fusion machinery in Drosophila and in mammalian cells (Yang et al 2008). 
An RT-PCR analysis was done to confirm the expression of the specific genes of the mitochondrial 
fission-fusion apparatus (figure 3-25), using total RNA extracted from ventral midbrain of C57Bl6 
adult mice and all the candidate genes (Drp1, Fis1, Opa1, March5) were confirmed to be expressed. 
We are currently performing real time PCRs on LCM-purified A9 and A10 neurons to confirm the 
differential expression of these genes. These data may suggest a different mitochondrial 
fusion/fission homeostasis between A9 and A10. This may have some consequences on the 
differential susceptibility of these neurons in PD. 
Figure 3-26. Schematic draws of mitochondrial fusion and fission pathways – from (Bossy-Wetzel et al 2003) 
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Figure 3-27. Schematic model of apoptotic mitochondrial 
fission. Ca2? signals from the ER or other apoptotic 
stimuli trigger the translocation of Drp-1 and Bax to the 
mitochondrial outer membrane. Bax interacts with 
endophilin-like molecules that contain an SH3 domain, 
such as Bif-1. Bax, endophilins and Drp-1 are postulated 
to form a large complex at sites of mitochondrial fission. 
Drp-1 may convey a conformational change to Bax and 
associated molecules, thereby facilitating an increase in 
outer membrane permeability and translocation of 
cytochrome c across the cytosol. 
Inactivation of PARL or OPA-1, a factor involved in 
mitochondrial fusion, may lead to the opening of cristae 
junctions and the liberation of apoptogenic factors like 
cytochrome c or AIF. This process may lead to 
disintegration of mitochondria and their removal by 
autophagy. Abbreviations: cyt-c, cytochrome c; TM, 
transmembrane region.  Picture taken from (Bossy-Wetzel 
et al 2003). 
 
 
 
 
Chromosomal distribution of the promoters in SN and VTA neurons 
 
The genomic distribution of nanoCAGE tag clusters along chromosomes can be visualized either by 
plotting the tpm density of A9 versus A10 clusters sorted by chromosome using R programming 
(scatter plot) or in a more visual friendly way using directly the wig tracks loaded on the Genome 
Browser. This allows the display of both sense and antisense TSS clusters. They are represented by 
vertical bars in correspondence of the TSS +1 position, having a positive value (tpm) for the tags on 
the (+) strand and negative value for tags on the (-) strand as shown in Figure 3-28/29 for some 
chromosomes. In general, there is a good overlap in the peaks of the tag cluters among A9 and A10 
libraries reflecting the expected large similarity among those two cell populations. However, at a 
more detailed visual inspection, peaks are clearly differentially expressed among libraries as can be 
noted in the case of chromosomes 15 and 18, as shown in figure 3-28. 
Therefore, A10 and A9 nanoCAGE tracks were manually screened selecting candidate genes for 
further evaluation.  
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Figure 3-28. nanoCAGE tracks loaded on UCSC Genome Browser for chromosomes 7, 19, 15, 18. 
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Figure 3-29. nanoCAGE tracks loaded on UCSC Genome Browser for chromosome 17 
 
 
 
 
 
Use of alternative promoters of biologically relevant protein 
coding genes in SN and VTA neurons 
 
While the analyzing differentially expressed nanoCAGE clusters associated to protein coding genes 
in A9 and A10 cells, it has been clear that some genes strongly implicated in regulating crucial 
aspects of dopaminergic cell’s physiology are associated to alternative TSSs. Therefore, they may 
generate cell-type specific transcripts. Here we describe four cases: α-synuclein, DAT, Vmat2 and 
Comt.  
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Alpha-synuclein (Snca): Differential usage of alternative promoters 
potentially linked to different splicing patterns and post-transcriptional 
modifications of the protein 
 
 
By means of nanoCAGE technology, we found that in mouse midbrain, the α-syn gene is 
transcribed by two main alternative TSSes, each associated to a specific type of neurons. As shown 
in figure 3-30, in A9 neurons transcription starts in correspondence of a more distal TSS, which is 
associated to the RefSeq mRNA (NM_009221), whereas in A10 neurons, transcription starts from a 
more proximal TSS associated to a different annotated RefSeq transcript (NM_001042451). 
 
 
 
 
Figure 3-30. nanoCAGE tracks for A10 and A9 libraries loaded on UCSC Genome Browser displaying the tpm values 
of the tags clusters in correspondence of the alternative TSS of alpha-synuclein gene. Blat sequences represent the 
5`RACE sequences from 2 independent clones, aligned on the mouse genome using Blat.  
 
Therefore, RT-PCR and 5`RACE amplifications have been carried out (figure 3-31) using exon 
spanning primers specific for each of the two transcript isoforms (see section 2 – Materials and 
Methods). 
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We thus velidated the existence of these two transcript variants in the mesencephalon. We are 
currently performing real time PCR on A9 and A10 neurons to confirm their differential expression. 
RACE data prove that NanoCAGE technology select for true 5’ ends of transcripts. 
 
Figure 3-31. RT-PCR amplification from mouse ventral midbrain total RNA, of Snca cDNAs corresponding to the 
transcripts generated by alternative TSSes: distal TSS (mostly represented in A9 neurons) associated to the transcript 
(NM_009221) gave an amplicon of the expected size (151bp). Snca proxi represents an amplicon of the expected size 
(240 bp) corresponding to the transcript (NM_001042451) associated to proximal TSS (mainly used by A10 neurons). 
TH was used as a positive control. 
 
 
 
 
Figure 3-32. Scheme of the alternative TSSs for Snca gene. There is a difference in the splicing pattern of 5`UTR 
without changing the CDS. Exons are depicted as boxes. Coding regions are shaded to show origin of protein isoforms. 
Dotted lines connecting exons represent splicing patterns. 
 
The two alternative promoters produced transcripts having different 5`UTR but with no change in 
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the coding sequence (CDS) of the respective proteins. The two alternative 5` untranslated regions 
were separated by approxymately 0.7 kbp distance and they differed in their predicted structures, 
having different fold energy (-61.30 kcal/mol for A9; and  -123.40 Kcal/mol for A10) as it can be 
seen in figure 3-33.  
 
Figure 3-33. Predicted structures of the 5`UTR regions specifically associated to the A9-A10 alternative transcripts as 
calculated by RNA Vienna package. A9 associated transcript (NM_009221) has a more branshed but less stable 5`utr 
(on the left) whereas A10 associated transcipt (NM_001042451) has more compact and stable folding (on the right).  
 
 
 
 
 
Figure 3-34. Gene structure diagram for the human SNCA locus, with Ensembl and RefSeq transcripts annotations. 
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Dopamine Transporter (Slc6a3/Dat): Different alternative TSSs associated to 
potentially different protein isoforms 
 
Slc6a3/DAT encodes for the dopamine transporter, and it is strongly involved in regulating the 
normal biological functions of these neurons. We have found evidences of potential alternative TSS 
usage in A9 and A10 neurons. Unlike α-syn, which is ubiquitously expressed in the brain, this gene 
is classically considered a marker for DA-ergic cells. 
The nanoCAGE libraries form A9 and A10 neurons reveal the existence of cell-type specific 
alternative TSSes associated to different transcripts (Figure 3-35). The main TSS in A10 map on the 
4th exon at position (chr13: 73,682,261 tag seq: GGAACAGCCCCAACTGCTCTGATGCA), giving rise to a 
transcript shorter than the canonical annotated RefSeq (NM 010020), whereas in A9 the main TSS 
is found in correspondence of the canonical start of transcription that has been reported in other 
studies (Bannon et al 2001). Interestingly, the two alternative TSSs have a different initiator-like 
dinucleotide sequences (suboptimal GG in the case of A10 TSS, canonical pyrimidine-purine TG in 
the case of the highly represented TSS of A9).  
Importantly, both A9- and A10-associated TSSs were confirmed by 5`RACE analysis as it can be 
seen in figures 3-35, 3-45. This proves again that nanoCAGE technology select for true 5’ ends of 
transcripts. 
Interestingly, as shown before in section 1 (Page 114-115), at least in human there are evidences of 
multiple transcripts at the SLC6A3 locus, many of which have a coding potential as demonstrated 
by the presence of in frame methionine residues.   
 
Figure 3-35. nanoCAGE tracks of A10 and A9 libraries loaded on UCSC Genome Browser displaying the tpm values 
of the tags clusters in correspondence of the alternative TSS of Slc6a3 gene. Samples sequences over the RefSeq gene 
represent the 5`RACE sequences from 2 independent clones, aligned on the mouse genome using Blat. 
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Vescicular Monoamine Transporter (Slc18a2): an alternative intronic TSS is 
mainly used by A10 neurons 
 
Slc18a2/VMAT2 encodes for the vescicular monoamine transporter, a protein involved in 
regulating the monoaminergic vescicular storage. It has been found to use alternative TSSes in the 
two DA cell populations of A9 and A10.  
The analysis of the nanoCAGE tracks for Slc18a2/Vmat2 murine gene revealed that two main 
TSSes are specifically used by the A9 and A10 neurons. The TSS used in A10 neurons lies within 
the intron 3, an exceptionally long intron spanning more than 10 kbps, whereas in A9 neurons the 
more 5`distal TSS is the canonical one, reported in literature and associated to the 5`end of the 
respective RefSeq transcript (NM_172523).  Interestingly, as in the case for DAT, the two 
alternative TSSes seems to have a different initiator-like dinucleotide sequences (a canonical TG in 
the case of A10 TSS, tag seq: TGCTTCTTTCTGGTTCAGGGTCTGTGC; and CA in the case of the highly 
represented TSS of A9). Both A9- and A10-associated TSSes were confirmed by 5`RACE and RT-
PCR analysis as it can be seen in figure 3-36.  
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Figure 3-36. nanoCAGE tracks of A10 and A9 libraries loaded on UCSC Genome Browser displaying the tpm values 
of the tags clusters in correspondence of the alternative TSS of Slc18a2 gene. Sample sequences over the RefSeq gene 
represent the 5`RACE sequences from 3 independent clones, aligned on the mouse genome using Blat. An additional 
5`RACE product has been cloned, corresponding to the TSS for other previously isolated cDNA clones (Jassen et al 
2005) 
 
At least for the human gene another isoform of the VMAT2 transcripts have been reported as 
shown by the informations retrieved from the AceView database (Figure 3-37). 
 
Figure 3-37. A scheme of the possibile alternative transcripts and their corresponding proteins associated to the human 
Slc18a2 locus as emerges from cDNA and  EST data collected from many tissues and summarized by the AceView 
gene prediction database. At least 3 different isoforms are reported for VMAT2; the isoform a (12 accessions from 
substantia nigra, brainstem, colon, embryo) isoform b (is the most represented with 46 accessions from pancreas, head 
neck, placenta, melanocytes, fetal heart, pregnant uterus) and isoform c (4 accessions from liver).  Picture taken from 
Aceview database. 
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The 5`RACE amplification have been done using exonic gene specific primers downstream of each 
TSS (distal or proximal) of the two transcript isoforms (see Materials and Methods) (figure 3-38). 
We are currently validate the cell-type expression by real time PCR on LCM-purified cells. 
 
Figure 3-38. 5`RACE amplification from mouse ventral midbrain total RNA, of specific cDNAs corresponding to the 
transcripts generated by alternative TSSes: Snca distal (mostly represented in A9 neurons) associated to the transcript 
(NM_009221); Snca proxi (mostly represented in A10) associated to the transcript (NM_001042451); Dat distal 
(mainly represented in A9) starting in 1st exon; Dat proxi (mostly present in A10) starting in the 4th exon; Vmat2 distal 
(mainly used by A9 neurons) from the 1st exon; Vmat2 proxi (A10) starting within 3rd intron; TH represents an RT-PCR 
amplicon obtained from the same cDNA, used as a positive control. 
 
 
 
Figure 3-39. Scheme of the alternative TSSes for Slc18a32 gene. There is a difference in the splicing pattern of 5`UTR 
and there is a drastical change of the CDS (to simplify the scheme the actual number of exons is not reported). Exons 
are depicted as boxes. Coding regions are shaded to show origin of protein isoforms. Dotted line are introns.  
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Catechol-O-methyltransferase (Comt): alternative promoter usage associated 
to MB-Comt and S-Comt in A9 and A10 dopaminergic neurons 
 
Another gene, Comt, coding for the enzyme catechol-O-methyltransferase has been found to have a 
differential expression from alternative promoters in A9 and A10 DA neurons. 
From the nanoCAGE libraries, the two transcripts corresponding to the S-COMT and MB-COMT 
are differentially expressed among A10 and A9 neurons. 
 
 
 
Figure 3-40. nanoCAGE tracks of A10 and A9 libraries loaded on UCSC Genome Browser displaying the tpm values 
of the tags clusters in correspondence of the alternative TSS of Comt gene. Sample sequences over the RefSeq gene 
represent the 5`RACE sequences from 2 independent clones, aligned on the mouse genome using Blat .  
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Figure 3-41. RT-PCR analysis of the alternative transcript isoforms associated to the Vmat2 and Comt mouse genes. In 
the first lane an amplicon of the expected size (199 bp) was obtained for Vmat2 isoform starting from a distal TSS 
(Vmat2 distal); an amplicon of the expected size (391 bp) was also obtained for the Vmat2 isoform starting from the 
intronic TSS (Vmat2 intronic) with RT- giving no signal for the same intronic isoform; Comt isoform transcribed from 
the internal TSS (Comt proximal) gave an amplicon of expected size (179 bp); Comt long isoform transcribe from the 
distal TSS (Comt distal) gave an amplicon of approximately 291 bp.  
 
 
 
 
 
 
Figure 3-42. Scheme of the alternative TSSs for Comt gene. There is a difference in the splicing pattern of 5`UTR but  
and a corresponding change of the CDS, with the longer ORF coding for a membrane-binding protein, and the shorter 
ORF coding for a soluble protein. Exons are depicted as boxes. Coding regions are shaded to show origin of protein 
isoforms. Dotted lines connecting exons represent splicing patterns. 
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In A10 neurons both isoforms are expressed at relatively high level, whereas in A9 neurons only the 
S-COMT form appears to be expressed at low levels. Interestingly, an antisense transcript is present 
at the distal TSS associated to the MB-COMT isoform. A 5`RACE analysis has confirmed the 
existence of both the TSS associated to the alternative promoters, as shown in figures 3-40 / 3-41. 
 
 
The non coding RNAs landscape in SN and VTA neurons as emerging from 
nanoCAGE and deep sequencing 
 
Relative abundance and different families of non coding RNAs 
 
The relative abundance of the non coding transcripts over the total count numbers has been 
calculated and plotted for each class of transcripts, ncRNAs (F3 conservative vote set, as reported 
before), RefSeq mRNA, miRNAs (mirBASE), and for the two different clustering methods 
(Parametric clustering - PC, 
and Tag proximity clustering - 
TC), (Figures 3-43, 3-44) 
 
Figure 3-43. It appears that 
ncRNAs account for about 
36% of the transcriptome, 
when considering all the PC, 
clusters, irregardless of their 
stability score or  the uniquess 
location in the genome. 
Whether coding RNAs 
account for about 38,8% of 
the transcriptome. 
nanoCAGE Tags matching 
intergenic locations in the 
genome are also quite an 
abundant class, accounting for 
about 18% of the total counts. 
However most of the 
intergenic tags are less 
representative and statistically much less relevant, due their low stability score. 
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Here you can find the association of tags clusters obtained with different clustering methods with 
current transcriptome annotations: 
Figure 3-44 
 
The distribution among different classes of transcripts gave similar results for the two different 
clustering methods (PC or TC). However, when we considered only tag clusters that have been 
stable and non ambigously positioned in the genome, an higher number of cluster associated to 
known transcripts was visible. 
 
 
 
Figure 3-45 
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Differentially expressed microRNA transcripts in SN and VTA neurons 
 
 
A list of putative differentially expressed miRNA transcripts has been compiled, searching for tag 
clusters lying in an interval of [-500..-1] bp from the annotated miRNA precursor sequence 
(coordinates were retrieved from miRBASE). The tpm values were then compiled according to two 
methods:, 1. counting the tags matching unambiguously in only one position, 2. considering the tags 
that map in more than one position in the genome. You can find the list of the most significantly 
expressed miRNA in A9 and A10 neurons in a decreasing order. 
 
Figure 3-46. 
Here are listed only 17 
entries, which have 
shown the most 
different values. 
It can be seen that 
some of these miRNA 
seem to be expressed 
at a significantly 
different level, like in 
the case of mir-677 
and mir-671. 
However, it has to be 
noted that the interval 
of 500bp upstream of 
the TSS of the 
precursor is likely to 
not comprise the 
promoter of the 
primary transcript of the microRNA, as it has been demonstrated that in the majority of the cases 
this is located in a range of 2-10 kilobases, from the precursor microRNA sequence. Since not so 
much data are currently available in databases that can be used for a more accurate bioinformatics 
analysis, these results should be considered only indicative. A more rigorous analysis of 
experimentally determined list of promoters should be reconsidered to refine the list.  
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Sense-Antisense pairs transcription 
 
To uncover potentially interesting antisense transcripts, all the sense-antisense pairs where a non 
coding antisense RNA was overlapping in the first intron/exon of a protein coding transcript were 
selected, using a perl script. Then a further selection was based on the difference in the normalized 
expression level (tpm) among A9 and A10. 
 
 
 
A further manual check of all the entries verified the reliability of the data and served to eliminate 
duplicated entries matching the same gene. A parallel further visual screening, which covered about 
1-2% of the genes in the mouse genome, allowed to look for other possible interesting candidates 
acting in specific pathways.). Interstingly, one of the gene that has been found associated to an 
antisense overlapping transcript was Ubc, encoding for polyubiquitin chains, whose function may 
be also implicated in many aspects of the physiology and pathophysiology of the A9 –A10 neurons. 
Here is the scheme of the nanoCAGE tracks for Ubc. 
Figure 3-47. nanoCAGE tracks for Ubc gene: in this case, vertical barswith negative tpm values represent sense 
transctpts, whereas positive tpm valuies are associated to antisense transcripts. UCSC gene predictions together with 
Swiss Bioinformatics alternative splicing, describe the presence of a very complex pattern of transcripts for this locus, 
which is confirmed by the multiple GenBAnk hits. 
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Candidate non coding genes for establishing functional differences 
 
 
From this zoom out view of the Ubc locus, the difference in the amount of sense and antisense 
transcripts can be better appreciated. They are the black bars on the line called (NC 000071-2396) 
and comprise at least two different transcripts, one overlapping within the 1st intron, and the other 
one overlapping at more 3`end region of the Ubc sense mRNA. 
 
 
Figure 3-48 
 
Interestingly, the predictions for antisense transcripts overlapping the sense Ubc mRNA, exhibit a 
complex alternative splicing pattern, which suggest an even further complex control in the 
transcriptional regulation of this locus. 
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The expression level of overlapping antisense RNAs at this locus is much higher in A9 compared to 
A10. To confirm that antisense transcripts do exist in vivo, an RT-PCR analysis has been done 
using specific combinations of oligonucleotides (figure 3-49).  
In many independent biological and technical replicates, a smear of bands could be detected.  
 
 
Figure 3-49. RT-PCR analysis of total RNA obtained from ventral midbrain and striatum respectively of  the same 
C57Bl6 mouse. After a random primed RT, for the amplification of the specific cDNAs, the following comniations of 
primers have been used: (1) AS-Ubc rev/ AS-Ubc fwd; (2) AS-Ubc rev/ S-Ubc rev;  (3) S-Ubc rev/ S-Ubc fwd. (see 
Oligonucleotide functional grouping for more details) The first combination of primers gave a much less clear smear , 
where a continuum of amplicons of different sizes are produced, whereas the combination (2) of primers gave a much 
more clear pattern of amplicons of the expected bands. Lane (3) represent a positive control for the expression Ubc of 
the sense transcript. In this case the primers S-Ubc fwd and rev were designed in a region at the 3`ends with no 
homology with the Ubb mouse gene, also coding for polyubiquitin chains. 
 
Interestingly a more detailed analysis of the motifs present in the promoter of Ubc gene 
(considering 2 kb upstream and 5 kb downstream of the sense annotations) has been conducted 
using the Match informatics tool (BIOBASE), and found the presence of many motifs which seems 
to occur more than chance, for Pitx3 and Nurr1, which are both well known transcription factors 
controlling numerous genes involved in specifying and maintaining the DA-phenotype of the 
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mesencephalic DA-neurons. Here you can find all the genomic sequences screened with the motifs 
is reported. 
>m m 9 _ r e f G e n e _ N M _ 0 1 9 6 3 9 range=chr5:125861335-125872387 5'pad=0 3'pad=0 revComp=TRUE strand=- repeatMasking=none 
cttctacactaggtactttcttccttaccccagagccttgaggatctctt 
cctttcaagctcaccttggccaggtccagggctcaagctttgcttcttcc 
tcgcccctacccccacccctacttctaaaatcaaggctgcctggctctga 
atcttctagactctggaaaaaaacctgatgccacaaagctggtgactcag   + 1 9 1S_AP-1➭  
ccaagaaccaggaatcacgaggctgaagcaaagcgacagccaaatatagc   + 2 3 6S_AGL-3➭ 
atggtgtggccggaagccagaatcactttagaaccaacttcagtgttttc   +2 5 6S_Elk-1➭ 
ttcccttcctcaaacttctgtctgaattctagaaagaactgacctgccca 
gaactctgcctcagaaatcactgtggcttcccagaaacccggagaatgac 
attttaattttatagtggcatatgacctcgattcatggaaaaaaatcaca 
gaaaattaagtctattctgaacaacacctgcagttaaagtatattttgaa 
caatacctctgatcttgaatgtttatgaattcctaaaccagggagccaga  - 5 4 4AS_Pax-4➭  
caggcctgaattctcagcgtctgggtggtagaggcaggagtatcaactgc 
aagttagaacccagcctgatctatgtcatgagtcccagggcagccagggc 
tacatataggaaccctgtctcaaaaaaactcaaaaaatgctgagattaaa   AS_Ptx-3↵ 
ggcatttaatagtgtgtgtccatctaagtgtgtgccacatgtatgtgaaa 
gtgtccctagggacattggaccctcctgaagctggagtcacaagctagct 
gcctgacagggttgctgggtattgaattcatgtactctggaaaaagacct 
gttcctactggggagccatctctccccatcagggattcaattcttacctt 
ctaaggtcttaggccttacatttcaaaaacctgagctgggcagtggtggc 
gcaggcctttaatcccagcactttggaggcagaggcaggtggatttctga-9 5 9S_Bcd/Ptx-3➭ 
gttcggggccagcctggtctacaaagtgagttccaggacagtcagggcta 
cacagagaaaccctgtctcaaaaaaccaaaaaaaaaaaaacaaaacaaaa 
caaaacaaaaaaaaccctgaataatttgattcgtataagtgggatatatg 
cttgctgtaatctgaacattgtactacacgtgcacatttgtgcttttttg   S_Ptx-3➭ 
tttttgtgggggttttttgtttggtttttggtttttcaagtcaagtgtag  +1 2 4 1S_Nkx2-5➭ 
ccctggccattctggaacttgatctgtagaccatacttgggaggcagagg 
caggaggacctatataaacttgagaccagcctggtctacatagcatattc 
caggacaggcagggctacacagagaaacccccatctgaacaacaaaaatt 
taaaaatcagggcttcagtgggttcagtctcagaatatgaacaacaaata 
tgaacaacatttggaaattttgacctttacttagtgacaagcacatagaa   S_Nurr1➭ 
aacatagaaccttctcgaatccaaggacacaaggtttaggaaaaatctgg   +1 5 0 6S_HSF➭ 
aaagatcaggttctgctgggcttcagatctaatgccaacagttttcaaga   + 1 5 9 6S_CRP➭ 
actgtgtagactgtctgctttccttgacaaactcagattcgtttttccaa   + 1 6 4 3S_AG➭   
atcggggagagattccctccttcgtattttttttttttaaatttattaaa 
aaccctttgtcattttccttgttaggagatttgcacagtcatccaccctg 
tcactgtgccaaaacagtgagggctgggcatagtgacccgccggggatga 
ggggattgaggaggcgaggtcaccaatgggatcccagtgtgacaggagcc 
aaagccctgggtccccctagcgcggaaagaaaacagggggggtggggggt   S_Ptx-3➭ 
ggtggcctgactaggggcgccaggccgcgaagccgcagggcgcctgcgcc 
aaggcccgctccggcctcagtgatcccagccgtgttttcgtgccgatcgt 
CTCACGCGCGCTGATCCCTCCGCGGAGTCGCCCGAGGTCACAGCCCTGCC   <5`UTR> 
CTCCCACACAAAGCCCCTCAATCTCTGGACGCCACCGTGAAACAACTCCG   S_Ptx-3➭ 
TGAGAGAGgtaccttgatagttttagcctgtcgctttcgctgccgagact   <intron> 
ggacccggcgttacaaagtagtccctgaccgcattgcccgcggagggacc 
gcgcggaagggggggggcggggcttcggtgactatataaagagacgccgg 
gcgtgccgcagctagttccgtggagactgcgagttccgtctgctgtgtga 
ggactgccgccaccaccgctggtgaggagaaagccgccgcacccggtcgg   S_Ptx-3➭ 
ggacgggaggctggaggcgagacggggcgagaggcagccccgcggcccag 
acgtttggtttccgtggcccgcgcggaccgcggctgccccgaggcagagg 
actgggcggcaagatggcggccagatggaagcctgagggggaagacgcgg 
ggctctgacgcgcaggacgaggttgggggaggaaaaaggcccgcgaggcc 
gctgccctccggttaagccggggacgtcggagactgtggggtggggactg 
aattagggttgcgcgccgtaggagcctctgctgtgagagccgtggatatt  annotated AS 
gggctggcccgagaggtcgattggcccggcgttcgtccgttcgtttgctg↵4930513I04 (FA N TO M 3) MGI:3647829 
aaagacggaagtgcgatcgagaccggaagggggttgggcggcggttcagc  +2 7 2 2S_NRF-2➭  
ctgcctggcctgccgccccctgtgacgtcgcgggttgcgtggcctcctaa 
tggatagtgacgtcactatcttgactttagctttccctcggttgtaggac ++ -- 2806CREBP12806CREBP1 -- cJUNcJUN➭  
agggtttgggtctcggcctccggtagcctctccagagtaaacaggaaccg ++ -- 2808CREB2808CREB➭ 
gaaattcagaggggaaatgtgagccattcttgtcctgtttcgttttaaga  +2 8 9 4S_Elk-1➭ 
atgtcgctgtacaactatgactactgaaacttttggggggggggttcgag 
acggtttctctatgtagtcctggctgtcccgcatctcactctgtagatca 
ggctggcctcgaacccagaaatcctcctgcctctgcctcccaagtgttgg 
gacgaaaggcaccaccattgtcctgcgacaagggtgtttttttttaaact 
gtcaaaatctctgcctctaccaccccatgtgatgaggtccaaggccagta 
ccaccactccagactaattttaatcgttcagacaaaagtttggtgttctt 
ttgggggaaggagagttgaggcaggattacactgtctctggctgaccttc    AS_Ptx-3↵ 
cagttagagatctgcccacctcagtgtccccagtgctgaggtcagcgata 
ggcatgggctcagacttagttttgcagtagtaacttgctatattaccatt 
ctgaaactgaatccgggactgctgtggtttcataacctcccagaggtcag   + 3 4 4 2S_Pax-4➭ 
gcttttctgcaaactgttcaaatagacagaaattgactttcagctgttgg 
tatactgaagtctccatcctgtaaatttggtaatacaaaaagactcacca 
tgccgaggtttcttaactttgttagtcaacaatcttattttcttgatggt 
ttttcggggtggggggattggattcaagacagaatctgtgtagatagacc 
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ttgctatttagacttatagcatccagttgacaaatgttgatgccatccca 
caaatatttgtgtcattcctgacctgtgaattgttttgtatattttgtga  +3 7 3 1S_BR-C Z1➭ 
cagACGATGCAGATCTTTGTGAAAACCTTAACTGGTAAGACCATCACCCT 
GGAGGTCGAGCCCAGTGACACCATTGAGAATGTCAAGGCAAAGATCCAGG 
ACAAGGAGGGCATCCCCCCTGACCAGCAGAGGCTGATCTTTGCAGGCAAG      STRE↵ 
CAGCTGGAAGATGGCCGCACCCTGTCAGACTACAACATCCAGAAAGAGTC 
CACCCTGCACCTGGTCCTTCGCCTCAGAGGTGGCATGCAGATCTTTGTGA↵ 
AGACCCTGACAGGCAAGACCATCACCCTGGAGGTCGAGCCCAGTGACACC 
ATAGAGAATGTCAAGGCAAAGATCCAGGACAAGGAGGGCATCCCCCCTGA      STRE↵ 
CCAGCAGAGGCTGATCTTTGCAGGCAAGCAGCTGGAAGATGGCCGCACCC 
TGTCAGACTACAACATCCAGAAAGAGTCCACCCTGCACCTGGTCCTTCGC↵     AS UBC forw 
CTCAGAGGTGGGATGCAGATCTTTGTGAAGACCCTGACAGGCAAGACCAT 
CACCCTGGAGGTCGAGCCCAGTGACACCATAGAGAATGTCAAGGCAAAGA 
TCCAGGACAAGGAGGGCATCCCCCCTGACCAGCAGAGGCTGATCTTTGCA      STRE↵ 
GGCAAGCAGCTGGAAGATGGCCGCACCCTGTCAGACTACAACATCCAGAA 
AGAGTCCACCCTGCACCTGGTCCTTCGCCTCAGAGGTGGCATGCAGATCT↵ 
TTGTGAAGACCCTGACAGGCAAGACCATCACCCTGGAGGTCGAGCCCAGT    AS UBC rev 
GACACCATTGAGAATGTCAAGGCAAAGATCCAGGACAAGGAGGGCATCCC 
CCCTGACCAGCAGAGGCTGATCTTTGCAGGCAAGCAGCTGGAAGATGGCC      STRE↵ 
GCACCCTGTCAGACTACAACATCCAGAAAGAGTCCACCCTGCACTTAGTC↵ 
CTTCGCCTCAGAGGTGGGATGCAGATCTTTGTGAAGACCCTGACAGGCAA 
AACCATCACCCTGGAGGTCGAGCCCAGTGACACCATTGAGAATGTCAAGG 
CAAAGATCCAGGACAAGGAGGGCATCCCCCCTGACCAGCAGAGGCTGATC      STRE↵ 
TTTGCAGGCAAGCAGCTGGAAGATGGCCGCACCCTGTCAGACTACAACAT 
CCAGAAAGAGTCCACCCTGCACCTGGTCCTTCGCCTCAGAGGTGGGATGC↵ 
AGATCTTTGTGAAGACCCTGACAGGCAAGACCATCACCCTGGAGGTCGAG 
CCCAGTGACACCATAGAGAATGTCAAGGCAAAGATCCAGGACAAGGAGGG 
CATCCCCCCTGACCAGCAGAGGCTGATCTTTGCAGGCAAGCAGCTGGAAG      STRE↵ 
ATGGCCGCACCCTGTCAGACTACAACATCCAGAAAGAGTCCACCCTGCAC↵ 
CTGGTCCTTCGCCTCAGAGGTGGCATGCAGATCTTTGTGAAGACCCTGAC 
AGGCAAGACCATCACCCTGGAGGTCGAGCCCAGTGACACCATAGAGAATG 
TCAAGGCAAAGATCCAGGACAAGGAGGGCATCCCCCCTGACCAGCAGAGG      STRE↵ 
CTGATCTTTGCAGGCAAGCAGCTGGAAGATGGCCGCACCCTGTCAGACTA 
CAACATCCAGAAAGAGTCCACCCTGCACCTGGTCCTTCGCCTCAGAGGTG 
GGATGCAGATCTTTGTGAAGACCCTGACAGGCAAGACCATCACCCTGGAG 
GTCGAGCCCAGTGACACCATAGAGAATGTCAAGGCAAAGATCCAGGACAA 
GGAGGGCATCCCCCCTGACCAGCAGAGGCTGATCTTTGCAGGCAAGCAGC      STRE↵ 
TGGAAGATGGCCGCACCCTGTCAGACTACAACATCCAGAAAGAGTCCACC↵ 
CTGCACCTGGTCCTTCGCCTCAGAGGTGGCATGCAGATCTTTGTGAAGAC 
CCTGACAGGCAAGACCATCACCCTGGAGGTCGAGCCCAGTGACACCATAG 
AGAATGTCAAGGCAAAGATCCAGGACAAGGAGGGCATCCCCCCTGACCAG      STRE↵ 
CAGAGGCTGATCTTTGCAGGCAAGCAGCTGGAAGATGGCCGCACCCTGTC 
AGACTACAACATCCAGAAAGAGTCCACCCTGCACCTGGTCCTTCGCCTCA↵ 
GAGGTGGCATGCAGATCTTTGTGAAGACCCTGACAGGCAAGACCATCACC 
CTGGACGTCGAGCCCAGTGTTACCACCAAGAAGGTCAAACAGGAAGACAG   S UBC forw 
ACGTACCTTCCTCACCACAGTATCTAAAAAGAGCCCTCCTTGTGCTTGTT 
CTTGGGTGTGATGGGGGAGGTGTCTTAGTTTTCCCTATCTTTTAAGCTGT 
TAACAAGTTTCATTGCACTTTGAATAAAGTTCTTGCATTCCAAAAAATCT   S UBC rev 
TCAtttgtgttgttggttggttccttgtattgggatgtgtagagacttat 
catatcaagtttgtgtcatcagtgtaacctatcaggtaagataatgttgg 
actagggactgtgtggcttttaaaagtattttccaaaaaccttgtttctc   AS_Ptx-3↵ 
agtgtgtagcctttgctgtcctggatcttcctctgtataccagtctgacc 
tagaattcccaagaaatccacctgtctttcaagtgctgggataaaaggta  +6 2 7 9S_Nkx2-5➭ 
tttgccgggctggagatttggcgcaccagtgaagtgcactgacagctctt  +6 3 1 7S_E2F➭ 
ccaggtcctgagttctagtcccagcaaccacatgttggttcataaccatc 
tgtaataggatctgatgccctcatctggtgtatctgaagacagctagtgt 
attaacatggaataaacaaatttaaaaagaaggtatttgccaccaccgcc  +3 7 3 1S_BR-C Z1➭   
ctgggtattgtaagatttttaaagttattagggtgttggtatttaatcta   S_Ptx-3➭ 
tgaaggaggtcaacagaagcgttcagtcccttggtgtttgaaccaccatg 
tggcctctgcctcccaagtgctgggattaaagtcgtgtgccaccatggcc   Bcd➭/Ptx-3↵ 
ggcctaaatctttttttttaaagattatttatttcacgtatgaatacact S_FOXD3➭ AS_Ptx-3↵ 
gttgctgtctttagacaacaccagaagagggcatcagatcccgttaaaga  +6 6 7 9S_Pax-6➭ 
tggctgtgagccaccatgtggttgctgggaattgaactctgaacctctgg +6 7 3 8S_Myogenin/NF-1➭   
aagagctaccagtgctcttaactactgagccatctcttcagccctgaact 
taaatcttataagaggaacaaattctttgttctaaaatggcaatttaagg 
tttaaacttaattttgcaaagtgtatatttgcatgtatatgaatgctcaa  -6 9 2 4AS_Oct-1➭   
ggcagttgtcacattcccctagagataaggtcatttaagatcaatcaaac      S_Pbx-3➭   
tgggttctctggcaagttattatctgctttcactctgctgtgtctagccc  -7 0 0 9AS_HNF-1➭ 
tgaagtggaattttctgtaaaacataccaggtaattatcacctagttgta 
ctgaggacattatatagtaatggtgaaaagaagctgaagtgagcatggtg   S_Ptx-3➭ 
gcactaacttttaatcctagcacctagcagaggcaagcagatctgagttc   S_Ptx-3➭ 
atgagttccaggccagccaaggctgtagtaagacttgtcacacacaaaaa  +7 1 9 4S_Pax-4➭  
aatttccctaggttatgtgataacagctaaaggtcttggatggagtattg 
acctgaatgttcccaagtgggtctagtcaggtgtgttaacgattggcctg  + 7 3 3 5S_COMP1➭ 
gagaagtgagtcagacattgtagtgctggtcttgtaattgacatactgtg 
cctcagtgccacttgtccagagtggcccagtaagtaagtctagccttagc 
atgtacctccactaaggattcaatgtatacgtagccatttcattaaaatt 
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gatactgaactggtcgtggtggcacatgcctttaatcccagcacttggga  S_Bcd/Ptx-3➭ 
tgcagaggcaggtggatttattgaatttgagaccagcctggtctacagag 
tgagttccaggacagccagagctacacaaagaaaccctgtctcgaaaaac 
caaaaggaaaaaaaaaaaaaaaactgataaaatgagtgtaatttgtcttg 
gctatcctggaacttgtgccaccaaaccaggctggtttgattcatctatg 
aggaaagtgcagggtattccatgaagacaatcctggactttgggaggaaa 
tgcttgctttttcttagttgctcatcctaagttagagctatgtaggcagc 
aatatgatttgatgaccctgtttctttgtacctgttctaagttgttggtt 
ttgttttgttttttttaaagatggtgaggaataatgaaataaccagcctt 
agccatgtaagcacatgatctgctctggagctaaaattcacctcactttg 
tttttttaattctagttctgttcagggagaacacatggtgtagtccagac 
tagctttgaacttgtatgttcctgcctcaacttccctaatgtcagattta 
taagctcggaggttaagcctgagcttaagggtttctccaacagaccaagg 
ttcaatttcttgtacccatatcacagatcgtttgtaatcccataccctct    S_Ptx-3➭ 
ttggacttttgggcagaaggcaggcaaaacaatacaaagattttaaagtt 
aaaagtatagcctgttggtgagtgtgttccagaggcaggcaaagttaagg 
ccagcctggtattcaagactgaatttcaggatatccagggctacacagag 
aaaccattaaaattagaagcatggttgccatgctcaacacaagcaagaat   AS_Ptx-3↵ 
tttttttttttacatttatttgtggctaagcaattgctgttctctagccc 
ttagcccaggatcccaccacagttgaaattaaaccacaacgcctactggg 
ttacagcaggtaagaggtcccaaccattccccaagtctgtctacatgtgt 
gaagattagagtcagtttttccactgtgtggttggtacccaaagctccat   AS_Ptx-3↵ 
atcggtctagcagcaagcacttgctgacctgttgctcatagtgtctgaat 
gtgtgctacttggtttcaaatactcattttataatgggaacaatgccatc   S_Ptx-3➭ 
cttgcttttggctggtgctcctaccccattgtgttcagcttcatacatac 
aggtcctcagagacactgggagagctctaggctatacactgactactgca 
tgttttcacttcagatctcggtattattaggtctattagccttacaacat 
atacaaaggggagaaattccttttctcaaaaacagaaagccagggtaaaa   S_Ptx-3➭ 
gaactggactgtcaggagcatatgaagctcggcttcctagagtcctcttt 
ctagagtcctcggtataatgaacagagtttaaagtactccatagtttcac 
ttcacacttggaactaagttcacttacagaggtgaggttgagtcagaaag 
tactaggcctgagtgtatatactaaccacttgtaactcaagctttaaggg 
gagtcaacagcaggcacctgcactcaaatgcccatacttccagatgggca 
gtcctggcaagcaatactctcccagaagaggacatcactgggccacatgc 
acgtttagtaatgaaggctgcagtgcccccaagaggttgtagatggttaa 
gcaattgctgttcttagccaagggtcccaccacagttgaaattaaaccac 
aacacccactgaattataccaagcaaaaggtctcaaccactccacagatt 
acccacattctgtaaagcctccccacaattttcctttacttcacccaagt   S_Ptx-3➭ 
tgtccttgttcctaaggccactgcacctacttaggtgtttcctctcctaa 
tttttttccccacagagtgtaccttgtaacccaggctgaccttgaacctc 
cttatgcctcagtgttgtgtaggactgttttacaagccacactgccacca 
tcttcatcaaatcagctgggccagcttgcaaaagtaacagggcctgttga 
ctattggtattgttttgtaggagaggcaggcagggtcatgggaccctcaa 
ctgaatatccagccagttctcccaactttctcataactgtatatagtctc 
caggaggggctagagaaaataggcaaaaaagaactaggagaagcaggctt 
tatgtgaccacagggaagacgtcatccatgctgggtacagactttacagt 
gtcattgctttagcggtcacccacgcttctgctcataacccctcacatat 
gatctgtaagtaagcccagtaaacttactcgtttcagtgagcaaactttg 
gtggactcaagccaacatttgtccttggaccttaggaggagggggagatg 
tggtttccgtttccccaagggaagggattttagcaacattgagtttccag 
gtgttaagagtcctttctttattctagtggcttaacattgggtagtcacc 
catggtgacaatgacacttgtagctctaggtggttcaggtgctaagggaa 
gtgctgcaaaactaaagagcctcagaggatggagccagggaccaggtgct 
gggagagaacttgggtgtagatcaacaggagacctcactttcaaaagggg 
ccaaatgtttggtgtggagcagggcctagacactggttttctgtagtgct 
tggaatgggacccaggaccttaaacagctgagagtttgaaaatctaggga 
attgattgattgactgattgatcctgcagctggcactggaaactctgagt 
gaacaccgggtacactgaagaatgatgatctcagactaaggcccagagtg 
tagagcactaactagtagtaaagccatgaggcacagggttctatctcttg   S_Ptx-3➭ 
cacagcataagtgggccccgtggtgcaggcctgcagttccagagagggag 
ctgaaggctggaggtttgaggacaactggaccacactagaccctatatca 
tcactaatgacttattgagactgtcttttgtccaaagtatgtgaaattaa 
cattttctcccagtagggttcattttgtggttgttcaaccaaagctttgt 
tgagctgctactcagaggctgctccagtagaggaaaatcaaaacatagag 
acccaaatctgctatgtgatggtgtttgaagctcctgtctctgttctcat 
caatacagctggtctgttggagatgtgccttgcaaacatcaatgcccaga 
aaaattaaggtgttacctctttcctgtgacttcctggaggtggaaactca 
agctgactttttccctcattactcttctttctcctctgtgttaaggacat 
gaattttggtaggaggtgaagattagggtatacctgtctccccttagaga   AS_Ptx-3↵  
tcatagaaaaccatggctcaggccaggggaggggtacactaagctcagca 
ctgaagaggtagaaaggagggccatcagtttagaccatctgggctacaaa 
atg    (5kb downstream)    RED AS tags & RT primers 
                           GREEN S tags & RT primers 
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Fig 3-50. Ubiquitination. Ubiquitin (Ub) is activated by E1, transferred to E2s, which bind to E3 for conjugation of Ub predominantly onto lysine 
residues in substrates; E3s confer substrate specificity to the system. Additional rounds of Ub conjugation onto substrate-attached Ubs lead to the 
formation of Ub chains. Different lysines in Ub can be used for chain formation. Chains linked through lysine in position 48 (Lys 48) in Ub are the 
predominant proteasome-targeting signals in vivo. Lys 63-linked chains function in a proteasome-independent manner. The function of other chain 
topologies in vivo is unclear. Figure taken from Kaiser and Fon, 2007. 
 
 
 
 
Figure 3-51. | Assembly and fates of various forms of the ubiquitin domain. The E1 activating enzyme adenylates the carboxyl terminus of ubiquitin 
(Ub) and then forms a thiolester with the E2 conjugating enzymes that act as mobile carriers of activated Ub. Ub ligases are responsible for the 
specificity of attachment of Ub to the target protein through the recruitment of both an E2 thiolester and a specific substrate.Modification by a single 
Ub domain regulates localization and/or activity of conjugated proteins. PolyUb chains can be formed with different linkages and these direct proteins 
to different fates, presumably requiring chain-specific receptors.Note that more than one E2 can work with a given E3 and that several E3s can use a 
single E2. BRCA1, breast cancer 1; UEV, ubiquitin-conjugating enzyme E2 variant protein. Picture taken from Wilkinson et al 2005. 
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SECTION 5. DISCUSSION and CONCLUSION 
 
Among all the biological systems, neural networks in the CNS probably has one of the most 
complex organization in terms of their diversity in properties and function as well as their 
interconnections. There is an underestimated hetereogeneity among neurons. 
Only a few morphologically defined cell types express usefully distinctive cytochemical markers, 
and those sharing common markers do not necessarily display the same patterns of connections or 
electrophysiological properties. 
To overcome the limits inherent to a classical anatomical description, in the last years, multiple 
methods and approaches have been used to gain insights into the molecular complexity which 
characterizes neuronal populations. The use of high-throughput techniques for genome-wide 
expression profiling such as microarray, provided invaluable tools for a deep analysis of the 
transcriptomes of specific subset of neurons, opening new possibilities in the field of functional 
genomics. However, for long time, the need for a sufficient amount of RNA to be used as template 
for subsequent analyses, strongly limited the application of these techniques, preventing their use 
for particularly small biological samples such as neuron subpopulations in the brain. To overcome 
these limitations, we first applied a two rounds amplification using method SMART7 to obtain a 
sufficient amount of cDNA to be used as fluorescent-labeled probe in a classical cDNA microarray 
experiment, which normally requires micrograms of starting material. The SMART7 protocol was 
applied to profile decreasing amounts of RNA obtained from serial dilutions of culture striatal 
neurons, and it has been shown to produce reliable results even in the range 1-10 ng.  
However results obtained from microarray analysis are biased towards the set of used probes, 
depending on each particular platform used in the experiment. To bypass these inherent limitations 
of the microarray, we took advantage of new high-throughput sequencing technologies, to adapt a 
classical tag-based method for genome-wide TSS discovery to be applied to small group of cells.  
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In a collaborative effort with dr. Piero Carninci from Genome Science Center at RIKEN (Japan), we 
developed nanoCAGE, based on Cap Analysis of Gene Expression (CAGE), as a simple method to 
analyze the gene network in small samples containing 10-50 nanograms of total RNA.  Few 
thousands DA cells were isolated using laser capture microdissection (LCM) technology by Dr. 
Christina Vlachouli from two different subpopulations (A9 and A10) of mouse midbrain from a 
transgenic TH-GFP mouse, in which a reporter gene is expressed in all catecholaminergic neurons. 
The RNA obtained from these highly selected neuronal populations was then used as starting 
material for a nanoCAGE profiling, which allowed an unbiased analysis of the promoters activity 
along the entire genome. After mapping and clustering the tag sequences on the mouse genomic 
DNA, a statistical analysis has been employed to uncover new interesting genes for subsequent 
experimental validation.  
The new nanoCAGE method has been proved to give informations about both the quantitative 
profile of gene expression and the TSS usage frequency. This allowed a complete description of the 
promoters used by a particular cell type, taking advantage of the depth of coverage reachable using 
new high-throughput sequencing platforms such as Illumina-Solexa.  
It has been calculated in fact that only having millions of tag sequences for experiment can ensure 
an almost complete coverage of the all RNA transcripts present in a cell (Zhu et al 2008). 
The usage of random primer in the reverse transcription step for cDNA synthesis gave an invaluable 
information about expressed non coding RNAs, which can often be devoid of a poly(A) tail and it is 
particularly useful for detecting antisense transcripts, often missed by the microarray analysis. The 
major advantage of nanoCAGE compared to all other methods was the detection of differential cell-
type specific promoter usage.  
We were able to detect new unannotated transcript isoforms, even in the case of widely studied 
genes, such as α-synulein, dopamine transporter, vescicular monoamine transporter and catechol-O-
methyltransferase, all of which have been subject to extensive research investigations, due to their 
central role in the physiology and pathophysiology of dopaminergic cells.  
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Most of the research conducted on these genes has considered the RefSeq annotations for their 
transcripts and corresponding proteins as reference ascertained points on which all the experimental 
framework has been based. But there are accumulating evidences proving that the current transcript 
annotations have to be revised and reconsidered in the view of more recent genome-wide 
investigations, which gave convergent results even using independent different platforms and 
systems such as RACE, genome tiling array, CAGE and more recently RNA-Seq (Carninci et al 
2005, Gustincich et al 2006, Sandelin et al 2007, Denoeud et al 2007, Cloonan et al 2008, Sultan et 
al 2008). These new unbiased analyses revealed that most of the genes in the genome have more 
than one associated transcript. Many genes are transcribed from new distal or internal TSSes, not 
comprised in the current annotations, which can either give rise to regulatory non coding RNAs or 
to potentially coding transcripts often producing shorter proteins (Denoeud et al 2007, Oyama et al 
2007). This hidden layer of transcripts contributes to the complexity of gene network regulatory 
dynamics in a cell (Yasuda and Hayashizaki 2008). 
Studying the midbrain dopaminergic cell system using an unbiased high-throughput approach 
together with single cell harvesting by LCM, we uncovered at least part of this hidden complexity 
to unveil that some of the genes involved in the dopamine homeostasis are actually transcribed from 
alternative promoters. 
 
The observation that cell-type specific alternative promoters are differentially used between A9 and 
A10 neurons in normal physiological conditions. may be important on our knowledge of the 
biology of these neurons. This may open new working hypotheses to explain, at least in part, the 
differential vulnerability of these two cell populations to environmental insults and their differential 
responses to pathological conditions. As previously described in section 4, all of these genes, α-
synuclein, Dat, Vmat2 and Comt, are involved at different levels, in establishing and regulating 
dopamine homeostasis inside the cell. Whereas for at least three of these genes (Dat, Vmat2 and 
Comt), it is clear and well established a role in dopamine metabolism, uptake, storage and 
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degradation, for α-synuclein, a normal physiological function inside the cell is not as much clear as 
one would expect from the large number of studies focused on this protein. 
Since the first times when Parkinson`s disease was recognized as a neurodegenerative condition 
mainly affecting the dopaminergic neurons, it became clear that there is a difference in the 
susceptibility among distinct neuron subpopulations: A9 neurons in the ventral tier of SN are the 
most affected group, whereas the A10 VTA neurons are relatively spared. 
However, the precise reasons for this different vulnerability are not known. It has been largely 
accepted that Lewy bodies, mainly composed of α-synuclein aggregates and other 
polyubiquitinated proteins, are almost invariantly found to be associated to PD surviving 
neruromelanin-positive SN neurons.  
How α-synuclein may be implicated in the pathophysiological process of PD is far from obvious. A 
puzzling aspect of α-synuclein -mediated cytotoxicity and LBs formation with regard to PD is the 
preferential and selective neurodegeneration of dopamine-producing neurons, such as the substantia 
nigra. α-Synuclein is ubiquitously expressed at high levels in virtually all regions of the brain, 
where it is believed to account for up to 0.1% of total brain proteins (Clayton et al 1998). If high 
expression levels of α-synuclein were the only cause of protofibril formation and LBs, then most 
brain regions could be expected to have aggregates of α-synuclein.  
Yet in PD the SN neurons, which express considerably less α-synuclein than other areas of the 
brain, are specifically affected, whereas other brain regions expressing higher levels of α-synuclein 
are relatively spared. Increasingly then, the evidence suggests the likelihood that the specific 
vulnerability of these neurons is linked to other factors, the prime candidate being dopamine itself, 
which necessarily can confer the selectivity for these neurons. 
Multiple evidences, both direct and indirect, have been recently accumulating showing a close 
relationship among α-synuclein and dopamine, whereby this protein probably participates in 
regulating the biosynthesis, storage into vescicles, release as well as reuptake of the 
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neurotransmitter, thus implicating α-synuclein as a central player and regulator of the dopamine 
homeostasis in those neurons.  
Dopamine is inherently unstable and can generate reactive oxygen species (ROS) and, via 
monoamine oxidase (MAO), H2O2 (Lotharius et al 2002). Dopamine is synthesized in the cytosol 
and rapidly pumped by vesicular monoamine transporter 2 (VMAT2) into synaptic vesicles, where 
the low vesicular pH and the absence of MAO limit its breakdown. Defects in the early secretory 
pathway could cause a shortage of synaptic vesicles and reduce delivery of VMAT2 to the synapse. 
This would impede dopamine loading and increase cytosolic dopamine levels and consequently 
ROS production. Although dopamine itself may not be toxic, dopamine metabolites play a role in 
α-syn aggregation (Xu et al 2002, Galvin 2006) and dopamine- α-syn adducts stabilize α-synuclein 
protofibrils (Conway et al 2001). It has been shown, that, dopamine can have an opposite effect on 
α-synuclein conformation depending from its redox state: dopamine istself normally is tought to 
induce the aggregation of α-synuclein in large fibrillar structures (Moussa et al 2008), whereas the 
oxidized metabolites of dopamine inhibit the fibrillization process stabilizing the protofibrills or 
toxic olgomeric species (Conway et al 2001). Therefore, dopamine can directly influence the 
conformation, hence the equilibrium among the membrane-bound form and the soluble cytoplasmic 
form of α-synuclein protein. More recently many studies have linked α-syn to the function of other 
key genes implicated in dopamine homeostasis: α-syn normally modulates the enzymatic activity of 
TH preventing its interaction with kinases (Perez et al 2002). On the contrary other chaperone 
proteins 14-3-3, favor TH activity by enhancing TH phosphorylation by calmodulin dependent 
kinases and ERKs (Ichimura et al 1988, Toska et al 2002). However it has been shown that 
aggregated α-syn while decreasing the total content of TH also stimulates its serine 
phosphorylation, suggesting that excessive aggregated α-syn is no longer able to inhibit TH (Alerte 
et al 2008). 
Morover α-syn has been shown to inhibit the activity of ERK through its direct binding to the MAP 
kinase (Iwata et al 2001a, Iwata et al 2001b), an effect also seen with the A53T mutant (Iwata et al 
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2001b). This inhibitory effect of α-syn can be extended to other kinases such as calcium-
calmodulin-dependent kinases (Lee and Lee 2002) and PKC (Okochi et al 2000) and contributes to 
counteract the TH activity. 
Τhe NAC region of α-syn has been also shown to directly interact with the C-terminal portion of 
DAT (Wersinger et al 2003), suggesting for the first time that α-syn can also play a direct role in 
the regulation of dopamine uptake process.  
DAT is a major determinant of dopamine homeostasis and synaptic strength since it is the primary 
mechanism by which endogenous neurotransmitter is rapidly removed from the synaptic cleft. 
Increases or decreases in DAT function will concomitantly decrease or increase synaptic dopamine 
concentrations, respectively, thereby regulating the activity of multiple post- and presynaptic 
dopamine D1- and D2-like receptors. The DAT is also the sole means by which the parkinsonism  
inducing neurotoxin MPP+ is transported into nigral neurons (Gainetdinov et al 1997, Takahashi et 
al 1997).  The importance of DAT function in the control of synaptic availability of DA suggests 
that its own regulation may be a crucial component in the maintenance of dopaminergic 
neurotransmission, since enhanced DAT activity would not only decrease extracellular levels of DA 
but also increase intracellular levels of DA upon reuptake.  
The principal means by which DAT function is regulated is through the rapid shuttling of DAT to 
and from the plasma membrane. Previous work in cellular expression systems has shown that 
reduced cellular dopamine uptake mediated by DAT may be directly correlated to the possible 
phosphorylation of DAT by kinases, causing rapid redistribution and internalization of DAT away 
from the plasma membrane (Pristupa et al 1998, Melikian and Buckley 1999,  Daniels and Amara 
1999). The participation of kinases such as PKC that are dynamically activated by changes in 
intracellular [Ca2+] levels, suggests rapid adaptations of the neuron in response to signal 
transduction-induced changes in calcium flux to attenuate DAT function. Recent data have shown 
that MAP kinases ERK1 and 2 phosphorylate DAT upon signal transduction, increasing the amount 
of DAT at the plasma membrane and dopamine reuptake (Moron et al 2003). Since α-syn binds to  
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MAPK and tends to inhibit its activity, as shown for the regulation of TH enzyme, it is likely that 
the presence of α-syn at the nerve terminals tends to blur MAPK activity and decrease the amount 
of DAT inserted in the membrane of nerve terminals. Sidhu and colleagues have shown that upon 
coexpression in fibroblasts or in basal conditions in mesencephalic neurons, α-syn tends to 
markedly decrease by 30– 50% the activity of DAT by reducing the reuptake of dopamine 
(Wersinger and Sidhu 2003, Wersinger et al 2003). The reduction in DAT activity was due to a 
decrease in DA uptake velocity by the transporter without any change in DAT expression levels.  
A consequence of the α-syn -mediated attenuation of DAT activity was that upon exposure of 
cotransfected cells to DA, there was a diminished DA-induced oxidative stress and cytotoxicity,  
suggesting that disruption of the ability of α-syn to regulate transporter function may be one of the 
most important determinants in the genesis of dopaminergic neurodegeneration. 
The cause that initiates the dysregulation of α-syn-mediated DA homeostasis is currently not 
known. It has been observed that a transcriptional dysregulation of α-syn is a common event since 
gene dosage seems to be crucial for regulating its activity. α-syn gene duplications and triplications 
lead to disease, and the same effect is observed when α-syn is overexpressed in transgenic animal 
models od PD. 
Interestingly, we have preliminary evidences that different subpopulations of mesencephalic DA 
cells amy use alternative promoters for α-syn and DAT. Currently, nobody knows what is the 
relative contribution that alternative promoters and different isoforms of the protein may play in the 
regulation of normal DA homeostasis and in the pathogenesis.  
With the development of a new high-throughput genome-wide technique (nanoCAGE) to study the 
promoters activity in few isolated homogeneous groups of neurons, we were able to demonstrate 
that a fine-tuning in the transcriptional regulation do exist among A9 and A10 neurons in vivo, and 
in particular the usage of cell-type specific alternative promoters might account for slight 
differences in the internal homeostasis control in those neurons, which may give some hints about 
the selective A9 vulnerability, and the relative resistance to stress of VTA A10 neurons.  
 235 
 
The fact that a cell-type specific transcriptional control seems to regulate in different ways the DA-
phenotype associated to these distinct neuronal populations, could change our current perspective, 
further confirming that those two neuronal populations have indeed much more differences than 
previously thought. These observations could also open new questions about the physiological 
function associated to each specific isoform of those genes in vivo. 
Since all of the genes on which we focused our attention are actually pharmacological targets in the 
cure of PD,  we plan testing how a selective modulation of the transcription of each isoform of 
those genes could affect the normal DA-homeostasis and/or the  their dysfunction which leads to 
develop a neurodegenerative condition. 
For instance, an isoform specific targeting with antisense oligonucleotides or transcriptional 
interference (Janowski et al 2006) would be one possibility to explore in the next future. 
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